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Preface to “Zinc Signaling in Physiology and
Pathogenesis”
Zinc, an essential trace element, plays indispensable roles in multiple cellular processes. It 
regulates a great number of protein functions, including transcription factors, enzymes, adapters, 
and growth factors, as a structural and/or catalytic factor. Recent studies have highlighted another 
function of zinc as an intra- and intercellular signaling mediator, which is now recognized as the 
zinc signal. Indeed, zinc regulates cellular signaling pathways, which enables the conversion of 
extracellular stimuli into intracellular signals, and controls various intracellular and extracellular 
events. Thus, zinc mediates communication between cells. The zinc signal is essential for physiology, 
and its dysregulation causes a variety of diseases such as diabetes, cancer, osteoarthritis, dermatitis, 
and dementia. This indicates that the zinc signal is an emerging topic that will assist in our 
understanding of the nature of physiology and pathophysiology.
This special issue, “Zinc Signaling in Physiology and Pathogenesis” has two main goals. The first 
is to update the current information available about the crucial role of zinc signaling in biological 
processes on both a molecular and a physiological level. This will assist in addressing the questions 
underlying this unique phenomenon and discerning its future direction through the publishing of 
review articles by experts, as well as original papers. The second aim is to feature the 5th Meeting of 
the International Society for Zinc Biology 2017 (ISZB-2017) in collaboration with Zinc-Net (COST 
Action TD1304), held in Cyprus. As Lowe and Moran reported, ISZB-2017 was held in conjunction 
with the final dissemination meeting of the Network for the Biology of Zinc (Zinc-Net) at the 
University of Central Lancashires Cyprus campus in June 2017, with over 160 participants, 17 
scientific symposia, four plenary speakers, and two poster discussion sessions [1]. Much of the 
research presented at this meeting had never been presented or published before, and the most of the 
authors featured in this special issue presented their research at this meeting. This means that this 
issue contains the most up-to-date information on zinc signaling and related biology. Twelve review 
articles by such invited authors, which have been included in this issue, are mentioned below.
From a molecular and biochemical point of view, the first article by Maret provides an overview 
of the regulatory functions of zinc signaling through its interaction with Ca2+, redox, and 
phosphorylation signaling, thus enabling the transmission of information within cells and 
communication between cells [2]. The article by Kambe et al. summarizes the various zinc 
transporters, i.e., the family of zinc transporters (ZNTs) and Zrt- and Irt-like proteins (ZlPs), and 
discusses the roles of these transporters in the early secretory pathway [3]. Further, Takagishi et al. 
review an update of zinc transporters and zinc signaling. They focus on the recent progress in 
determining the roles of SLC39A/ZIP family members in vivo [4]. Sunuwar et al. focuses on ZnR/
GPR39, a G-protein coupled receptor that senses changes in the concentration of extracellular zinc, 
reviewing its physiological role in skin and the colon, as well as its implication in cancer [5]. In 
addition, Subramanian Vignesh and Deepe provide an overview of the current understanding of a 









From a viewpoint of physiology and medicine, Takeda and Tamano describe the impact of 
synaptic zinc signaling on cognition and its decline [7]. Portbury and Adlard highlight the role of 
zinc signaling in the central nervous system, and its potential implications in brain diseases such 
as cognitive decline, depression, and Alzheimers disease [8]. Fukunaka and Fujitani emphasize the 
contribution of zinc homeostasis on the pathophysiology of metabolic diseases, by focusing on the 
zinc transporters ZnT8 and ZIP13 [9]. Maywald et al. review the critical role of zinc homeostasis 
in the immune system. In addition, they describe the molecular mechanisms and targets that are 
affected by altered zinc homeostasis and illustrate several types of zinc signaling that are involved 
in the immune system [10]. Pyle et al. describe the possible molecular relationship between 
tuberculosis and zinc homeostasis. They also review the protective role of the zinc transporter ZIP8 
in macrophages in Mycobacterium tuberculosis infection [11]. Turan and Tuncay review the current 
understanding of the physiological role of zinc signaling on heart functions and related diseases [12]. 
Cherasse and Urade suggest the potent connection between zinc status and sleep, and investigate its 
molecular mechanisms [13].
In addition to the reviews mentioned above, five research articles are included in this special 
issue. Hence, we must emphasize that this special issue will provide new insights into the role of 
zinc signaling, mediated by zinc transporters and zinc-binding proteins, in health and disease from a 
molecular to a physiological level. We hope that this will present our readers with novel opportunities 
to raise new ideas and connections to resolve persisting questions in the future. Finally, we would 
like to express our heartfelt gratitude to all of the authors and referees for their tremendous efforts 
in supporting this special issue. Without their valuable assistance, we would not have had even a 
glance of this timely and successfully publication with its useful updates on zinc signaling biology.
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Abstract: From 18 to 22 June 2017, the fifth biennial meeting of the International Society for Zinc
Biology was held in conjunction with the final dissemination meeting of the Network for the Biology
of Zinc (Zinc-Net) at the University of Central Lancashire, Cyprus campus. The meeting attracted
over 160 participants, had 17 scientific symposia, 4 plenary speakers and 2 poster discussion sessions.
In this report, we give an overview of the key themes of the meeting and some of the highlights from
the scientific programme.
Keywords: zinc; conference report; Zinc-Net; ISZB; COST Action
1. Introduction
The meeting was jointly hosted as a partnership between the International Society for Zinc Biology
(ISZB) and the Network for the Biology of Zinc (Zinc-Net), a European Union Framework Programme,
Horizon 2020-funded Collaboration in Science and Technology (COST) Action. It was the fifth biennial
meeting of the ISZB, which is now celebrating a decade of achievements. The society was established
to allow unique interactions between scientists interested in zinc biology and has been successful in
fostering links between the chemical, biological and clinical fields of zinc biology [1]. Zinc-Net was
launched in 2013 and has been funded for 4 years. It is comprised of over 200 scientists from 26
different European countries, as well as Australia. The overall mission of the network was to create
a multi-disciplinary research platform that brings together expertise from research groups throughout
the COST countries and beyond, as well as to stimulate and accelerate new, innovative and high-impact
scientific research [2]. The clear synergy between these two organisations created a stimulating forum
for lively scientific debate over the 5 days of the conference.
2. Meeting Overview
2.1. Zinc-Net Celebration Symposium
The meeting was the final major event of the 4 year COST Action, Zinc-Net. Therefore, it began
with a symposium that celebrated the achievements of Zinc-Net, with presentations from each
of the theme leaders in Chemical Biology, Biomarker Discovery and Clinical Coordination. A key
note lecture by Professor Janet King (Chair of the International Zinc Nutrition Consultative Group,
Children’s Hospital Oakland Research Institute, Oakland, CA, USA), and Professor Nicola Lowe
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(Chair of the Zinc-Net Management Committee, University of Central Lancashire, Preston, UK),
with comments by Professor Mukhtiar Zaman (Lady Reading Hospital, Khyber Pakhtunkhwa,
Pakistan), placed zinc research into a global context, highlighting the extent of zinc deficiency
worldwide, with the highest prevalence of over 40% of the population in low- and middle-income
countries. A display of posters showcasing some of the short-term scientific missions
(laboratory exchange visits) that had been undertaken by early career researchers in the network
were available to view [3].
2.2. Keynote Lectures
The first keynote lecture of the main conference was given by the Founding President of the
ISZB, Professor Glen K. Andrews (University of Kansas School of Medicine, Kansas City, MO, USA).
He was introduced by the current president, Dr. Kathryn Taylor (Cardiff University, Wales, UK).
Professor Andrews’s lecture recognised the contributions of key scientists whose research was of
fundamental importance to the advancement of the field of zinc. These included the discovery of the
metallothionein (MT) and the recognition that these proteins have a wide species distribution and
are inducible by metals, the elucidation of a zinc-sensing mechanism of transcriptional regulation
of MT genes, and the discovery of the Slc30a (ZnT) and Slc39a (ZIP) families of zinc transporters.
These findings informed further studies of the mechanisms of zinc-dependent regulation of the
ZIP proteins and their important physiological role. Each of these discoveries led to thousands of
subsequent research publications and provided the foundation for much of the current research into
the biology of zinc [4].
The second keynote lecture, by Professor Hidenori Ichijo (Graduate School of Pharmaceutical
Sciences, U-Tokyo, Japan) discussed the physiological and pathophysiological roles of copper/zinc
superoxide dismutase (SOD1) under conditions of zinc deficiency. The importance of understanding
the molecular mechanism of zinc homeostasis in living organisms is highlighted by zinc’s essentiality
in a wide variety of biological processes and the consequences of zinc deficiency in human health
and disease. Ichijo’s group recently reported that SOD1 is one of the key factors to regulate cellular
zinc homeostasis under zinc-deficient conditions. In zinc deficiency, SOD1 adopts an abnormal
conformation and evokes endoplasmic reticulum (ER) stress through specific interaction with Derlin-1,
a component of ER-associated degradation (ERAD) machinery, leading to the restoration of cellular
homeostasis. Intriguingly, they found that wild-type SOD1 under zinc-deficient conditions and over
100 types of amyotrophic lateral sclerosis (ALS)-linked SOD1 mutants share the common aberrant
conformation, suggesting that wild-type SOD1 has a potential to exert neuronal toxicity under stress
conditions. Professor Ichijo’s group have performed genome-wide siRNA screening to identify
mediators of the conformational alteration in wild-type SOD1 under conditions of zinc deficiency,
and he discussed the physiological and pathophysiological implications [5].
Professor Stephen J. Lippard’s (Massachusetts Institute of Technology, Cambridge, MA, USA)
keynote discussed the role of zinc probes as tools in the study of mobile Zn2+; these serve as signaling
agents in a number of biological processes, including neurotransmission. A new class of hybrid
fluorescent sensors that facilitate the tunability of small molecule probes and the targetability of
protein-based sensors was described, which can detect exogenous Zn2+ and endogenous mobile Zn2+
in response to reactive nitrogen species in live cells. The functional role of Zn2+ in the olfactory system
was discussed, including results obtained from fluorescence imaging and electrophysiology recordings
of live animals exposed to a variety of odours. Synaptically released mobile Zn2+ attenuates excitatory
postsynaptic currents carried by N-methyl-D-aspartate (NMDA) receptors in the olfactory bulb, thus
attenuating sensory input gain [6].
Despite increasing access to sufficient food for all and significant achievements in reducing global
hunger, micronutrient deficiencies (“hidden hunger”), especially zinc deficiency, still remain a major
public health problem in the world. An inadequate daily intake of zinc is the major reason for the
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with very low concentrations of bioavailable zinc. In the final keynote lecture, Professor Ismail
Cakmak (Sabanci University, Istanbul, Turkey) described several agricultural strategies that are known
to improve grain-zinc concentration, including conventional plant breeding, genetic engineering,
and plant nutrition-based agronomy. In recent years, there has been an increase in the number of
published reports showing that the maintenance of the high pool of zinc in the leaf tissue during
the reproductive growth stage is required to achieve desirable concentrations of zinc in grains for
human nutrition. Field experiments conducted in different countries under the HarvestZinc project [4]
on maize, wheat and rice demonstrated that a foliar spray of zinc and other micronutrients such
as iodine and selenium results in substantial increases in concentrations of those micronutrients,
in both the whole grain and the endosperm. In addition, foods made from cereal grains that have
been biofortified agronomically with micronutrients, such as bread and cookies, also had elevated
micronutrient concentrations, evidencing the stability of the micronutrients in products. Consuming
agronomically biofortified foods is expected to result in a significant contribution to human nutrition
with the potential to impact on micronutrient deficiencies worldwide [7].
3. Research Themes of the Meeting
The 17 scientific symposia that comprised the meeting can be grouped into three main themes:
zinc in health and disease, zinc signalling, and zinc proteins and transporters. A summary of each is
reported below and further up-to-date information on key topics in zinc research has been published
by Rink [8] and zinc signalling by Fukada and Kambe [9].
3.1. Zinc in Health and Disease
The role of zinc in immunity and infectious disease was explored and debated. Zinc is recognized
as an important metal ion in relation to nutritional immunity, a process by which the immune system
withholds micronutrients from potential invaders. An understanding of the underlying mechanisms by
which host immune defences manipulate metal levels to attack invading microbes by metal-restriction
and/or exposure to metal-excess may have considerable clinical significance. Giving Campylobacter
jejuni (Cj), a common cause of acute human gastroenteritis, as an example of an important foodborne
pathogen that targets different host niches with different metal challenges, how Cj adapts to different
metal stresses within its different hosts was described. Exploring the functions and mechanisms of
the zinc handling systems in Campylobacter will expand our understanding of how they contribute
to infections. Zinc deficiency is linked to an increased susceptibility to bacterial infection, such as
Streptococcus pyogenes (Group A Streptococcus—GAS), a Gram-positive human pathogen responsible
for a wide spectrum of diseases ranging from pharyngitis and impetigo, to severe invasive diseases
including necrotizing fasciitis and streptococcal toxic shock-like syndrome. It was demonstrated that
zinc homeostasis is an important contributor to GAS pathogenesis and innate immune defence against
infection. Strategies to manipulate zinc homeostasis in order to reduce GAS infection were discussed.
Zinc-based therapeutics were explored in relation to cognitive disorders, cancer and
cardiovascular disease. One of the critical cell processes that becomes dysregulated with age and
also in disease, and which participates both directly and indirectly in cognitive function, is metal
homeostasis and the neurochemistry of metalloproteins. This is particularly true for zinc, for which
10–15% of brain zinc exists in a chelatable form, primarily within synaptic vesicles at glutamatergic
synapses, highlighting its potential importance in synaptic plasticity/cognition. Zinc dyshomeostasis
has been implicated in dementia and autism spectrum disorders. Taken together with other supporting
data in the literature, this demonstrates a critical role for zinc in cognitive function, and that it may be
a therapeutic target for improving functional outcomes in health and disease.
A significant body of evidence has shown that zinc plays important roles in metabolism and
the development of metabolic disease. Zinc has a role in insulin secretion, insulin signalling and
subsequent glucose metabolism. Low zinc status also promotes inflammatory stress, and using
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enhanced by marginal zinc deficiency. Increased intestinal permeability plays an important role in the
onset of a variety of chronic inflammatory conditions and metabolic diseases, and zinc has been found
to improve gut barrier integrity in vitro. In humans, a low-zinc diet is associated with a decrease in
fatty acid desaturase enzyme 1 (FADS1) activity, lowered arachidonic acid incorporation into lipid
subclasses, and an increase in DNA strand breaks, suggesting that FADS1 activity and DNA strand
breaks respond to small changes in dietary zinc that may be provided by food fortification programmes.
3.2. Zinc Signalling
The roles of zinc in modulating cellular function in various disease states emerged as a key
theme of this meeting. These included new advances in understanding how disrupted Zn2+
homeostasis in chronic heart failure is linked to dysregulated intracellular Ca2+ responses, resulting
in leakage of Ca2+ from the sarcoplasmic reticulum in cardiac tissue. Research describing the
pathophysiological role of zinc in neurological disorders provided insights into possible novel
therapeutic approaches. Examples included the role of zinc in triggering neuronal apoptosis and
blocking optic nerve regeneration after injury, as well as the role of extracellular zinc in the modulation
of the cytokine-induced pro-inflammatory response following brain ischaemia, which may contribute
to impaired memory function. New research examining the pathophysiological role of extracellular
Zn2+ in cognitive decline with aging was received with interest. Highlights within this theme also
included new understandings of the molecular mechanisms for maintaining cellular zinc homeostasis
and the use of novel zinc sensors, which can be activated by UV light or enzymes for the study of the
dynamics of cellular “free” zinc.
3.3. Zinc Proteins and Transporters
One of the most exciting areas of research over the last decade has been the discovery of the
zinc transporter families ZIP and ZnT and the elucidation of their role in the control of cellular zinc
homeostasis. Within this theme, the relationship between the loss of ZnT2 function within paneth
cells and intestinal dysbiosis was discussed. This research revealed that genetic polymorphisms
that influence the ZnT2 transporter function might lead to clinically relevant shifts in the intestinal
microbiome of preterm infants, which is a fascinating new area of research relating to infant nutrition.
Similarly, ZIP7 plays a critical role in ER function within connective tissue cells, such that a loss of the
function of this transporter results in inhibited cell proliferation, preventing proper dermis formation.
Highlights within this theme included potential new therapies for the treatment of cancer, linked to the
inhibition of mitosis through the selective blocking of ZIP transporters. Additionally, the unexpected
association between genetic mutations in ZIP13, zinc homeostasis and beige adipocyte biogenesis may
contribute to new therapies for obesity and metabolic syndrome.
Other zinc binding proteins also shared the limelight in this theme. Notably, the influence of
zinc binding on protein folding and aggregation may have deleterious consequences if intracellular
zinc homeostasis becomes imbalanced. Also discussed was the mechanism of the activation of the
zinc-requiring ectoenzymes, defined as secretory, membrane bound, and organelle-resident enzymes,
which play pivotal roles in numerous biological responses. One such example is tissue non-specific
alkaline phosphatase, which is activated in a two-step process involving ZnT transporters.
4. Focus on Early Career Researchers
The conference was attended by over 160 scientists, including early career researchers (ECRs),
many of whom presented posters in one of the two evening poster sessions. Both Zinc-Net and
ISZB place a strong emphasis on providing training opportunities, capacity building and support for
the next generation of zinc biologists. In a competitive process, ECRs were invited to present their
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5. Final Remarks
Much of the research presented at this meeting had never been presented or published before.
The meeting had a strict embargo on the photographing of slides without the presenters’ permission,
and the abstracts, although made available to all participants, were not to be published in proceedings
of the meeting. However, it was gratifying to observe that the atmosphere within the meeting was
extremely open and collegiate, with new collaborations initiated and many animated discussions
during the social, networking and poster events. The zinc research community is clearly thriving, and
it is exciting to be a part of it.
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Abstract: In the last decade, we witnessed discoveries that established Zn2+ as a second major
signalling metal ion in the transmission of information within cells and in communication between
cells. Together with Ca2+ and Mg2+, Zn2+ covers biological regulation with redox-inert metal ions
over many orders of magnitude in concentrations. The regulatory functions of zinc ions, together
with their functions as a cofactor in about three thousand zinc metalloproteins, impact virtually all
aspects of cell biology. This article attempts to define the regulatory functions of zinc ions, and focuses
on the nature of zinc signals and zinc signalling in pathways where zinc ions are either extracellular
stimuli or intracellular messengers. These pathways interact with Ca2+, redox, and phosphorylation
signalling. The regulatory functions of zinc require a complex system of precise homeostatic control
for transients, subcellular distribution and traffic, organellar homeostasis, and vesicular storage and
exocytosis of zinc ions.
Keywords: zinc; homeostasis; signalling; regulation
1. Zinc in Enzymatic Catalysis, Protein Structure, and Regulation of Proteins
It is ingrained in our understanding of the scientific literature that zinc has catalytic, structural,
and regulatory functions in proteins. However, while the first two functions are well-established,
validated examples of regulatory molecular functions are much more difficult to pinpoint. Catalytic and
structural functions occur in an estimated 3000 human zinc metalloproteins, a number that translates
into about every tenth protein being a zinc protein [1]. This myriad of functions demonstrates the
major role of zinc in cell biology [2], which is now reinforced by the emerging roles of zinc ions in
cellular regulation [3]. Many earlier postulates about regulatory functions of zinc in proteins are
based on outdated premises, were not linked to specific molecular actions in physiological events,
and involved zinc/protein interactions that occur with micromolar affinities. Compelling arguments
put such interactions outside the physiological range of cellular zinc ion concentrations. They are based
on experimental results and the requirement to control zinc in a range of concentrations that avoids
interference with the biochemistry of the other essential metal ions. Measurements of zinc binding
constants of zinc proteins, and total and available (“free”) zinc concentrations now provide a different
view of the physiological significance of zinc/protein interactions. Affinities of structural and catalytic
zinc in cellular proteins are in the picomolar to femtomolar range, and at present, evidence is lacking
that these sites are regulated via zinc binding and release [4,5]. As a consequence of this high affinity,
the “free” zinc ion concentration is in the picomolar range, as shown experimentally, despite the total
cellular zinc concentration being in the range of hundreds of micromolar [6]. This large difference
between total and “free” zinc is a distinctive chemical property of zinc in biology [7]. It rules out low
affinity zinc binding sites as being physiologically significant for cellular regulation, and suggests that
regulatory sites of zinc in cellular proteins must have binding constants commensurate with these
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chemical and biological constraints. In fact, a couple of examples of zinc inhibiting enzymes with
picomolar affinity are now known [8–10]. Also, it was reported about 50 years ago that picomolar
concentrations of zinc (II) ions inhibit phosphoglucomutase by replacing the magnesium ion required
for activity [11]. The authors discussed the physiological significance of the finding, but their reports
received very little, if any recognition in the field of metallobiochemistry [12]. In terms of its rather
high affinity for binding sites, Zn2+ is different from Mg2+ and Ca2+, and makes an additional range
available for biological regulation using all three redox-inert metal ions (Figure 1). What is needed for
regulation is a change in the concentration of “free” zinc ions (zinc transients). This article discusses
how such changes can be effected, and controlled, in a zinc-buffered biological environment. In the
cell, zinc transients occur from a basal level of tens to hundreds of pM free zinc (about 0.2 mM total
cellular zinc). They leave a gap of three orders of magnitude before calcium transients can set in,
which are above a basal level of 100 nM free calcium (about 2 mM total cellular calcium). Like calcium,
zinc needs a system to control these transients, and is cytotoxic if not properly controlled. Regarding
magnesium, recently described circadian rhythms of total magnesium concentrations in cells provide
strong evidence for regulatory functions [13].
Figure 1. Biological regulation with the three redox-inert metals ions: Mg2+, Ca2+, and Zn2+.
Zinc extends the range of regulation with metal ions. The regulatory function of each metal ion
is in a specific range of concentrations, thus avoiding overlap with the signalling functions of the other
metal ions. However, there are interactions among the metabolism of the metal ions.
2. Control of Cellular Zinc Homeostasis
Knowledge about the proteins that control cellular zinc now provides a basis for understanding
how zinc ions can regulate cellular processes. In humans, at least twenty-four membrane transporters
(14 Zrt, Irt-like proteins (ZIP) zinc importers and 10 zinc transporters (ZnT) zinc exporters),
about a dozen metallothioneins (MTs), and a zinc-sensing transcription factor, metal-response element
(MRE)-binding transcription factor-1 (MTF-1), are involved in controlling cellular zinc [14]. A few of
these transporters have a role—or an additional role—in Mn2+ and Fe2+ transport, while MT also has
a function in copper metabolism [15]. The number of membrane transporters is much higher than
what one would expect for simple control of homeostasis of a metabolite. Cellular iron, for example,
is essentially controlled by one importer (DMT1) and one exporter protein (ferroportin). It turned
out that many additional transporter proteins are necessary for the subcellular distribution of zinc,
the control of organellar zinc homeostasis, and the generation and control of zinc transients. Most of
the ZIP transporters have been found on the plasma membrane, but some have roles intracellularly.
The large number of ZIP transporters on the plasma membrane is likely a reflection of the importance
of securing the correct supply of zinc for the cell under various conditions. Remarkably, zinc ions
accumulate in cellular vesicles for storage and/or release, and in secretory vesicles for exocytosis.
The occurrence of zinc ions in cellular vesicles is a characteristic feature of cellular zinc biology,
and resolves the long-standing issue why a storage protein akin to ferritin, which stores several
thousand iron ions in its core, was never found for zinc. There is some ambiguity in the nature
of some of these vesicles. Vesicular stores that accumulate zinc added to cultured cells have been
called zincosomes [16]. Others are secretory vesicles from which zinc ions are exocytosed for various
purposes. These vesicles differ from intracellular vesicular/organellar stores of zinc, as ZIP transporters
do not seem to counteract the action of the ZnT transporters (ZnT2, 3, and 8) loading these vesicles
with zinc ions. The “lethal milk” mouse has a truncated form of ZnT4, and presents with low zinc
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ZnT4–7 are involved in loading zinc-requiring ectoenzymes with zinc at the trans Golgi network
(TGN)/early secretory pathway [18]. Zinc is also translocated to lysosomes, mitochondria, and nuclei,
but very little is known about the transporters involved. Zincosomes and related vesicles require
additional components for control of zinc homeostasis in order to link cellular uptake and store loading.
Thus, there is an at least three-tiered system for the homeostatic control of cellular zinc: import and
export through the plasma membrane, including cytosolic binding proteins such as metallothioneins
and sensors such as MTF-1 (tier 1); intracellular storage and release of zinc generating zinc transients
(tier 2); and allocation of zinc for exocytosis in some cells, somehow linked to re-uptake (tier 3)
(Figure 2). It appears that a hierarchy is associated with these three tiers, namely, that the capacity
of loading vesicles is compromised, first, under zinc deficiency, as suggested by investigations with
cultured cells [19].
Figure 2. Control of cellular zinc homeostasis including regulation of zinc and functions of zinc in
regulation. (1) Tier 1: cellular homeostasis through import and export through the plasma membrane
and subcellular distribution; (2) Tier 2: vesicular storage and/or release of zinc associated with zinc
importers and exporters on the vesicles; (3) Tier 3: loading of secretory vesicles with zinc associated
only with zinc exporters on the vesicles. Regulatory functions of zinc require additional complexity
in homeostatic control, namely, molecules that control the spatiotemporal fluctuations of zinc ions
in a metal-buffered environment, above the fluxes in re-distributing zinc for supply as a cofactor in
catalytic and structural sites of proteins. With this distinction, we assume that the functions of bona
fide zinc proteins are not regulated by zinc coming on and off from their catalytic and structural sites.
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There are at least three pathways for transient release of zinc ions within and from cells.
The proteins participating in the control of homeostasis (ZIPs, ZnTs, metallothioneins, and MTF-1)
restore the steady-state after the transients have occurred (Figure 3). A breakthrough that triggered the
discovery of these pathways, and the functions associated with them, came with the synthesis and
availability of fluorescent chelating agents for measuring zinc ions, similar to the ones employed in the
field of calcium biology to measure calcium fluxes [20].
Figure 3. Cellular zinc transients and their control. Several pathways generate rapid zinc transients
(zinc signals) with biological responses on various time scales. The amplitude of these zinc signals is
about a few nanomolar globally, from picomolar basal “free” zinc ion concentrations, but may be higher
in microdomains. Proteins involved in the control of zinc homeostasis serve as mufflers (ZIPs, ZnTs)
and buffers (MTs) to restore the steady-state. A much slower process (arrow) leads to an overall
change of the zinc-buffering characteristics of the cell, establishing different basal levels of “free” zinc
ion concentrations.
3. The Paradigms for Using Zinc Ions in Information Transfer/Regulation/Communication
A long train of discoveries followed the original observation of a histochemically stainable pool of
zinc ions in the brain over half a century ago [21]. It culminated in the demonstrations that (i) the zinc
ions localize to presynaptic vesicles (boutons) of specialized neurons; (ii) the zinc transporter ZnT3
loads the vesicles with zinc; and (iii) the zinc ions are exocytosed upon electrical stimulation of such
neurons. Subsequently, three types of “zinc signals” in the brain have been defined: the synaptic signal,
described as a type of chemical transmitter/neuromodulator; the transmembrane signal, where the
zinc ions are translocated through the plasma membrane; and the intracellular zinc signal, with release
of zinc ions from a source within cells [22]. All of these signals have now been shown to have
physiological roles, not only in the brain, but importantly, in many other tissues, thus establishing at
least three general pathways for the generation of zinc ion transients.
3.1. Release of Zinc Ions from Cells by Vesicular Exocytosis
Every cell has the capacity to export an excess of zinc. It appears that zinc is sequestered
first in cellular vesicular stores, and that export from the cell occurs only after the capacity of the
stores is exhausted. However, a number of cells, including neurons with glutamatergic/zincergic
synaptic vesicles, have the additional capacity to secrete zinc ions by calcium-dependent exocytosis for
a specific purpose [23,24]. In neurons, in addition to postsynaptic effects, zinc has a presynaptic effect,
re-entering the neuron and affecting phosphorylation signalling via inhibition of protein tyrosine
phosphatases (PTPs) [25,26]. In cells secreting zinc via exocytosis, there is an additional demand for
zinc, as zinc brought into the secretory vesicles can reach relatively high concentrations (about mM) and
needs to be replenished after secretion. High zinc concentrations have a function within the vesicles,
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endocrine pancreas or inhibiting proteases in zymogen granules of acinar cells in the exocrine pancreas.
Zinc ions are co-secreted from these vesicles, and paracrine, autocrine, and even endocrine roles for
the zinc ions [Zn2+]e have been suggested, e.g., in β-cells, in addition to their function in preventing
amyloidosis of the secreted amylin and insulin [27]. For an endocrine effect, proof is lacking that the
secreted cellular zinc increases the rather high total zinc concentration of blood sufficiently, in order
for the liver to detect a zinc signal emanating from the pancreas [28]. It would seem that a specific
complex of zinc needs to carry the information of the endocrine signal. Zinc-secreting cells also include
prostate epithelial cells (zinc in prostate fluid), mammary gland epithelial cells (zinc in milk), intestinal
Paneth cells, cells of the immune system (mast cells, granulocytes, neutrophils), and platelets. It is not
clear whether zinc is the only cargo in any of these exocytotic vesicles. In fact, it is highly unlikely
because secretory vesicles are biochemically quite complex, as shown for the dense granules of β-cells,
which contain more than 300 different proteins [29]. It is also not clear how zinc is made available in
the cytosol, where the concentration of free zinc is only picomolar, for loading the vesicles, and what
the chemical forms of zinc are, in addition to protein-bound zinc in the vesicles.
Zinc in secretory vesicles → Ca2+-dependent exocytosis → increase of [Zn2+]e → multiple targets
Another important biological event is the release of zinc ions from fertilized mouse oocytes [30].
These “zinc sparks” are preceded by calcium oscillations after fertilization/chemical-induced activation
of the oocyte. The secreted zinc ions have a role in hardening the zona pellucida (glycoprotein matrix)
to avoid polyspermy—yet another function of the secreted zinc on proteins.
3.2. Intracellular Release of Zinc Ions through Reactive Species Modifying Proteins
This pathway is based on the recognition that zinc coordination environments with thiolate
(cysteine) sulphur, such as in MTs, are redox-active, despite zinc ions being redox-inert in biology.
Oxidation of the sulphur ligand donor controls the dissociation of zinc ions [31]. It was the first
pathway to show a way of releasing zinc intracellularly and increasing the free zinc ion concentrations,
[Zn2+]i, overcoming the paradox of how zinc can be made available when it is bound with such high
affinity to proteins. The list of oxidants is extensive, and includes reducible sulphur and selenium
compounds [32,33]. In addition, reactive species such as nitric oxide, and electrophiles such as
carbonyls react with the sulphur ligand donor [34]. The release of zinc has been shown in many
cellular systems, e.g., nitric oxide signals target MTs and release zinc [35,36], and cell-permeable
disulphides increase the available cellular zinc ion concentration [37]. The majority of investigations
has addressed pathophysiological (oxidative stress releasing zinc), pharmacological (drugs releasing
zinc), and toxicological (toxins releasing zinc) events. The released zinc ions first have a cytoprotective,
and then a cytotoxic effect [38]. Many of the agents investigated react with MTs with concomitant
release of zinc, which then activates MTF-1 to induce gene expression. In this pathway, MT is a signal
transducer, generating zinc signals in response to redox signals. The physiological significance seems
to be that signalling with many growth factors generates reactive species that can then generate cellular
zinc transients [Zn2+]i for the purpose of modulating signal transduction.
Reactive species/redox signalling → MTs → increase of [Zn2+]i → multiple targets and
MTF-1-dependent gene expression
3.3. Intracellular Release of Zinc Ions through Channels of Vesicular Stores
It was summarized, at the turn of the millennium, that zinc has functions at all levels of cellular
signalling, and that growth factor signalling affects intracellular zinc re-distribution and functions [39].
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A key discovery that expanded the possibilities of zinc as a signalling ion was that cross-linking
of the high affinity immunoglobulin E receptor (Fcε receptor I) in mast cells causes release of zinc ions
intracellularly from the perinuclear area, including the endoplasmic reticulum (ER). The response
was dependent on calcium influx, caused mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK) activation, and was called a “zinc wave”. While the targets of zinc
were not identified, it demonstrated that zinc serves the role of a second messenger in modulating the
signalling of plasma membrane receptors [40].
Another key observation was that zinc ions are released from an ER store through a specific
pathway that includes the casein kinase 2-mediated phosphorylation and opening of the ZIP7
channel [41]. The released zinc affects phosphorylation signalling, and it appears to do so primarily by
inhibiting PTPs [42].
Growth factor signals → casein kinase 2 (CK2) → ZIP7 phosphorylation → increase of [Zn2+]i →
inhibition of protein tyrosine phosphatases (PTPs) and enhanced phosphorylation signalling
4. Targets of Zinc Signals (Sensors, Effectors, and Stimuli)
Zinc binds to and stimulates a zinc-sensing receptor (ZnR) that triggers intracellular calcium
release [43]. This receptor turned out to be the G-protein coupled receptor GPR39 [44–46],
which activates inositol triphosphate (IP3) signalling and calcium release. What is not resolved,
as yet, is where the zinc signal originates from, i.e., how a zinc signal can occur in a zinc-buffered
extracellular milieu, whether it is part of the exocytotic pathway of zinc ions, and whether it originates
from the same cell or another cell. GPR39 is an orphan receptor, and it is not clear whether or not zinc
is the primary agonist or merely a modulator.
[Zn2+]e → GPR39 → IP3 → increase of [Ca2+]i → phosphorylation signalling
(ERK/protein kinase B (AKT))
With the exception of ZnR/GPR39 and activation of MTF-1, the investigated effects downstream
of the signalling zinc ions are, in most cases, not the zinc-dependent proteins themselves.
Therefore, the direct molecular targets of the signalling zinc ions remain poorly defined. This is
an important missing piece of information that is affecting the wider acceptance of Zn2+ as a second
messenger, and so is the issue in which chemical form zinc ions transmit the signal, in particular,
since a zinc-binding messenger protein, such as the calcium signal transducer calmodulin, has not
been identified. In none of the cases of zinc signalling is the chemical identity of the zinc signal
known. It is an important issue as the bioinorganic chemistry of zinc is quite different from
that of calcium, and the term “free” does not apply in the same way. Any ligand of zinc could
impact the specificity of the zinc signal, and thus, its information content [7]. Links between
signals and effectors (targets) have been established, though. In neuronal zinc signalling, the NMDA
(N-methyl-D-aspartate) receptor, a calcium channel, is a well characterized target. Zinc inhibits this
receptor with nanomolar affinities at a structurally characterized site [47]. In the case of GPR39, calcium
signalling is a downstream event of the zinc signal, too. Calcium signals can also be upstream of
the zinc signal, e.g., when Ca2+/calmodulin activates nitric oxide synthase, and nitric oxide releases
zinc from proteins. The intracellularly released “zinc wave” modulates phosphorylation signalling.
Here, it seems that protein tyrosine phosphatases (PTPs) are targeted. Their inhibition enhances the
phosphorylation signalling, i.e., the effect of kinases. PTPs are not described as metalloproteins, but zinc
inhibits them with picomolar to nanomolar affinities with a specific mechanism that is independent of
their redox modulation [48]. In the case of ZIP7 channel-released zinc, the phosphorylation signal is
upstream and downstream of the zinc signal. There are other targets of zinc transients, and we are far
from having a complete list of them [10]. The zinc signals downstream of redox signals seem to be
a response to redox or carbonyl stress, and are linked to repair and defence pathways, and to initiating
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greater number of targets, depending on the intensity of the stress signal, and hence, the amplitudes
of the zinc signal. Here, too, like in calcium and phosphorylation signalling, zinc transients/signals
are upstream and downstream of redox effects, as zinc ions have pro-antioxidant and pro-oxidant
effects, depending on their intracellular concentrations [49]. The observation of both upstream and
downstream effects of zinc ion signals in signal transduction by calcium, redox, and phosphorylation
signalling, suggests that the regulatory function of zinc signals is one of feedforward or feedback on
these pathways and other pathways [50,51]. Zinc inhibition of phosphodiesterases controlling cAMP
and cGMP signalling have been described, expanding this network of zinc regulation even further [39].
It appears that zinc, as the redox-inert metal ion with the highest affinity, is well suited for a regulatory
position higher up in the hierarchy.
It remains crucial to quantitate the amplitudes and duration of zinc signals, and match them
to the affinities of targets of zinc, in order to tease apart the biological significance of the signalling
effects. Proteins targeted by transient zinc signals need to be differentiated from proteins affected
by long-lasting changes in cellular zinc concentrations. In one case, the effect of the signal is readily
reversible, while it will be long-lasting when the cell is brought into a different physiological state.
Importantly, such a transition does not necessarily require a change in total zinc concentrations,
but a change in the zinc buffering capacity, such as an increase or decrease in the concentrations of
MTs. The very high affinity of some PTPs for zinc suggests that they are inhibited tonically, and then
activated [9]. It is not known whether this occurs via a general mechanism, with generation of higher
chelating capacity of the zinc-buffering species, or by specific molecules that bind to PTPs and remove
the inhibitory zinc ion.
5. Genomic Effects and the Roles of Metallothioneins (MTs) and MTF-1 in Buffering and
Muffling Zinc
Zinc signalling and zinc regulation are two different aspects. The discussed pathways of
non-genomic zinc signalling eventually lead to genomic (transcriptional) responses via their effects
on classical signal transduction pathways. These responses are part of zinc regulation. MTF-1 can
sense zinc signals directly and induce gene transcription. More than 1000 genes have cis-acting metal
response elements (MREs), but only 43 were identified as putative MTF-1 targets [52,53]. Among these
targets, about 50% are transcription factors, and 19 are genes involved in development, demonstrating
the role of zinc in developmental programmes as genetic ablation of MTF-1 is embryonically lethal
in the mouse. Other target genes are γ-glutamate-cysteine ligase heavy chain needed for glutathione
biosynthesis, and the zinc exporter ZnT1, and most, but not all MTs. In addition to the constitutively
expressed ZnT1 and MT proteins buffering zinc signals/transients, the induced ZnT1 and MT proteins
can adjust the zinc buffering capacity, and hence, the free zinc ion concentrations (Figure 4). Two effects
are responsible for such adjustments. One is zinc buffering by MTs, and the other is a process called
muffling, which refers to transporting metals into and out of the cytosol, and is a typical component
of biological buffering mechanisms [54]. Knockdown of MTF-1 results in more genes becoming
zinc-responsive and in unmasking repression of transcriptional responses of genes that have a zinc
transcriptional regulatory element (ZTRE). It suggests that MTF-1 is high up in a hierarchy of sensors,
and that its control of the expression of ZnT1 and MTs buffers the transcriptomic response to zinc [55].
A postulated mechanism of how MTF-1 functions is that a 10–50-fold difference in affinity of its zinc
fingers is used for zinc sensing [56]. This direct effect of zinc on gene expression, via the zinc sensor
MTF-1, is in addition to its indirect effects as a structural cofactor in hundreds of transcription factors
with zinc fingers and related motifs.
The biochemistry of both MTF-1 and MTs shows that the control of zinc homeostasis interacts
with numerous other cellular systems. A host of factors induce MT expression, not only with the
purpose of sequestering any surplus of zinc, but also for providing enough metabolically available zinc
for cellular processes. The rapid zinc binding, the mechanisms of releasing zinc, and the affinities of
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with an understanding of both the quantitative aspects of zinc metabolism and the complexity of
cellular homeostatic control of zinc, the role of the particular zinc/thiolate cluster chemistry of MTs in
zinc metabolism, believed to be elusive, is becoming evident [15].
MT (buffer)
Zinc binding









Figure 4. Genomic effects as a consequence of sensing zinc signals. MTF-1 induces the expression of the
zinc exporter ZnT1 (muffler) and MT (buffer), which adjust the cellular zinc buffering capacity, and other
proteins. In addition, constitutively expressed zinc transporters and MTs control the zinc signals.
6. Definition of Signalling/Regulation with Regard to Zinc
It was the intent of this short account to introduce the paradigms of zinc signals and zinc signalling
for some of the regulatory roles of zinc. The terms “signals” and “signalling” have been applied to
describe different scenarios where zinc (II) ion transients are detectable. With some ambiguity in the
use of the terms, the credibility of the field will suffer without a clear definition of the role of zinc in
cellular signalling.
First, the terms zinc signals and zinc signalling should be used only where zinc ions participate
as messengers in cellular signalling. The criteria for a second messenger, namely that changes of
a short-lived metabolite—and a mechanism to terminate the response—lead to a rapid alteration
of the activity of (an) enzyme(s), are fulfilled in the above pathways. Of course, with metal ions,
the metabolite itself is not short-lived—the availability of the metal ion controls the signal. As pointed
out in calcium biology, where IP3 is the second messenger that releases calcium from the ER, calcium
is actually the third messenger. This distinction is rarely made, and calcium is generally referred to
as a classical second messenger. In the same line of thought: zinc will be the fourth messenger in
the signalling cascade when the calcium signal is upstream of the zinc signal. The other signalling
functions discussed refer to extracellular zinc ions. Here, Zn2+ is a first messenger, a stimulus like
a hormone binding to a receptor, when it binds to GPR39. For such an action, a zinc signal must be
generated in the extracellular environment which has a buffered steady-state concentration of zinc.
Second, the terms should be reserved for transient physiological signals and not be used for
non-physiological concentrations of zinc that are the result of an imbalance or a breakdown of
homeostatic control. The two situations are part of a spectrum of actions, and can be distinguished
only when it is known that the homeostatic system is unable to cope with the zinc concentrations.
Third, like calcium signals, zinc signals have spatiotemporal characteristics with relatively short
transients. I suggest that the terms “late” zinc signals and signalling should not be used because they
are a consequence of the short-lived zinc transients, and refer to slow transcriptional, or other responses
to zinc. For example, cells adjust to different physiological states requiring a re-programming that may
involve gene expression. Resting, proliferating, differentiating, and apoptotic cells all have a different
basal “free” zinc ion concentration [7].
7. Conclusions
The most important message is that zinc is a major cellular regulatory ion in the series of
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topic with isolated modes of actions, but a general one in cellular biochemistry/biology. The regulatory
functions are in addition to its roles as a catalytic and structural cofactor in the already impressive
number of zinc metalloproteins. Cellular zinc is controlled by a large network of specific proteins that
interact with virtually all pathways controlling metabolism and cell fate. A most recent example is the
identification of ZIP9 as an androgen receptor that is coupled to G-proteins, and mediates non-classical
responses to androgens [57].
Recent developments show the field of zinc biology to be as important as the fields of iron or
calcium biology. Zinc shares relatively high abundance and cellular concentrations with both. Zinc is
not a trace element, but rather a mineral and major constituent of the cell. While iron biochemistry has
been a forerunner in metallobiochemistry, zinc biochemistry turns out to be an even more pervasive
topic. Zinc has been classified as a type 2 nutrient, such as magnesium, with a general function in
metabolism, as opposed to type 1 nutrients, such as iron with more specific functions [58]. With iron,
it shares the many functions in metalloproteins, and with calcium, it shares the signalling capacity.
Like calcium, genetic and environmental factors that affect homeostatic control can cause zinc disorders
and dysregulation, which are the cause of many diseases [59].
The physicochemical properties that make zinc ideally suited for the wide range of biological
functions have been pointed out repeatedly, and the potential of the field was predicted in a now
classic review published 25 years ago [60]. Likewise, the anticipation that zinc will be the calcium
of the 21st century, in terms of its signalling capacities, seems to be gaining traction [61]. The time
has come for the implications of zinc serving major regulatory functions in the cell to be recognized
outside the relatively small community of zinc biologists.
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Abstract: More than one-third of newly synthesized proteins are targeted to the early secretory
pathway, which is comprised of the endoplasmic reticulum (ER), Golgi apparatus, and other
intermediate compartments. The early secretory pathway plays a key role in controlling the folding,
assembly, maturation, modification, trafficking, and degradation of such proteins. A considerable
proportion of the secretome requires zinc as an essential factor for its structural and catalytic functions,
and recent findings reveal that zinc plays a pivotal role in the function of the early secretory pathway.
Hence, a disruption of zinc homeostasis and metabolism involving the early secretory pathway will
lead to pathway dysregulation, resulting in various defects, including an exacerbation of homeostatic
ER stress. The accumulated evidence indicates that specific members of the family of Zn transporters
(ZNTs) and Zrt- and Irt-like proteins (ZIPs), which operate in the early secretory pathway, play
indispensable roles in maintaining zinc homeostasis by regulating the influx and efflux of zinc. In this
review, the biological functions of these transporters are discussed, focusing on recent aspects of their
roles. In particular, we discuss in depth how specific ZNT transporters are employed in the activation
of zinc-requiring ectoenzymes. The means by which early secretory pathway functions are controlled
by zinc, mediated by specific ZNT and ZIP transporters, are also subjects of this review.
Keywords: ZNT/Solute carrier family 30 member (SLC30A); ZIP/SLC39A; early secretory pathway;
ER stress; unfolded protein response (UPR); zinc-requiring ectoenzymes; tissue non-specific alkaline
phosphatase (TNAP); metallation
1. Introduction
Zinc is an essential trace element that is required for a large variety of cellular processes [1,2].
Approximately 10% of the eukaryotic proteome requires zinc for cellular activity [3,4], and thus any
disturbance in zinc homeostasis can result in disease, including cancer, neuronal degeneration, chronic
inflammation, hypertension, osteoarthritis, and age-related macular degeneration. A diverse range of
symptoms is also found in cases of zinc deficiency [1,2,5–8]. The biological functions of zinc can be
grouped into three major categories, structural, catalytic, and regulatory. However, the molecular basis
of how zinc engages in such diverse functions is still far from being completely understood [1,2].
At the cellular level, zinc plays a pivotal role in the function of a variety of subcellular
compartments, one of which is the early secretory pathway constituted by the endoplasmic reticulum
(ER), the Golgi apparatus, and other intermediate organelles, such as the ER-Golgi intermediate
compartment. Zinc homeostasis in the lumen of these compartments requires a transport system to
translocate zinc across biological membranes. In vertebrates, Zn transporters (ZNTs)/Solute carrier
family 30 member (SLC30A) and Zrt- and Irt-like proteins (ZIPs)/SLC39A are widely recognized as
being critical transporters in zinc metabolism under physiological conditions [1,2,9]. Both of these
proteins are clearly important for zinc metabolism involved in early secretory pathways. This review
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outlines the functions of ZNT and ZIP transporters in the regulation and function of secretory
pathways, in particular, the early secretory pathway, focusing on several recent aspects of the molecular
processes underlying the ER stress response, as well as the activation of zinc-requiring ectoenzymes.
Zinc transporters also play important roles in secretory granules/vesicles that contain high amounts
of zinc, such as insulin granules, synaptic vesicles, and secretory vesicles involved in milk secretion;
these are discussed in this review for comparison. Further details of these transporters can be found in
other comprehensive reviews of zinc transporters [1,10–12].
2. Brief Overview of the Properties of ZNT and ZIP Transporters
In mammals, there are nine ZNT and 14 ZIP transporters that play distinct roles in the maintenance
of systemic, cellular, and subcellular zinc homeostasis. These transporters act in a cell or tissue-specific
manner, and are developmentally regulated [1,2,9] (Figure 1). ZNTs transport zinc from the cytosol
into either the lumen of intracellular compartments or the extracellular milieu, whereas ZIPs
transport zinc in the opposite direction. Zinc transport by ZNT and ZIP transporters is coordinately
controlled through precisely timed increases or decreases in their expression, and by their precise
subcellular localization [2,13]. A growing body of evidence has shown that cooperative zinc transport
across biological membranes mediated by both transporters contributes to the control of expression,
localization, and functional activity of target proteins [1]. The molecular features of ZNT and ZIP
transporters have been extensively summarized in other review papers [1,2], and thus only their main
features are outlined briefly here.
 
Figure 1. Subcellular localization of ZNT and ZIP transporters. ZNT transporters move cytosolic zinc
into the lumen of vesicles involved in the early secretory pathway, including the endoplasmic reticulum
(ER), Golgi apparatus, as well as into cytoplasmic vesicles/granules such as synaptic and secretory
vesicles and insulin granules, in which specific ZNT proteins are localized. ZNT5 and ZNT6 form
heterodimers to transport zinc. ZIP transporters move zinc in the opposite direction. In contrast to
the specific localization of ZIP9, ZIP13, and ZIP7 in the Golgi apparatus and the ER, the subcellular
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Based on the three-dimensional structure of the Escherichia coli homolog YiiP, ZNT transporters are
predicted to have six transmembrane (TM) helices (TM helices I-VI) [14–18]. ZNT transporters function
as zinc/proton exchangers [19,20], and can form homodimers or heterodimers [21–24]. With respect to
the zinc transport mechanism used by YiiP, two models have been proposed, the alternative access
mechanism model, in which the TM helices form inward- and outward-facing conformations [17,18],
and the allosteric mechanism model, in which cytosolic zinc binding induces a scissor-like movement
of the homodimers and interlocks the TM helices at the dimer interface [15,16]. ZNT transporters
likely transport zinc using either of the two proposed mechanisms. As has been observed for YiiP,
which has an intramembranous zinc-binding site formed by TM helices II and V, ZNT transporters
are also thought to have a conserved intramembranous zinc-binding site, which is indispensable for
zinc transport activity [19,20,25,26]. The intramembranous zinc-binding site in most ZNT transporters
consists of two His and two Asp residues in TM helices II and V [19,27]. Interestingly, ZNT10 has an
Asn residue in TM helix II instead of His, which confers the ability to transport manganese [28], as
has also been seen for the homologous bacterial protein [29]. The nine ZNT transporters belong to
the cation diffusion facilitator (CDF) family of transporters, which are classified into three subgroups,
namely Zn-CDF, Zn/Fe-CDF, and Mn-CDF [14,30]. All of the ZNT transporters are classified as
being Zn-CDF members (although ZNT10 is a manganese transporter), and, based on their sequence
similarities, can be further subdivided into four groups: (i) ZNT1 and ZNT10, (ii) ZNT2, ZNT3, ZNT4,
and ZNT8, (iii) ZNT5 and ZNT7, and (iv) ZNT6, [14,31,32] (Figure 2). Of interest to this review, some
characteristics of the transporters, such as subcellular localization, are conserved in the members of
the same group [32] (Figure 1).
 
Figure 2. Phylogeny of ZNT and ZIP transporters. The neighbor-joining phylogenetic tree was
constructed using ClustalW (http://clustalw.ddbj.nig.ac.jp/index.php?lang=en) protein alignment.
(A) ZNT and (B) ZIP transporters. Subfamilies and subgroups are designated according to the text.
Computational analysis suggested that ZIP transporters have eight TM helices [33], and this was
confirmed by the first three-dimensional structure reported for a ZIP transporter homolog in bacteria
(Bordetella bronchiseptica) [34]. The structure shows that the ZIP transporter has a novel 3 + 2 + 3 TM
architecture with a binuclear metal center, in which two His residues, one each in TM helices IV
and V, form two intramembranous zinc binding sites [34]. As in ZNT transporters, ZIP transporters
form functional homo- or heterodimeric complexes, which are essential for their zinc transport ability,
although no dimer formation was seen in the crystal structure [34–36]. ZIP transporters may function as
selective electrodiffusion channels [37], or as zinc/bicarbonate symport transporters [38–40]. However,
their definitive mode of transport has not yet been completely elucidated. Phylogenetic analysis
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(ZIP1-ZIP3), LIV-1 (ZIP4-ZIP8, ZIP10, ZIP12-ZIP14), and gufA (ZIP11) [1,41]. In the LIV-1 subfamily,
features of their extracellular domains further classify the proteins into four subgroups as follows:
(i) ZIP4 and ZIP12, (ii) ZIP8 and ZIP14, (iii) ZIP5, ZIP6, and ZIP10, and (iv) ZIP7 and ZIP13 [42]
(Figure 2). Members of the LIV-1 subfamily have an extended extracellular N-terminus, whose
structure has been solved only in the case of ZIP4 [42]. The extracellular portion of ZIP4 can form
homodimers without the need for TM helices [42], which may facilitate dimerization. Interestingly,
in ZIP transporters belonging to subgroup (iii), a prion-like domain is present in the extracellular
N-terminal portion proximal to the first TM helix; hence, there is an evolutionary link between these
transporters and the prion protein [43]. ZIP8 and ZIP14 in subgroup (ii) have the ability to transport
manganese [39,40], because they have a Glu residue in TM helix V rather than a His residue [1,44].
The His residue is therefore involved in metal substrate specificity, because of its contribution to
forming intramembranous zinc binding sites [34].
Over the last two decades, the physiological roles of ZNT and ZIP transporters and their
involvement in disease pathology have been clarified at the molecular level, as has been described
elsewhere [1,2,8,9], and a deeper understanding will likely come in the future.
3. Regulation of Zinc Homeostasis by Zinc Transporters in the Early Secretory Pathway
Approximately one-third of all the cellular proteins in eukaryotes are targeted to the ER, and
thus the early secretory pathway [45], in which nascent proteins are folded, assembled, and modified
during their trafficking to final destinations. Importantly, a considerable proportion of the secretome
requires zinc as a structural and catalytic cofactor. Moreover, resident chaperones require zinc for
modulation and potentiation of their functions [46–48]. Hence, any disruption of zinc homeostasis
in the early secretory pathway can cause and exacerbate ER stress [49,50], and trigger the unfolded
protein response (UPR) in cells. Therefore, elaborate regulatory mechanisms are used to control zinc
homeostasis in the early secretory pathway. Accumulating evidence clearly shows that both ZNT and
ZIP transporters play crucial roles in this process [49–53], and this is summarized in this section.
With the exception of ZNT1 and ZNT10 (which are members of ZNT subgroup (i) described
above [28,54]), ZNT transporters are mainly localized to intracellular compartments. Of these, ZNT5,
ZNT6, and ZNT7 (members of ZNT subgroups (iii), and (iv) described above) are involved in the early
secretory pathway [12,55]. ZNT5 has been shown to be mainly localized to coat protein complex II
(COPII) vesicles and the Golgi apparatus [56], whereas ZNT6 is localized to the Golgi apparatus [57],
although these ZNTs can also form heterodimers as functional complexes [21,22] (Figure 1). The actual
subcellular localization of these heterodimers has however been poorly investigated. ZNT7 is also
located in the Golgi apparatus [58], and a recent study indicates that it is also localized to the
sarco(endo)plasmic reticulum (S(E)R) [52] (Figure 1). These ZNT transporters are employed as zinc
entry routes in the early secretory pathway, suggesting that a lack of them would be potentially to
elicit an ER stress response. In fact, it has been clearly shown that cells lacking these ZNT transporters
do exhibit an exacerbated ER stress responses [50,59] (Figure 3). A similar exacerbation of ER stress is
found in yeast lacking ZNT orthologs [49,60], which highlights the fact that the important role these
ZNT transporters play in maintaining zinc homeostasis in the secretory pathway is well-conserved
among subgroups. However, there remains the interesting questions of how and where these ZNT
transporters transport zinc, and their association with ER stress, because ZNT5, ZNT6, and ZNT7
all appear to be principally localized to the Golgi apparatus [57,58,61]. Recent studies have shown
that another ZNT transporter, either ZNT3 or ZNT10, may play a protective role in ER stress-induced
toxicities [62,63], although their contributions to the early secretory pathway have not yet been clarified.
In contrast to ZNT transporters, most of which are located in intracellular compartments, most,
but not all, ZIP transporters are found on the plasma membrane. Of the 14 ZIP transporters, ZIP7,
ZIP9, and ZIP13 (the ZIPI subfamily and the LIV-1 subgroup (iii) described above) are involved in
the early secretory pathway [64–67] (Figure 1), although recent reports also indicate that ZIP9 is also
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that ZIP13 can also be found in intracellular vesicles [69]. It has also been suggested that ZIP11 can
localize to the Golgi apparatus [70], but this has not yet been thoroughly established. Accordingly,
this protein is not further discussed here. ZIP7, ZIP9, and ZIP13 are known to release zinc, which is
stored in the early secretory pathway, into the cytosol in response to various stimuli, thus contributing
to the signaling function of zinc [66,71–73]. Importantly, ZIP7, ZIP9, and ZIP13 are also thought
to contribute to homeostatic maintenance of the secretory pathway. In this regard, ZIP7, which is
located in the ER, plays an indispensable role in the proper regulation of ER function, through the
fine-tuning of zinc homeostasis [51,53]. The loss of ZIP7 probably increases zinc levels in the ER, which
triggers zinc-dependent aggregation of protein disulfide isomerase, leading to ER stress [53] (Figure 3).
This critical functional role of ZIP7 in ER homeostasis contributes to self-renewal processes of intestinal
epithelium [51] and appropriate epidermal development [53]. ZIP7 is also involved in the induction of
ER stress by mediating the redistribution of zinc into the cytosol from the S(E)R in cardiomyocytes
under hyperglycemic conditions [52]. Consistent with the involvement of ZIP7 in ER stress, the yeast
ZIP7 homolog, yKE4, has been shown to be involved in ER stress responses [74]. Similarly, Catsup, a
Drosophila ZIP7 ortholog, which plays a crucial role in catecholamine synthesis, is also involved in
the ER stress response [75,76]. Along with ZIP7, Golgi-localized ZIP9 is also thought to contribute to
secretory homeostasis [67], and likewise, ZIP13 contributes directly to zinc homeostasis in the early
secretory pathway by mobilizing zinc from the Golgi apparatus, or indirectly by releasing zinc from
intracellular vesicles [69]. Recently, although it is localized to the plasma membrane [77,78], ZIP14 has
also been shown to play a significant role in the adaptation to ER stress [79,80], suggesting that zinc
homeostasis in the early secretory pathway might be indirectly controlled by ZIP transporters that are
located in other subcellular regions.
 
Figure 3. Model of feedback regulation for the maintenance of zinc homeostasis in the ER (in the early
secretory pathway). A disturbance in zinc homeostasis, such as zinc deficiency or zinc overload, in
the ER (and perhaps in the early secretory pathway) induces homeostatic ER stress. The unfolded
protein response (UPR) leads to the activation of transcription factors such as ATF4, ATF6, and XBP1,
and increases the transcription of several ZNT and ZIP transporter genes. These activities of ZNT and
ZIP transporters then contribute to the maintenance of zinc homeostasis in the ER (and in the early
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With respect to the direction of zinc transport mediated by ZNT and ZIP transporters, both
decreases and increases in zinc levels in the early secretory pathway exacerbate its proper functioning
and thus either increases or decreases in zinc levels will result in the homeostatic ER stress response.
The molecular basis underlying this phenomenon may be explained by changes in the activity of
chaperone proteins that are either positively or negatively regulated by zinc [46–48], although this has
not yet been completely elucidated.
4. Regulation of Expression of ZNT and ZIP Transporters by ER Stress
Based on the crucial functions of zinc mobilized by ZNT and ZIP transporters in the early
secretory pathway, it is easy to imagine that the transcription of ZNT and ZIP genes would be
regulated by homeostatic ER stress. In fact, ZNT5 transcription increases in response to inducers
of ER stress, and its promoter harbors a UPR element, which serves as the binding site for the
transcription factor XBP-1 [50] (Figure 3). ZIP14 transcription is also induced by inducers of
ER stress [79,80], and its promoter also has several ER stress response elements, to which the
transcription factors ATF6 and ATF4 bind [79,80]. Moreover, the treatment with inducers of ER
stress or N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine, a zinc chelator which also causes ER
stress, has been shown to induce the expression of ZIP3, ZIP7, ZIP9, ZIP13, and ZIP14, as well as
ZNT3, ZNT6, ZNT7, and ZNT10 [51,62,63,79,80], although the elements responsible for the induction
have not yet been identified in the promoter regions of these genes. Several homologues of both types
of transporter have been shown to be increased by inducers of ER stress [81]. Thus, the fine-tuning of
zinc homeostasis by these zinc transporters in the early secretory pathway, as well as the regulation of
their expression triggered by homeostatic ER stress, are important control mechanisms in maintaining
homeostasis [12].
5. Importance of ZNT Transporters in the Activation of Ectoenzymes in the Early
Secretory Pathway
Zinc-requiring ectoenzymes, which are defined here as secretory, membrane-bound, and
organelle-resident enzymes, have attracted considerable attention because they play crucial roles
in various physiological functions, and in a number of pathological processes, such as cancer
progression, and metastasis [1,55]. Thus, they are regarded as potential therapeutic targets in the
treatment of diseases [82–86]. Moreover, the activities of some zinc-requiring ectoenzymes, e.g.,
alkaline phosphatases (ALP), may be used as clinical markers to reflect systemic zinc status [87,88].
These enzymes are synthesized in the early secretory pathway, at which point they acquire zinc for their
activity, before being trafficked to the plasma membrane via the constitutive secretory pathway [12,55].
How zinc is made available to zinc-requiring ectoenzymes is largely unknown, but the importance
of ZNT transporters has been partially clarified in the activation of specific enzymes. This section
addresses these specific ectoenzyme activation processes in detail.
5.1. ZNT Transporters Involved in Zinc-Requiring Ectoenzyme Activation
Zinc-requiring ectoenzymes likely become active by coordinating with zinc at their active site (i.e.,
they become metallated) during the secretory process. Zinc coordination is generally achieved by the
interaction of zinc with three or four amino acids, including His, Asp, and Glu residues [4,89,90], which
must undergo precise regulation for the conversion from the apo- to holo-forms. When compared
with cytosolic zinc-requiring enzymes, zinc-requiring ectoenzymes require more complicated and
elaborate regulatory processes involving zinc mobilization, because their activation process requires at
least two types of zinc transporters that involve two biological membranes. In the first process, zinc
transport from the extracellular milieu to the cytosol (i.e., ZIP transporters) occurs, and in the second
process zinc transport from the cytosol to the lumen (i.e., ZNT transporters) occurs. Information
regarding the identity of the ZIP transporters involved is lacking, while information relating to the
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have been shown to be indispensable in ectoenzyme metallation; one complex is formed by ZNT5
and ZNT6 as a heterodimer, in which ZNT6 operates as an auxiliary subunit, and the other is formed
by ZNT7 homodimers [21,91,92]. Both of these ZNT complexes can specifically activate several
zinc-requiring enzymes, such as tissue-nonspecific ALP (TNAP) and placental ALP, as well as autotaxin
(ATX) [24,56,93]. These three enzymes have similar active site geometry with a bimetallic core, which
consists of two zinc ions, one of which is coordinated by one Asp and two His residues, and the
other coordinated by one His and two Asp residues (Table 1), although ALPs and ATX catalyze
different enzymatic reactions and have different biological roles. Based on these enzymes, it could be
hypothesized that specific regulation mechanisms are operative in this bimetallic core enzyme family
during conversion from the apo- to holo-enzymes. Both ZNT complexes, however, can activate other
zinc-requiring ectoenzymes, such as matrix metalloproteinase (MMP)-9 and probably MMP-2 [24],
and thus, they likely play a critical role in the activation of many zinc-requiring ectoenzymes in the
early secretory pathway.






Defects Caused by Loss
of ZNTs
ALP Bimetallic center Asp, His, His for Zn1His, Asp, Asp for Zn2





Asp, His, His for Zn1,





Loss of enzyme activity
Decreases in enzyme activity
MMP-2
MMP-9 Mononuclear Zn ** His, His, His ZNT5-ZNT6, ZNT7
Loss of enzyme activity
Protein destabilization ***
* The structures of the zinc-requiring ectoenzymes are predicted based on homologous proteins; ** MMP-2 and
MMP-9 have an additional zinc for stability of protein structure; *** Zinc supplementation partially restores both
enzyme activity and protein stability. Zn: zinc.
However, some enzymes can be metallated by zinc and become activated through different
pathways involving these zinc transporters. For example, carbonic anhydrase IX (CAIX) can acquire
zinc via ZNT4 homodimers, in addition to ZNT5-ZNT6 heterodimers and ZNT7 homodimers [24].
ZNT4 homodimers may also be involved in carbonic anhydrase VI maturation [94]. These findings are
interesting for two reasons. The first is that ZNT4 homodimers have multifunctional roles depending
on their subcellular localization. For example, ZNT4 was originally reported to be localized to late
endosomes [95], where it has a role in reducing cytosolic zinc toxicity [25,96], but it has also been
shown to be involved in secretory pathways involving the trans-Golgi network, cytosolic vesicles, and
probably other secretory vesicles. In addition, it has been shown to be involved in zinc secretion into
breast milk in mice [97,98]. The second is that ZNT4 homodimers can become functionally equivalent
to ZNT5-ZNT6 heterodimers or ZNT7 homodimers in the activation of specific ectoenzymes, including
CAIX, in the early secretory pathway. The involvement of ZNT4 in CAIX activation is specific because
ZNT2 expression failed to result in CAIX activation [24].
5.2. Insight into the Activation of TNAP and Other Ectoenzymes by ZNT5-ZNT6 Heterodimers and
ZNT7 Homodimers
What affects the metallation of TNAP via ZNT5-ZNT6 heterodimers or ZNT7 homodimers?
This question remains to be fully resolved but some important insights have been made to date. First,
the number of zinc ions and their coordination manner at the active site does not seem to affect the
activation process mediated via ZNT5-ZNT6 heterodimers or ZNT7 homodimers. The ALP protein
possesses two zinc ions at the active site (zinc bimetallic core), which are coordinated by His, His, and
Asp residues or Asp, Asp, and His residues, as described above [55], whereas MMP-9 has a single zinc
ion at the active site, which is coordinated by three His residues (MMP-9 has another zinc ion that
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ZNT5-ZNT6 heterodimers and ZNT7 homodimers [24], as described above, possesses a single zinc ion
coordinated by three His residues at the active site, supporting this notion.
Second, a specific motif may be significantly involved in TNAP activation via ZNT5-ZNT6
heterodimers and ZNT7 homodimers [55,99]. In cells lacking both ZNT complexes, the TNAP protein
is destabilized, although it is not destabilized by zinc deficiency [93]. These data show that both
ZNT complexes can stabilize the TNAP protein, in addition to supplying it with zinc. In other words,
the TNAP activation process can be separated into two steps: the TNAP protein is first stabilized by
ZNT5-ZNT6 heterodimers or ZNT7 homodimers in the early secretory pathway and then is metallated
by zinc supplied by both ZNT complexes [93] (Figure 4). In this two-step mechanism, the Pro-Pro
(PP)-motif in luminal loop 2 of ZNT5 (which corresponds to luminal loop 7, because of the fact
that ZNT5 has extra N-terminal TM helices [61]) and ZNT7, which is highly conserved in ZNT5
and ZNT7 homologs across multiple species, is thought to be important [100]. In model structures
of ZNT5 and ZNT7, the PP-motif is located just above the intramembranous zinc-binding site in
the TM helices [100], suggesting that a unique cooperative mechanism might operate between the
intramembranous zinc-binding site and the PP-motif in the activation of TNAP. In contrast, a similar
two-step activation mechanism does not seem to operate in the activation of ATX, because the ATX
protein is not destabilized in cells lacking both ZNT5-ZNT6 heterodimers or ZNT7 homodimers, and
so the PP-motif plays a somewhat minor role [24]. This discrepancy between TNAP and ATX may
be explained by differences in the degree of their glycosylation, although this needs to be clarified in
future studies.
Figure 4. ZNT5-ZNT6 heterodimers and ZNT7 homodimers function to activate tissue-nonspecific
ALP (TNAP) in a two-step mechanism. TNAP is specifically activated in a two-step mechanism
involving ZNT5-ZNT6 heterodimers and ZNT7 homodimers as follows: first, the apo-form of TNAP is
stabilized by either ZNT5-ZNT6 heterodimers or ZNT7 homodimers; second, the apo-form of TNAP is
converted to the holo-form by zinc metallation. The PP-motifs in ZNT5 and ZNT7 likely play important
roles in this process (see text). TNAP possesses a bimetallic core, is dimeric, and is localized to the
plasma membrane via a glycophosphatidylinositol anchor. The subcellular localizations of ZNT5-ZNT6
heterodimers or ZNT7 homodimers have not been well defined. Zn: zinc.
Znt5 or Znt7 knockout (KO) mice show various phenotypes [101–105], but the association of
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phenotype of osteopenia [101], which may be associated with reduced TNAP activity caused by a lack
of ZNT5-ZNT6 heterodimers.
6. Importance of ZNT Transporters in Zinc-Related Regulated Secretory Pathway: After the Early
Secretory Pathway
There are a number of cells that accumulate large amounts of zinc in cytoplasmic vesicles/granules
(Figure 1). One can think that zinc, which is transported to the early secretory pathway, traffics those
vesicles/granules through the secretory pathway and gets accumulated there. However, this is not
the case. In fact, specific ZNT transporters are localized to the specific vesicles/granules and perform
specific functions. In this section, representative vesicles/granules and the ZNT transporters involved
in their function are briefly summarized to emphasize these points. Other aspects of this have been
extensively reviewed elsewhere [1,10–12].
Insulin granules in pancreatic islet β-cells require high amounts of zinc in order to form
insulin-zinc crystals, a process in which ZNT8 plays an indispensable role [106–110]. Nevertheless, a
clear and crucial role for ZNT8 in regulating glucose homeostasis is yet to be established (Znt8 KO
mice are largely glucose tolerant), and thus the physiological relevance of zinc accumulation in insulin
secretory granules remains unclear. Although, an interesting hypothesis is that zinc, which is secreted
in concert with insulin, suppresses the insulin clearance in the liver by inhibiting clathrin-dependent
insulin endocytosis [110]. Alterations in ZNT8 function are thought to lead to an increase in the risk of
type 2 diabetes [111,112], because the R325W polymorphism in ZNT8 is associated with an increased
risk of type 2 diabetes [113], and the R-form (i.e., the increased-risk form of ZNT8) likely alters its
zinc transport activity [111,112]. In addition, another study has shown that haploinsufficiency of
ZNT8 is protective against type 2 diabetes [114]. The relationship between ZNT8 and type 2 diabetes
therefore requires further investigation [115]. The transporters ZNT5 and ZNT7 are also relatively
highly expressed in pancreatic β-cells, [61,116,117], and both may be associated with β-cell function:
loss-of-function of Znt5 is associated with attenuation of the incidence of diabetes and mortality [103],
whereas loss-of-function of Znt7 impairs glucose tolerance and reduces glucose-stimulated increases in
plasma insulin levels, hepatic glycogen levels, and pancreatic insulin content [104,105,118]. Moreover,
loss-of-function of Znt7 results in a markedly-reduced zinc content in β-cells, which is made more
profound by the combined loss of function of Znt8 [118]. ZNT5 and ZNT7 may therefore contribute to
β-cell function in the early secretory pathway, but not in the insulin granules themselves.
Synaptic vesicles present in a subset of glutamatergic neurons in the hippocampus and neocortex
also accumulate high amounts of zinc, which is mediated by ZNT3: Znt3 KO mice lack synaptic
zinc [119]. Zinc secreted from the synaptic vesicles into the extracellular space, as a result of ZNT3
activity, acts as a signaling molecule by modulating neuronal transmission and plasticity through
binding to multiple ion channels, transporters, and receptors on postsynaptic neurons involved in
neurotransmission [120–122]. The importance of synaptic zinc has been confirmed in knock-in mice
studies, using glycine and N-methyl-D-aspartate receptors, in which the zinc-binding sites in each
receptor were mutated [123,124]. A disturbance of synaptic zinc homeostasis or a dysfunction in ZNT3
has been suggested to result in neurodegenerative diseases [125–127].
Because zinc is essential for the growth and health of neonates, breast milk contains high amounts
of zinc, considerably higher than the levels found in serum. The transporter ZNT2 is responsible for
supplying zinc to the breast milk produced by the mammary epithelial cells in humans. Mothers with
missense or nonsense mutations in the ZNT2 gene secrete zinc-deficient milk (75–95% reduction), and
thus infants exclusively breast-fed by mothers carrying the mutation experience transient neonatal
zinc deficiency (TNZD; OMIM 608118) [87,128–131]. Zinc-deficient milk is produced by mothers with
a heterozygous mutation in the ZNT2 gene, and their infants also suffer from TNZD, suggesting that
having one active copy of the ZNT2 gene is not sufficient to provide zinc levels in breast milk adequate
to support normal infant growth. One report has also suggested the involvement of ZNT5-ZNT6
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breast milk can be attributed to mutations in the ZNT4 gene in humans, although Znt4 is involved in
low-zinc breast milk in mice [97,98].
Zinc that accumulated in granules/vesicles can be released in response to various stimuli
and thereby regulate a number of diverse processes [110,133,134]. This phenomenon can be
divided into two classes, the first being zinc secretion into the extracellular environment (e.g., zinc
“sparks”) [133,134], as described for synaptic zinc, and the second being zinc release from intracellular
stores into the cytosol (e.g., zinc “wave”) [135]. The latter phenomenon is strongly associated with
the signaling functions of zinc and thus contributes to driving major signaling pathways [71,72,136].
The function of zinc in signaling has been extensively reviewed [2,41,137].
7. Perspectives
This review focuses on crucial functions of specific ZNT and ZIP zinc transporters in the early
secretory pathway. As we have shown, these two classes of zinc transporter are doubtless key molecules
required for the proper function of the early secretory pathway. However, there are many unsolved
and fundamental questions that remain to be addressed. Specifically, how do both zinc deficiency
and elevation in the early secretory pathway cause and exacerbate ER stress? How do those ZNT and
ZIP transporters properly regulate zinc metabolism in a spatiotemporal manner in the early secretory
pathway? Moreover, how is zinc coordinated in zinc-requiring ectoenzymes in the early secretory
pathway? Are zinc chaperones required to facilitate zinc metallation of the large number of nascent
proteins found in the early secretory pathway? Even the most fundamental question as to what the
actual zinc concentration is in the early secretory pathway has not yet been definitively addressed,
because the proposed zinc concentrations in the ER and the Golgi are controversial [138,139]. Moreover,
clarification of a functional relationship(s) between the early secretory pathway and constitutive
secretory or the regulated secretory pathway is required from the perspective of zinc metabolism.
The answers to these questions can help our understanding of zinc in the early secretory pathway, and
provide information that should be useful for the treatment of numerous diseases.
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Abstract: Zinc (Zn), which is an essential trace element, is involved in numerous mammalian
physiological events; therefore, either a deficiency or excess of Zn impairs cellular machineries
and influences physiological events, such as systemic growth, bone homeostasis, skin formation,
immune responses, endocrine function, and neuronal function. Zn transporters are thought to
mainly contribute to Zn homeostasis within cells and in the whole body. Recent genetic, cellular,
and molecular studies of Zn transporters highlight the dynamic role of Zn as a signaling mediator
linking several cellular events and signaling pathways. Dysfunction in Zn transporters causes various
diseases. This review aims to provide an update of Zn transporters and Zn signaling studies and
discusses the remaining questions and future directions by focusing on recent progress in determining
the roles of SLC39A/ZIP family members in vivo.
Keywords: zinc transporter; SLC39A/ZIP; zinc signaling; physiology; diseases
1. Introduction
Zn is an essential micronutrient required for growth, development, immunity, and many other
physiological processes. The total amount of Zn in the human body is 2–3 g, with ~60% in the
skeletal muscle, ~30% in bone, and ~5% in both, the liver and skin, while the remaining 5% is in
other tissues (Figure 1) [1]. Approximately 10% of human proteins may bind to Zn [2], reflecting the
indispensability of Zn in numerous physiological processes. Therefore, either a deficiency or excess of
Zn is detrimental [1].
Maintenance of intracellular Zn homeostasis mainly depends on two families of Zn transporters:
Zrt- and Irt-like proteins (ZIPs), also known as solute carrier family 39A (SLC39A), and Zinc
transporters (ZnTs), also known as SLC30A proteins, and metallothioneins (MTs) [1]. ZIPs are known
to function in the uptake of Zn across the cytoplasm from the extracellular environment or regulate
the release of Zn into the cytosol from intracellular organelles, including the endoplasmic reticulum
(ER), mitochondria, and Golgi apparatus; ZnTs acts in the efflux of Zn from the cytoplasm to the
extracellular environment or the uptake of Zn into intracellular compartments from the cytosol [1].
Vignesh and Deep describe MTs in detail in this IJMS special issue [3].
ZIPs and ZnTs are involved in many cellular responses, including cytokine- and growth
factor-meditated signaling, and the regulation of enzymes, receptors, and transcription factors
belonging to cellular signaling pathways [4]. Numerous Zn transporters regulate Zn homeostasis and
have crucial functions in physiology; dysfunctions that are caused by mutations result in inherited
diseases [1]. Moreover, single-nucleotide polymorphisms, which are related to disease pathology,
in each transporter gene have been identified [5–8]. Thus, impaired Zn transporter function is strongly
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linked to clinical human diseases, and numerous studies have examined these membrane transporters
for their great potential as drug targets.
Figure 1. Scheme for Zinc (Zn) storage and distribution in the body. Dietary Zn is absorbed in the
small intestine and distributed to the peripheral tissues, including skeletal muscle (60%), bone (30%),
skin (5%), and other tissues (5%). Zn deficiency causes various abnormalities in humans and animal
models, such as growth retardation, immune dysfunctions, diarrhea, and skin diseases, including
acrodermatitis enteropathica (AE).
In this review, we provide the updated information related to Zn transporters, focusing on ZIP
family members and their roles in Zn homeostasis, cellular functions, signal transduction, development,
and human diseases. We also discuss the remaining questions by reviewing recent progress in studies
of Zn transporters and Zn signaling.
2. Overview of Mammalian Zrt- and Irt-like Protein (ZIP) Transporters
Zn regulates a broad range of cellular functions; therefore, the dysregulation of Zn homeostasis
causes various abnormalities in mammalian models [1,9,10]. Under physiological conditions,
ZnTs reduce the intracellular availability of Zn by accelerating Zn efflux from the cell or into
intracellular vesicles, while ZIP transporters import Zn into the cytosol from the extracellular space
or intracellular compartments (Figure 2). Some ZIPs and ZnTs have been shown to be involved in
the development of human diseases. Moreover, gene deficient (knockout, KO) mouse studies of ZIP
and ZnT family members have revealed many unique phenotypes (Table 1), indicating that each Zn
transporter-mediated Zn signaling exerts profound effects on non-overlapping molecular events to
coordinate physiological conditions. Thus, Zn homeostasis is tightly regulated by the coordination of
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Figure 2. Cellular localization of Zinc transporters (ZnTs) and Zrt- and Irt-like proteins (ZIPs).
The diagram shows the localization of ZIPs (orange) and ZnTs (green). The black arrow shows
the direction of Zn transport in the plasma membrane and each organelle. ZIPs and ZnTs regulates the
flux of Zn ion in the extra- or intra-cellular environment and tightly controls cellular Zn homeostasis in
numerous cell types.
2.1. ZIP1
ZIP1 is a prototypic ZIP transporter that transports Zn into the cytosol and is ubiquitously
expressed in human tissues [11]. Zip1-KO mice are sensitive to dietary Zn deficiency during
pregnancy [12]. Previous studies showed that the downregulation of ZIP1 in malignant cells is
accompanied by a decrease in Zn [13]. Recently, Furuta et al. observed increased ZIP1 expression
in mouse astrocytes under oxidative stress conditions [14]. However, the role of ZIP1-mediated Zn
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2.2. ZIP2
ZIP2 is known to exist at the plasma membrane in human leukemia cells and functions as
an importer of Zn, which increases Zn cellular levels [39]. Zip2-KO mice are sensitive to dietary Zn
deficiency during pregnancy [15], as are Zip1-KO mice [12]. Gene expression analysis revealed high
levels of ZIP2 expression in the epidermis, and RNAi knockdown of ZIP2 gene expression inhibited
the differentiation of keratinocytes [40]. Moreover, Zip2-KO mice exhibited skin blistering during early
embryogenesis [15]. These results indicate that, in the skin, ZIP2 is involved in the differentiation of
keratinocytes [40]; thus, ZIP2 is a potential therapeutic target for skin epidermis diseases.
2.3. ZIP3
ZIP3 is localized at the plasma membrane in mammary epithelial cells [41], and it functions
as an importer of Zn [42]. Zip3-KO mice are more likely to show abnormal development during
Zn-deficient pregnancy [12,42]. The absence of ZIP3 is evident in early and progressive malignancy;
previous studies showed that ZIP3 expression is regulated by Ras-responsive-element-binding-protein
(RREB1) in the normal ductal/acinar epithelium [43], indicating that the RREB1/ZIP3 pathway is
involved in regulating oncogenesis.
2.4. ZIP4
ZIP4 plays an indispensable role in Zn absorption in the small intestine, and it is expressed
at the apical membrane of enterocytes [44,45]. Homozygous Zip4-KO mice are embryonic lethal
during early development, and heterozygous offspring are hypersensitive to Zn deficiency,
displaying developmental defects, such as exencephalia, anophthalmia, and growth retardation [16].
Loss-of function mutations in ZIP4 cause acrodermatitis enteropathica (AE), a congenital disease that is
characterized by extreme Zn deficiency if it is left untreated without supplemental Zn (OMIM 201100)
(Table 2) [46,47]. It has been suggested that dietary Zn is mostly absorbed in the duodenum, ileum,
and jejunum by active transport through ZIP4 [48]. However, the molecular mechanisms of dermatitis
that is caused by ZIP4 mutation remain unclear. A more recent study investigated whether ZIP4
is cell-autonomously essential for maintaining human epidermal homeostasis [17]. In normal skin,
Zn in the basal layer is transported to cells via ZIP4 and sufficiently supplied to Zn-binding proteins,
including ΔNp63, which are essential for epidermal differentiation; thus, epidermis-localized ZIP4
has cell-autonomous functions to develop the epidermis. Taken together, ZIP4 has dual roles:
ZIP4 increases Zn mass in the body via intestinal ZIP4, and is involved in the development of
epidermal tissues by epidermis-localized ZIP4 [17].







Slc39a4/ZIP4 Mutation 607059/201100 8q24.3 Acrodermatitis enteropathica (AE) [17]







Congenital disorder of glycosylation
type II
[50,51]
Slc39a13/ZIP13 Mutation 608735/612350 11p11.2 Spondylocheiro dysplasticEhlers-Danlos syndrome (SCD-EDS) [32,33]
Slc39a14/ZIP14 Mutation 608736/617013 8q21.3
Childhood-onset
parkinsonism-dystonia,
Hypermanganesemia with dystonia 2
[52]
2.5. ZIP5
ZIP5 is homeostatically expressed in acinar cells and enterocytes, localized to the basolateral
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the liver and failure to accumulate excess Zn in the pancreas [18]. A study of pancreas-specific Zip5-KO
mice revealed that ZIP5 in pancreatic acinar cells plays a key role in Zn accumulation/retention and
protects cells from Zn-induced acute pancreatitis [18]. Although ZIP5 function is required for the
survival of mammary gland epithelial cells in culture, homozygous KO mice did not show visible
phenotypes. More recently, Feng et al. detected mutations in ZIP5 in patients with high myopia
(Table 2) [49]; however, the relationship between ZIP5 and its pathophysiology are not understood.
Therefore, ZIP5 may play a unique role in polarized cells by sensing Zn status via serosal-to-mucosal
transport of Zn.
2.6. ZIP6
ZIP6 localizes to the plasma membrane and functions to import Zn across the cell membrane
into cells [54]. The expression of ZIP6 was shown to be associated with estrogen receptor-positive
breast cancer, metastatic ability, and cancer progression [20,55,56]. ZIP6 is known to be involved in
the epithelial-mesenchymal transition (EMT) and cell migration. During gastrulation in zebrafish,
STAT3 transactivates the expression of ZIP6, which promotes nuclear translocation of the
transcriptional factor Snail and represses E-cadherin expression [19]. Several studies have revealed
similarities and a functional relationship between ZIP6 and ZIP10, suggesting that these Zn transporters
interact to conduct biological activities [54,57,58]. It was also shown that ZIP10 is transcriptionally
regulated by signal transducer and STAT3 and STAT5, and suppresses apoptosis during the early
development of B lymphocytes, and ZIP10 is also overexpressed in human lymphoma [28], as described
below. Thus, both, ZIP6 and ZIP10 may be associated with the aggressive behavior of malignant cells,
which is regulated by STAT3/5 signaling.
2.7. ZIP7
ZIP7 is localized to the Golgi apparatus [59] and ER [60], and plays a critical role in maintaining
the intracellular balance of Zn and regulates both cell growth and differentiation pathways involving
HER2, EGFR, Src, and IGF1R signaling [1,21,61]. ZIP7 has been shown to be consistently overexpressed
in numerous breast cancers with poor prognosis and contributes to the tamoxifen resistance of breast
cancer cells [21,62,63].
It has been reported that ZIP7 is involved in growth factor signaling-dependent and/or
phosphorylation-mediated signaling pathways [63]. Taylor and colleagues reported that a Zn gate in
the ER releases Zn from intracellular stores in response to phosphorylation by casein kinase 2 (CK2),
which promotes the activation of tyrosine kinases AKT and ERKs, followed by the regulation of cell
migration and proliferation [63]. These findings suggest that ZIP7 acts as a multifunctional protein in
regulating a wide range of cellular processes, including ER stress during development and adult tissue
homeostasis. In fact, Zn is required for normal ER function, which is supported by the observation that
Zn deficiency in the ER lumen causes ER stress [64,65]. In Drosophila, Catsup, a member of the ZIP7
protein family, mediates Zn release from the ER and Golgi [66], indicating the possible involvement of
ZIP7 in ER functions in vivo.
Recent investigations demonstrated that mice with an intestinal epithelium-specific Zip7 deletion
exhibited ER stress in proliferative progenitor cells, leading to disrupted epithelial proliferation and
intestinal stemness (Figure 3A) [23]. Moreover, connective tissue-specific Zip7-KO mice exhibited an
inhibition of protein disulfide isomerase (PDI), leading to ER dysfunction, which revealed dysgenesis of
the dermis and hard connective tissue, including the bone and teeth [22]. Thus, ZIP7 plays an important
role in maintaining intestinal epithelial homeostasis and skin dermis development by regulating ER
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Figure 3. Biological relevance of ZIP7, ZIP10, and ZIP13. (A,B) ZIP7 is expressed in the endoplasmic
reticulum (ER) membrane of various cells including dermal fibroblasts and intestinal epithelial cells,
maintains Zn levels in the ER, and contributes to reducing ER stress. (A) In intestinal epithelial
cells, ZIP7 promotes intestine epithelial self-renewal by resolving the upregulation of ER stress.
Therefore, ZIP7 is a new regulator of intestinal epithelium homeostasis by regulating ER function;
(B) In the dermal fibroblast ER, ZIP7 contributes dermal development. ZIP7 dysfunction induces
ER stress caused by Zn-dependent protein disulfide isomerase (PDI) aggregation. PDI aggregation
in dermal fibroblast disturbs adequate protein folding, which impairs dermal development; (C,D)
ZIP10 contributes to the development and functions of B cells and skin epidermis; (C) ZIP10 inhibits
caspase activity in progenitor B cells and promotes B cell development in the early stage (green color).
ZIP10 also modulates B cell receptor (BCR) signaling in the late stage (orange color). Thus, ZIP10 is
crucially involved in B cell-mediated immunity; (D) In skin epithelial cells, ZIP10 up-regulates p63
transactivation, which promotes epidermal and hair follicle development (yellow circle: nucleus).
Therefore, the ZIP10-Zn-p63 signaling axis plays an important role in maintaining the skin epidermis;
(E) ZIP13 is expressed in chondrocytes, osteoblasts, and fibroblasts and contributes to connective
tissue development. ZIP13-mediated Zn signaling is required for Smad proteins activation in bone
morphogenetic protein (BMP)/transforming growth factor beta (TGF-β) signaling, which regulates
connective tissue development.
2.8. ZIP8
ZIP8 is localized to the plasma membrane and apical surface of polarized cells, mitochondria,
and lysosomes [67,68]. Zip8 mRNA expression is a transcriptional target of nuclear factor (NF)-κB,
and ZIP8 negatively regulates proinflammatory responses through Zn-mediated downregulation of IκB
kinase (IKK) activity, thereby inhibiting NF-κB activity (Figure 4B) [69]. Clinical studies revealed highly
elevated serum Zn levels in osteoarthritis (OA) [70]. Kim et al. found that ZIP8 expression is specifically
upregulated in OA cartilage of humans and mice, resulting in increased levels of intracellular Zn and
the activation of a catabolic cascade by upregulating matrix-degrading enzymes, whereas upregulation
of MT1 and MT2 proteins by metal responsive transcription factor (MTF1) forms a negative feedback
loop and causes destruction during OA pathogenesis (Figure 4A) [24]. Thus, ZIP8 may be a potent
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Figure 4. Physiological control by multiple metal transport through ZIP8 and ZIP14. (A–C) ZIP8 is
involved in inflammatory responses and pathophysiology. ZIP8 expression is induced by (A)
inflammatory cytokines and endotoxin in chondrocyte and (B) monocytes and macrophages,
respectively. (A) In chondrocytes, ZIP8-mediated Zn activates MTF-1 and increases MMP expression,
followed by cartilage degeneration of osteoarthritis; (B) In monocytes and macrophages, ZIP8-mediated
Zn decreases IKKβ activity and NF-κB signaling and promotes inflammatory responses; (C) Mn (red)
is transported by ZIP8. Loss of function of mutated ZIP8 reduces Mn uptake followed by a decrease in
Mn-activated enzymes, resulting in cerebellar atrophy syndrome; (D) ZIP14 is required for systemic
growth and modulates G protein-coupled receptor signaling by inhibiting hormone-stimulated
phosphodiesterase (PDE) in chondrocytes; (E) Mn (red) and iron (green) are transported by ZIP14.
Loss of function of mutated ZIP14 decreases Mn and iron uptake followed by a decrease in either Mn-
or iron -activated enzymes, which results in neurodegenerative disease or iron overload disorders.
Interestingly, the mutation of ZIP8 causes human pathogenesis, including Crohn’s disease and
cerebellar atrophy syndrome (Table 2) [50,51]. In fact, ZIP8 possesses higher affinity for Mn than for Zn
in cells [67]; moreover, mice with liver-specific Zip8-KO mice showed decreased activity of arginase and
β-1,4-galactosyltransferase, which are Mn-dependent enzymes (Figure 4C) [71]. Therefore, ZIP8 can
regulate both Mn and Zn homeostasis. A loss-of-function mutation in ZIP8 induces the dysfunction of
Mn and Zn homeostasis, resulting in human diseases, such as cerebellar atrophy syndrome (Figure 4C).
2.9. ZIP9
Previous studies showed that ZIP9 regulates cytosolic Zn levels, resulting in the activation of B cell
receptor (BCR) signaling by enhancing Akt and Erk phosphorylation [26]. Notably, ZIP9 is expressed in
breast cancer and prostate cancer cell lines [72], and ZIP9 acts as a membrane androgen receptor (mAR)
that is independent of nuclear androgen receptors [27]. Testosterone treatment increases intracellular
Zn concentrations, thereby upregulating a gene related to apoptosis [72]. These findings suggest that
ZIP9 is important for various cellular functions, particularly in some types of cancer cells, where it
regulates Zn homeostasis and/or hormone functions.
2.10. ZIP10
ZIP10 is mainly localized to the plasma membrane, and it functions as a cell surface Zn
importer [28,73]. As described above, ZIP10 forms a functional heteromeric complex with ZIP6 [58].
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E-cadherin in breast cancer cells and renal carcinoma cells [20,74]. ZIP10 is transcriptionally regulated
by STAT proteins in early B cells, and is overexpressed in lymphoma, indicating that ZIP10 is involved
in the initiation or development of cancers [28]. Interestingly, Bin et al. showed that ZIP10 is
required for skin epithelium development, such as the epidermis and hair follicles (Figure 3D) [30].
Together with the requirement of ZIP10 in B cell functions and skin developments, updates on the
roles of ZIP10 are described in the next section.
2.11. ZIP11
ZIP11 is localized to the nucleus and Golgi apparatus [75,76]. Recently, Martin et al. suggested
that ZIP11 plays an important role in the Zn homeostasis required to maintain mucosal integrity,
function, and pH within the mouse stomach and colon [75]. Another study suggested that ZIP11
modulates the risk of bladder cancer and renal cell carcinoma [77]. However, the physiological and
cellular functions of ZIP11 are not well-defined.
2.12. ZIP12
ZIP12 is highly expressed in human, mouse, and Xenopus tropicalis brain tissue [78]. Inactivation
of ZIP12 caused developmental arrest and lethality during neurulation in Xenopus tropicalis [78].
ZIP12 was shown to play an important role in neuronal differentiation involving the activation
of cAMP response element binding protein (CREB) signaling, neurite outgrowth, and tubulin
polymerization [78]. A recent study detected ZIP12 expression in pulmonary vascular smooth
muscle cells under hypoxic conditions. The inhibition of ZIP12 suppressed cell proliferation and
increased intracellular labile Zn in hypoxic-cells [31]. Genetic disruption of ZIP12 in rat attenuates
hypoxia-associated pulmonary hypertension in hypoxic environments [31]. Thus, inhibition of ZIP12
may be useful for treating pulmonary hypertension.
Interestingly, a recent study showed that increased ZIP12 expression in the dorsolateral prefrontal
cortex causes schizophrenia [79], as described below.
2.13. ZIP13
ZIP13 is expressed in hard and connective tissues and, it is mainly localized to the Golgi
apparatus [32,33]. Interestingly, a recent study showed that Drosophila ZIP13 (dZIP13) transports
not only Zn, but also Fe [80]. The amino acid sequence of mammalian ZIP family members determined
by the Protein Basic Local Alignment Search Tool (BLASTP) search, revealed that dZIP13 is highly
homologous to human ZIP13 [80]. Both the gut and rest of the body exhibited Fe reduction after
dZIP13 knockdown, and Fe increase when dZIP13 was overexpressed. dZIP13 affects Fe absorption,
as described above, and it is known that dietary Fe absorption is mediated by ferritin in Drosophila [81].
Thus, these results suggest that knockdown of dZIP13 inhibits Fe transport into the secretory pathway
to be available to ferritin, reducing Fe export from the gut for systemic use, while the overexpression of
dZIP13 increases Fe concentrations in the body by facilitating Fe transport into the secretion pathway,
making less Fe available in the cytosol of the gut cells. Taken together, dZIP13 potently mediates Fe
export to the secretory pathway [80].
Previous studies reported that ZIP13 is involved in bone morphogenetic protein
(BMP)/transforming growth factor β (TGF-β)-mediated Smad localization to the nucleus
(Figure 3E) [32]. It was demonstrated that bone, tooth, and connective tissues development and
systemic growth are impaired in Zip13-KO mice, as well as in patients with the loss of functions
of ZIP13 proteins [32,82,83]. These patients exhibited significantly decreased white fat mass.
Recently, Fukunaka et al. demonstrated that ZIP13-mediated Zn transport plays a critical role in
suppressing adipocyte browning by reducing C/EBP-β proteins [84], which are discussed in this issue
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2.14. ZIP14
ZIP14 is localized to the plasma membrane and endosome, and expressed in the small
intestine, liver, pancreas, and heart [85,86]. Recent studies have shown that ZIP14 is highly
expressed in the various cancers in human including the colorectal cancer, hepatocellular cancer, and
prostate cancer [87–90]. In Zip14-KO mice with dwarf body sizes, osteopenia, and impaired skeletal
growth, cellular and molecular investigations revealed that ZIP14 modulates G protein-coupled
receptor-mediated cAMP-CREB signaling by suppressing basal phosphodiesterase (PDE) activity
(Figure 4D) [38]. Moreover, studies with Zip14-KO mice have indicated that ZIP14-mediated Zn
transports involved in the metabolic endotoxemia, acute and chronic inflammation, intestinal barrier
function, hypertrophic adiposity, and impaired glucose metabolism and ER stress [34–37,91,92].
In addition to Zn transportation, ZIP14 has been reported to transport metals such as Fe and
Mn in vivo [93,94]. Fe is required for vital metabolic processes in cells; however, excess Fe has toxic
effect in cells and can initiate Fe-overload disorders, such as hereditary hemochromatosis, resulting in
liver cirrhosis, diabetes, and heart failure [95]. Fe uptake is also known to be regulated by two
principle pathways, transferrin (Tf)-Fe via the Tf-receptor (TfR) pathway and nontransferrin-bound Fe
(NTBI) through divalent metal transporters, such as DMT1, which is required for intestinal Fe uptake.
A previous study using a cell culture system showed that SLC39A14/ZIP14 transport is involved not
only in the uptake of Zn, but also in that of Fe in hepatocytes (Figure 4E) [96]. Moreover, a tissue
expression array showed that Zip14 mRNA is ubiquitously expressed at high levels in the liver,
pancreas, and heart [86]. Therefore, Jenkitkasemwong et al. evaluated the role of ZIP14 in NTBI uptake
in vivo [94]. Zip14-KO mice showed decreased 59Fe-NTBI uptake in hepatocytes. The authors crossed
Zip14-KO mice with Hfe-KO and Hfe2-KO mice to develop an animal model of hemochromatosis in
order to determine if ZIP14 is required for tissue Fe accumulation in Fe overload. Analysis of single-
or double-KO mice revealed that ZIP14 deficiency in hemochromatotic mice greatly diminished Fe
overloading in the liver and prevented Fe deposition in hepatocytes. These findings suggest that ZIP14
is required for NTBI uptake into hepatocytes. Thus, ZIP14 is essential for the developments of hepatic
Fe overload in hemochromatosis and for Fe loading of hepatocytes (Figure 4E) [94].
In addition to Zn transportation, ZIP14 has also been reported to transport Fe and manganese
(Mn) [93,96]. A recent study demonstrated that ZIP14 is a potent candidate molecule for inducing
hemochromatosis [94], and, more recently, ZIP14 was reported to transport Mn in humans [52].
Its loss of function causes similar symptoms as parkinsonism-dystonia with neurodegeneration and
hypermanganesemia in childhood (Table 2) [52], indicating that although ZIP14 may be a therapeutic
target, further investigations to clarify the molecular basis of ZIP14 are needed, as described below.
3. Updates on the Role of ZIP Transporters in Pathophysiology and Human Diseases
In this section, we describe updated information on the role of ZIP transporters, mainly focusing
on the pathophysiology. Recently, many studies of ZIP transporters have been conducted, which
have improved the understanding of their crucial involvement in physiological events and showing
that the loss of their functions causes diseases. Among the ZIP members, we selected ZIP7, ZIP10,
ZIP12, ZIP13, and ZIP14 as ZIP transporters, of which investigations in vivo have been remarkably
and rapidly progressed, so that advanced information of these molecules are reviewed below.
3.1. ZIP7
3.1.1. ZIP7 Contributes to Intestinal Epithelial Homeostasis
Although ZIP7 has attracted much interest in numerous research fields and many studies have
been performed in primary cells and cell lines, as described above [21,59,61], the in vivo functions
of ZIP7 remained unclear because of the lack of a Zip7-KO animal model. A recent investigation
demonstrated that ZIP7 is highly expressed in transit-amplifying (TA) cells and Paneth cells at the
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gene specifically in intestinal epithelium cells [23]. They demonstrated that Zip7-cKO mice, which died
within a week with the loss of intestinal stem cells and epithelial integrity, showed a loss of the
proliferating compartment under increased ER stress.
ER stress triggers a signaling reaction known as the unfolded protein response (UPR), which
plays a crucial role in regulating the proliferation of the intestinal epithelium [97,98]. However,
excessive UPR induces ER stress, leading to the activation of apoptosis signaling in the Zip7-KO TA cell
population. Collectively, these findings suggest that TA cells enhanced UPR signaling and maintained
cell proliferation in the lower region of the intestinal crypt. ZIP7 upregulated by UPR signaling
maintained Zn homeostasis under ER stress, which promoted epithelial proliferation. This mechanism
plays an important role in maintaining intestinal stemness, and it is highly sensitive to the death of
neighboring cells induced by ER-stress. Thus, ZIP7 may be a novel regulator of intestinal epithelium
homeostasis by maintaining ER function [23].
3.1.2. ZIP7 Is Required for Dermal Development in Skin
Skin is the first area that manifests Zn deficiency [99]. However, the molecular mechanisms
by which Zn homeostasis affects skin development remain largely unknown. A recent study
by Bin et al. further confirmed that ZIP7 is a critical molecule for regulating ER functions in the
dermis, and thus it is necessary for proper skin formation [22]. Connective tissue-specific Zip7-cKO
mice exhibited growth retardation, decreased hair follicles, abnormal incisor teeth, and sunken
and down-slanting eyes. Microarray experiments analyzing ZIP7 expression profiles in human
mesenchymal stem cells indicated that the upregulated genes were mainly involved in the response
to ER stress, while downregulated genes were mainly involved in cell cycle-related processes and
differentiation processes. Moreover, deletion of ZIP7 downregulated PDI activity by increasing ER
Zn levels, and induced overexpression of UPR genes [22]. These findings indicate that ZIP7 is a key
regulator for resolving ER stress to normalize ER functions; therefore, control of ZIP7 may unlock
therapeutic opportunities for overcoming human diseases that are arising from ER dysfunction.
3.2. ZIP10
3.2.1. ZIP10 Is Necessary for the Development and Functioning of B Lymphocytes
Zn deficiency leads to lymphopenia and the attenuation of both cellular and humoral immunity,
resulting in an increased susceptibility to various pathogens [100,101]; however, little is known about
how Zn regulates immune function. Miyai and Hojyo et al. investigated the expression profile
of ZIP transporters and found that ZIP10 was highly expressed in B lymphocytes, particularly in
cells in the early stages of B cell development, such as in pro-B cells [28,102]. They evaluated the
physiological role of ZIP10 in early B cells by generating B cell-specific KO mice by using Mb1-cre
mice, which exhibited fewer peripheral B cells and decreased pro-B cell survival. Zip10 ablation
in pro-B cells in vitro enhanced the activities of caspase-3, -8, -9, and -12, resulting in increased
apoptotic cell death, which was mimicked by chemically chelating intracellular Zn; these negative
effects were reversed by Zn supplementation [28] (Figure 3C left). Moreover, they demonstrated that
activated STAT3 and STAT5 regulate the ZIP10 expression upon cytokine stimulation [28]. Because it is
well-known that JAK-STAT signaling induced by cytokine stimulation controls pro-B cell survival and
development [103,104], these findings clearly demonstrate that “the JAK/STAT-ZIP10-Zn signaling
axis” is crucial for the survival of pro-B cells during their development [28,102].
Additionally, Hojyo et al. found another role for ZIP10 in late stage B cells by using mice, in
which Zip10 was deficient in antigen-presenting cells; these mice exhibited severely decreases germinal
center (GC) formation, which was similar to the abnormalities observed in Zn-deficient mice [29,102].
Zip10-cKO late stage B cells showed dramatically decreased proliferation after BCR cross-linking
in vitro. BCR signaling is initiated by Lyn, a Src-family protein tyrosine kinase, and Lyn activates Syk,
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Zip10-cKO B cells showed hyperactivated BCR signaling, which reduced cell proliferation (Figure 3C
right). Furthermore, CD45R protein tyrosine phosphatase activity was downregulated in Zip10-cKO B
cells. Thus, the deletion of ZIP10 in late stage B cells led to dysregulated BCR signaling due to reduced
CD45R protein tyrosine phosphatase activity and impaired proliferation, as well as decreased GC
formation, indicating that the ZIP10-mediated Zn stream is required for proper B cell signaling.
Together, these findings indicate that ZIP10 is indispensable for both, the homeostasis and
functioning of B cells; therefore, ZIP10-mediated Zn homeostasis is relevant to B cell-immunity,
explaining the importance of Zn in acquired immunity [10].
3.2.2. ZIP10 Is Necessary for Epidermal Homeostasis
The most recent study by Bin et al. revealed that ZIP10 is essential for epidermal formation [30].
As described above, Zn appears to be primarily essential for the differentiation, proliferation, and
survival of epidermal keratinocytes in the skin [107]. However, the molecular relationship between Zn
homeostasis and cells forming the skin epidermis is not well-understood. ZIP10 was found to be highly
expressed in the outer root sheath of hair follicles [30]. Epithelium tissue-specific Zip10-cKO mice that
were generated by using Keratine14-cre mice exhibited severe hypoplasia in the stratified epithelia,
decreased hair follicles, and thymus atrophy, as the thymus medullae predominantly expresses ZIP10,
which plays a role in maintaining this structure [30]. Moreover, the loss of ZIP10 interferes with the
functions of p63, a master epidermal regulator containing a DNA-binding domain and Zn binding
site [108], indicating the relevance of ZIP10-mediated Zn signaling in p63 function. Thus, ZIP10 plays
important roles in epithelial tissue development via, at least in part, the ZIP10-Zn-p63 signaling
axis, highlighting the physiological significance of Zn regulation in maintaining the skin epidermis
(Figure 3D). These results provide insight for generating new therapeutic approaches by targeting hair
follicle-localizing ZIP10. Furthermore, ZIP10-specific agonist may be useful as a trichogenous agent.
3.3. ZIP12
ZIP12 Contributes to Cortical Functions
It has been reported that ZIP12 is related to the pathogenesis of pulmonary hypertension [31].
However, the relationship between ZIP12 and human disease remains unclear. Scarr et al.
demonstrated that in schizophrenia patients, ZIP12 expression is increased in the cortex according to
gene expression profiling [79]. Moreover, Zn uptake analysis showed that two variants of ZIP12 have
Zn transport functions in cells. However, total cortical Zn levels were not altered in brain tissues from
schizophrenia patients, which may be because of changes in Zn homeostasis that are controlled by ZnTs.
These results suggest that the increased expression of ZIP12 in brain tissues induces an imbalance in Zn
homeostasis, causing the onset of schizophrenia. If ZIP12-specific antagonists are identified, this may
be alternative approach for developing more effective drugs for schizophrenia when compared to
existing drugs.
3.4. ZIP13
Molecular Mechanisms of ZIP13 Pathogenic Mutated Proteins
The first identified genetic disease that was associated with a ZIP family member was AE
associated with a mutation in ZIP4 [46,47]; however, the pathophysiological role of ZIP family members
except for ZIP4 in human diseases were unknown until 2008. Fukada et al. found that Zip13-KO
mice show delayed growth and abnormalities in hard and connective tissue development [32],
and a loss of function mutations were found in a novel variant of human Ehlers–Danlos syndrome
(EDS): Spondylocheirodysplastic Ehlers–Danlos syndrome (SCD-EDS; OMIM 612350), demonstrating
the importance of ZIP13 in the development and homeostasis of hard and connective tissues
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loss-of-function mutation in ZIP13 gene, and genetic analysis showed that the pathogenic mutation
was a glycine to aspartic acid substitution at position 64 (G64D) in the ZIP13 protein, which is encoded
by SLC39A13 [32]. Another mutant ZIP13 protein contains a deletion of amino acid residues 162–164
(phenylalanine–eucine–alanine) in ZIP13, which was also reported in SCD-EDS patients [83]. Bin et al.
revealed that human ZIP13 protein forms a dimer [33,109]. Both mutant ZIP13 proteins are readily
degraded by the valosin-containing protein-linked ubiquitin (Ub)-proteasome pathway, presumably
by their misfolding during the protein maturation process, resulting in ZIP13 proteins with reduced
functions [82]. Thus, ZIP13 mutants are susceptible to Ub-proteasome pathways, and the maintenance
of Zn homeostasis via ZIP13 is impaired in cells expressing mutant ZIP13, leading to severe SCD-EDS
pathogenesis in Zip13-KO mice [33,109] (Figure 3E). However, whether this also occurs in mammals
and whether this conclusion explains the onset of SCD-EDS remain unclear. Further studies
are required to resolve the complexity of ZIP13-mediated mammalian in vivo physiology and its
molecular mechanisms.
3.5. ZIP14
ZIP14 Mediates Manganese Homeostasis
Mn is also an essential element for humans and is normally present in various tissues,
including the brain, liver, and kidney. Mn imbalance impairs brain functions and causes disorders
such as parkinsonism dystonia [110]. Previous studies showed that Mn transport is regulated
by several transporter proteins, including DMT1 [111], ferroportin [112], SLC39A8/ZIP8 [71],
and SLC30A10/ZnT10 [113], in addition to SLC39A14/ZIP14 [93]. Among these, the molecular details
of ZIP14 in Mn transport are currently being examined. The expression and Mn transport function
of ZIP14 is regulated by interleukin-6 in human neuroblastoma cells [114]. Recently, Tuschl and
colleagues found that loss-of-function mutations in ZIP14 cause hypermanganesemia and progressive
parkinsonism [52]. Mutation in Zip14 by CRISPR/Cas9 genome editing resulted in reduced Mn
disturbance in Zip14-mutated zebrafish [52], clearly demonstrating the relevant role of ZIP14-mediated
Mn homeostasis in maintaining health.
The most recent reports described the physiological role of ZIP14 in Mn uptake in vivo [93,115].
Interestingly, Zip14-KO mice began to show signs of dystonia with a progressive inability to coordinate
their motor activities [93], similar to PD-like motor disability in patients with a mutation in ZIP14 [52].
ZIP14 has been shown to be highly expressed in the liver [94]. Therefore, hepatocyte-specific Zip14-cKO
mice that were generated using Albumin-cre mice showed significantly reduced hepatic Mn levels,
but not normal levels of Mn in other tissues such as the brain, kidney, and pancreas [93]. In contrast,
upon consuming a high-Mn diet, hepatocyte-specific Zip14-cKO mice showed increased Mn levels
in the serum and brain, but not in the liver. Based on these findings, hepatic ZIP14 regulates the
uptake, transport, and storage of Mn. Our results provide insight into Mn homeostasis in humans.
Thus, ZIP14 is a potent and major Mn importer in the liver, and recent studies have revealed the clinical
effects of disrupting Mn homeostasis (Figure 4E) [52].
4. Conclusions and Perspectives
As evident from previous and current studies on the role of Zn in the physiological and
pathophysiological events described above, information that is related to the biological relevance of
Zn as an essential trace element is accumulating rapidly. Recent studies involving mice and humans
suggested that Zn transporters have various physiological functions in tissue development and
homeostasis. As described in the sections above, some studies have revealed the relation between the
functions of Zn transporters and specific diseases. Despite the current progress in our understanding
of the physiological functions of Zn transporters, many questions remain regarding the role of Zn
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Zn transporters are expressed in various tissues and cell types, and they are localized in distinct
subcellular compartments; these proteins transport not only Zn, but also Fe, Mn, cadmium, and other
trace elements into subcellular compartments, indicating that the functions of Zn transporters are
complex and diverse. Thus, studies clarifying the transportation mechanisms, not only of Zn but also
of other metal ions, are required to understand the relation between the homeostatic mechanisms of
metal ions and various diseases. This information will improve our understanding of the wide-range
of functions of Zn ion and its transporters in diverse organisms. These studies may reveal how Zn ion
regulates biological functions, and provide information related to its homeostasis (Figure 5) [116].
Figure 5. Summary of Zn signal axis in physiology and pathogenesis. Each Zn transporter
regulates specific target molecules and cellular responses known as the “Zn-signal axis” [117] which
transduces their signals to various physiological processes such as the bone and skin development,
endocrine system, and aging. Dysfunction of the Zn signal results in impaired numerous cellular
events, leading to various pathophysiological conditions such as inflammation, energy metabolism
disorders, and cancer.
According to reports on the involvement of Zn transporters in tissue development and
homeostasis, the dysfunction of Zn transporters is crucial not only to disease progression, but also
to disease onset. Thus, investigating the functions of Zn transporters in tissue development and
homeostasis using pluripotent stem cell lines from patients with abnormal Zn-homeostasis is important
for addressing these fundamental questions regarding useful disease models. If Zn transporter
dysfunctions determine the onset of diseases, modulating their function by specific compounds will
provide crucial clues for the development of therapeutic strategies. In addition, no studies have
examined the specific compounds that are regulating Zn transporter functions, but such compounds
may have great potential for the development of novel therapeutic strategies.
Finally, further intensive research effort to examine Zn transporters would reveal critical molecular
mechanisms that are related to mammalian health and disease.
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PDI Protein disulfide isomerase
SCD-EDS Spondylocheirodysplastic Ehlers-Danlos syndrome
SLC Solute carrier
TGF-β Transforming growth factor beta
UPR Unfolded protein response
ZIP Zrt- and Irt-like protein
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Abstract: A distinct G-protein coupled receptor that senses changes in extracellular Zn2+,
ZnR/GPR39, was found in cells from tissues in which Zn2+ plays a physiological role.
Most prominently, ZnR/GPR39 activity was described in prostate cancer, skin keratinocytes,
and colon epithelial cells, where zinc is essential for cell growth, wound closure, and barrier formation.
ZnR/GPR39 activity was also described in neurons that are postsynaptic to vesicular Zn2+ release.
Activation of ZnR/GPR39 triggers Gαq-dependent signaling and subsequent cellular pathways
associated with cell growth and survival. Furthermore, ZnR/GPR39 was shown to regulate the
activity of ion transport mechanisms that are essential for the physiological function of epithelial and
neuronal cells. Thus, ZnR/GPR39 provides a unique target for therapeutically modifying the actions
of zinc in a specific and selective manner.
Keywords: zinc; ZnR/GPR39; zinc signaling; neuron; keratinocyte; epithelium; intestine; colon; bone
1. Introduction
The symptoms of zinc deficiency are particularly prominent in the digestive, immune, nervous,
endocrine, and integumentary systems [1–5]. In many cases dietary zinc supplementation can
ameliorate the symptoms and indeed zinc supplementation is widely used to treat diarrhea,
the common cold, and skin conditions. The mechanisms underlying the roles of zinc have been
revealed in the last two decades, but there is still a lot to learn about the pathways and regulation of
zinc ions (Zn2+). Initially, Zn2+ was identified as a structural element and cofactor in enzymes [6,7]
and transcription factors [8–10]. It is estimated that about 3000 proteins contain Zn2+ binding sites,
and interaction with Zn2+ regulates or modulates the activity of these proteins, thereby affecting
numerous cellular processes [11]. Cellular Zn2+ is associated with these proteins with a very
high affinity and is considered a tightly bound pool of Zn2+ [10,12]. The labile Zn2+ pool in cells
includes proteins that interact with Zn2+ via histidines, cysteines, or glutamate/aspartate residues;
most prominent are the metallothioneiens (MTs) Zn2+ binding proteins [13]. This is a dynamic
pool that releases Zn2+ upon redox signaling and oxidative or nitrosative stress, and contributes to
cellular signaling [14–18]. In addition, cytosolic Zn2+ rise, likely mediated by Zn2+ transporters
on the endoplasmic reticulum (ER), was monitored in mast cells following activation of the
immunoglobulin receptor [19,20]. Subsequent studies determined that Zn2+ transporters found on
various cellular organelles induce changes in cytosolic or organellar Zn2+ and thereby modulate cellular
signaling [21–26]. Indeed, Zn2+ transport from the ER, Golgi, or mitochondria plays an important
role in the function of mammary gland or prostate epithelial cells and other secretory cells [27–29].
Similar release of Zn2+, from the ER, during cardiac function regulates Ca2+ leakage from the ER in these
cells [30,31]. These studies established Zn2+ as a second messenger that is released following diverse
stimuli and triggers the regulation of kinases or phosphatases as well as protein expression [20,32].
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Cellular Zn2+ is buffered by interaction with proteins and formation of complexes to rapidly reduce
levels of Zn2+ to the picomolar range [17,33]. Importantly, transient changes in extracellular levels
of Zn2+ can also occur following release of Zn2+-containing vesicles. Such vesicular Zn2+ is found in
neurons, epithelial Paneth cells of the intestine or the salivary gland, as well as in pancreatic β-cells [34].
The vesicular Zn2+ can be released during normal activity of the cells; for example, Zn2+ is released into
the synapse during neuronal activity or is secreted from β-cells or mammary epithelial cells [35–40].
Release of Zn2+ from cells can also occur following cellular injury and cell death, which liberates
Zn2+ from the numerous Zn2+-binding proteins or cellular organelles [41]. Extracellular Zn2+ can
interact with specific binding sites on numerous proteins and regulate their activity. For example,
extracellular Zn2+ allosterically modulates numerous neuronal receptors, i.e., N-methyl-D-aspartate
(NMDA), γ-Aminobutyric acid (GABA), or glycine receptors, thereby modulating the excitatory
and inhibitory responses [42–46]. In epithelial cells, extracellular Zn2+ regulates the activity of
purinergic receptors and the store-operated Ca2+ (SOC), representing an important link between
Zn2+ and intracellular Ca2+ [47–49]. Application of Zn2+ was also suggested to upregulate the
phosphatidylinositol-4,5-bisphosphate 3 (PI3) kinase/AKT pathway [50] or mitogen-activated protein
kinases (MAPKs) [51], both essential to cell survival and proliferation.
2. Identification of a Zn2+-Sensing Receptor, ZnR/GPR39
In addition to the large numbers of Zn2+ homeostatic proteins described above, a distinct
target for extracellular Zn2+ is the plasma membrane G-protein coupled receptor that is sensitive
to Zn2+, ZnR/GPR39 [52–54]. G-protein coupled receptors are a large family of seven-transmembrane
proteins that mediate cellular signaling in response to a diverse array of extracellular stimuli [55].
The endogenous Zn2+, released during physiological activity, acts as a first messenger and triggers
intracellular Ca2+ signaling via the specific Gαq-coupled receptor ZnR/GPR39 [34,56]. Activity of
ZnR/GPR39 in tissues relevant to Zn2+ signaling has been identified in neurons, colon epithelial cells
(colonocytes), skin epidermal cells (keratinocytes), pancreatic cells, prostate cancer cells, salivary gland
cells, and in bones [57–61]. In neurons, stimulation of the mossy fibers triggers ZnR/GPR39-dependent
Ca2+ rises in postsynaptic CA3 (Cornu Ammonis 3) neurons [62] that are diminished in the presence of
a non-permeable Zn2+ chelator, or in the absence of the Zn2+ transporter-3 (ZnT3), which is responsible
for synaptic Zn2+ accumulation. Similar ZnR/GPR39 responses were observed in postsynaptic
neurons of the auditory brainstem nucleus, the dorsal cochlear nucleus [63]. Importantly, ZnR/GPR39
activity was shown to enhance neuronal inhibitory tone, and zinc deficiency is associated with
epilepsy and seizures, suggesting the significant physiological role of ZnR/GPR39 [53,64–68]. Luminal
application of Zn2+ to colon epithelial cells, colonocytes, was sufficient to activate the plasma membrane
ZnR/GPR39 [69], which is highly expressed in this tissue [70,71]. In colonocytes, ZnR/GPR39
activated cellular pathways that are strongly associated with cell growth, MAP, and PI3 kinases.
The prominent role of zinc supplementation in digestive system function, taste disorders, and salivary
secretion suggests that ZnR/GPR39 may play an important role in the physiological functions of
this system. A specific role for zinc in wound healing and the strong link between its deficiency and
skin lesions suggested that ZnR/GPR39 may mediate cell proliferation and wound healing, thereby
contributing to skin health. A recent study also describes ZnR/GPR39 expression in the oviduct,
where it colocalized with a higher concentration of Zn2+ but its activity has not been studied [72].
While a link to Zn2+ physiology is still not clear, ZnR/GPR39 was also associated with adipocyte
and myoblast proliferation and differentiation [73,74]. Activation of ZnR/GPR39 was triggered by
transient changes in extracellular Zn2+. While exogenous application of Zn2+ may trigger ZnR/GPR39
activation, the endogenous sources of vesicular Zn2+ may be the physiological trigger of ZnR/GPR39
activation, i.e., Zn2+ released from neuronal vesicles, salivary gland vesicles, pancreatic enzymes,
or Paneth cells in the intestinal epithelium [35–40,75]. In addition, extracellular Zn2+ levels may
transiently change following efflux mediated by Zn2+ transporters, such as ZnT6 [76], or following
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3. ZnR/GPR39-Dependent Signaling
Intracellular Ca2+ signaling triggered by extracellular Zn2+ was the first functional identification
of a distinct Zn2+ sensing receptor, named ZnR [77]. Use of pharmacological inhibitors of
Gαq [78,79], inositol 1,4,5-trisphosphate (IP3) receptor and the phospholipase C (PLC), indicated
that a Zn2+-dependent Ca2+ rise is mediated by activation of a Gαq-coupled receptor, such that the
Ca2+ is released from thapsigargin-sensitive stores following activation of the IP3 receptor [52,57]
(see Figure 1). Importantly, the Zn2+-dependent signaling was mediated by changes in extracellular,
and not intracellular, levels of this ion, as expected from a G-coupled receptor [52,57]. The search
for the protein that mediates Zn2+-dependent signaling focused on members of the Gαq family of
receptors, their possible isoforms, or interactions between these receptors that may affect the affinity
towards Zn2+; the main candidate in this family was the Ca2+-sensing receptor (CaSR). Most G-protein
coupled receptors are activated by peptides and not cations, but a CaSR was already identified and its
physiological significance to cellular signaling was established [80,81]. The similarity of the ligands
and the signaling pathway activated by the CaSR and the putative ZnR suggested that these may
be isoforms of the same receptor. Surprisingly, Zn2+ turned up in a screen of serum for the agonist
of GPR39, which was an orphan receptor until then [82], subsequent studies confirmed that ZnR
and GPR39 are one receptor, termed ZnR/GPR39. Despite their ligand similarity, CaSR and GPR39
are not members of the same subfamily of G-protein coupled receptors. The GPR39 is a member of
ghrelin receptor family A, while CaSR is a member of family C of the G-protein coupled receptors [83].
It is important to note that ZnR/GPR39 is not activated by extracellular Ca2+, nor is the CaSR activated
by Zn2+ [52,84]. Nevertheless, the affinity of ZnR/GPR39 to Zn2+ is modulated by Ca2+, as the K0.5
of ZnR/GPR39 in salivary gland cells was ~55 μM in the presence of Ca2+ and only ~36 μM in its
absence [58]. This may be mediated by a direct effect of CaSR on ZnR/GPR39 conformation or its
membrane expression or by a direct effect of Ca2+ on the Zn2+-binding site. Indeed, ZnR/GPR39 and
the CaSR have been shown to directly interact in an exogenous overexpression system and may thereby
modulate cation-dependent signaling in many systems where they are both expressed [84]. Importantly,
the orphan receptor GPR39 was initially suggested to mediate signaling triggered by the obesity-related
peptide obestatin [85]. These results were not reproduced by other laboratories and a study using serum
identified Zn2+ as the endogenous ligand of GPR39 [82]. Using silencing and overexpression, it has been
shown that the endogenous Zn2+-dependent signaling is mediated by GPR39, which is highly selective
for Zn2+ and is not activated by Mn2+, Cu2+, or Fe2+ [52,53]. The affinity of ZnR/GPR39 to Zn2+ was
physiologically adapted to the relevant tissues. For example, Zn2+ concentration in the digestive system
lumen may reach hundreds of μM [86–88] and the colonocytic ZnR/GPR39 has an EC50 (half maximal
effective concentration) of 80 μM [52,57]. Physiological relevance was further established when Zn2+
release from Caco-2 colonocytes was sufficient to induce ZnR/GPR39-dependent cell growth and
tight junction formation [69,89]. In addition, in a cholera toxin model of diarrhea or a dextran sodium
sulfate model of colitis, ZnR/GPR39-dependent pathways were not activated following dietary Zn2+
depletion [90,91]. Similarly, in the prostate, where there are high concentrations of Zn2+/citrate
complex and transient release of this ion is likely to occur following cell death or changes in pH,
ZnR/GPR39 is adapted to the relevant concentrations, which range from 10 to 200 μM [59]. In contrast,
in keratinocytes ZnR/GPR39 EC50 to Zn2+ is in the nanomolar range, likely because this tissue contains
much lower concentrations of labile Zn2+ [41]. Most importantly, the ZnR/GPR39 is triggered during
keratinocytic injury, as shown using a scratch assay [41]. In addition, the neuronal ZnR/GPR39 has
an affinity that is adapted to the release of Zn2+ from the synaptic mossy fiber terminals, and indeed
very mild activation of these fibers induces sufficient Zn2+ levels to trigger postsynaptic ZnR/GPR39
signaling [62,92]. The differences in the affinity of the ZnR/GPR39 may result from its interaction with
other, physiologically relevant G-protein coupled receptors in the tissues, as has been established for
many receptors of this family [93].
Since Zn2+ can interact with numerous intracellular and extracellular proteins, application of this
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would be of importance. Using various screening methods, agonists for ZnR/GPR39 have been
suggested but very few were successfully tested in endogenous tissues. A recent study identified
several compounds that may interact with ZnR/GPR39 and were shown to affect gastric function
in wild-type but not GPR39 knockout mice, yet these compounds only potentiated the response
of the ZnR/GPR39 to Zn2+ itself [94]. The use of molecular approaches to modulate expression of
ZnR/GPR39, together with pharmacological inhibition of its signaling pathway, is therefore still
important to study the effects of ZnR/GPR39. Indeed, the first description of the role of ZnR/GPR39
was established using a knockout mouse, which exhibited accelerated gastric emptying and increased
body weight and fat composition [70]. This phenotype strengthened the link between the receptor and
the well-known effects of Zn2+ on the gastrointestinal system. Future studies using knockout mice
required challenging the mice to trigger a phenotypic distinction from the wild-type mice, suggesting
that ZnR/GPR39 has a role in stress conditions. Finally, overexpression of ZnR/GPR39 in exogenous
systems resulted in signaling that exhibited constitutive activity or was suggested to trigger Gαs or
Gα12/13 signaling and CRE- or SRE-dependent gene expression [83], but the physiological significance
of these pathways is yet to be determined.
Figure 1. Schematic representations of common Zn2+ sensing receptor, ZnR/GPR39, signaling in
epithelial cells. Extracellular signal–regulated kinases, ERK; Phosphatidylinositol-4,5-bisphosphate 3
(PI3) kinase/AKT, PI3K/AKT; Phospholipase C, PLC.
Activation of the Gαq is triggering PLCβ activation and subsequent Ca2+ release from
thapsigargin-sensitive ER stores. Insets show the Fura-2 fluorescent signals in cells expressing
ZnR/GPR39 following application of Zn2+. The top left inset shows the calibrated level of Ca2+
change, monitored with Fura-2, obtained in the presence or absence of extracellular Ca2+; the right
upper inset shows the % change of Ca2+ levels, relative to baseline Fura-2 fluorescence, in the presence
or absence of the Gαq inhibitor (YM-254890); and the right bottom panel shows the % change of Ca2+
levels in the presence of the PLC inhibitor (U73122 active form, or U73343 inactive form). Subsequent
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(shown in blots in the lower panels), indicating activation of the MAPK or PI3K pathways, respectively.
(The figure was composed using Servier Medical Art templates (http://smart.servier.com/)).
Subsequent to the Ca2+ rise, ZnR/GPR39-triggers activation of the ERK/MAPK and AKT/PI3K
pathways [57,84] that are essential for cell survival and proliferation [95]. ZnR/GPR39 activation
in keratinocytes, colonocytes, and prostate cancer cells was shown to upregulate ERK and AKT
phosphorylation and thereby cell growth. Activation of the Zn2+-dependent Ca2+ response was first
shown to activate ERK1/2 phosphorylation, which was attenuated by functional de-sensitization
of ZnR/GPR39, critical for protecting cells from excessive activation of the signaling [84].
In androgen-insensitive prostate cancer cell lines, ZnR/GPR39 activation by Zn2+ triggers PI3K
pathway upregulation, which is reflected by increased expression and phosphorylation of AKT [84],
associated with more malignant phenotypes of carcinomas [96–98]. Butyrate is a short-chain fatty
acid found to affect colon epithelial cell growth and carcinogenesis [99–102]. In the colonocytic cell
line, butyrate-induced apoptosis was attenuated by ZnR/GPR39-dependent activation of MAPK
and PI3K pathways that increased expression of the pro-survival protein clusterin [69]. Moreover,
enhanced cell proliferation was monitored using BrdU in colon tissue from ZnR/GPR39 expressing
mice, but not in GPR39 knockout mice, during recovery from treatment with the toxin dextran sodium
sulfate [90]. Under normal conditions BrdU staining in knockout mice lacking ZnR/GPR39 did
not show differences from the wild-type tissue, suggesting that the baseline proliferation is intact,
in agreement with the mild phenotype of these mice. The requirement for enhanced proliferation
following the injury is the process that is impaired in the absence of ZnR/GPR39. As such, a role for
ZnR/GPR39 may also underlie the healing effects of Zn2+ on gastric ulcers [103]. Topical application
of zinc-containing ointments to enhance wound healing and re-epithelialization of the skin is well
established [104–107]. Indeed ZnR/GPR39 activation in keratinocytes was shown to trigger MAPK
phosphorylation and increased rate of scratch closure, suggesting that the receptor may mediate
the effects of Zn2+ [41]. Finally, pre-adipocyte proliferation and differentiation are also induced
following AKT activation, associated with ZnR/GPR39 expression [73,108]. In neurons, ZnR/GPR39
and subsequent Ca2+ release are essential for activation of MAPK by Zn2+ [92,109]. Such activation
of the MAPK pathway by metabotropic signaling mediates changes in synaptic plasticity [110,111].
Finally, activation of ZnR/GPR39 in a salivary gland ductal cell line was shown to induce ATP
release that mediated metabotropic signaling via the purinergic system in neighboring smooth muscle
cells [58]. Thus ZnR/GPR39 has paracrine effects on neighboring cells, which may provide an
important mechanism by which Zn2+ can affect physiological processes in tissues where not all cells
express ZnR/GPR39 itself.
Zn2+, in contrast to most ligands of G-protein coupled receptors, is not rapidly degraded
and a desensitization mechanism to protect cells from excessive Ca2+ signals is important for the
regulation of ZnR/GPR39 signaling. Indeed, profound and prolonged desensitization [112] is
monitored following exposure to subtoxic concentrations of Zn2+ [57,59,92]. The desensitization
of ZnR/GPR39 by prolonged Zn2+ treatment induces internalization and possible degradation of
the receptor, and profound loss of ZnR/GPR39 signaling is sustained for several hours. As such,
Zn2+-induced desensitization was also used to specifically identify the roles of Zn2+ via ZnR/GPR39.
For example, following ZnR/GPR39 desensitization the Zn2+-dependent ERK1/2 phosphorylation was
diminished in prostate cancer cells [59]. The pathways that lead to ZnR/GPR39 desensitization are not
fully understood. Recruitment of β-arrestin following ZnR/GPR39 with an allosteric modulator in the
presence of Zn2+ did not induce desensitization but inhibition of Rho kinase blocked this process [113].
Zn2+ binding to ZnR/GPR39 occurs via two histidine residues, His17 and His19 [114],
and an aspartate residue, Asp313. The pH sensitivity of these residues matched the regulation of
ZnR/GPR39 response by extracellular pH. The ZnR/GPR39-dependent Ca2+ response and subsequent
phosphorylation of MAP or PI3 kinase is completely abolished at pH 6.5 [41,109,115]. Hence,
ZnR/GPR39 activity is regulated by physiologically relevant changes in extracellular Zn2+ or pH [115].
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of Zn2+ [116]. In contrast, local pH changes during inflammatory bowel disease may attenuate
ZnR/GPR39-dependent cell proliferation in the digestive system and may contribute to epithelial
erosion and barrier breakdown [117].
4. ZnR/GPR39 Regulation of Physiological Functions
4.1. ZnR/GPR39 Regulates Ion Transport Mechanisms
Downstream to activation of ZnR/GPR39, it has been shown that transport of Na+, K+, and Cl−
are regulated. The movement of these ions is essential for the physiological functions of epithelial cells
and neurons.
The ubiquitously expressed Na+/H+ exchanger (NHE) is upregulated following cytoplasmic
acidification, to induce recovery of intracellular pH [118]. Activation of ZnR/GPR39 upregulates
NHE activity in colonocytes, keratinocytes, and neurons [41,57,69,89,109], thereby providing
a Zn2+-dependent homeostatic mechanism. Colonocytes are constantly exposed to cellular acidification,
for example by short-chain fatty acid penetration [119], which can be recovered by NHE activity.
Indeed, activation of ZnR/GPR39 in colonocytes and native colon tissues induced activation of
NHE, downstream to the Ca2+ signaling and ERK1/2 activation, which enhanced the recovery
of the colonocytic pH [57,69]. Thus, ZnR/GPR39 plays a role in pH homeostasis that is essential
for colonocytes’ survival. Importantly, Na+-dependent H+ export can lower the extracellular pH.
In keratinocytes, ZnR/GPR39 upregulation of NHE activity was also mediated via the same signaling
pathway [41]. The extracellular acidification triggered by ZnR/GPR39-dependent activation of NHE
may be required for migration of cells during wound healing or for the formation of an effective
permeability barrier [120,121]. Intracellular acid loading in neurons affects neuronal excitability
and results from metabolic H+ generation during repetitive firing [122]. Neuronal ZnR/GPR39
activation following release of Zn2+, concomitant with the neurotransmitter, resulted in increased NHE
activity, thus relieving the metabolic acidification [109]. However, acidification of neuronal surfaces,
by upregulating NHE activity, may contribute to tissue acidosis during ischemic neuronal injury [123].
Interestingly, ZnR/GPR39 itself is inactive at acidic pH [109], suggesting a homeostatic mechanism
that can attenuate ZnR/GPR39 activation of NHE and excessive tissue acidification.
The K+/Cl− cotransporters (KCC) family is responsible for mediating Cl− efflux and thereby
maintaining cell volume, as well as transepithelial ion transport and neuronal excitability [124].
These transporters are highly regulated via their phosphorylation and changes in surface
expression [125,126]. In neurons, KCC2 is crucial for mediating Cl− efflux and thereby rendering the
GABAA and glycine receptors inhibitory [127–130]. Activation of ZnR/GPR39 results in enhanced
K+-dependent Cl− transport, which is mediated by KCC2 [62,131]. This Zn2+-dependent upregulation
is abolished in the absence of ZnR/GPR39, or its downstream Ca2+ and MAPK activation. Moreover,
Gαq-dependent signaling triggered by ZnR/GPR39 enhances KCC2 surface expression and thereby
upregulates KCC2-dependent Cl− transport [62]. Similar upregulation of K+-dependent Cl− transport
was also monitored following ZnR/GPR39 activation in colonocytes [91]. Loss of Cl− and Na+ into
the colon lumen, via CFTR (cystic fibrosis transmembrane conductance regulator) upregulation for
example, produces the driving force for water loss, thereby inducing diarrhea [132]. Yet, Cl− absorption
pathways are not fully identified. Activation of ZnR/GPR39 in native colon epithelial tissue
or in colonocytic cell lines resulted in activation of KCC1, which was mitogen activated kinase
(MAPK)-dependent [91]. Moreover, KCC1 expression was shown to be basolateral, thereby providing
a pathway for modulation of Cl− absorption in the colon.
4.2. ZnR/GPR39 Regulates Tight Junction Formation
Formation of epithelial barriers strongly depends on expression of junctional proteins, such as
E-cadherin of the adherens junctions and zonula occludens-1 (ZO-1) or occludin of the tight junctions.
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exposed to pathogens, such as the digestive tract. A role for Zn2+ in modulating colon epithelial tight
junctions was previously described, but the prolonged application in that study may have resulted
in changes of intracellular Zn2+ and not only activation of ZnR/GPR39 [133,134]. Using siRNA
silencing of ZnR/GPR39 in Caco-2 colonocytic cell line revealed that ZnR/GPR39 was essential
for Zn2+-dependent upregulation of tight junction formation, thus establishing that ZnR/GPR39
has a specific role in enhancing tight junctional complexes and epithelial barrier function [89].
It was further established that these colonocytic cells release Zn2+ in a manner that activates the
ZnR/GPR39-dependent formation of the barrier, since a chelator of extracellular Zn2+ attenuated
tight junction formation. Colon from ZnR/GPR39 deficient mice exhibited diminished expression
level for the tight junction protein occludin, further revealing an important role of ZnR/GPR39 in
barrier formation in vivo [90]. This loss of tight junctions may underlie some of the immune system
effects associated with Zn2+ deficiency: as the permeation of pathogens is easier, inflammation may
be prevalent during Zn2+ deficiency. A recent study showed that Zn2+ enhanced the expression of
protein kinase C ζ (PKCζ), which was associated with ZnR/GPR39 levels, and linked to tight junction
formation during Salmonella enterica serovar Typhimurium infection [135].
5. A Role for ZnR/GPR39 in Disease
5.1. ZnR/GPR39 in Wound Healing
Perhaps the oldest known use of zinc as a treatment is in dermal ointments for enhancing wound
healing [104–107]. Zinc has been associated with proliferating tissues and is indeed accumulated in the
skin [136]. Zinc transporters, i.e., ZIP4 (Zrt-Irt-like protein) or ZIP7, knockdown or mutations in these
proteins also reveal an important role for these Zn2+ homeostatic proteins in skin formation during
development [137]. Activation of ZnR/GPR39 in primary keratinocytes and in HaCaT cells suggested
that Zn2+ may trigger this receptor signaling and may be the missing link between topical application
of zinc and wound healing [41,52]. Indeed, the pro-proliferation/migration pathways were activated
by ZnR/GPR39: ERK1/2 phosphorylation was increased via ZnR/GPR39-dependent activation of
PKC and PI3K. In a scratch assay model, silencing of ZnR/GPR39 expression or activity inhibited
the Zn2+-dependent increased rate of scratch closure [41]. One of the suggested benefits of zinc
application was associated with anti-inflammatory effects. The ZnR/GPR39-dependent activation of
NHE in keratinocytes induces acidification of the extracellular region. Such acidification is essential for
reducing barrier permeability in the skin [120]. Hence NHE activation and the subsequent acidification
by the ZnR/GPR39 may also exert an anti-inflammatory effect. Finally, if paracrine release of ATP
following ZnR/GPR39 activation [58] also occurs in keratinocytes, it suggests another mechanism to
increase the proliferation of neighboring fibroblasts that do not express ZnR/GPR39. Activation of
cellular signaling by ZnR/GPR39 may affect numerous pathways and Zn2+ binding proteins. As such,
a role for MG53, a Zn2+ binding protein, has been associated with myoblasts’ cell membrane recovery
following permeation of Zn2+ into the cells [138]. The ZnR/GPR39 has also been described in myogenic
processes, but the role of Zn2+ in this aspect has not been addressed [74], hence future studies on the
role of ZnR/GPR39 in muscle cell recovery would be of interest.
5.2. Diarrhea and Inflammatory Bowel Diseases
Prominent roles of Zn2+ include attenuation of diarrhea and amelioration of symptoms of
inflammatory ulcerative disease, such as Crohn’s disease and colitis [139–143]. Initial breakdown
of tight junctions is considered a trigger to recurrence of inflammatory bowel diseases.
The ZnR/GPR39-dependent enhancement of junctional complex proteins ZO-1 and occludin [69,89]
suggested that ZnR/GPR39 may be involved in ameliorating symptoms of inflammatory bowel
diseases. Indeed, ZnR/GPR39 deficient mice showed increased susceptibility to dextran sodium
sulfate (DSS) model of colitis [90]. Even more profound was the effect of ZnR/GPR39 during a recovery
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proliferation and crypt formation, and formation of the physical barrier, via increased expression of
occludin. The benefit of Zn2+ treatment in inflammatory bowel disease is controversial. The results
described here suggest that during bouts of the inflammatory state the epithelial erosion and loss of
ZnR/GPR39 on the epithelial barrier may render Zn2+ inefficient, yet if provided during remission
Zn2+, via ZnR/GPR39, may extend this period. In fact, ZnR/GPR39 expression in the epithelial cells
may serve as a therapeutic target that can be specifically activated to extend the remission periods.
Maintenance of osmotic gradients, for proper water movement, is mediated by ion transporters
found on the epithelial cells [144]. In diarrhea, impaired transporters function results in excessive loss
of Na+ and Cl− into the lumen and subsequent water loss. The Zn2+ and ZnR/GPR39 upregulation of
Na+/H+ exchanger activity [57,69] can serve to enhance uptake of Na+ from the lumen. Indeed many
previous studies showed that the colonocytic apical NHE3 upregulation enhances Na+ absorption and
thereby reduces water loss and diarrhea [144–146]. In addition, activation of a basolateral KCC1 by
ZnR/GPR39 increases absorption of Cl−, which is also essential to reducing fluid loss. Cholera toxin
infection, a common cause of diarrhea, induced significantly worse diarrhea in GPR39 knockout mice,
lacking ZnR/GPR39 signaling, compared to WT mice [91]. Thus, ZnR/GPR39 activation can reduce
fluid loss during the disease, but reduced luminal Zn2+, which may be a dietary or disease-mediated
condition, may diminish the protective effect of this pathway. While Zn2+ is suggested by the World
Health Organization (WHO) as an important supplement to treat diarrhea [142,147], ZnR/GPR39 is
a novel and specific target that may be more effectively targeted.
5.3. Epilepsy
Several studies linked the loss of synaptic Zn2+ or Zn2+ deficiency with increased incidence
of seizures [148–151]. Despite a well-known role for Zn2+ in modulating numerous excitatory
and inhibitory post synaptic targets, how synaptically released Zn2+ can affect epileptogenesis
was not clear. Nevertheless, the major phenotype of the ZnT3 knockout mice, lacking synaptic
Zn2+, is enhanced sensitivity to kainate-induced or febrile hyperthermia induced seizures [152,153].
This indicated that synaptic Zn2+ itself does have a role in epilepsy. The results showing regulation of
Cl− transport by ZnR/GPR39 activation of KCC2, taken together with the prominent role of loss of
KCC2 function in increasing seizure susceptibility [128,154,155], suggested that ZnR/GPR39 may play
a role in epilepsy via this pathway. Indeed, GPR39 knockout animals, lacking ZnR/GPR39 signaling,
exhibit enhanced susceptibility to kainate-induced seizures, with significantly higher behavioral seizure
severity scores and more seizures over longer periods of time compared to wild-type controls [156].
Kainate-induced upregulation of KCC2 activity is dependent on Zn2+, which is released by the
increased firing under these enhanced excitability conditions. Moreover, ZnR/GPR39 signaling via
the Gαq and subsequent MAPK pathway are required for increased KCC2 activity and thereby
inhibitory tone. Thus the homeostatic role of ZnR/GPR39, activated by Zn2+ co-released with
glutamate, is essential during excessive firing to reduce excitatory activity via enhancing GABAergic
responses. In contrast, loss of this signaling in the absence of synaptic Zn2+ or ZnR/GPR39 may result
in epileptogenesis [53]. A similar effect on increasing inhibitory neuronal signaling is monitored in
the dorsal cochlear neurons, where ZnR/GRP39 activation enhances endocannabinoid release and
reduces excitatory glutamate release [63]. In addition, enhanced excitability and thereby seizure
activity has been associated with neuronal acidification and loss of Na+/H+ exchanger (NHE)
activity [157,158]. Thus ZnR/GPR39-dependent upregulation of NHE activity, which was monitored
in primary neurons, may also link the receptor to reduced seizures [109]. In Alzheimer’s disease,
Aβ oligomers interact with Zn2+ [159,160], thus lowering levels of labile Zn2+. Indeed, in the presence
of Aβ, the ZnR/GPR39-dependent Ca2+ responses in primary neurons were significantly reduced and
resulted in much lower MAPK activation [161]. This decrease in ZnR/GPR39-dependent signaling,
reducing the homeostatic activation of KCC2, may serve as a link to the increased incidence of seizure
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5.4. Depression
Zinc deficiency is associated with neurological and psychiatric disorders [162]; however, it is not
yet clear if the decrease in Zn2+ results from aberrant intake, especially in depression, when appetite
is lost and general uptake of nutrients is low, or is a cause of the disorder. Several studies reported
a role for ZnR/GPR39 in depression, based on apparent changes in the expression level of this
receptor following Zn2+-deficiency that were correlated with behavioral changes, also in suicide
victims [163,164]. Changes in ZnR/GPR39 expression were also shown following treatment with
monoaminergic inhibitors, such as used to treat depression, thus suggesting a link between the
receptor and this disease. Surprisingly, despite the extensive use of antibodies against ZnR/GPR39 in
this study, the antibodies were not verified in GPR39 knockout mice [165]. A role for ZnR/GPR39 in
the regulation of the CREB/BDNF/TrkB (cyclic AMP response element binding protein/brain-derived
neurotrophic factor/tyrosine receptor kinase B) pathway, and thereby in depression, has also been
postulated, though it is not clear at present how Gαq signaling activates this pathway or whether these
effects are lost in ZnR/GPR39 deficient mice [166,167].
5.5. Insulin Secretion
Pancreatic β-cells contain vesicular Zn2+ that is released together with insulin [168].
Several studies have highlighted a role for Zn2+ in the regulation of β-cell function and glucagon
release [169–171]. The Zn2+ transporter ZnT8 is responsible for transporting Zn2+ into the insulin
vesicles, and a mutation in this transporter of an Arg replacing Trp325 is associated with increased risk
of developing type 2 diabetes [172]. Thus a role for ZnR/GPR39 in this tissue may have important
physiological implications in the regulation of the Zn2+ releasing β-cells or neighboring cells within
the islets of Langerhans. Knockout of ZnR/GPR39 does not immediately produce a phenotype under
baseline conditions, and the knockout mice show normal insulin secretion. However, when fed
a sucrose-rich diet, older mice show increased glucose levels and decreased insulin compared to
the wild type [173]. Similarly, higher glucose levels were monitored in GPR39 knockout mice fed
a high-fat diet [174]. In agreement, overexpression of ZnR/GPR39 in β-cells resulted in protection
from streptozotocin-induced diabetes [175]. A recent study showed ZnR/GPR39 expression and
Zn2+-dependent Ca2+ release in association with Zn2+-dependent insulin secretion [176]. Yet how
ZnR/GPR39 activity regulates insulin secretion and whether this is an autocrine effect of endogenous
Zn2+ released from the β-cells is still poorly understood.
5.6. Defects in Bone Composition
Zinc is accumulated in bone and plays a role in the dynamic maintenance of the structure of bones.
Supplementation with dietary zinc enhances the strength of bones, but an underlying mechanism is
not available. While several zinc transporters of the ZIP family have been associated with skeletal
function [137], a role for ZnR/GPR39 was not described. Using GPR39 knockout mice, a recent
study indicates that this receptor is important for osteoblast differentiation [61]. Hence, mice lacking
ZnR/GPR39 showed impaired bone composition with decreased collagen content, likely involving
ADAMTS metalloproteinase, which regulates collagen processing [61]. Most importantly, ZnR/GPR39
deficient osteoblasts showed lower ZIP13 expression, linking ZnR/GPR39 and Zn2+ transporters for
the first time. Future studies aiming to determine how ZnR/GPR39 modulates Zn2+ transporters’
activity or expression can provide a more complete picture of the network of zinc homeostasis and its
physiological implications.
5.7. ZnR/GPR39 in Cancer
Increased cell proliferation and migration, as well as the activation of MAPK and AKT, suggest
a possible role for ZnR/GPR39 in cancer. Activation of ZnR/GPR39 signaling was monitored in
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via activation of ZnR/GPR39 in the prostate cancer cell line PC-3 enhances expression of S100A4 [84],
a protein that is thought to enhance metastatic prostate cell proliferation and angiogenesis [177].
Other studies that associated ZnR/GPR39 expression in epithelial cells with cancer did not employ
changes in extracellular or dietary Zn2+ to specifically study whether signaling pathway activation
or Zn2+-dependent processes are affected in the cancer cells. These studies nevertheless indicate
the importance of this receptor as a therapeutic target for cancer treatment. As such, GPR39 was
overexpressed in primary human esophageal squamous cell carcinomas and its silencing reduced the
tumorigenicity of these cells [178]. A recent study suggested that GPR39 expression is modulated
in gastric adenocarcinoma [179], yet this study applied a previously incorrectly suggested ligand
of GPR39 and not Zn2+ [180]. Interestingly, a link between the ZnR/GPR39 and mRNA levels of
the Zn2+ transporter ZIP13 was recently shown in bone [61], but whether ZnR/GPR39 regulates
other members of the ZIP family of Zn2+ transporters is unknown. Such a link between ZnR/GPR39
and ZIP transporters may further link the receptor to tumorigenesis. For example, ZIP6 and ZIP7
overexpression in breast cancer has been previously shown [181,182], and ZIP4 has recently been
associated with ovarian stem cell growth and carcinoma [183]. Future studies aiming to specifically
test the role of ZnR/GPR39 in cancer tissue and the link to ZIP transporters expression are of major
interest and can provide a novel target for therapeutic tools.
6. Conclusions
ZnR/GPR39 is an important regulator of Zn2+-dependent signaling, functional in numerous
epithelial cells, bone cells, and neurons—all tissues associated with Zn2+ homeostasis. Transient
changes in extracellular Zn2+ occur during physiological activity and are sufficient to activate
ZnR/GPR39. While dietary or serum zinc itself has been suggested to affect the physiological function
or pathological conditions in these tissues, these changes in zinc concentration do not directly reflect
local or cellular changes in the concentrations of the ionic Zn2+. In addition, Zn2+ interacts with
a multitude of intracellular or extracellular proteins and modulates their activity, as described in the
introduction; therefore, changes in Zn2+ concentration may affect many proteins and cellular functions
and not just ZnR/GPR39 activity. Thus, this micronutrient is a poor therapeutic compound with
inconsistent effects. However, elucidation of ZnR/GPR39 as a regulator of Zn2+-dependent cellular
signaling can offer a novel handle to effective therapeutic approaches that will depend on ZnR/GPR39
agonists. Of note, ZnR/GPR39 is a member of the G-protein coupled receptor family, which is currently
considered a major candidate for targeted therapies [184,185]. Finally, what regulates the activity of
Zn2+ transporters is only partially understood; for example, it was previously shown that intracellular
Zn2+ activation of metal-responsive elements regulates ZnT expression or that phosphorylation of
ZIP regulates their expression [24,25]. In this context, a possible link between ZnR/GPR39 and the
transporters may be a key to understanding Zn2+ homeostasis and is an important aim for future
studies. Thus ZnR/GPR39 may serve as a specific and efficacious handle to modulate Zn2+ homeostatic
proteins and signaling, thereby ameliorating physiological processes to enhance recovery.
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Abstract: Metallothioneins (MTs) are a family of metal-binding proteins virtually expressed in all
organisms including prokaryotes, lower eukaryotes, invertebrates and mammals. These proteins
regulate homeostasis of zinc (Zn) and copper (Cu), mitigate heavy metal poisoning, and alleviate
superoxide stress. In recent years, MTs have emerged as an important, yet largely underappreciated,
component of the immune system. Innate and adaptive immune cells regulate MTs in response
to stress stimuli, cytokine signals and microbial challenge. Modulation of MTs in these cells in
turn regulates metal ion release, transport and distribution, cellular redox status, enzyme function
and cell signaling. While it is well established that the host strictly regulates availability of
metal ions during microbial pathogenesis, we are only recently beginning to unravel the interplay
between metal-regulatory pathways and immunological defenses. In this perspective, investigation
of mechanisms that leverage the potential of MTs to orchestrate inflammatory responses and
antimicrobial defenses has gained momentum. The purpose of this review, therefore, is to illumine
the role of MTs in immune regulation. We discuss the mechanisms of MT induction and signaling in
immune cells and explore the therapeutic potential of the MT-Zn axis in bolstering immune defenses
against pathogens.
Keywords: Metallothioneins; zinc; cytokines; signaling; infection; antimicrobial defenses; metals;
nutritional immunity
1. Introduction
Regulation of metal homeostasis is crucial in biological and cellular processes such as development and
functions of organs, optimal enzyme activity, intracellular signaling and cell to cell communication [1].
Metallothioneins (MTs) are low molecular weight, cysteine-rich proteins that physiologically bind Zn
and Cu in cells, but also sequester heavy metals such as cadmium (Cd) and mercury (Hg). They are
induced by a variety of physiological and xenobiotic stimuli, buffer Zn and Cu ions, mitigate oxidative
damage and protect against heavy metal intoxication [2]. In light of their ability to regulate metal ion
availability, distribution and transport in cells, MTs have emerged as prominent players in maintaining
overall organism fitness.
Development of mice genetically deficient in MT1/2 (MT-null) and MT3 isoforms has facilitated
analysis of their functions in the resting state and in disease. In these models, in an unperturbed
environment, MT deficiency does not result in apparent developmental, reproductive or age-related
defects suggesting that MTs may be dispensable for normal development [3–5]. However, challenging
MT-nullmice with common environmental stressors such as heavy metals, microbes or oxidative
stress profoundly impacts fundamental processes such as DNA repair mechanisms, cell viability
and inflammatory processes that rely on metal ion homeostasis and redox regulation for optimal
functions [4–7]. For example, in mice and humans, Cd exposure induces MTs that sequester the metal
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to mitigate heavy metal poisoning. MT-null mice, however, exhibit decreased tolerance to Cd, and
exposure results in nephrotoxicity and liver damage [3,4,8]. MT dysregulation is also observed under
a wide spectrum of diseases including cancer, atherosclerosis, metabolic disease, autoimmunity, and
infections [9–14]. Thus, it is clear that MTs respond to and are modulated in disease settings. However,
a vast underlying gap in knowledge exists about the inducers and regulators of their complex functions
in immunological responses. Deciphering how MTs shape the fate of development, dynamics and
resolution of an immune response will be a crucial step in identifying novel therapeutic targets in
pathways regulated by MTs. On the one hand, Zn and Cu have long been known to be involved
in development and function of the innate and adaptive arms of our immune system [15] and on
the other hand, numerous studies have reported MT regulation in the context of immunity [16].
However, our understanding of how this metalloprotein executes metal modulation in immune cells
and molecular cues that drive these functions is fairly recent. The focus herein, stems from such recent
insights into the fundamental role of mammalian MTs in immune regulation, with an emphasis on their
ability to leverage host-pathogen interactions. We summarize the fundamental aspects of MT function
and its role in Zn homeostasis (reviewed in greater detail elsewhere [2,17–20]) prior to exploring the
interplay between MTs and immune responses.
2. The Metallothionein Family: Master Zinc Regulators
MTs are low molecular weight (6–7 kD), highly conserved, cysteine (Cys)-rich proteins that bind
metals through thiol-clusters [17]. The MT protein family constitutes four isoforms (MT1–4) in mice
and several isoforms with subtypes/variants in humans (MT1A, MT1B, MT1E, MT1F, MT1G1, MT1G2,
MT1H, MT1HL1, MT1M, MT1X, MT2A, MT3, and MT4, and the pseudogenes MT1DP, MT1JP, MT1L,
MT2P1, MT1CP, MT1LP, MT1XP1, MT1P3, MT1P1 and MTL3P) [21–24].
In the early 1970s, a role for MTs in sequestering heavy metals such as Cd and Hg pinpointed
their effect in alleviating xenobiotic stress [25]. Long since their discovery, the physiological functions
of MTs remained unknown. Why did prokaryotes, lower eukaryotes and complex organisms evolve to
express highly conserved thiol-rich proteins with an apparent crucial role in moderating heavy metal
poisoning? The enigma was gradually dispelled when Zn homeostasis surfaced as being essential to all
biological processes. About 10% of the mammalian genome encodes Zn binding proteins that regulate
a diverse spectrum of biological functions [26]. Zn, unlike Cu and iron (Fe), is redox-inert, supporting
evolutionary conservation of Zn binding sites in a large number of metalloproteins [27]. Undoubtedly,
Zn availability is strictly regulated by MTs and Zn transporters [28,29]. MTs are master Zn regulators
that sense intracellular cues and modulate Zn through sequestration, mobilization or release. The Zn
binding constant of thionein was thought to be the highest (>3 × 1013/M) in biological systems, but,
more recently, MTs have been shown to bind Zn ions sequentially with graded affinity and exist
in metamorphic states [30,31]. The possibility of random occupancy of metal binding sites on MTs,
followed by rearrangement of ions to a thermodynamically stable state has also been proposed [32].
Zn excess induces MTs, whereas Zn deficiency causes release of the metal from MTs, in effect scaling the
intracellular Zn pool in response to cellular redox and energy state [33,34]. Intriguingly, Zn handling
by MT1 and MT2 is distinct from that of MT3 [35]. The former sequesters Zn and readily releases
only 1 Zn ion; the metal-thiolate cluster of MT3, however, assumes an “open conformation” to readily
release Zn [35–37]. Moreover, Zn binding to MT3 is non-cooperative, suggesting that excess Zn may
not stimulate saturation of all metal-ion binding sites in MT3 [38]. Thus, MT1/2 and MT3 share
common ground in Zn regulation, but also exert discrete functions in scaling the intracellular Zn quota.
The literature on MT4 function is scarce. Zn coordination by MT4 results in weaker folding of the
protein compared to that of MT1; it has been suggested that MT4 may function as a Cu-thionein [39].
Of note, our knowledge of MT structure and function is gathered from an amalgamation of studies
performed in solution, ex vivo, in vitro as well as in vivo. Thus, it is essential to recognize that the
biology of MTs is highly complex; their behavior under different biochemical and cellular environments
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Upstream of these events, the Zn-sensing metal-response element-binding transcription factor-1
(MTF-1) regulates MT expression to maintain precision in the size of the intracellular free Zn
pool [40,41]. MTs mobilize Zn into the nucleus, mitochondria, Golgi apparatus, lysosomes, endoplasmic
reticulum, cytosol and, possibly, zincosomes [42–47]. How MTs achieve this feat in intracellular
compartments with diverse Zn demands is not clear. Their amino acid sequence lacks signals
that dictate localization to specific organelles. The 3′ untranslated region of MT1 mRNA signals
transcript localization to the perinuclear region, arming the ability of MT1 protein to gain entry into
the nucleus [48]. Another mechanism explicating MT targeting is protein-protein interaction. While
it is well established that peptides and small molecules such as glutathione, ATP and GTP interact
with MT, other interacting partner proteins have also been identified [27,33,34]. MT3 interacts with
proteins involved in heat shock response, secretion, signaling pathways, metabolic enzymes and
chaperones [49]. Such associations enable MT targeting to the extracellular milieu. Indeed, MTs have
been detected outside cells [50]; whether they are actively secreted or passively released as a result
of compromised membrane integrity is unclear. Mounting evidence points to an active involvement
of MTs in modulating extracellular cues [51–53]. Nonetheless, in the field of MT biology, several
unknowns remain. Do cells export MTs in their apo-form or as MT-Zn/Cu complexes? How do cells
sense the need to tune extracellular Zn availability? Stretching beyond metal-ion buffering, what
functions do MTs execute extracellularly? The rapid response of MTs to changing redox potential
and Zn demands justifies their presence in this environment. Outside cells, MTs may participate in
regulating chemotaxis, signaling, cell–cell communication, and mitigating oxidative damage [50,54].
A detailed understanding of MT functions will open new arenas for exploring their therapeutic
potential in a variety of inflammatory disease conditions including Alzheimer’s, coronary heart
disease, arthritis, obesity, cancer and infections.
3. Immunity: Do Metallothioneins Take Center Stage?
Metal homeostasis, particularly Zn regulation, is essential for the development and adequate
functioning of the innate and adaptive arms of immunity. The adverse impact of Zn deficiency on
antibody production, cytokine production, chemotaxis, cell signaling, proliferation and functions of B,
T helper (Th) and natural killer (NK) cells is well established [55–59]. Aberrant Zn regulation caused
by Zn deficiency increases susceptibility to bacterial, viral and fungal infections, whereas Zn excess can
exert toxic effects on immune cells [57,60]. MTs calibrate Zn availability; it is therefore conceivable that
MTs are important regulators of immune cell function and promote immunological fitness. However,
the underlying evidence supporting this hypothesis is still in its infancy.
Our current understanding of the role of MTs in immunity is fueled by studies on MT1 and
MT2. In the mouse thymus, a primary lymphoid organ, MT expression peaks prior to thymic growth
and wanes during thymic involution [61]. These changes parallel the impact of Zn on thymic mass,
wherein Zn deficiency promotes thymic involution during aging [62]. The specific MT isoforms altered
during thymic development and involution are undetermined, but the Zn-inducible nature of the MT
response may result from dynamic changes in MT1 and MT2 expression [61,62]. The MT3 isoform,
that is largely associated with neuronal functions, is also detected in the thymus [62]. However, MT3 is
not Zn-inducible and data clearly elucidating the expression and functional roles of MT3 in the thymus
are lacking. Overall, our understanding of how MTs and Zn control immunological functions in the
thymus is limited and requires further investigation.
Thymic spatio-temporal regulation of MTs over the lifespan of an animal may impact T cell
development and maturation in this organ. Thymic epithelial cells secrete thymulin, a Zn-dependent
hormone [63]. MT expression in the thymic epithelial cells correlates with that of thymulin in humans
and its expression is enhanced in thymomas [64,65]. Whether MTs regulate thymulin expression or vice
versa is not known, but it may be postulated that in thymic epithelial cells, MTs deliver Zn to thymulin,
whose function critically depends on the availability of this ion. Aberrant MT regulation may therefore
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and lymphocyte function. Interestingly, thymic abnormalities in MT-null mice have not been reported,
albeit, this is a poorly studied field. An essential process in T cell selection is the presentation of self
and non-self antigens by thymic non-lymphoid cells and professional antigen presenting cells (APCs)
such as dendritic cells (DCs). Zinc influences the expression of major histocompatibility complex class
(MHC)II on the surface of DCs [66,67]. A rise in intracellular Zn diminishes MHCII, while Zn chelation
elevates it [66,67]. The occurrence of this phenomenon in DCs residing within the thymus remains
unknown, but stimulates the proposition that MT-Zn sequestration may calibrate MHCII levels on
DCs in the thymus, ultimately influencing thymic T cell selection.
The strategic placement of lymph nodes enables immunological surveillance and is the center for
cross-talk between innate and adaptive immunity. Expression of different MT isoforms, their regulation
and functional aspects in myeloid and lymphoid populations in the lymph nodes have not been
characterized. Lymph-node associated MT expression is emerging as a prognostic marker in disease
diagnosis, especially in patients with tumors. For example, MTs exhibit significant elevation in sentinel
lymph node biopsies obtained from breast cancer and melanoma patients [68,69]. This modulation
is prognostic and signals disease progression. It is noteworthy that the lymph node harbors a highly
dynamic environment as circulating immune cells, signaling molecules and foreign agents continually
drain in and out of these nodes through the lymphatic system. Thus, the myriad factors that condition
the lymph node milieu may potentially influence MT regulation and function in macrophages, DCs,
CD4+ Th cells, cytotoxic CD8+ cells and NK cells that enter and leave the lymph nodes. It may
be conceived that MTs regulate Zn metabolism, proliferative, apoptotic, oxidative and nitrosative
responses of these cells. However, as is evident, our understanding of MT regulation in lymph node
biology is very limited and we may be far from uncovering the interplay between MT regulation and
immune cell function in these tissues.
Only a handful of studies have shed light on MTs in the bone marrow, spleen and Peyer’s
Patches; our knowledge of the functional significance of MTs in these organs is extremely scarce.
Hematopoietic stem cells in the bone marrow produce progenitors that differentiate into cells
of the myeloid and lymphoid compartments [70]. Although data directly linking MTs to the
immunological functions of the bone marrow are lacking, several lines of evidence suggest that
MT-Zn homeostasis may play a significant role: (i) Dietary Zn deficiency or chronic Zn exposure
results in precursor-B and -T cell apoptosis in the bone marrow [71,72]. MT1 expression in the
bone marrow of rats is modulated by dietary Zn status [73]. The absence of MTs may perturb bone
marrow Zn homeostasis, unless compensatory Zn transporters and other metalloproteins replace
the loss; (ii) Several Zn-dependent transcription factors dictate terminal differentiation of precursor
cells in the bone marrow. Early growth response-1 (Egr-1), a Zn-dependent transcription factor
promotes monocyte differentiation to macrophages [74,75]. In contrast, another Zn-finger transcription
factor, growth factor independent-1 (Gfi-1), antagonizes monocyte/macrophage lineage commitment
and promotes neutrophil differentiation [75]. A number of studies support a role for Zn transfer
from MTs to other metalloproteins including Zn-dependent transcription factors [76–78]. As such,
metalation of proteins residing in the Golgi and endoplasmic reticulum (ER) must occur in these
organelles [46,79]. The nucleus is another site where Zn availability must be tightly regulated
to mediate Zn binding/release by gene-inducer and repressor molecules and prevent oxidative
DNA damage [80,81]. MTs are detected and/or regulate the functions of these organelles [42,43,82].
The finding that MT resides in the nucleus raises questions about its contribution to nuclear functions
such as gene regulation and provides clues to its crucial influence in regulating the size of nuclear Zn
pool. (iii) Mt-null mice contain fewer CD4+, CD8+ T and B cells in blood [83]. The ubiquitous expression
of MT1 and MT2 and control of proliferative, apoptotic, oxidative and chemotactic responses imply
that MTs potentially shape the bone marrow immunological milieu.
The spleen is a major site for antibody production, erythrocyte clearance and filtration of
pathogens. The splenic composition of CD4, CD8 and B cells in MT-null mice was found to be similar
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these MTs are involved in regulating splenic cellularity and function. One study reported elevated
number of lymphoid cells and a 19% increase in splenic weight under MT1/2 deficiency. The number
of circulating lymphocytes and splenic B cells were reduced in these mice, but number and proportion
of splenic CD4+ and CD8+ T cells were marginally elevated [83]. Differences in age, gender and/or Zn
concentration in the mouse diet used in the two studies may have led to discrepancies in the findings.
Nonetheless, substantial evidence points to the role of MTs in regulating splenic T and B cell biology.
MT-null splenic T cells fail to proliferate robustly upon stimulation with an antigen-independent T
cell mitogen, concanavalin A or α-CD3. These splenocytes produce substantially lower interleukin
(IL)-2 and the proliferative defect of purified T cells is reversed by addition of this cytokine [84].
Treatment of splenocytes with purified MT induces a hyper-proliferative response that is subdued in
the presence of a reducing agent. Interestingly, while apo-MT, Zn-MT and Cd-MT comparably trigger
proliferation, addition of Cu-MT inhibits this response [53], suggesting that MTs impart disparate
effects pertinent to the metal bound to thionein. Accessibility to thiol groups on MTs is crucial in
driving the lymphoproliferative response. Post activation, rapid T cell expansion is accompanied by
superoxide burst [85]. The MT promoter possesses an antioxidant response element (ARE) that triggers
MT expression in response to reactive oxygen species (ROS) [86]. An MT-ROS feedback loop may
be operative in T cells, wherein basal MT levels mitigate oxidative damage, while ROS triggers the
expression of MTs through ARE that feeds back to control the intracellular redox environment. Such a
mechanism may operate to shield T cells from oxidative disruption of intracellular processes and
improve T cell viability (Figure 1). Concentration, transport mechanisms and regulation of metals in the
spleen await thorough investigation, but clearly, erythrocyte infiltration and hemoglobin metabolism
in this organ place a demand on strictly regulating Fe homeostasis [87]. Although MT does not directly
mobilize Fe, dietary Fe intake and MT1 expression share a reciprocal relationship in blood cells in rats,
perhaps indicating changes in cellular Zn homeostasis or redox state [88,89]. Excess Fe interferes with
Zn availability to proteins and vice versa, suggesting that, in addition to mechanisms that control Fe
homeostasis, an MT-Zn axis may well be functional in sizing the Zn pool in this organ [90,91].
Figure 1. MTs (Metallothioneins) promote T cell survival and hyperproliferation. Activation of T cells
with a T cell-specific mitogen generates ROS. MT1 and MT2 are induced by ROS produced during T cell
activation, possibly by engagement of the antioxidant response elements (ARE) on the MT promoter.
MTs quench ROS by oxidation of Cys residues, thereby preventing oxidative damage to T cells. MTs
are required to produce optimal IL-2 that through autocrine and paracrine signaling, supports T cell
survival. Exogenously added Zn-MT associates with the T cell membrane, possibly by binding to a
yet unidentified MT receptor. Extracellular or membrane bound MTs reduce surface thiols (Cys-SH)
on T cells. Mitigation of oxidative stress, reduction of surface thiols and an IL-2 response converge to
promote T cell survival and hyper-proliferation by MTs. Red dots, Zn ions; all solid lines and arrows
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Contrary its role in promoting T cell proliferation, an immunosuppressive effect of MTs on
humoral immune responses has been described. The first evidence of modulation of humoral
immune responses by MTs came from in vivo studies on ovalbumin (OVA) injected mice treated
with Zn-MT or Cd-MT. MT injection suppresses serum anti-OVA specific IgG responses [52]. Moreover,
neutralization of MT1 and MT2 boosts IgG responses, indicating that MTs are a negative modulator
of T-cell antigen-dependent humoral immunity. Complementing these data, MT-null mice mount
a pronounced IgG and IgM humoral response to OVA injection, 58% greater than that observed in
wild type mice [83]. Perhaps, the splenic environment of these mice increases the propensity of B cell
differentiation to plasma cells. The precise mechanism(s) that escalate plasma cell differentiation is
enigmatic. One postulate is that MTs regulate nuclear factor-kappa B (NF-κB) activation that hastens
B cell differentiation into plasma cells. Although this hypothesis has not been specifically explored
in B cells, splenocytes from naïve MT-null mice exhibit increased NF-κB p50 subunit activation.
Additionally, stimulation of these splenocytes with phorbol myristate acetate (PMA) and a calcium
(Ca) ionophore increases p50 and p65 subunit activation compared to wild type splenocytes [83].
How does the function of a metal regulatory protein intersect with the globally significant
transcriptional regulator, NF-κB? At least two hypotheses may be projected: (i) Redox control by MTs
calibrates NF-κB activation; and (ii) Intracellular Zn buffering by MTs modulates the NF-κB activation
pathway. These postulates are centered on the premise that ROS produced by mitochondria and
phagosomes have signaling functions that may be stimulatory or inhibitory in the NF-κB pathway.
Mitochondrial ROS and NADPH oxidase-derived phagosomal ROS enhance IκB degradation in the
cytoplasm, resulting in increased NF-κB activity [92]. Oxygen intermediates also inactivate protein
tyrosine phosphatases and dual specificity phosphatases, in turn, sustaining kinase activation [92].
While these mechanisms prolong NF-κB activation, MTs could subdue this response by quenching
ROS through oxidation of Cys residues and Zn release from MTs. Zn itself is redox inert, but release
of the metal upon oxidation tunes the intracellular redox state [27,93]. The redox regulating capacity
of MTs is approximately 50 times greater than that of the major antioxidant, glutathione (GSH) [94].
Thus, when MTs are lacking, elevated ROS likely signals activation of NF-κB and its downstream
pathways—resulting in enhanced humoral responses. On the flip side, Zn import by Zn importer
protein (ZIP)8 directly modulates NF-κB function by inhibiting IκB kinase (Iκκ) [95]. This mechanism
results in increased IκB mediated degradation of NF-κB. Whether MTs contribute to this process by
altering Zn availability is not known. One may predict that heightened labile Zn in immune cells
lacking MTs subdues NF-κB signaling. In fibroblasts, MT deficiency results in reduced levels of p65 [96].
These studies suggest that the impact of MTs on NF-κB signaling may vary by cell type. Whatever be
the case, how MTs manipulate signaling to dictate immunological fate clearly deserves attention.
Of note, primary and secondary lymphoid organs exhibit remarkable architectural organization
that regulate the development and function of immune cells [97–99]. Determining MT distribution
and localization in these organs may reveal how MT expression patterns interweave with the thymic,
lymph node and splenic architecture, providing clues to the mechanisms by which MTs guide immune
cell programming, metabolism, maturation and lineage commitment.
4. Metallothionein Induction and Signaling in Immunity
Immunological surveillance places a unique “rapid adaptation” demand on cells of the innate
and adaptive immune system. For example, unlike a hepatocyte that resides in the hepatic tissue,
circulating immune cells constantly traffic in and out of tissues, through the lymphatic system and into
primary and secondary lymphoid organs [100,101]. This implies that, in addition to preparation for an
immune response, these cells must adapt to an ever-changing extracellular biological milieu that varies
in oxygen tension and concentrations of cytokines, chemokines, hormones, metabolites, other small
molecules and metals. Zn concentrations can exhibit large variations between circulation and within
tissues—as much as 9 μg/cc (9 μg/g) in whole-blood to 520 μg/g in prostrate tissue [101,102]. It is not
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rapidly changing Zn environment. Cytokines such as tumor necrosis factor (TNF)α, IL-1α, IL-6 and
interferon (IFN)γ modulate MTs and Zn metabolism in non-immunological organs such as the hepatic
tissue [103]. However, do these mediators signal changes in MTs within immune cells? An integrative
analysis of all immunological modulators of MTs in immune cells is lacking, but mounting evidence
indicates that cytokines have a profound impact on MT gene regulation and functions in both myeloid
and lymphoid compartments [44,104,105].
In response to the pro-inflammatory or M1 cytokine, granulocyte macrophage colony stimulating
factor (GM-CSF), macrophages upregulate MT1 and MT2, with the latter exhibiting heightened changes.
While both MT1 and MT2 are ubiquitously expressed and respond to Zn, MT2 induction is pronounced
in response to GM-CSF [44]. Why MT2 responds more strongly to cytokine stimulation is elusive,
but one possible explanation is that basal MT1 expression in macrophages is already high, perhaps
near saturation. Further studies are needed to pinpoint the specific roles of MT1 versus MT2 in
tackling redox changes and Zn metabolism in macrophages. In MT-null peritoneal macrophages,
lipopolysaccharide (LPS) fails to strongly induce TNFα, suggesting that MT1 and MT2 are required
for a macrophage pro-inflammatory response [106]. Moreover, MT-null macrophages manifest gross
defects in antigen-presentation, expression of MHCII and co-stimulatory CD80 and CD86 molecules
and cytokine production [107].
Interestingly, the isoform of MT augmented in immune cells is pertinent to the nature of the
stimulating signal. The anti-inflammatory M2 cytokine, IL-4, unlike GM-CSF, strongly induces MT3,
but not MT1 and MT2 in macrophages [104]. The distinct Zn demand and defense functions of
pro-inflammatory vs. anti-inflammatory macrophages may determine preferential expression of
specific MTs. Indeed, MT1 and MT2 in M1 macrophages sequester the Zn pool, whereas MT3 in M2
macrophages serves to expand this fraction [44,104] (Figure 2). An immunological role for the MT4
isoform remains to be uncovered.
Figure 2. MTs shape the macrophage Zn pool and antifungal defenses. M1 macrophage (left side of
center dotted line): GM-CSF binds to its receptor, CSF2RA, to trigger STAT3 and STAT5 activation.
GM-CSF also upregulates Zn import via ZIP2. MT1 and MT2 induction is STAT3, STAT5 and ZIP2
dependent. While STAT3/5 can directly induce MTs by binding to the MT promoter, it is possible
that ZIP2 mediated Zn import activates the transcription factor, MTF-1 to induce MT1 and MT2.
In fungi infected macrophages, these MTs sequester Zn from H. capsulatum contained in phagosomes,
possibly via Zn import into the cytosol, starving the pathogen of this essential element. M2 macrophage
(right side of center dotted line): IL-4 binds to its receptor, IL-4RA to activate STAT6 mediated MT3
response. The MT3 gene is not Zn inducible; IL-4 may prompt demethylation of the MT3 promoter to
enable transcriptional activation by STAT6. M2 macrophages acquire Zn from extracellular sources
that is rendered labile by MT3 and transported to the phagosome, possibly via ZnT4. This expanded
labile Zn pool is exploited by H. capsulatum for survival within the macrophage. Red dots, Zn ions;
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DCs bridge innate and adaptive immunity through professional antigen presentation and
expression of costimulatory molecules. The many flavors of DCs execute very distinct functions,
in effect, shaping the fate of adaptive T cell immunity [108]. For example, inflammatory DCs promote
effector T cell responses, whereas tolerogenic DCs induce fork head box P3 (FoxP3) expressing
regulatory T cells (Tregs) that suppress inflammation [109,110]. Mounting evidence suggests that DCs
modulate MTs in response to molecular cues, and that they may, in fact, regulate their phenotype
and function. LPS upregulates MT2A in mature and activated human DCs [111], but downregulates
MT1 in mouse bone marrow derived DCs [112]. Murine DCs express MT1 in response to thermal
stress, dexamethasone or ZnCl2 [112,113]. One may decipher that MT induction by stress modulates
Zn distribution and regulates the intracellular redox environment in DCs. MTs (particularly MT1)
promotes the development of tolerogenic DCs. These DCs express MT1 on their surface; blocking
MT1 suppresses their tolerogenic potential, subduing naïve T cell differentiation into FoxP3 expressing
Tregs [112]. This finding is intriguing because MT1 lacks a hydrophobic leader peptide sequence
signaling surface expression or secretion. Whether DCs position MTs on the surface through interaction
with other membrane proteins is not known. How MT expression on the DC surface confers a
tolerogenic advantage also remains enigmatic. We and others have demonstrated that Zn handling in
DCs is associated with modulation of DC phenotype [66,67]. DCs stimulated with LPS decrease their
intracellular labile Zn pool leading to heightened surface MHCII expression. Overexpression of the
Zn importer ZIP6 reverses this phenomenon [67]. Exposure of DCs to Zn salts also dampens surface
MHCII, reduces pro-inflammatory cytokines such as IL-1β, IL-6 and IL-12 and promotes emergence
of a tolerogenic signature characterized by increased programmed death ligand (PDL)1, PDL2 and
enzyme indoleamine 2,3 dioxygenase expression [66]. Based on this premise, one may hypothesize
that Zn, possibly via import through ZIP6, induces MTs in DCs that in turn regulate cellular processes
associated with transport of MHCII containing vesicles. By localizing on the surface, MTs could
gain access to the extracellular Zn pool, sequester it and subsequently interfere with Zn-dependent
DC-T cell interactions. Indeed, superantigen presenting DCs rapidly trigger an ionic Zn signal that
localizes to the subsynaptic region of the TCR activation complex in T cells [114]. Is it possible that MTs
“soak up” Zn in extracellular spaces to stall TCR signaling? By scaling the size of the extracellular Zn
pool, MTs potentially regulate T cell activation and proliferation in response to antigen presentation.
Exogenously added MT binds to the membrane of purified CD4+ T cells [115]. Thus, it is also possible
that DC-MT directly interacts with the T cell plasma membrane (Figure 3). In this case, MT may be
envisioned as a co-stimulatory molecule on the surface of DCs. Perhaps, the protein reduces thiols on
the surface of T cells that serve dual function: (i) mitigate oxidative damage to T cells; and (ii) calibrate
ROS mediated T cell activation [115]. How such an interaction favors FoxP3+ Treg differentiation
entails further investigation. Zn inhibits the histone deacetylase Sirt1, an enzyme that degrades FoxP3
in T cells [116]. Thus, on a paradoxical note, if MTs on the surface of DCs acted as Zn donors to T cells,
the inhibitory effect of Zn on Sirt1 may in turn sustain FoxP3 expression.
MT expression within T cells regulates their activation, proliferation and differentiation potential.
MT1 and MT2 manifest a late induction response in naïve T cells stimulated with IL-27 [105,117].
This cytokine stimulates generation of type-1 regulatory T (Tr)1 cells that drive immunosuppression
via IL-10. In the absence of MT1 and MT2, Tr1 generation by IL-27 is greatly augmented, indicating
that MTs thwart Tr1 differentiation [105]. In support of these data, exogenously added MT1/2 severely
impair the emergence of IL-10 expressing Tr1 cells [118]. MTs interfere with signal transducer and
activator of transcription (STAT)1 and STAT3 phosphorylation that are crucial for Tr1 generation [105].
The mechanism possibly involves modulation of Zn homeostasis by MTs. Numerous studies point
to a role for Zn signaling in kinase and phosphatase functions [58,119]. In this view, one postulate
is that by sequestering Zn, MT1 and MT2 sustain protein tyrosine phosphatase 1B (PTP1B) activity
(an enzyme inhibited by Zn) that in turn dephosphorylates STATs (Figure 3). Indeed, MT-null Tr1 cells
exhibit hyperphosphorylation of STAT1 and STAT3 and a pronounced IL-10 response [105]. T cells
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This idea is supported by at least two observations: (i) a late MT1 and MT2 response (past 48 h) is
observed in Tr1 differentiating cells [105]; and (ii) early burst in the T cell–intracellular labile Zn pool
is MT independent [117], and is likely governed by ZIP6 mediated Zn import. Contrary to its role
in STAT inhibition, MT-driven Zn mobilization supports p38 MAPK signaling in Tr1 cells [117,120].
These data suggest that the MT-Zn pool plays distinct roles during early and late stages of Tr1 cell
differentiation. It is noteworthy that MT1 and MT2 are also highly upregulated in the Th17 subset
generated by IL-6 and TGFβ stimulation, but not in Th1 and Th2 cells [105]. In Th17 cells however,
a clear role for MTs remains to be determined as MT-null Th17 cells develop normally and produce
IL-17 [105]. Whether MTs dictate transcriptional programming, lineage commitment, regulate T cell
plasticity and skew the Treg-Th17 balance remain open areas of investigation.
Figure 3. MT-Zn axis in tolerogenic DC–Treg interactions. DCs exposed to a pool of extracellular Zn
develop a tolerogenic phenotype. Zn imported into DCs triggers MT-1 expression, possibly in an MTF-1
dependent manner. MT1 is expressed on the membrane of tolerogenic DCs and may also be actively
secreted and bind to the T cell membrane. Upon activation, T cells import Zn via ZIP6 that mobilizes
to the DC-T cell synapse. Zn sequestration by extracellular MTs may hinder this process, potentially
stalling T cell activation. However, MT expression within T cells suppresses Treg development. IL-27
induces Tregs (in this case, IL-10 producing Tr1 cells) via STAT1 and STAT3 signaling. These STATs
induce MT1 and MT2 that negatively feedback to inhibit STAT activation. MTs plausibly sequester Zn
from PTP1B, an enzyme that is inhibited by Zn. Active PTP1B mediates dephosphorylation of STAT1
and STAT3 ultimately attenuating Treg development. Red dots, Zn ions; all solid lines and arrows are
known links; all dotted lines and arrows are predicted links; red T bar depicts inhibition of STAT1/3 by
PTP1B (active).
The immunomodulatory role of MTs is further highlighted by its impact on CD8+ T cell responses.
Exposure of cytotoxic T lymphocytes (CTLs) to MTs diminishes surface MHCI and CD8 expression and
impacts their ability to proliferate and mount cytotoxic responses against allogeneic target cells [121].
Zn deficiency reduces the proportion of CTLs in humans [122]. Moreover, in mice fed a Zn deficient
diet, the ability of CTLs to kill tumor cells is impaired in vivo [123]. Taken together, our understanding
of Zn-empowerment of CTL functions is vague, but the following postulates may be proposed: (i) MTs
sequester Zn from the extracellular space, yielding a Zn-deficient environment; (ii) Zn deficiency
alters membrane mobility, thereby affecting pore formation by perforins and exocytosis of cytolytic
mediators by CTLs; and (iii) MTs quench ROS, in effect, impeding oxidative damage caused by CTLs.
These postulates may well be interlinked, given the intimate relationship between MTs, Zn buffering
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inclined towards an important role for Zn, the ability of MTs to donate Zn or modulate Cu homeostasis
during CTL responses cannot be ruled out. MTs could additionally manipulate antigen presentation
and interfere with surface receptors by formation of disulfide bridges with Cys residues, subsequently
barring CTL-target cell interactions. Pending further research, these possibilities offer an opportunity
to utilize MTs as therapeutic targets in disease conditions wherein CTL activity is crucial. For example,
MT neutralization may benefit target cell killing by CTLs resulting in improved tumor outcomes or
enhanced viral clearance.
Aside from its direct impact on immune cell behavior, MTs may act as chemoattractants to regulate
cellular infiltration [54]. The arrangement of Cys residues in the MT molecule is reminiscent of its
chemotactic properties; these motifs are also identified in chemokines. Clustal alignment of the MT
protein sequence with that of C-C motif ligand (CCL)17 (both are encoded by genes on chromosome 8),
reveals similarities in their Cys motifs, suggesting that MTs have a chemotactic attribute [54]. In vitro,
exposure of Jurkat T cells to MTs results in F-actin reorganization and migration of the cells towards
an MT gradient [54]. This phenomenon may be potentiated by direct MT and F-actin interactions [124].
In vivo evidence demonstrating MTs’ chemotactic potential is lacking, but, if true, why should the
immune system utilize MT as a chemoattractant? This thought is intriguing, particularly because the
immune system possesses a highly-organized array of chemokines and corresponding receptors that
cater to cell infiltration demands. Perhaps, extracellular release of MTs is recognized as an “early alarm”
by the immune system, a premise, supported by the observation that a variety of immunological
stressors rapidly and strongly induce MTs. In light of their chemotactic potential, important questions
emerge. How does extracellular MT communicate with immune cells? As indicated previously, MTs
bind the surface of T and B cells [53]. Surface and nuclear receptors for MTs have been identified in
astrocytes [125], however, there are no known receptors for MTs on immune cells. The chemotactic
property of MTs can be blocked by cholera or pertussis toxins that also block G-protein coupled
receptor signaling [54]. Thus, it is reasonable to propose that that MTs share chemokine binding sites
on chemokine receptors. The specific chemokine receptors involved, the impact of metal occupancy
on MTs on receptor binding and the downstream signals relayed by MTs in immune cells need to
be dissected.
Thus, it is clear that MT regulation is intricately tied to immunological responsiveness. As
discussed earlier, the classical inducer of MT1 and MT2 is the Zn responsive transcription factor,
MTF-1 [41]. Nitric oxide (NO) produced by immune cells causes Zn release from MTs that activates
MTF-1-dependent transcription of genes involved in Zn regulatory pathways, including MT1 and
MT2 [126]. However, studies on MT regulation in MTF-1 deficient immune cells will be required to
decipher whether MTF-1 is absolutely necessary for MT gene regulation. In addition to metal response
elements (MRE), the MT promoter harbors sequences that respond to STATs, hypoxia, redox status and
hormones, implying that immune cells are armored with additional means of MT regulation. TLR4
stimulation induces IL-6 dependent MT1 expression via STAT1 binding to the MT1 promoter [127].
Likewise, GM-CSF driven activation of STAT3 and STAT5 elevates MT1 and MT2 in macrophages. This
response can be abrogated by RNA interference or pharmacological inhibition of STAT3 and STAT5
signaling. In these cells however, MT1 and MT2 expression is also governed by Zn import via ZIP2 [44].
STAT binding sites have been identified on ZIP genes [128]. Whether STAT3 and STAT5 drive ZIP2
expression in macrophages is not known. It may be proposed that these STATs provide the initial
impetus to elevate ZIP2 as well as MT1 and MT2 genes and Zn import by the former sustains expression
of the latter via an MTF-1 dependent mechanism. In essence, there is active STAT3/5–Zn–MT crosstalk
that shapes the “Zn sequestering” phenotype of GM-CSF activated M1 macrophages [44]. In M2-IL-4
polarized macrophages, STAT6 specifically elevates MT3, but not MT1 and MT2 expression [104]. Thus,
through distinct signaling pathways, immune cells calibrate levels of different MT isoforms, in effect,
shaping the intracellular Zn environment and redox status. Based on this premise, it is conceivable
that STATs function as “Zn modulators”, whereby STAT signaling establishes the communication link
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in MT regulation (Figure 2), but the findings raise an intriguing question: Are MTs armored with the
ability to modulate cytokine signaling? As discussed earlier, at least in the context of T cells, MT1 and
MT2 subdue STAT1 and STAT3 activation during Tr1 differentiation [105] (Figure 3). The undisputed
significance of Zn ions in enzyme function and cell signaling is reminiscent of the potential of MTs in
controlling downstream effects of cytokine stimulation in immune cells.
Oxidative stress is intricately tied to innate and adaptive immunological functions. Rapidly dividing
T cells heighten ROS production and phagocytes such as macrophages and neutrophils produce ROS
to combat bacterial and fungal infections [85,129–132]. Thus, immune cells must mount antioxidant
responses that selectively minimize damage to the host. Given its major antioxidant functions in
addition to that of glutathione, MTs are rapidly induced by oxidative stress [93]. This response, is at
least in part, driven by intracellular changes in Zn released from oxidized Cys and His residues on
proteins that in turn modulate MTF-1 transcriptional activity. One contributor to this phenomenon is
MT itself; the protein liberates Zn as a consequence of Cys oxidation [19,93]. Thus, MTs orchestrate a
“self-amplifying response”, whereby mitigating oxidative stress activates a Zn-driven positive feedback
loop to further propel MT synthesis. However, under oxidative stress, cells may not solely rely on Zn
status to dictate MT expression. This proposition may be especially true in immune responses,
wherein Zn changes promote key defense functions such as DC maturation and antimicrobial
responses of macrophages and neutrophils [44,66,133,134]. The proximal promoters of MT1 and
MT2 genes contain the ARE consensus sequence GTGACnnnGC. In the presence of H2O2, the basic
helix-loop-helix-leucine zipper upstream stimulatory factor family (USF) protein recognizes a USF
binding site that overlaps with ARE on the MT1 promoter to trigger transcription [135]. The roles that
USF and ARE play in driving MTs during oxidative stress in immune cells is unknown. Perhaps, in an
effort to avert oxidative disruption of crucial host immunological processes, transcriptional activation
via both, MRE and ARE synergize to maximize MT production. Mouse MT1 and MT2 genes as well as
the human MT2 gene possess enhancer glucorticoid response elements (GREs) [136]. Glucocorticoids
bind the glucocorticoid receptor (GR) to transcriptionally regulate genes involved in suppressing
inflammation. HeLa cells respond to the synthetic glucocorticoid, dexamethasone, by inducing
MT1 and MT2 that is further elevated by Zn supplementation [136]. In the context of immunity,
these steroids have been widely used to treat autoimmunity and inflammation, primarily due to
their ability to exert immunosuppression by influencing macrophage polarization, DC tolerogenicity,
skewing Th1/Th2 responses and promoting IL-10 production by Tregs [137]. The significance of
MTs in the suppressive impact of glucocorticoids remains unraveled. Do MTs promote or inhibit
glucocorticoid mediated immunosuppression? Perhaps, the answer to this question lays in determining
temporal—acute versus late phase—MT responses driven by GREs, MREs and AREs. The effect of
dexamethasone parallels that of IL-27 and Vitamin D3 in differentiation of IL-10 generating Tr1
cells; these factors also promote MT1 and MT2 gene expression [105,117]. At least in the case of
IL-27, MTs are late response genes and thwart emergence of suppressive immunity [105]. These
data and ancillary evidence from studies on UVB radiation reveal that absence of MT1 and MT2
enhances immunosuppression [138], implying that MTs incline immune response progression towards
“inflammation sustenance”. However, considering that MTs suppress B cell responses, the impact of
MTs on humoral versus adaptive responses is discrete [83]. Deciphering the complex nature of MT
regulation demands thorough investigation of how MT gene regulation, redox status, intracellular Zn
levels intersect to influence signaling mechanisms and shape the outcome of inflammatory processes.
Evidently, a majority of the focus of MTs in immunity has rested on the functional significance of
MT1 and MT2. This bias primarily stems from restricted association of MT3 with the CNS and a few
other organs such as kidney and pancreas as opposed to ubiquitous MT1 and MT2 expression [139–141];
the former is also non-responsive to factors such as Zn and Cd that commonly induce MT1 and MT2.
Epigenetic control has surfaced as another layer that regulates MTs; such a mechanism may especially
be true for MT3 induction. This process has not been specifically investigated in different immune cells,
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Hypermethylation of CpG islands is observed upstream of the MT3 transcription start site in breast
cancer epithelial cells, myeloid leukemic cells and esophageal adenocarcinomas and is associated
with poor disease outcome [142–144]. Chromatin compaction in the DNA region where MT3 gene
resides possibly explicates the highly restricted nature of MT3 transcription. The finding that MT3 is a
cytokine-inducible gene in macrophages suggests that polarizing stimuli manipulate the epigenetic
structure of this gene, rendering it accessible to signaling mediators such as STAT6 [104,145]. MT1 may
also be subject to such epigenetic control, whereby its induction is associated with extensive promoter
demethylation [146]. Epigenetic regulation is a critical component of immune cell development
and functions [147]. It is likely that immunological stimuli influence the epigenetic structure of MT
promoters, adding another layer of complexity to the control of MTs during an immune response.
However, the epigenetic status of MT promoters in different immune cell types and the impact of
immune mediators on epigenetic control of MT expression is unknown. Nevertheless, a multitude of
factors including the nature of the immunological stimulus, signaling environment, Zn availability
and oxidative stress dictate the isoform of MT expressed and intracellular level of each isoform in
immune cells. Notably, MT regulation in immune responses is frequently reported, but there exists a
vast gap in our knowledge of the factors that regulate their expression and the functional significance
of these proteins. For example, do immune cells employ multiple signaling platforms to modulate
MT levels? How do immune cells distinguish the need to preferentially trigger MT1 and MT2 versus
MT3 and what benefit does this confer? Are MTs involved in regulating fundamental differentiation
and lineage commitment processes of macrophages, DCs and T cell subtypes? Finally, does MT4
play a role in immunity? Addressing these questions will necessitate analysis of MT functions using
models that exhibit conditional deficiency of the MT isoforms in specific myeloid and lymphoid
compartments. MT regulation is context dependent, is influenced by the stimulus in question and
controlled at multiple levels of gene regulation, translation and protein turnover. It is crucial to factor
these in, especially when data about MT functions are extrapolated from one immunological setting
to another.
5. Metallothioneins Respond to Microbial Stress
A primary function of immune surveillance is to screen microbial invaders and rapidly respond
by activating myriad immune pathways that converge to mount effective antimicrobial defenses.
Microbial challenge is thus, a potent “stressor” that immune cells must be prepared to cope with
or alleviate to maintain the hosts’ integrity during host-pathogen interactions. On the innate
end, nutritional immunity and ROS are two principal defense mechanisms deployed by immune
cells to curtail microbial growth and dissemination [132,148,149]. It is not surprising then, that
numerous studies have reported dramatic upregulation of MTs, particularly MT1 and MT2 isoforms
during bacterial, viral and fungal infections [44,103,150,151]. A classic example is hepatic MT1
and MT2 elevation during endotoxin (LPS) challenge. This is an acute phase response associated
with rapid reduction in plasma Zn and ~29% increase in hepatic Zn. Production of IL-1α, IL-1β,
TNFα and IL-6 precede this response and each of these cytokines independently trigger LPS
driven MT transcription [96]. Additionally, in children with sepsis, MT elevation is a predictor
of survival [152]. While precise pathways that link the cytokine response to MT induction remain
elusive, hyperglucagonemia is a feature of endotoxin challenge that regulates MTs. In this view,
a role for metabolic alterations and elevated blood glucose in modulating MT levels upon endotoxin
challenge may be proposed. Indeed, several immune mediators impose unique metabolic demands on
glucose and fat utilization to cope with inflammatory stress [153,154]. Another notable acute phase
response during endotoxemia is the rapid elevation in ZIP14 that imports Zn into hepatocytes [155].
MT elevation likely signifies sequestration and retention of the newly imported Zn, as mice lacking MT1
and MT2 exhibit hepatic Zn loss and concomitant rise in plasma Zn [103]. This peculiar phenomenon
confers, at least, dual benefit to the host: first, it restricts Zn access to pathogens in the extracellular
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towards the site of inflammation. The former surfaces as an arm of nutritional immunity, wherein
the immune system attempts to starve microbial invaders by withholding nutrients essential to
biological processes. Localized Zn redistribution by MTs may shape the course of immune response by
escalating DC maturation and skewing T cell responses towards that of an inflammatory phenotype.
MT-dependent hypozincemia has similarly been reported in other gram-negative infection models
including Salmonella typhimurium and the live vaccine strain of Francisella tularensis [156], implying
a broadly applicable role of MTs in orchestrating hypozincemic responses upon bacterial challenge.
The MT response is transient; withdrawal of the endotoxin stimulus results in rapid degradation
of accumulated MT justifying the short half-life of Zn-thionein complex [154]. The fate of liberated
Zn, however, is obscure. One obvious consequence appears to be redistribution and restoration of
Zn homeostasis after infection has subsided. Beyond these, is there a role for Zn in suppressing
pro-inflammatory responses and promoting tissue repair? If yes, do MTs partake in this process?
Zn has a well-recognized role in wound healing and inflammation. Experimental models of Zn
deficiency and Zn deficient individuals exhibit markedly delayed tissue repair [157,158]. Moreover,
recent revelations of the role of MTs in wound-healing M2 macrophages, discussed in the following
paragraphs, illuminate this possibility [104].
Perhaps, the impact of MTs on immune responses to infection is highly complex, depending on
the cell type, regulation dynamics, degree of induction and the pathogen in question. On the one hand,
in mice infected with the gram-negative bacterium Helicobacter pylori, MT1 and MT2 do not contribute
to bacterial clearance but confer protection against erosive lesions in the gastric epithelium [159]. In this
model, a lack of MTs aggravates infiltration of inflammatory cells, enhances macrophage inflammatory
protein (MIP)-1α and monocyte chemoattractant protein (MCP)-1 expression and augments NF-κB
DNA binding activity in the stomach tissue. How Zn buffering and antioxidant mechanisms of
MTs converge to modulate the inflammatory process to yield subdued ulceration awaits further
experimentation. On the other hand, genetic deficiency of MT1 and MT2 or increased MT gene dose,
accelerate clearance of the gram-positive bacterium, Listeria monocytogenes in mice [160]. Thus, swaying
MT expression in either direction favorably promotes antibacterial defenses. This observation may be
explicated by disrupted redox control, as prolonged MT deficiency or MT overdose interferes with
alleviation of oxidative stress. Indeed, the splenic lymphocyte population exhibits increased oxidized
surface thiols in MT-null mice and augmented ROS in MT overexpressing mice [160].
Complementing the aforementioned studies on bacteria, a plethora of studies have revealed MT
modulation in viral infections. Influenza A/PR8 strain that causes upper respiratory tract and lung
infections strongly elevates MT1 and MT2 in the lung and liver [86]. Infection triggers engagement
of MREs, ARE, GRE and STAT3 binding sites on the MT promoters, perhaps, signifying an effort to
rapidly maximize MT production to curtail oxidative injury caused by heightened inflammation [86].
This hypothesis is further supported by an inverse correlation between hepatic MT expression and
hepatitis C virus (HCV) pathogenesis and that MTs improve response of chronic HCV patients to IFNα
therapy [161,162]. In an experimental model of human coxsackievirus B type 3 infection, MT1 and MT2
are augmented in the liver, kidney and spleens of mice, facilitating Cu and Zn redistribution across
different organs [163]. Metal ion redistribution is frequently reported but how such a process benefits
the host is enigmatic [164]. Viruses must explicitly supply all of their metal ion demands through the
host metal pool; thus, it is reasonable to predict that changes in MTs and Zn or Cu redistribution are
“virus-induced” phenomena. However, from the hosts’ perspective, can such a mechanism deter viral
binding and dissemination? Studies on respiratory syncytial virus reveal an inhibitory role for Zn
but not Ca, magnesium (Mg) and manganese (Mn) in viral replication [165]. Zn-ejecting compounds
inhibit the activity of the transcription anti-termination cofactor protein, M2-1 that is crucial for viral
RNA-dependent RNA polymerase function [166]. Zn also directly inhibits binding of common cold
causing rhinoviruses to intracellular adhesion molecule-1 (ICAM1) receptor in the nasal epithelium,
stalling viral entry into the host [167]. However, to directly obstruct viral entry, MTs must be present
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preparation for antiviral responses is unknown. Upon sensing viral insult, it is possible that some of the
upregulated MT protein is released from cells to curtail further viral invasion. Nonetheless, a number
of questions will need to be addressed. What signals MT release and how does the host decide how
much should be released during infection? What is the fate of extracellular MTs after infection has
subsided? Do viruses encapsulate host MTs as they are released from cells? The latter, if true, may be
exploited as a mechanism of piracy by viral invaders that depletes the host of intracellular MT stores
and manipulates MT levels in the extracellular space. An increased focus on Zn binding proteins and
Zn ionophores in the development of antivirals suggests that harnessing MTs and their Zn modulating
potential may prove beneficial to the host [168,169]. However, a thorough understanding of how
MTs manipulate the course of an antiviral response will be necessary to pinpoint precise molecular
processes involved in MT-mediated host-protection.
Immune responses against microbial challenge modulates host-MTs, but very little is known
about the contribution and functions of immune-cell derived MTs in this context. The pulmonary
fungal pathogen Histoplasma capsulatum establishes a replicative niche within macrophages prior to
pro-inflammatory activation by cytokines such as IFNγ or GM-CSF [44,170]. The latter purposes as a
“Zn reprogramming signal” that induces MT1 and MT2 to deplete intracellular labile Zn that would
otherwise be readily accessible to H. capsulatum containing phagosomes (Figure 2). As indicated earlier,
GM-CSF also triggers Zn import via ZIP2 in macrophages. This finding appears paradoxical, but
the Zn flux probably serves to meet an increased demand of Zn-dependent processes that arm the
macrophage defense machinery. In the host-pathogen combat, the Zn pool could be envisioned as
“drifting” towards the former; one apparent advantage of this mechanism is that the host is guarded
against oxidative disruption of critical cellular processes, while rendering the pathogen in a Zn-starved
state [171]. A macrophage superoxide-boost is interwoven into the umbrella of MT-driven effects
that ultimately cripples fungal replication [44,172]. Parallel to this phenomenon, is the finding that
MT1 and MT2 detain intracellular labile Zn from S. typhimurium within macrophages [173]. Genetic
deficiency of MT1 and MT2 elevates labile Zn and impairs oxidative and nitrosative macrophage
defenses, a situation, that S. typhimurium exploits to acquire Zn and colonize the macrophage. Even in a
Zn-restricted state, S. typhimurium secures the metal ion via the ZnuABC Zn importer [174]. On the flip
side, macrophages also employ “Zn stress” to poison invading microbes. Human macrophages hosting
Mycobacterium tuberculosis rapidly deploy Zn into the phagosome to intoxicate the pathogen. A similar
mechanism is functional in E. coli eradication by macrophages [150]. Contrary to ZIP2 mediated Zn
import in H. capsulatum infected macrophages, the source of this Zn pool is intracellular [44,150].
In these cells, MTF-1 localizes to the nucleus and various MT transcripts (MT1H, MT1M, MT1X,
and MT2A) are elevated. However, whether MTs contribute to the Zn-burst is unclear. It has been
proposed that ROS liberates Zn from MT-Zn complexes; the metal ion is channeled into the phagosome
by yet unknown transport mechanism(s) to drive mycobacterial poisoning [150]. It is conceivable
that cytosolic Zn is redirected by means of Zn transporters, but what signals the entry of this ion
into vacuoles housing mycobacteria? Do MTs localize within late-endosomes and lysosomes, or do
they bind to the phagosomal membrane and interact with transporters to guide entry of Zn into
these vacuoles? Are extracellular Zn-MT complexes and mycobacteria “co-engulfed” as a result of
phagocytosis? Regardless of the mechanism in action, it is reasonable to postulate that MT1 and MT2
arm phagocyte defenses, particularly that of macrophages. Pertinent to the pathogen in context, the
precise molecular cues that instruct Zn poisoning as opposed to Zn sequestration by MTs remain
enigmatic, but likely represents a carefully elected immunological decision that caters to incline Zn
concentrations beyond the narrow “tolerance” window that succumbs pathogens to Zn-starvation
versus Zn-overload (Figure 2).
From the pathogens’ standpoint, survival within the host demands subversion strategies. In the
case of mycobacteria, alleviation of Zn poisoning is achieved by activation of P1-type ATPases [150].
Interestingly, contrary to the hosts’ Zn-restriction defense strategy reported for S. typhimurium,
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The involvement of MTs in this situation has not been deciphered, but the pathogen evades this
response by virtue of Salmonella pathogenicity islands, expression of the bacterial Zn exporter,
ZntA and yet unidentified mechanisms [175]. Thus, in their struggle for survival, pathogens
launch counter-strategies that rely on Zn regulation to subvert host defenses. Given the highly
conserved nature of MTs from single-celled to multicellular organisms, that pathogen-derived MTs
are determinants of virulence within the host is an interesting conjecture to be explored. The finding
that the fungal pathogen, Cryptococcus neoformans produces Cu-binding MTs to neutralize toxic
copper-overload imposed by host macrophages is a classic premise demonstrating that MTs may
also belong to the pathogen-defense armor [176].
Over half a century of research has emphasized the roles of MT1 and MT2 in immune responses.
Until recently, virtually nothing was known about the contribution of MT3 in host defenses. Existing
data on the regulatory and functional attributes of MT3 suggests that from an immunity point of
view, the impact of MT1 and MT2 versus MT3 on host immunity is unparalleled. In M2 macrophages
polarized with IL-4 or IL-13, MT3 is elevated and enriches the labile-Zn pool [104]. These type-2
cytokines promote parasite clearance, wound healing and tissue repair, but exaggerated IL-4 and IL-13
production worsen allergic inflammation and render the host susceptible to invasion by intracellular
pathogens [177,178]. M2 macrophages harbor a favorable niche for the survival of H. capsulatum.
Although the regulation of transferrin and arginase in these cells imply roles for iron metabolism and
subdued NO defenses [179,180], emerging evidence pinpoints to the significance of Zn homeostasis
by MT3 in suppressing macrophage defenses. M2 macrophages source the metal ion from the
extracellular environment, but instead of sequestering it, render it readily accessible to the pathogen.
This “expansion” effect on the Zn-pool is MT3-dependent and is at least partially driven by cathepsins
that trigger Zn release from the protein. The pathogen ultimately gains access to the host-Zn resource,
possibly via the transporter ZnT4, to thrive within phagosomes of M2 macrophages [104]. MT1 and
MT2 act in stark contrast in M1 macrophages invaded by H. capsulatum; in these cells, Zn that once
belonged to the pathogen befits the macrophage Zn-pool [44,104] (Figure 2). It is intriguing that,
rather than being poisoned, this fungal pathogen exploits Zn-release tactics of MT3 to its advantage.
The findings seed a fundamental query: Why did M2 phagocytes evolve to increase the labile-Zn
pool? The existence of such a Zn modulatory machinery in M2 macrophages is reminiscent of the
importance of Zn in anti-parasitic defenses [181]. Nonetheless, much remains to be unraveled about
the involvement of the MT3-Zn axis in immune processes regulated by IL-4 and IL-13 signaling.
6. Concluding Remarks
The evolutionary web of MTs has casted its presence on virtually every life form—prokaryotes
to lower eukaryotes, invertebrates to higher vertebrates including mammals. Within its lifespan,
a living cell must adequately tap the potential of highly dynamic redox chemistries and metal
ion environments to conduct various biological processes. Evidently then, through duplication
and functional segregation, a number of MT isoforms emerged to support metal-ion buffering,
maintaining homeostasis and protecting the host from oxidative assault. The complexity of MT
evolution is readily demonstrated by differences in the MT gene clusters, copy number and functional
characteristics between different species within the same genera [182]. The mouse has four MT
isoforms, but numerous isoforms and subtypes/variants contribute to the heterogeneity of this
family in humans; that newer proteins may line the MT queue pending annotation and functional
characterization may not be a surprise. The question is: Will the MT family evolve further, and why?
From a mammalian-immunity viewpoint, innate and adaptive barriers are constantly confronted with
tremendous evolutionary pressure from environmental cues such as xenobionts including pathogens
that rapidly manipulate their genomes and virulence strategies to sustain infection [183]. While direct
evidence that immunological pressure imposed divergence of the MT family remains to be discovered,
the >10 trillion microbes that have harmlessly populated the human gut and skin for eons suggests
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the gut, known to be guided largely by dietary Zn status, maintains integrity of the gut epithelium,
an important barrier that guards against dissemination of opportunistic pathogens [184,185]. On a
captivating contrary note, is it possible that, evolutionarily, MTs exerted selective pressure to shape
the human microbiome? The fundamental differences in metal-ion requirements, susceptibility to
sequestration or intoxication and ability to withstand superoxide damage between microbes provide
a framework to test this hypothesis. Nonetheless, investigating this possibility demands a rigorous
understanding of microbial metal-ion homeostasis and how immune responses employ MTs to lay
“beneficial” microflora within the host. Perhaps, the functions of MTs are intricately interwoven into
the complex attributes of innate and adaptive cells; thus, in the world of immunity, we may have
only scraped the surface of vast perturbations that underlie a dysregulated MT response. With careful
consideration to how MTs globally impact the immune response, unearthing the potential of MT as
an “antimicrobial protein” will take the next leap forward in battling the rising menace of antibiotic
resistance and emerging virulent pathogens. Such a proposition must be supported by an unparalleled
understanding of interactions of MTs with microbes and immune cells, half-life, fate of the protein and
significance of its apo- and metal-bound forms in bolstering immunological defenses. Finally, gaining
deeper insight into the immunoregulatory role of MTs holds promise in levitating this class of proteins
in the therapeutic ladder targeting infections and the myriad diseases that engage host immunity.
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APC antigen presenting cell
ARE antioxidant response element
Ca calcium
CCL C-C motif ligand
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Egr-1 early growth response-1
ER endoplasmic reticulum
Fe iron
FoxP3 Fork head box P3
Gfi-1 growth factor independent-1
GM-CSF granulocyte macrophage-colony stimulating factor
GRE glucocorticoid response element
GSH glutathione (reduced)
HCV hepatitis C virus
Hg mercury
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MCP monocyte chemotactic protein
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MIP macrophage inflammatory protein
Mn manganese
MRE metal response element
MT Metallothionein
MT-null MT1/2 deficient
MTF-1 metal-response element-binding transcription factor-1
NF-κB nuclear factor-kappa B
NK natural killer
NO nitric oxide
PMA phorbol myristate acetate
PTP protein tyrosine phosphatase
ROS reactive oxygen species
STAT signal transducer and activator of transcription
Th T helper cell
TNF tumor necrosis factor,
Tr1 Type-1 regulatory T cell
Treg regulatory T cell
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Abstract: The basal levels of extracellular Zn2+ are in the range of low nanomolar concentrations and
less attention has been paid to Zn2+, compared to Ca2+, for synaptic activity. However, extracellular
Zn2+ is necessary for synaptic activity. The basal levels of extracellular zinc are age-dependently
increased in the rat hippocampus, implying that the basal levels of extracellular Zn2+ are also
increased age-dependently and that extracellular Zn2+ dynamics are linked with age-related cognitive
function and dysfunction. In the hippocampus, the influx of extracellular Zn2+ into postsynaptic
neurons, which is often linked with Zn2+ release from neuron terminals, is critical for cognitive
activity via long-term potentiation (LTP). In contrast, the excess influx of extracellular Zn2+ into
postsynaptic neurons induces cognitive decline. Interestingly, the excess influx of extracellular
Zn2+ more readily occurs in aged dentate granule cells and intracellular Zn2+-buffering, which is
assessed with ZnAF-2DA, is weakened in the aged dentate granule cells. Characteristics (easiness)
of extracellular Zn2+ influx seem to be linked with the weakened intracellular Zn2+-buffering in the
aged dentate gyrus. This paper deals with the impact of synaptic Zn2+ signaling on cognition and its
decline in comparison with synaptic Ca2+ signaling.
Keywords: Zn2+ signaling; hippocampus; memory; Ca2+ signaling; perforant pathway; dentate
granule cell
1. Introduction
Cognitive activity has been closely linked to strengthening and weakening synaptic connections
between neurons that is synaptic plasticity such as long-term potentiation (LTP) and long-term depression
(LTD). The hippocampal formation, which spans the posterior-to-anterior extent of the base of the temporal
lobes, plays a key role in learning, memory, and recognition of novelty [1]. In its transverse axis,
the hippocampal formation consists of the entorhinal cortex, the dentate gyrus, the CA3 and the CA1
subfields, and the subiculum. The entorhinal cortex functions as the gateway into the hippocampal
formation [2]. The entorhinal cortex layer II projects to dentate granule cells via the perforant pathway,
and dentate granule cells project to CA3 pyramidal cells via the mossy fibers. CA3 pyramidal cells
interconnect with other CA3 neurons and project to CA1 pyramidal cells via the Shaffer collaterals. Finally,
CA1 pyramidal cells connect to the subiculum. The entorhinal cortex layer II also projects to CA3 pyramidal
cells, and the entorhinal cortex layer III also projects to CA1 pyramidal cells and the subiculum [3].
In the process of changes in synaptic structure for memory formation, glutamatergic neurons
play a key role in the main neural circuit of the hippocampal formation. Research on synaptic
plasticity opens a window for the molecular mechanisms of memory. Changes in both presynaptic
and postsynaptic strength have been implicated in the mechanisms of LTP and LTD, and attention
has been paid to changes in postsynaptic glutamate receptor density [4]. Intracellular Ca2+ signaling
via the network of signaling molecules controls the glutamate receptor density and induces synaptic
signals, as is observed in learning situations [5], followed by cognitive performance and memory.
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For N-methyl-D-aspartate (NMDA)-receptor-dependent plasticity, the influx of extracellular Ca2+
into postsynaptic neurons through NMDA receptors plays a key role [6]. However, glutamate receptor
activation by excess of extracellular glutamate, which is known as glutamate excitotoxicity [7,8], leads
to a final common pathway for neuronal death and is linked with pathophysiological processes of
neurological disorders [9,10]. CA1 pyramidal cells are the most vulnerable to neurodegeneration in the
hippocampus after stroke/ischemia [11–13]. A well-known fact is that extracellular Ca2+ influx into
postsynaptic neurons, in addition to Ca2+ release from the calcium stores results in neuronal death.
On the other hand, extracellular glutamate signaling also induces cellular transients in Zn2+
concentration, i.e., intracellular Zn2+ signaling, which is required for synaptic plasticity [14,15] and
may have crosstalk to intracellular Ca2+ signaling via calcium channels [16,17]. On the basis of the
subsequent evidence that glutamate-induced neuronal death is due to extracellular Zn2+ influx into
postsynaptic neurons, which is dynamically linked with Zn2+ release from zincergic neurons, a subclass
of glutamatergic neurons that concentrate zinc in the presynaptic vesicles [18–22], this paper deals
with the impact of synaptic Zn2+ signaling on cognitive function and dysfunction in comparison
with synaptic Ca2+ signaling. While the hydrated Ca2+ ion is the major species in intracellular Ca2+
signaling, this is not the case in intracellular Zn2+ signaling because the Zn2+ ion has much higher
affinities for donors of ligands [23]. The Zn2+ ion is different from the Ca2+ and Mg2+ ions because it
forms much stronger complexes with water and various anions and ligands. These characteristics are
important for its synaptic functions.
2. Physiology of Brain Zn2+
Divalent cations such as Ca2+ and Mg2+ are involved in synaptic neurotransmission [24]. Among
divalent cations, Ca2+ concentration is the highest in brain parenchyma cells and is approximately
1.2 mM in the cerebrospinal fluid (CSF) and brain extracellular fluid in the adult rats (Figure 1) [25].
Approximately 2 mM Ca2+ is added to artificial cerebrospinal fluid (ACSF) based on essentiality of
intracellular Ca2+ signaling in neurons and glial cells [26,27]. However, excess influx of extracellular
Ca2+ into neurons is linked with the pathophysiological process of neurodegeneration [28–30].
Figure 1. Zn2+-mediated cognitive decline via rapid influx of extracellular Zn2+. Estimated basal
concentration of extracellular Zn2+ is ~10 nM in the adult brain. When the basal concentration of
extracellular Zn2+ reaches 100 nM in the adult brain, it induces cognitive decline. In contrast, even if the
basal concentration of extracellular Zn2+ reaches 100 nM in the aged brain, it does not induce cognitive
decline, suggesting that the basal concentration of extracellular Zn2+ is ~100 nM in the aged brain.
Extracellular Zn2+-mediated cognitive decline is induced by glutamateric synapse excitation, in which
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Zinc concentration in the CSF is in the range of 150–380 nM [31–33]. It is estimated that the
basal (static) concentration of extracellular Zn2+ is approximately 10 nM in the brain of the adult rats
(Figure 1) [34]. A small part of extracellular zinc is free ion (Zn2+) in the brain under the basal condition.
To research synaptic function, much less attention has been paid to the essentiality of Zn2+ in brain
extracellular fluid. ACSF, i.e., brain extracellular medium, without Zn2+ has been used for in vitro and
in vivo experiments. It is likely that not only neuronal excitation but also LTP is modified in brain
slices immersed in ACSF without Zn2+, in which original neurophysiology might be modified [35,36].
Clarifying the action of extracellular Zn2+ in the range of physiological concentrations is important to
precisely understand synaptic function. Furthermore, such clarification is also important to understand
the bidirectional action of Zn2+ under physiological and pathological conditions. It is recognized that
low nanomolar concentrations of Zn2+ are more physiological than micromolar concentrations of Zn2+,
which are widely used and often neurotoxic.
Spontaneous presynaptic activity assessed with FM4-64, an indicator of presynaptic activity
(exocytosis), in the stratum lucidum where mossy fibers are contained is significantly suppressed in
brain slices from young rats immersed in ACSF containing 10 nM Zn2+, but not in ACSF containing
10 nM Cu2+ or 10 nM Fe3+, indicating that hippocampal presynaptic activity is enhanced in brain slices
prepared with ACSF without Zn2+ [36]. Suh et al. [37] report that acute brain slice preparations are
poorly suitable to research the role of endogenous Zn2+ released from zincergic neurons. Vesicular
Zn2+ levels are decreased in the process of slice preparation, and in vitro Zn2+ release is reduced to
approximately 25% of in vivo Zn2+ release. While physiological concentration of extracellular Zn2+
is low nanomolar in young rat brain, it may be elevated along with aging (Figure 1), based on the
age-related increase in extracellular zinc concentration in the hippocampus [38].
3. Impact of Synaptic Zn2+ Dynamics on Cognition
Extracellular Ca2+ concentration is not affected by neuronal excitation. In contrast, extracellular
Zn2+ concentration is dynamically increased by zincergic excitation, but not by non-zincergic excitation.
In any case, extracellular dynamics of Ca2+ and Zn2+ is critically linked with their intracellular
dynamics. The basal concentration of intracellular (cytosol) Ca2+ is 10–100 nM, while that of
intracellular Zn2+ is extremely low and estimated to be less than 1 nM (Figure 1) [39,40]. While
intracellular Ca2+ serves as a signaling factor for plastic changes at synapses, intracellular Zn2+ is
increased for not only signaling for plastic changes during learning and cognitive activity but also
plastic changes in synapse structure [41,42]. The optimal range of intracellular Zn2+ increased during
learning and cognitive activity, which is dynamically linked with Zn2+ release at zincergic synapses,
remains to be clarified. Even at non-zincergic synapses, postsynaptic intracellular Zn2+ may reach
~1 nM and the increase originates in internal stores/proteins unlike the neurotoxic increase via
extracellular Zn2+ influx as described below.
LTP at zincergic mossy fiber-CA3 pyramidal cell synapses is induced by the presynaptic
mechanism, in which glutamate release is persistently increased. Mossy fiber LTP induction critically
depends on the rise in presynaptic Ca2+ [43–45], which activates the calcium-calmodulin-sensitive
adenyl cyclase I [46]. Zn2+ released from mossy fibers is immediately retaken up into
presynaptic terminals through Ca2+ channels and activates a Src family kinase, which promotes
tropomyosin-related kinase B (TrkB) activation. The activation leads to the phosphorylation and
activation of phospholipase Cγ1, followed by calcium-calmodulin-sensitive adenyl cyclase I activation.
Zn2+ increases presynaptic glutamate release, while it inhibits postsynaptic mechanism of mossy fiber
LTP via Zn2+ influx [47,48].
LTP at the Schaffer collateral/commissural-CA1 pyramidal cell synapses depends on the
postsynaptic activation of NMDA receptors [49]. NMDA receptor activation increases postsynaptic
Ca2+ concentration, which leads to LTP and LTD. NMDA receptors consist of multiple subclasses [50]
and the subtypes have different sensitivities to Zn2+, an endogenous blocker [51–54]. ZnAF-2DA
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a membrane-permeable Zn2+ indicator, is taken up into neurons through the plasma membrane
and is hydrolyzed by esterase in the cytosol, resulting in the production of ZnAF-2, which cannot
permeate the plasma membrane [55,56]. When ZnAF-2DA is locally injected into the hippocampal
CA1, intracellular ZnAF-2 is detected only in the injected area in the CA1 and can block cellular
transients in Zn2+ concentration (Kd, 2.7 nM for Zn2+). The concurrent evaluations of in vivo LTP and
learning behavior in separated experiments using ZnAF-2DA answer whether the in vivo LTP via
intracellular Zn2+ signaling is linked with learning behavior. The influx of extracellular Zn2+ into CA1
pyramidal cells, which is linked with Zn2+ release form the zincergic Schaffer collateral, is required
for object recognition memory via in vivo Schaffer collateral LTP [57]. Glutamatergic input to CA1
pyramidal cells via the medial perforant pathway (the temporoammonic pathway) from the entorhinal
cortex facilitates memory consolidation [58] and is required for temporal association memory [59]
and spatial working memory [60]. Although the medial perforant pathway from the entorhinal
cortex, is non-zincergic [61], intracellular Zn2+ signaling, which originates in internal stores/proteins,
is required for LTP at medial perforant pathway-CA1 pyramidal cell synapses [62]. It is likely that
intracellular Zn2+ signaling in CA1 pyramidal cells is also involved in cognitive function via in vivo
perforant pathway LTP.
The lateral and medial entorhinal cortices are connected with the dentate gyrus. The lateral
and the medial perforant pathways, which originate in the lateral and the medial entorhinal cortices,
respectively, comprise physiologically distinct inputs to the dentate gyrus. The lateral perforant
pathway transmits nonspatial information, while the medial perforant pathway transmits spatial
information [63]. In regard to LTP at medial perforant pathway-dentate granule cell synapses,
calmodulin-dependent protein kinase II α (α-CaMKII)/brain-derived neurotrophic factor (BDNF)
signaling pathway plays a key role for LTP induction. Zinc deficiency-induced cognitive and synaptic
impairments are linked with disruption of α-CaMKII/BDNF signaling pathway [64]. In dentate
granule cells, intracellular Zn2+ signaling originates in internal stores/proteins and is necessary for
object and space recognition memory via medial perforant pathway LTP [65,66]. In postsynaptic
neurons innervated by non-zincergic medial perforant pathway, glutamate receptor activation triggers
off Zn2+ release from internal stores/proteins that remain to be clarified.
Hippocampal neurogenesis always produces dentate granule cells, in which NMDA
receptor-dependent synaptic plasticity is involved in learning and memory [67,68]. Zn2+ is
concentrated in the dentate gyrus of the hippocampus [69] and is required for neurogenesis process [70].
In human neuronal precursor cells, zinc deficiency induces apoptosis via mitochondrial p53- and
caspase-dependent pathways [71], suggesting that dynamic Zn2+ transport to neuronal precursor cells
is critical for learning and memory via hippocampal neurogenesis [72].
4. Impact of Synaptic Zn2+ Dynamics on Cognitive Decline
Aging has progressive pathophysiological features and is linked with altered cell metabolism,
damaged nucleic acid, oxidative stress, and deposition of abnormal forms of proteins. Aging also
is characterized by cognitive decline, neuronal loss, and vulnerability to neurological disorders [73]
and may be often related with altered Zn2+ homeostasis in the brain [74,75]. Hippocampal zinc
concentration is decreased in aging, which decreases zinc transporter-3 (ZnT3) protein. ZnT3 controls
synaptic vesicular Zn2+ levels. Zn2+ release from zincergic neuron terminals, which dynamically
modifies the basal concentration of extracellular Zn2+, is decreased in aging [74], while the basal
concentration of extracellular Zn2+ may be increased [38], probably as a compensatory mechanism.
A negative modulation of extracellular glutamate signaling by extracellular Zn2+ may be involved in
cognitive function.
Metal chaperones i.e., clioquinol and PBT2, prevent normal age-related cognitive decline [76,77],
suggest that metal chaperones are effective for preventing Zn2+-mediated cognitive decline that is
observed in aging and disease. The hippocampus is vulnerable to Zn2+ neurotoxicity [78] and the
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poorly understood, it is possible that synaptic Zn2+ dynamics is involved in the vulnerability. New
granule cells are continuously produced in the subgranular zone of the dentate gyrus (Figure 2) and
the decreased rate of hippocampal neurogenesis is involved in age-related cognitive decline [80].
Neurogenesis-related apoptosis, which seems to be increased along with aging, always occurs in
the dentate gyrus. In the subgranular zone, the apoptosis locally increases extracellular K+ and
the increase is due to the efflux of intracellular K+ (approximately 140 mM) by disruption of the
plasma membrane. The increase in extracellular K+ may excite granule cells and pyramidal basket
cells, which exist nearby in the dentate gyrus, and disturbs intracellular dynamics of Ca2+ and Zn2+
(Figure 2). As a matter of fact, both memory acquisition via LTP induction and memory retention via
LTP maintenance are impaired after local injection of high K+ into the dentate gyrus [81–83] or the
CA1 [84]. The impairments are due to an increase in intracellular Zn2+, but not that in intracellular
Ca2+, because the impairments are rescued with CaEDTA, which forms membrane-impermeable
ZnEDTA in the extracellular compartment and inhibits the influx of extracellular Zn2+, but not that
in extracellular Ca2+ [82]. The evidence indicates Zn2+-mediated cognitive decline via transient Zn2+
accumulation in dentate granule cells (Figure 1) and CA1 pyramidal cells.
 
Figure 2. Neuronal depolarization via neurogenesis-related apoptosis. Neurogenesis-related apoptosis
increases extracellular K+ concentration ([K+]o), which is due to the efflux of intracellular K+ as shown
by red arrows, in the dentate granule cell layer and can lead dentate granule cells to depolarization,
followed by extracellular Zn2+ influx-mediated cognitive decline. The blue arrow shows the process of
neurogenesis and red up-arrows show the process of apoptosis and efflux of intracellular K+. [K+]i:
intracellular K+ concentration.
If the basal level of extracellular Zn2+ is increased age-dependently in the hippocampus
(Figure 1) [38], it is estimated that Zn2+-mediated cognitive decline more readily occurs in the aged
brain. High K+-induced increase in intracellular Zn2+ is facilitated in the aged dentate gyrus and leads
to attenuating both LTP induction and maintained LTP at medial perforant pathway-dentate granule
cell synapses of aged rats [38,83], suggesting that the influx of extracellular Zn2+ into dentate granule
cells more readily occurs in aged rats and is a cause of age-related cognitive decline via attenuation of
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GluR2-lacking calcium-permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)
receptors are involved in Zn2+-mediated neurodegeneration in the hippocampal CA1 and
CA3 [18,85,86]. In the hippocampus, the levels of GluR1 and GluR2 mRNA are highest in the dentate
gyrus and the GluR1/GluR2 mRNA ratios are elevated along with aging [87]. The findings suggest
that Zn2+ influx through Ca2+-permeable AMPA receptors, which more readily occurs in the aged
dentate gyrus, plays a key role for cognitive decline [38,83]. Intracellular Zn2+ can reach approximately
10 nM via the rapid influx of extracellular Zn2+ (Figure 1) [34]. Both increases in extracellular Zn2+ and
Ca2+-permeable AMPA receptors contribute to Zn2+-mediated cognitive decline in aging.
Although intracellular Zn2+ level in the process of LTP maintenance is unknown, LTP maintenance
at medial perforant pathway-dentate granule cell synapses is affected by chelation of intracellular
Zn2+ with intracellular ZnAF-2 [66] and the aged dentate gyrus is more susceptible to the chelating
effect on LTP maintenance [83]. When ZnAF-2DA is used as an index of the capacity binding
intracellular Zn2+, interestingly, the capacity of intracellular ZnAF-2 for binding intracellular Zn2+ is
more rapidly lost in the aged dentate molecular layer where medial perforant pathway-dentate granule
cell synapses are contained than in the young dentate molecular layer, suggesting that intracellular
Zn2+-buffering is weakened in the dentate gyrus along with aging (Figure 3) [83]. Characteristics
(easiness) of extracellular Zn2+ influx may be linked with weakened intracellular Zn2+-buffering
in the aged dentate gyrus [28]. Although the actual state of intracellular Zn2+-buffering is poorly
understood, Ca2+-permeable channels, zinc transporters (ZIP and ZnT), zinc-binding proteins such as
metallothioneins, and Zn2+-containing internal stores are involved in the Zn2+-buffering system.
Figure 3. Is intracellular Zn2+-buffering weakened in the dentate gyrus along with aging? In vivo
intracellular Zn2+-buffering is assessed in the dentate molecular layer where non-zincergic media
performant pathway (MPP)-dentate granule cell synapses are contained. Intracellular ZnAF-2, an index
of intracellular Zn2+-buffering capacity, can bind Zn2+ at young MPP synapse 2 h after ZnAF-2DA
injection into the dentate molecular layer, but not at aged MPP synapses. Capacity of intracellular
ZnAF-2 for binding intracellular Zn2+ is more rapidly lost in in aged dentate gyrus, probably due to
easiness of extracellular Zn2+ influx, suggesting a reduced capacity of intracellular Zn2+-buffering in
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5. Perspectives
Vulnerability to Ca2+ dysregulation has been observed in the process of brain aging [88–90].
It has been reported that Ca2+ dysregulation is not ubiquitous. The mechanisms of dysregulation
are observed in specific cell populations and areas in the brain. For example, L-type Ca2+ channels
is age-dependently increased in hippocampal pyramidal cells [91]. Age-dependent reduction in the
NMDA receptor function is observed in the hippocampus and the frontal cortex [92], suggesting
a compensatory mechanism to availability/restriction for intracellular Ca2+ signaling. Intracellular
Ca2+-buffering, which is involved in cognitive function, is weakened during brain aging [89].
In contrast, intracellular Zn2+-buffering is also dynamically involved in cognition and its decline.
However, the Zn2+-buffering system is more poorly understood than the Ca2+-buffering system,
and its clarification is required for understanding cognition and its decline.
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Abstract: The divalent cation zinc is an integral requirement for optimal cellular processes, whereby it
contributes to the function of over 300 enzymes, regulates intracellular signal transduction, and contributes
to efficient synaptic transmission in the central nervous system. Given the critical role of zinc in a breadth
of cellular processes, its cellular distribution and local tissue level concentrations remain tightly regulated
via a series of proteins, primarily including zinc transporter and zinc import proteins. A loss of function
of these regulatory pathways, or dietary alterations that result in a change in zinc homeostasis in the
brain, can all lead to a myriad of pathological conditions with both acute and chronic effects on function.
This review aims to highlight the role of zinc signaling in the central nervous system, where it may
precipitate or potentiate diverse issues such as age-related cognitive decline, depression, Alzheimer’s
disease or negative outcomes following brain injury.
Keywords: zinc; brain; neurodegeneration; cognition
1. Introduction
The essential trace ion zinc is a stable divalent cation that participates in numerous biological
processes, and after iron, is the second most abundant trace element [1]. It is a known contributor to the
functionality of over 2000 proteins [2], and as such plays a role in many diverse cellular mechanisms
including cell division [3], DNA synthesis [4], protein synthesis [5], wound healing [6], immunity [7],
and cognition [8]. Thus, zinc is an indispensable micronutrient for humans, the deficiency of which
has been linked to numerous disorders [1]. Indeed, zinc deficiency is a recognized global public
health concern in developing countries [9], and is also becoming a prevalent concern in the ageing
population of developed countries [10]. Whilst supplementation of dietary zinc may be efficacious in
the prevention of certain zinc deficiency related conditions, excess zinc can also induce adverse effects
due to its role in numerous biochemical reactions in the human body [11]. Thus, the maintenance of
zinc at natural homeostatic levels, usually attainable through a balanced diet, is both desirable and
essential for optimal physiological function. In the central nervous system (CNS), maintenance of zinc
homeostasis is critical for brain health, particularly as it pertains to cognition [12,13]. Moreover, altered
zinc homeostasis is considered a contributing factor to the pathogenesis of multiple CNS diseases [14].
In this review, we will provide a brief overview of zinc regulation and will then focus on detailing a
number of examples of the role of zinc in different brain diseases.
2. Zinc in the Brain
Compared to other organs in the human body, zinc concentration is highest in the brain where it
is estimated at 150 μmol/L, representing a 10-fold increase over serum zinc [15]. Zinc occurs in the
brain as a structural component of about 70% of proteins, contributing to the efficient performance
of over 2000 transcription factors and over 300 enzymes. 10–15% of brain zinc occurs in a “free” or
chelatable form, and is present at much lower concentrations (~500 nM) in brain extracellular fluids [15].
However, the concentration of zinc in synaptic vesicles of excitatory glutamatergic forebrain neurons
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has been shown to be >1 mmol/L [16], and as such has resulted in these cells commonly being referred
to as “gluzinergic” neurons. Other cell populations in the brain containing zinc ions in pre-synaptic
boutons have similarly been designated as “zinc-enriched” (ZEN) neurons [17].
Zinc homeostasis in the brain is tightly regulated, primarily via three families of proteins.
They are the metallothioneins (MTs) involved in the regulation and maintenance of intracellular
zinc homeostasis [12], the zinc- and iron-like regulatory proteins (ZIPs) responsible for zinc uptake
from extracellular fluids into both neurons and glia [18], and the zinc transporters (ZnTs) which are
associated with cellular zinc efflux [1,18]. Whilst historical data has suggested that a number of the
ZIP and ZnT proteins were specific for zinc, there is evidence now emerging that suggests that many
of these zinc regulatory proteins also regulate other metal ions and are found in a more diverse suite
of cellular compartments than originally thought.
3. Metallothioneins
Approximately 5–15% of the cytosolic zinc pool is bound by metallothioneins, of which there are
four isoforms, designated MT-1, MT-2, MT-3, and MT-4 [19]. Each metallothionein is composed of
61–68 amino acids, comprising 20–21 cysteines which can incorporate up to 7 atoms of zinc for storage,
or for the function of a zinc acceptor or donator [1] (these proteins typically also bind copper, and can
also bind metals such as cadmium, lead and others). MT-1, MT-2 and MT-3 are all synthesized in the
CNS, however MT-1 and MT-2 are expressed in all tissues, and in the CNS are primarily expressed
by astrocytes. Similarly, MT-3 is principally expressed in the CNS [19], whereas MT-4 is a minor
metallothionein localized in stratified epithelial cells [20].
4. Zinc- and Iron-like Regulatory Proteins
There are 14 ZIP transporters currently known in humans [18], each of which contain eight
transmembrane domains with extracellular N- and C-termini. Whilst zinc transport activity has been
confirmed for ZIPs 1-8 and -14 [21], ZIP transporters do not transport exclusively zinc. They have been
shown to regulate intracellular iron, copper, manganese and cadmium transport as well [1]. Most ZIP
transporters are localized on plasma membranes where they function in the cytosolic replenishment of
zinc from the extracellular space and within the lumen of intracellular components [22]. Cell surface
localization and expression of ZIP transporters accordingly increase in zinc-deficient environments,
and rapid internalization of the transporters has been observed in conditions of excess zinc [22]. In the
CNS, ZIP1 and ZIP3 appear to be the major regulators of zinc uptake, however, ZIP1 expression
is greater in the brain than ZIP3, and as such is believed to be the key facilitator of neuronal zinc
uptake [22].
5. Zinc Transporter Proteins
Currently there are ten known human ZnT proteins, each of which function to regulate zinc
primarily via efflux out of cells and intracellular compartments [23]. Whilst there is no precise
structural information on ZnTs, based on the structure of the bacterial ZnT homolog YiiP [24], ZnTs are
predicted to have six transmembrane domains with cytoplasmic amino- and carboxy-termini.
The first mammalian zinc transporter to be identified and characterized was ZnT1, and it was
shown to be primarily localized in the plasma membrane where it functioned by exporting cytosolic
zinc ions into the extracellular space [25]. As such, ZnT1 was predicted to protect cells from zinc
influx during pathological conditions. Indeed, the mRNA for ZnT1 is upregulated in response
to increases in cellular zinc levels in transient forebrain ischemia [26], and to high dietary zinc
intake [27]. ZnT2 and ZnT3 both function to transport cytosolic zinc into the lumen of vesicular
compartments [23]. ZnT3, which is enriched in the hippocampus and cortex, plays a significant
role in modulating neurotransmission and plasticity in glutamatergic neurons [28]. ZnT3 achieves
this via its role in loading zinc into pre-synaptic vesicles (whilst other proteins have been
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When zinc ions are then released into the synaptic cleft, which is co-incident with the vesicular
release of glutamate [29], it aids in regulating the neuronal processes related to cognition and
memory such as long-term potentiation (LTP) and long-term depression (LTD), by acting on
N-methyl-D-aspartate (NMDA) receptors [30]. Zinc released into the synaptic cleft can also regulate
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors on post-synaptic cells, further
regulating synaptic function and plasticity [31]. Other interactions with targets such as the zinc
sensing receptor (ZnR/GPR39 [32]), the tyrosine kinase receptor TrkB [33], glutamate receptors [34]
and p75 [35] also contribute to its role as a modulator of synaptic transmission and plasticity [36]
and have led to zinc being labelled as an “atypical neurotransmitter” [37]. These data, together with
other detailed studies examining the role of zinc in various aspects of learning and memory in the
hippocampus [38–43], highlight the significance of zinc in cognition. Significantly, the ablation of
ZnT3 has been demonstrated to result in age-dependent cognitive deficits in mice [44]. ZnT3 protein
levels are decreased across normal ageing in humans, and further decreased in Alzheimer’s disease
postmortem brain tissue [44], together with significant reductions in ZnT3 mRNA levels in disease [45].
Furthermore, there is an emerging notion that single nucleotide polymorphisms in specific genes,
such as that for ZnT3 (SLC30A3), may have an interaction with the nutrient status that impacts
upon short- and long-term memory scores in the normal population [46]. Thus, changes in specific
ZnT proteins, or indeed ZIPs or other alterations that alter the normal zinc regulatory apparatus,
and that subsequently then precipitate the abnormal homeostasis of zinc within critical brain structures,
are likely to alter cognition across both “healthy” and “pathological” ageing. ZnT4 is expressed in the
endosomes/lysososmes, Golgi apparatus and trans-Golgi network (TGN) and cytoplasmic vesicles,
in the brain, mammary glands and intestinal epithelial cells, where it is involved in vesicular secretory
functions [1,23]. ZnT5 and ZnT6 uniquely form heterodimer complexes and function by delivering
zinc into early secretory pathways, and both are located in the Golgi apparatus and TGN [23]. ZnT7 is
expressed in the large and small intestine, and as such is involved in the absorption of dietary
zinc, evidenced through poor growth and reduced adiposity in mice with a disruption in the ZnT7
gene [1,23]. ZnT8 is a pancreatic specific zinc transporter localized to the membrane of insulin storage
granules [27]. ZnT9 has been classified as a zinc transporter, however, due to an absence of essential
histidine residues, is believed to have no zinc transport functions [1]. ZnT10 has been localized to
early/recycling endosomes or the Golgi apparatus, and data suggests that the primary function of
ZnT10 is manganese transport. Indeed, patients with homozygous mutations in the ZnT10 gene show
disturbances in cellular manganese homeostasis, not zinc perturbations [1].
In the brain, there is a low expression of ZnT2, 5, 7, and 8, however ZnT1, 3, 4, and 6 are highly
expressed [23]. Whilst each of these proteins are essential in the modulation of intracellular cytosolic
zinc in the brain, it should be noted that ZnT1 and ZnT3 are unique with regards to the other ZnTs
in that ZnT1 is present on plasma membranes and ZnT3 is located on synaptic vesicle membranes,
with the latter playing a significant role in cognition in aging and pathogenesis of disease.
6. Zinc Signal in Brain Diseases
There exists a wide-range of neurological diseases where zinc homeostasis is impacted and
subsequently associated with the pathogenesis of the disorder. These include Alzheimer’s disease
(AD), amyotrophic lateral sclerosis (ALS), traumatic brain injury (TBI), depression, schizophrenia
(SCZ), and Parkinson’s disease (PD). The role of zinc in each of these disorders will be briefly discussed
in the following sections.
6.1. Alzheimer’s Disease
Alzheimer’s disease is the most common progressive dementia affecting the elderly today. It is
a multi-factorial disease of both genetic and non-genetic aetiology. The principal theory of AD








Int. J. Mol. Sci. 2017, 18, 2506
larger amyloid precursor protein (APP). Significant efforts have also focused on the role of abnormally
phosphorylated forms of the microtubule associated protein tau in the onset and progression of AD.
The interest of zinc in AD pathogenesis is derived from the observation that zinc, above 300 nM
concentration, can precipitate Aβ to result in its aggregation into senile plaques, one of the major
pathological hallmarks of the disease [47]. The extracellular concentration of zinc during synaptic
transmission rises to 300 μM, and as such it is possible that synaptic transmission could contribute to Aβ
deposition in AD [48]. More recently, Deshpande and colleagues [49] also demonstrated that the zinc
emanating from the glutamatergic synapse (following neurotransmission) was critical for the targeting
of Aβ oligomers to the synapse (where the Aβ subsequently colocalised with the NMDA receptor
subunit NR2B). Supporting this notion is the observation that β-amyloid deposits are pronounced in
the neocortex, an area in which the highest zinc concentration occurs [48]. The amyloid plaques are also
enriched in metals such as zinc [50,51], and Aβ itself is a metalloprotein containing binding sites for
metals such as zinc [52]. Further evidence of zinc involvement in Aβ deposition in AD arose from the
observation of a significantly reduced plaque load in the brains of Tg2576 transgenic mice (a common
mouse model of AD that overexpresses mutant human APP) that were cross-bred with ZnT3 knockout
mice, indicating that synaptic zinc does indeed contribute to amyloid deposition in the TG2576
mouse [53]. In contrast to this, plaque number and size have been shown to be enhanced by dietary zinc
modulation (both by zinc supplementation, which also resulted in cognitive deficits [54,55], and severe
zinc deficiency) in various transgenic mouse models of AD [56,57]. These seemingly paradoxical
data may reflect the diverse roles played by zinc in the regulation of Aβ—as zinc has been shown to
prevent the proteolytic degradation of Aβ by matrix metalloprotease 2 [58], and also to modulate the
activity of α, γ and β-secretase [59] that processes APP to generate Aβ and various cleavage products.
Together with the impact of zinc on other pathways, and indeed on other metals (such as copper) that
are reported to be involved in the evolution and progression of AD-like neuropathology, it is clear that
there is not a simple linear relationship between zinc and Aβ/AD. These observations are not definitive,
however, with other studies suggesting a minor role for Aβ and zinc binding [60]. The apparent effect
of zinc on modulating the toxicity of Aβ also appears to be concentration dependent, with low
concentrations being protective [61]. Similarly, post mortem analysis of AD brain zinc concentrations
was contradictory with several studies showing increased zinc levels in the AD brain [50,62], decreased
levels in the AD brain [63,64], or no change at all [65].
There is an additional pathway through which zinc may be involved in the pathogenesis of
AD, which involves its role in the development of the hyperphosphorylated tau protein and causing
the polymerization and subsequent generation of neurofibrillary tangles (NFTs), the other major
neuropathological feature of the AD brain. Zinc has been revealed to regulate phosphorylation of
tau protein through the extracellular signal-regulated kinase pathway (MAP/ERK) [66]. Additionally,
low micromolar zinc concentrations can cause the aggregation of human tau fragments [67–69],
and in rat hippocampal slices synaptically released zinc has been demonstrated to promote the
hyperphosphorylation of tau [70]. Recent studies have also demonstrated that zinc inactivates the
major tau phosphatase, protein phosphatase 2A (PP2A), via an Src-dependent phosphorylation of PP2A
to result in the hyperphosphorylation of tau [71]. Furthermore, zinc may bind to and directly mediate
the toxicity of tau [72]. Adding validity to these observations is the fact that the use of zinc chelators
or a blockade of synaptic zinc signaling abolishes zinc mediated tau hyperphosphorylation [70].
Cumulatively, these data support an interaction of zinc with the two key proteins, and their regulatory
pathways, that are believed to drive disease pathogenesis in AD. This has been the subject of numerous
reviews over the last two decades [48,73,74].
6.2. Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of the human motor
system. It is both sporadic and familial in nature with around 5–10% of cases being familial and
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dismutase (SOD1) gene [75]. The mutation, which results in the SOD1 protein having a reduced
affinity for zinc, leads to a toxic gain of function in motor neurons when zinc is missing from its active
site [76]. In addition to the SOD1 mutation, both ZnT3 and ZnT6 are downregulated in the spinal
cords of patients with sporadic ALS, independent of the loss of motor neurons, suggesting that ZnTs
may also have a role in disease pathogenesis [77]. A parallel study in SOD1 (G93A) mutant transgenic
mice, however, indicated that ZnT3 and ZnT6 protein levels were not altered in the mouse spinal
cord before or after the onset of ALS symptoms when compared with controls [77]. In another study,
it has also been shown that the levels of zinc are significantly higher in the cerebrospinal fluid (CSF) of
patients with ALS [78], however, the precise mechanism underlying this elevation and the potential
implications for this in disease are yet to be clarified.
6.3. Traumatic Brain Injury
Traumatic brain injury (TBI) is a disruption in the normal structure and/or function of the brain
that can be attributed to a blow or jolt to the head, or by a penetrating head injury. TBI can destroy
neurons via direct mechanical damage such as cellular membrane rupture and diffuse axonal injury
(DAI), and indirectly through the ischemia [79]. The ischemia associated with TBI (and ischemic stroke)
initiates a release of glutamate from pre-synaptic axon terminals after injury, leading to excitotoxicity
and cell death of post-synaptic neurons [80]. Evidence also suggests that the synaptic release of zinc
from presynaptic boutons can additionally cause injury and death to post synaptic neurons under
excitotoxic conditions. Research findings in both ischemia [81] and status epilepticus [82], both of
which occur as secondary complications in TBI [83,84], clearly demonstrate that zinc is translocated
from zinc-containing presynaptic boutons to dying postsynaptic soma. In TBI, synaptically released
zinc has been shown to contribute to neuronal injury [85], and occurs concomitantly with the glutamate
release observed after head injury [86]. However, the role of zinc in the injured brain is not yet clearly
defined, with multiple chelation [87,88] and supplementation [89,90] studies demonstrating both
neuroprotective and neurotoxic roles for zinc in the pathogenesis of TBI. However, in a rat brain
model of TBI, protective effects of zinc chelation were shown to be associated with the upregulation of
neuroprotective genes in combination with decreased neuronal death, potentially indicating a toxic
role of zinc in TBI [88].
6.4. Depression
Depression affects millions of individuals world-wide, and is comorbid with many neurodegenerative
diseases [91]. The evidence for a role of zinc in depression has gained much traction over the last decade
after the observation that depressed patients exhibited lower serum zinc levels than psychiatrically
normal controls, and that zinc levels negatively correlated with the severity of depressive symptoms [92].
Moreover, other studies indicated that serum zinc levels may be normalized after successful antidepressant
therapy [93,94]. One explanation as to the role of zinc in depression is its ability to regulate the NMDA
receptor [95]. As noted previously, zinc can act as an antagonist to NMDA receptors, and studies of
depression have shown that zinc and other antagonists of the NMDA receptor show antidepressant-like
effects [96]. Rodent models of depression also support the notion that zinc and NMDA receptors are
intimately involved in depression. A recent study by Szewczyk et al., indicated that zinc pre-treatment
negated depressive features in the forced swim test, whereby it was observed that zinc treated
rodents exhibit longer periods of escape behavior before immobility [97]. Moreover, other studies have
demonstrated that zinc administration in rodents can reduce the number of NMDA receptor complexes,
indicative of downregulation [98,99]. Other studies have examined the interaction of zinc in relation to
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6.5. Schizophrenia
Schizophrenia (SCZ) is a long-term mental disorder typified by a breakdown in the association
between thought, emotion, and behaviour, leading to faulty perception, inappropriate actions
and moods, withdrawal from reality into fantasy, and delusion. It is a condition with both
neurodegenerative and neurodevelopmental pathologies with potential causation from maternal
zinc deficiency and genetic risk factors [101]. Supporting the notion of the contribution by maternal
zinc deficiency is that prenatal zinc deficiency in rodent models produces decreased brain volume [102].
In human SCZ patients, there is a 30–50% reduction in brain zinc content demonstrated for early
onset cases compared to control samples in postmortem brain tissue [103,104]. Whilst pre-natal zinc
deficiency may not be solely causative of SCZ, interactions with other risk genes, and/or ongoing zinc
deficiency following birth may be a contributing factor.
Recently, a genome-wide association study between SCZ and control patients revealed a
nonsynonymous single nucleotide polymorphism (nsSNP) in the ZIP8 gene as a risk factor for
SCZ [105]. Its direct effect upon zinc transport in SCZ, however, has yet to be elucidated. Additionally,
allelic variants in the ZnT3 gene, SLC30A3, revealed an increased and gender-specific effect of allele
on the risk of SCZ in females [106,107]. Similarly, another study demonstrated an increased cortical
expression of the zinc transporter SLC39A12. The expression microarray study revealed messenger
RNA (mRNA) for solute carrier family 39 (zinc transporter). Member 12 (SLC39A12) was higher in the
dorsolateral prefrontal cortex from subjects with SCZ in comparison with controls [108]. These results
suggest that a breakdown in zinc cellular homeostasis is likely a part of the pathophysiology
of schizophrenia.
6.6. Parkinson’s Disease
Parkinson’s disease (PD) is a long-term degenerative disorder of the CNS that mainly affects
the motor system. Symptoms develop slowly over time, the most obvious being shaking, rigidity,
slowness of movement and difficulty with walking. Both thinking and behavioral problems can occur,
and dementia is not uncommon at the advanced disease stage.
There is an observed clinical zinc deficiency in patients presenting with PD [109,110], and while
scientific evidence of zinc supplementation in PD patients cohorts are scarce, other animal models of
PD demonstrate the efficacy of zinc supplementation. A Drosophila melanogaster PD disease model in
which the orthologue of the human Parkin gene was disrupted, was shown to have beneficial responses
to zinc supplements [111]. Parkin mutant flies exhibit muscle abnormalities, locomotor defects,
an inability to fly owing to the degeneration of indirect flight muscles, as well as a severely reduced
lifespan, and as such mimic human PD symptoms. Zinc supplementation, however, ameliorated
these deficits. In humans, early onset PD is associated with a mutation of PARK9, a lysosomal type 5
P-type ATPase, which has been shown to lead to a reduction of lysosomal zinc storage with an increase
in cytosolic zinc and α-synuclein accumulation, a pathological hallmark of the disease [112,113].
Additionally, in PD patients there is an observed accumulation of zinc in the substantia nigra, caudate
nucleus and lateral putamen areas associated with PD pathology [114]. Taken together, these data
suggest that zinc homeostasis is distorted in PD, and as such may play a contributory role to the
pathogenesis of the disease.
7. Conclusions
As noted in this review, irregularities in zinc homeostasis may represent a point of intersection
for both the pathogenesis and the symptoms that characterize multiple neurodegenerative disorders,
in addition to potentially also being involved in the ageing process and associated cognitive decline.
If zinc is indeed critical to such a breadth of conditions, then understanding how and why zinc levels
change across age and/or prior to or during disease is key to providing the insight necessary to harness
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toxicity). For example, do zinc levels change because of dietary insufficiency (or perhaps some other
aspect of diet or a disease state that alters the absorption of zinc)? Is it due to an age- or disease-related
change in zinc importer/transporter levels or function that alters the distribution of zinc? Or perhaps
some other change in a different metal or aspect of the metalloproteome that adversely impacts
zinc? Is there just one or multiple zinc signaling pathways that are impaired? All these questions
and many more require thorough interrogation in order to optimize a zinc-based targeted therapy
(e.g., at what stage might zinc supplementation versus chelation be optimal in a given disease state; if it
is supplementation, then is bulk dietary modulation sufficient, or is a more targeted pharmacological
approach required?). Answers to these questions will ultimately need to be validated in a human
clinical trial in order to gain the burden of proof necessary for the wide spread acceptance of zinc as a
critical player, and therapeutic target, in disorders of the CNS.
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Abstract: Zinc deficiency is a risk factor for obesity and diabetes. However, until recently, the underlying
molecular mechanisms remained unclear. The breakthrough discovery that the common polymorphism
in zinc transporter SLC30A8/ZnT8 may increase susceptibility to type 2 diabetes provided novel insights
into the role of zinc in diabetes. Our group and others showed that altered ZnT8 function may be
involved in the pathogenesis of type 2 diabetes, indicating that the precise control of zinc homeostasis is
crucial for maintaining health and preventing various diseases, including lifestyle-associated diseases.
Recently, the role of the zinc transporter ZIP13 in the regulation of beige adipocyte biogenesis was
clarified, which indicated zinc homeostasis regulation as a possible therapeutic target for obesity and
metabolic syndrome. Here we review advances in the role of zinc homeostasis in the pathophysiology
of diabetes, and propose that inadequate zinc distribution may affect the onset of diabetes and metabolic
diseases by regulating various critical biological events.
Keywords: zinc; zinc transporters; diabetes; obesity; ZnT8; ZIP13; pancreatic β cell; beige adipocyte;
therapeutic target
1. Introduction
Type 2 diabetes is now a crucial health problem in many parts of the world. Type 2 diabetes
mellitus (T2DM) is characterized by peripheral insulin resistance and pancreatic beta (β) cell
dysfunction. The disease is thought to be caused by defects in insulin signaling or secretion, the
activation of various stress pathways, and dysregulation of the central nervous system (CNS). It is well
accepted that the most accurate predictor for developing T2DM is obesity. Therefore, much attention
has also been paid to the contribution of nutrients and nutrient-sensing pathways in situations
of chronic caloric excess. Most of the interest in the role of nutrients in diabetes is centered on
macronutrients, such as carbohydrate and fat, but micronutrients, such as iron and zinc, are also closely
associated with diabetes [1,2]. Whole-body level dysregulation of zinc is known to occur in both type 1
and type 2 diabetes. However, it remains unclear as to whether zinc deficiency causes the disease or is
merely a consequence of the disease. A possible causal link between changes in zinc homeostasis and
pancreatic β cell function was suggested in 2007 with the identification of an association between the
risk of T2DM and polymorphisms in the SLC30A8 gene, which encodes zinc transporter ZnT8 [3].
Several groups have been analyzing the roles of zinc homeostasis in the health and disease of
endocrine organs, with particular focus on zinc transporter function. In this review, we will discuss the
roles of zinc homeostasis in glucose metabolism, particularly in association with ZnT8. Furthermore,
we will discuss the role of ZIP13 in beige adipocyte biogenesis and energy expenditure, which we
have recently elucidated.
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2. Zinc Homeostasis and Pancreatic β Cells
2.1. Insulin Biosynthesis in Pancreatic β Cells
Pancreatic β cells are known to contain very high concentrations of zinc compared with various
other cells. In particular, insulin secretory granules have been shown to have the highest zinc content
within β cells [4,5]. In vertebrates, three protein families have been shown to regulate cellular zinc
homeostasis, namely, metallothioneins (MTs), zinc importers (ZIP, SLC39A), and zinc exporters (ZnT,
SLC30A). MTs have been shown to bind zinc with low affinity, whereas zinc transporters mediate the
compartmentalization of zinc into various organelles and vesicles for their storage, and to supply zinc
to various proteins that require zinc for their function [6]. Nine ZnTs and 14 ZIP transporters have
been identified to play important roles in whole body maintenance, as well as in zinc homeostasis at
the cellular and subcellular levels. These transporters act either independently or coordinately, and in
a cell-specific or tissue-specific manner [7,8]. ZnT8 plays a key role in the accumulation of zinc within
insulin secretory granules [9]. Furthermore, zinc is essential for the appropriate synthesis of insulin,
as well as its storage and structural stability [10].
Insulin comprises a hexamer of six insulin and two zinc molecules [11,12]. The mature insulin
molecule comprises two polypeptide chains, namely, chains A and B. Initially, insulin mRNA is translated
into an inactive preproinsulin molecule, which comprises two chains that are connected by a c-peptide,
with the signal peptide at the N-terminus. Proinsulin is formed from preproinsulin by signal peptide
cleavage in the endoplasmic reticulum (ER). Proinsulin then folds into the final three-dimensional
structure, upon formation of the correct disulfide bonds. Subsequently, the proinsulin protein forms
dimers via electrostatic interactions. Proinsulin hexamers are then formed by electrostatically-coupled
proinsulin dimers and zinc binding to histidine residue 10 of the B chain (His B10) [13]. After entering the
Golgi apparatus, insulin hexamer formation is completed upon the dissociation of c-peptide, mediated by
prohormone convertase (PC) dissociation [14]. Insulin crystallization occurs under specific conditions
in insulin secretory granules, in which both insulin and zinc exist in high concentrations and acidic pH
is maintained [15,16]. This crystallized insulin can be observed as “dense core granules” by electron
microscopy [17,18], and insulin crystals that are secreted from pancreatic β cells are believed to dissociate
rapidly into monomers as they enter the bloodstream.
2.2. Zinc Supplementation in Diabetic Animals and Patients
Mice with zinc deficiency were found to have a decreased number of insulin granules in their
pancreaticβ cells [19], as well as impaired glucose-stimulated insulin secretion (GSIS) [20]. Since pancreatic
β cells synthesize a large amount of ATP, this makes them prone to oxidative stress exposure, which can
subsequently cause cellular damage [21]. As zinc is required for the actions of many antioxidative
enzymes, including Cu-Zn-SOD (superoxide dismutase) [22] and catalase [23], a lack of zinc will lead to
further damage of pancreatic β cells under oxidative stress, such as in T2DM.
Regarding humans, a prospective cohort study in the United States analyzed 82,000 women and
demonstrated that low zinc intake results in a 17% increased risk of developing diabetes compared
with those women taking sufficient amounts of zinc [24]. Recently, a study from China has reported
a negative correlation between concentrations of plasma zinc and the onset of diabetes [25]. Interestingly,
this report suggested that an interaction between SLC30A8 (ZnT8) dysfunction and decreased plasma
zinc concentrations regulates glucose tolerance and diabetes. Furthermore, the authors suggested that
a decrease in plasma zinc concentrations as well as ZnT8 function may coordinately increase the risk
of diabetes. Although these data suggest that zinc supplementation prevents disruption of glucose
homeostasis, particularly in people with zinc deficiency, prospective intervention studies should be
performed to clarify the efficacy of zinc supplementation in preventing the onset of diabetes. On the other
hand, excessive supplementation with zinc may have deleterious effects, as excessive zinc intake may
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A genome-wide association study (GWAS) demonstrated that a nonsynonymous single-nucleotide
polymorphism, namely, rs13266634 in the SLC30A8 gene, results in the replacement of tryptophan-325
to arginine, which modestly increases the risk of T2DM [3]. Furthermore, recent studies on human
SNPs demonstrated the association of 12 rare loss-of-function ZnT8 mutants with a 65% decreased
risk of T2DM [27]. Taken together, the data indicate that polymorphisms in the SLC30A8 gene are
associated with altered risk of T2DM.
3. ZnT8 Plays a Crucial Role in Glucose Homeostasis
3.1. Insulin Secretory Granule of ZnT8-KO Mice
ZnT8 is found in the plasma membrane of insulin secretory granules of pancreatic β cells, and is
implicated in zinc transport into insulin secretory granules [9]. Several groups, including our own
have aimed to clarify the role of ZnT8 in glucose homeostasis by establishing SLC30A8-deficient
(ZnT8-KO) mice [18,28,29] (Supplemental Table S1). Each mouse model shows variation in certain
phenotype traits, which are attributed to differences in deletion strategy, genetic background, and
housing condition. Most of the ZnT8-KO mice have been reported to have mildly impaired glucose
tolerance and there have been no reports of the improvement of glucose tolerance in the ZnT8-KO
mice model [18,30–35] (Supplemental Table S1). Furthermore, hZnT8 transgenic mice showed mildly
improved glucose tolerance [31], suggesting that the expression levels of ZnT8 determines the risk of
T2DM in these mouse models. Electron microscopy analysis revealed that dense-core granules, which
are a hallmark of crystallized insulin usually seen in normal β cells, were absent in the ZnT8-KO mouse
β cells. In most of the ZnT8-KO mice, some of the granules appeared atypical granules possessing
abnormal “rod-like” or empty cores, while some ZnT8-KO mice revealed the nearly complete loss of
crystal containing granules [18,30].
3.2. Phenotypes of ZnT8-KO Mice Regarding Glucose Metabolism
As described above, glucose tolerance was mildly impaired in ZnT8-KO mice. This demonstrates
that peripheral insulin levels in ZnT8-KO mice were reduced compared with control mice. Indeed, we and
others have observed decreased insulin levels in ZnT8-KO mice, despite GSIS levels being unchanged
or slightly increased in ZnT8-KO mouse islets [18,34] (Supplemental Table S1). To understand this
discrepancy, we performed a pancreas perfusion experiment, and found that insulin secretion was still
enhanced upon pancreas infusion in ZnT8-KO mice, further supporting that insulin secretion is increased
in ZnT8-KO mice. However, pancreas-liver dual perfusion analysis demonstrated that in these mice,
a large proportion of the secreted insulin is actually degraded during its passage through the liver,
suggesting that ZnT8 regulates hepatic insulin clearance [18]. A set of in vivo and in vitro experiments
demonstrated that ZnT8-mediated zinc inhibits hepatic insulin uptake by counteracting clathrin-mediated
endocytosis of the insulin receptor. These results suggested that ZnT8 plays an important role in
determining the amount of insulin that is delivered to the liver and other peripheral organs, and thus
optimizes the effect of insulin on whole body glucose metabolism [18].
For the assessment of in vivo insulin clearance, the c-peptide/insulin ratio may be useful [36,37].
Consistently, although insulin secretion was increased in ZnT8-KO mice, peripheral insulin levels were
lower and c-peptide/insulin ratios were increased [18]. Studies of c-peptide/insulin ratios and rates of
insulin clearance in humans with the rs13266634 polymorphism also demonstrated results consistent
with this idea [18]. Furthermore, the Eugene study showed that when human homozygous carriers of
the SLC30A8 risk allele are subjected to the intravenous glucose tolerance test, they demonstrate low
peripheral insulin levels in the early phases [38]. These results indicate that SLC30A8/ZnT8 regulates
hepatic insulin clearance, and importantly, the same mechanism appears to be conserved in humans
(Figure 1) [18].
Clinically, the inhibition of hepatic insulin clearance seems likely to be a therapeutic target
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insulin-degrading enzyme, which regulates insulin catabolism [39,40]. Our findings hence might
provide novel insights into the molecular pathology of diabetes, which involves dysregulated insulin
clearance from the liver, and hence may be a promising future therapeutic target for diabetes [18].
Figure 1. Schematic representation of insulin clearance in WT and ZnT8-KO mice. Zinc co-secreted
with insulin suppresses insulin secretion from pancreatic β cells and inhibits hepatic insulin clearance
in WT mice (left). In contrast, reduced zinc secretion results in enhanced insulin secretion from β cells
in ZnT8-KO mice and hepatic insulin clearance is not suppressed (right). Thus, peripheral insulin
levels in ZnT8-KO mice are maintained at lower levels than in WT mice.
3.3. Involvement of Other ZnT Transporters
Although there is a substantial decrease in total zinc levels in the islets of ZnT8-KO mice
compared with wild-type mice, the phenotypes of ZnT8-KO mice regarding glucose metabolism
were fairly modest. Several other ZnT isoforms were expressed at low levels in the pancreatic islets.
Thus, functional compensation by other ZnT isoforms might reduce the effect of the ZnT8-KO phenotype.
ZnT3 is a candidate ZnT transporter for this compensation. ZnT3 is known to play a role in the uptake
of zinc in the synaptic vesicles of glutaminergic hippocampal neurons [41,42]. Considering that β cells
and neurons share some similar characteristics, ZnT3 might be involved in the transport of zinc into
insulin secretory vesicles. However, it is unclear whether ZnT3 is expressed in the islets of mice [43],
and ZnT3-KO mice appear to undergo normal glucose metabolism [44], suggesting that ZnT3 is not
involved in this process.
As zinc is required for the hexamerization of insulin and its conversion from proinsulin to insulin
in the Golgi compartment, a sufficient amount of import of zinc to this compartment is also required.
ZnT5 and ZnT7 are also reported to be expressed in β cells and to co-localize with the Golgi apparatus
and secretory vesicles [43,45,46]. Thus, ZnT5 and ZnT7 transporters might be involved in these
processes. A recent study analyzed this possibility by crossing ZnT7-KO mice with ZnT8-KO mice.
However, whether ZnT7 has a redundant role of ZnT8 remains to be clarified because global ZnT7-KO
mice displayed several defects in insulin-sensitive tissues outside of β cells, as described below,
and because the report did not include data on ZnT8 single-knockout mice [47]. Further analyses are
needed to identify the zinc transporters involved in each step from insulin processing to storage.
3.4. Zinc Transport Activity of ZnT8 Variants
One of the important unresolved issue regarding ZnT8 is whether the ZnT8 variant 325Arg(R)
increases or decreases zinc transport activity. In one study, the fluorescent dye FluoZin-3 was used to
monitor cytosolic zinc and the fluorescent dye Zinquin was used to monitor vacuolar zinc accumulation
in MIN6 cells transiently expressing the Arg(R) or Trp(W) variants of hZnT8. Cells expressing the
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this variant was a more active transporter of zinc [34]. In another study, HEK293 cells inducibly
expressing hZnT8 variants were established, and both the R and W variants of hZnT8 were purified in
the native state, and a reconstitution system was developed to measure zinc transport activities [48].
The authors found the R variant to be more active than the W variant, suggesting that the common
high-risk R variant is hyperactive and thus may be a therapeutic target to reduce the risk of T2DM
in the general population [48]. An additional report described the possible association between the
diabetes risk allele in hZnT8 and the higher zinc concentration in human islets [49]. These results
suggest that β cells with lower zinc levels may be protection from T2DM, whereas higher zinc in
β cells may be associated with T2DM. Interestingly, these new findings appear to be consistent with
the finding that rare loss-of-function mutations in ZnT8 are associated with reduced T2DM risk in
humans [27]. This suggests that the role of ZnT8 might be contradictory between humans and mice,
as a loss-of-function of ZnT8 in humans decreases the risk for T2DM, whereas ZnT8-KO mice have
impaired glucose tolerance [50]. In the course of evolution, the role of ZnT8 in glucose homeostasis
has been altered. There are some factors to explain this discrepancy. Since synaptic ZnT3-mediated
zinc contributes predominantly to amyloid deposition in human amyloid precursor protein (hAPP)
mice [51,52], human islet amyloid polypeptide (hIAPP) might be able to explain this discrepancy.
Compared to mouse IAPP, hIAPP can form toxic oligomers, which affect β cells by inducing apoptosis
and amyloidogenesis in T2DM [53,54] (Figure 2A). A recent computational analysis showed that zinc
concentration determines insulin oligomer equilibrium and that the hIAPP monomer preferentially
binds to both the insulin monomer and dimer, compared to the formation of hIAPP homodimer.
Therefore, regarding the loss of ZnT8 function, the zinc deficiency shifts the equilibrium of the insulin
oligomers toward monomers and dimers, which isolate hIAPP monomers (nontoxic form) and prevent
hIAPP from self-association and subsequent aggregation (toxic forms), thereby reducing the risk of
T2DM (Figure 2B) [55]. The theory of altered hIAPP aggregation in β cells in response to altered ZnT8
function is a promising but still correlative hypothesis at this point. Therefore, this hypothesis can be
validated by creating hIAPP transgenic (hIAPP-Tg) mice from ZnT8-KO mice, to investigate whether
hIAPP cytotoxicity can be ameliorated by the deletion of ZnT8.
Figure 2. Schematic model of the relationship among hIAPP, insulin, and zinc. (A) hIAPP can easily
form toxic oligomers that induce apoptosis and amyloidogenesis in β cells in T2DM patients; (B) When
the zinc concentration in insulin secretory granules is high, zinc is used to form zinc-insulin-hexamer,
and hIAPP can easily form toxic oligomers. On the other hand, when the zinc concentration is low
in insulin secretory granules (such as insulin secretory granule in ZnT8-KO mice), insulin exists
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4. Zinc Distribution Affects Adipocyte Metabolism
4.1. Zinc Distribution in Obesity
Chronic low intake of zinc is associated with an increased risk of diabetes. Hence, zinc supplementation
is expected to be an effective method for preventing metabolic syndrome and diabetes. A previous
study analyzed the effect of zinc supplementation to prepubertal obese children on insulin resistance and
metabolic syndrome. Zinc supplementation was suggested to be a useful and safe additional intervention
treatment [56]. However, to our knowledge, the effectiveness of zinc supplementation for the treatment of
obesity and diabetes has not been demonstrated in large-scale studies, particularly in adults. Therefore, it is
important to establish the safety, efficacy, and effective dose of zinc supplementation in adults.
Nevertheless, zinc might be referred to as the insulin-mimetic, since zinc stimulates lipogenesis
and glucose uptake in isolated adipocytes, and zinc ion acts as an insulin-mimetics through their direct
effect on the insulin-signaling pathway [2]. The insulin-sensitizing effect of zinc has been attributed
to the inhibition of the tyrosine phosphatase activity of protein tyrosine phosphatase 1B (PTP1B)
(Figure 3) [57,58]. Zinc ion inactivates PTP1B by non-covalent binding to its cysteine residues which is
crucial for the enzymatic activity and reactive oxygen species is also known to inactivate the enzyme
in a similar manner. In fact, oxidative stress is upregulated in the most of the patients with diabetes
and diabetic animals, further mechanistic analysis is needed to examine the risks and benefits of zinc















Figure 3. Insulin signaling pathway and insulin mimicking function of zinc ions. Insulin binds to the
insulin receptor located in the plasma membrane in the peripheral tissues, such as liver and muscle.
The insulin-signaling pathway is activated and the glucose transporter GLUT4 is translocated to the
plasma membrane. Zinc might inhibit the activity of PTP1B, which activates the insulin-signaling
pathway. PI3K, phosphatidylinositol-3-kinase; IRS, insulin receptor substrate; PKD, protein kinase D.
4.2. Association between Adipocyte Metabolism and Zinc Homeostasis
Obesity and its associated metabolic diseases develop when energy intake exceeds energy
expenditure; this can be caused by decreased physical activity, the inability of the CNS to downregulate
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and also functions as an endocrine organ to release free fatty acids (FFA) and adipokines, such as
leptin, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and adiponectin [60]. In addition,
adipose tissue comprises numerous types of stromal cells, including preadipocytes, endothelial cells,
immune cells, and fibroblasts. During the course of obesity, adipocyte cells and stromal cells in adipose
tissue change in number and characteristics. Invasion of macrophages into the adipose tissue of obese
individuals is associated with increased secretion of inflammatory adipocytokines, including TNF-α
and IL-6, which leads to insulin resistance [61]. Macrophages have recently been reported to be
involved in adipose tissue inflammation as well as in the regulation of adipose metabolism through
the disrupted modulation of adipocytokines production [61].
Several reports have addressed the association between zinc transporters and adipose metabolism.
For example, in the adipose tissue of Zip14-KO mice, hypertrophy together with enhanced
proinflammatory signaling is observed through activation of nuclear factor-kappaB (NF-κB) and the
Janus-activating kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway,
and this might contribute to obesity-induced insulin resistance [62]. Consistent with this idea, Zip14
expression is significantly reduced in obese individuals compared with non-obese individuals, and is
increased markedly following weight loss [63].
Adipose tissue plays a crucial role in controlling energy balance. It comprises white and brown
adipocytes, which perform different functions. White adipocytes store excess energy, whereas brown
adipocytes play a role in energy expenditure [59]. In mammals, brown adipose tissue (BAT) dissipates
energy in the form of heat and acts as a defense mechanism against hypothermia. Brown adipocytes
are unique in that they have a very large number of mitochondria and are also able to metabolize
glucose and fats to produce heat rather than ATP. This thermogenic activity of brown adipocytes is
mediated largely via the actions of uncoupling protein-1 (UCP1) [64]. Furthermore, two distinct types
of thermogenic adipocytes have recently been identified, namely, the “classical brown adipocytes” and
the “beige adipocytes”. Beige adipocytes are induced in white adipose tissue (WAT), particularly in
inguinal WAT upon various external factors, including exercise, chronic cold exposure, and bariatric
surgery [65]. Identification and implementation of therapies based on beige fat require a detailed
understanding of the differences in the developmental mechanisms and functions of white, brown,
and beige adipocytes.
Many transcriptional regulators and transcription factors are used for differentiation into these
various fat cell types, such as peroxisome proliferator-activated receptor gamma (PPARγ) and the
CCAAT/enhancer binding protein (C/EBP) family of transcription factors, respectively [66]. The induced
differentiation of preadipocytes triggers DNA replication and reentry into the cell cycle (mitotic clonal
expansion). Mitotic clonal expansion involves a transcription factor cascade, followed by the expression of
adipocyte genes. A critical event is phosphorylation of C/EBP-β, which is a form of activated C/EBP-β,
which then triggers PPARγ and C/EBP-α, which in turn coordinately activate genes whose expression
produces the adipocyte phenotype, such as aP2 [67]. Several studies have analyzed the roles of zinc and
the zinc transporter in the differentiation process of white adipocytes. Expression of the Zip14 gene was
found to be upregulated during early adipocyte differentiation [63,68]. During mitotic cell expansion,
zinc and MT levels within cells are rapidly increased. This elevation is essential for the transition from
G0/G1- to S-phase of the cell cycle [69] (Figure 4). ZnT7-KO mice show a mild zinc deficiency, with low
body weight gain as well as body fat accumulation. The underlying mechanism of these characteristics in
ZnT7-KO mice is that ZnT7 is likely to be involved in lipogenesis in adipocytes, rather than in the early
adipocyte differentiation process, such as mitotic clonal expansion [70].
Most of the transcription factors that are known to direct cells toward a brown/beige
adipocyte lineage instead of a white adipocyte lineage act via the core transcriptional machinery of
adipogenesis. PR domain containing 16 (PRDM16), which is an essential transcriptional coregulators of
brown/beige adipocyte differentiation [71], determines the brown/beige adipocyte lineage mainly via
its interaction with various transcriptional factors, including PPARγ, peroxisome proliferator-activated
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many zinc-containing transcriptional factors participate in brown/beige adipocyte differentiation
and function.
Figure 4. The expression of zinc transporters during white adipocyte differentiation. Preadipocytes are
differentiated and trigger DNA replication and reentry into the cell cycle (mitotic clonal expansion,
MCE). The expression of several genes related to zinc homeostasis is altered.
4.3. ZIP13 Regulates Beige Adipocyte Biogenesis and Energy Expenditure
As explained above, we have been investigating the roles of zinc homeostasis in the health and
disease of endocrine organs by focusing on the biological functions of zinc transporters. Zip13-KO
mice were reported to show impaired bone formation and growth retardation [73]. Importantly, ZIP13
is also plays a crucial role in connective tissue development in humans. Patients with a loss-of-function
mutation in ZIP13 showed a similar phenotype to Zip13-KO mice and were diagnosed as having
a novel type of Ehlers-Danlos syndrome. Interestingly, human patients of Ehlers-Danlos syndrome
were reported to display lipoatrophy [73]. Therefore, we aimed to clarify the roles of ZIP13 in fat tissue.
During our investigation, we found that Zip13-KO inguinal WAT had a high number of functional
beige adipocytes [74]. Furthermore, Zip13-KO mice showed a significantly higher oxygen consumption
rate than wild-type mice, although there were no differences in food intake, suggesting that Zip13-KO
mice have a tendency to not gain weight. Consistent with this idea, Zip13-KO mice showed resistance
to high fat diet-induced obesity [74].
Furthermore, both gain-of-function and loss-of-function experiments have demonstrated that
the accumulation of C/EBP-β, which is involved in determining brown/beige adipocyte lineage
in cooperation with the dominant transcriptional coregulator PRDM16, is crucial for the increased
adipocyte browning resulting from the loss of ZIP13 [74], implying most likely that ZIP13-mediated
zinc transport is required for the inhibition of adipocyte browning (Figure 5), and that ZIP13 may
deliver zinc ions to specific molecular targets that control the function of C/EBP-β or/and other
target proteins. Further analyses of Zip13-deficient cells will clarify the specific roles of ZIP13 in beige
adipocyte biogenesis.
Importantly, the presence and activity of thermogenic beige adipocytes are associated with improved
global metabolic fitness, such as improvements in insulin resistance and glucose homeostasis [65].
Indeed, Zip13-KO mice reportedly have improved glucose tolerance and insulin tolerance compared with
control mice in addition to increased energy expenditure [74]. Furthermore, given that recent studies
demonstrated that adult human brown adipocytes share biological characteristics with rodent beige
adipocytes, rather than rodent brown adipocyte [75]. The results of our study may hence contribute to the
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Figure 5. Zinc transporter ZIP13 inhibits adipocyte browning. Schematic model of the role of ZIP13 in
adipocyte browning.
5. Involvement of Zinc in the Insulin Signaling Pathway
5.1. Zinc Transporters Affect Skeletal Muscle Insulin Signaling
Skeletal muscle plays a key role in insulin-stimulated glucose uptake in the postprandial state.
Under insulin-resistant conditions, there is a decrease in insulin signaling via IRS-1, PI3K, and Akt,
resulting in decreased translocation of the GLUT4 glucose transporter, to the plasma membrane,
as well as decreased insulin-stimulated glucose transport into cells (Figure 3).
Skeletal muscle is the major reservoir for zinc, containing approximately 60% of the total whole-body
zinc [76]. Zinc transporter SLC39A7 (ZIP7) has been reported to be involved in glycemic control within
skeletal muscle. The knockdown of Zip7 in the mouse skeletal muscle cell line C2C12 demonstrated
that glucose metabolism is enhanced by ZIP7 via Akt phosphorylation, in which ZIP7-mediated zinc
activates insulin receptor signaling via its binding to PTP1B [77]. A different study reported that ZnT7-KO
mice demonstrate impaired glucose tolerance and insulin sensitivity, resulting from a decrease in the
insulin signaling pathway, such as decreased levels of Akt phosphorylation in skeletal muscle and
adipocytes, as described above, which thereby reduce glucose uptake [78]. Although many studies have
been performed to analyze the insulin-mimetic actions of zinc [79], the specific zinc transporters that are
responsible for initiating these signaling processes remain unclear. In particular, given that ZIP7 acts as
the gatekeeper of zinc release from the Golgi apparatus [80] and that insulin-signaling cascades in skeletal
muscle are affected by ZIP7-mediated zinc, it will be very important to analyze the metabolic phenotypes
of skeletal muscle in tissue-specific Zip7-KO mice.
5.2. Zinc Homeostasis and Sarcopenia
Sarcopenia is the age-associated degenerative loss of skeletal muscle mass, quality, and strength.
In older people, sarcopenia is often accompanied by diabetes [81]. Some of the mechanisms involved
in the development of sarcopenia, such as insulin resistance, mitochondrial dysfunction, and chronic
inflammation, are also thought to play roles in the pathogenesis of diabetes [82]. Recently, the zinc/zinc
transporter and MT expression levels have been reported to be upregulated during skeletal muscle
atrophy. For example, the blocking of MTs 1 and 2 has been shown to increase skeletal muscle mass
and strength [83], suggesting the potential of MTs as therapeutic targets for sarcopenia. Furthermore,
muscle zinc levels and Zip14 expression levels are known to increase with age [84], although the
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Further analyses are required to understand the precise roles of zinc transporters in sarcopenia that
occurs in association with diabetes.
6. Summary
Since human patients with Zip13 deficiency have been reported to show lipoatrophy, we expected
Zip13-KO mice to be resistant to insulin [73]. However, on the contrary, Zip13-KO mice showed
improved insulin sensitivity owing to the acceleration of adipocyte browning. To our knowledge,
our data are the first to show that the Golgi-to-cytoplasm transport of zinc by ZIP13 is necessary for the
regulation of beige adipocyte metabolism and insulin sensitivity, because simple zinc supplementation
cannot inhibit adipocyte browning. On the other hand, a study of ZnT8-KO mice also showed that the
release of adequate amounts of zinc from β cells together with insulin is important for the regulation
of insulin clearance, suggesting that the zinc transported by ZnT8 acts as a signaling molecule between
organs and mediates pancreas-to-liver organ communication. ZnT7-KO mice demonstrate mild zinc
deficiency accompanied with low body weights and very little accumulation of body fat. Dietary zinc
supplementation in ZnT7-KO mice cannot rescue these phenotypes. The main tissue responsible for
the phenotypes of ZnT7-KO mice might be adipose tissue, which results in impaired glucose tolerance
and insulin sensitivity.
Considering the aforementioned phenotypes of zinc transporter KO mice, we would like to
suggest a new perspective; that adequate local zinc delivery by zinc transporters are important,
and their disruption leads to the pathogenesis of a variety of diseases. In particular, as sarcopenia is
an important issue in aging societies, zinc transporters or factors associated with zinc homeostasis
might be candidate biomarkers or therapeutic targets. Further analyses are required toward the
development of zinc transporter-mediated therapies against both obesity and diabetes.
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Abstract: Zinc homeostasis is crucial for an adequate function of the immune system. Zinc deficiency
as well as zinc excess result in severe disturbances in immune cell numbers and activities, which can
result in increased susceptibility to infections and development of especially inflammatory diseases.
This review focuses on the role of zinc in regulating intracellular signaling pathways in innate as
well as adaptive immune cells. Main underlying molecular mechanisms and targets affected by
altered zinc homeostasis, including kinases, caspases, phosphatases, and phosphodiesterases, will be
highlighted in this article. In addition, the interplay of zinc homeostasis and the redox metabolism in
affecting intracellular signaling will be emphasized. Key signaling pathways will be described in
detail for the different cell types of the immune system. In this, effects of fast zinc flux, taking place
within a few seconds to minutes will be distinguish from slower types of zinc signals, also designated
as “zinc waves”, and late homeostatic zinc signals regarding prolonged changes in intracellular zinc.
Keywords: zinc flux; zinc wave; homeostatic zinc signal; signaling pathways; innate and adaptive
immunity; zinc deficiency; immune function
1. Introduction
The metal zinc is nowadays well established to be essential for a well-operating immune system.
However, knowledge about zinc homeostasis, zinc deficiency, and related diseases is comparatively
new. In 1963, Dr. Prasad proved for the first time the existence of zinc deficiency in man [1]. Since then,
knowledge about zinc evolved rapidly uncovering molecular mechanisms being indispensable for
regulating zinc homeostasis in humans. Its significance as a structural component in proteins [2] and
its participation in numerous cellular functions include, but are not limited to, cell proliferation and
differentiation [3,4], RNA and DNA synthesis [5,6], stabilization of cell structures/membrane [7,8],
as well as redox regulation [9,10], and apoptosis [11,12]. Zinc is involved in various metabolic
and chronic diseases such as: type 1 diabetes, rheumatoid arthritis, cancer, neurodegenerative
diseases, and depression [13–19]. Moreover, there is also strong evidence between zinc deficiency
and several infectious diseases such as shigellosis, acute cutaneous leishmaniosis, malaria, human
immunodeficiency virus (HIV), tuberculosis, measles, and pneumonia [20,21].
When zinc deficiency was first discovered, it was thought to be a rare disease. However,
zinc deficiency is very common, with estimated two billion people worldwide being affected, and is
identified as a major contributor to the burden of disease in developing countries. It is the 5th leading
life-threatening factor, especially in developing countries [22]. In addition, industrial counties are
affected by zinc deficiency, particularly the elderly population [23]. Despite zinc deficiency and
related symptoms can easily be treated by proper zinc intake, suboptimal zinc status cannot simply
diagnosed by reason of the lack of clinical signs and reliable biochemical indicators of zinc status.
To date, no specific and reliable biomarker of zinc status is known, although serum/plasma zinc
concentrations, hair zinc concentration, and urinary zinc excretion can be seen as potentially useful.
Nevertheless, zinc status is highly impacted by the immune status itself (infection, inflammatory
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conditions), but also by diet, absorption and conserving mechanisms via gastrointestinal tract and
kidneys [24]. Zinc uptake in the gastro intestinal (GI) tract is facilitated by an influx into the enterocyte,
through the basolateral membrane and the transport into the portal circulation. Uptake mechanisms
are not fully understood yet, however zinc transporters are mainly involved in zinc uptake or zinc
efflux [25]. In this regard, Zrt-like, Irt-like protein (ZIP)4 is highly important since it is expressed
along the entire GI tract acting as a major processor of zinc uptake into enterocytes from the apical
membrane [26]. Moreover, zinc transporter (ZnT)3, is highly expressed in the human large and
porcine small intestine and the esophagus [27,28]. Herein, its concrete function in the GI tract is
largely unknown. However, studies in the esophagus uncovered its co-localization with sensory
neuromediators and/or neuromodulators that are essential for the control of all functions of the GI
tract either under physiological and pathological conditions as well as during diseases [27–29]. Hence,
there is an ongoing need for the discovery of a reliable biological marker of zinc status.
Although the plasma pool is very small, it is highly important for cellular signaling since it is
rapidly exchangeable and mobile. Consequently, intracellular zinc level can be altered resulting in
altered cell function and differentiation [30,31]. The zinc-dependent regulation of the immune system
is particularly interesting and will be discussed in more detail in this review. We will particularly
focus on the importance of different types of zinc signals in innate as well as adaptive immunity,
and highlight altered signaling pathways due to changed intracellular free zinc level.
2. Zinc Homeostasis and the Immune System: An Overview
With a total amount of 2–4 g, zinc is the second most abundant trace metal in the human body,
iron being first. In contrast to the latter, zinc cannot be stored and has to be taken up via food daily
to guarantee sufficient supply. A large number of especially inflammatory diseases, but also aging,
pregnancy, lactation, and vegetarian or vegan lifestyles are associated with zinc deficiency. Thus,
an important role of zinc in development and exacerbation of diseases can be assumed, as indicated
earlier. This underlines the importance of a deep understanding of the various functions of zinc in the
immune system and thereby for health and disease [21,32–34]. Already marginal-to-moderate zinc
deficiency impairs immunity, delays wound healing, causes inflammation-independent low-grade
production of inflammatory cytokines and increases oxidative stress [35]. Immune cells might even
react more quickly to zinc deficiency than it is measurable in the plasma [36]. Imbalances including
strong zinc deficiency but also zinc overload cause severe immune dysfunctions. Zinc intoxication is
however rare and its symptoms mostly due to copper deficiency. Immunological hallmarks of zinc
deficiency are thymic atrophy, lymphopenia, especially decreased CD4+ T helper (Th) cell numbers,
resulting in a decreased CD4+/CD8+ ratio [37]. In vitro data suggest that monopoiesis is increased
during zinc deficiency [38], natural killer (NK) cell activity is decreased and monocyte cytotoxicity
is increased [21]. Zinc dependent alterations in chemotaxis, phagocytosis, respiratory burst and
formation of neutrophil extracellular traps by innate immune cells offer one explanation for the
increased susceptibility to infections during zinc deficiency [39–41].
In humans, high zinc concentrations are found in retina (3.8 μg/g dry weight), choroid of the eye
(274 μg/g) and in bone (100–250 μg/g), while only 1 μg/mL zinc is found in plasma, which equals
around 0.1% of total body zinc. Within body fluids, zinc is predominantly bound to proteins including
albumin, α2 macroglobulin (A2M), transferrin and others. Hypoalbuminemia can even result in
zinc deficiency [42]. Zinc binding to those proteins can activate or inactivate their activity, or change
characteristics important for substrate binding [43].
Zinc homeostasis is primarily controlled via the expression and action of 14 zinc transporters that
increase cytoplasmic zinc (Zip1–14) and 10 zinc transporters that lower cytoplasmic zinc (ZnT1–10).
Zrt-like, Irt-like proteins (Zip) are also named solute carrier family 39 (SLC39) A1–A14, while members
of the zinc transporter (ZnT) family are also denoted SLC30A1–A10. Many of those transporters
are found spanning the plasma membrane, but others are also located within mitochondrial,
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decreasing cytoplasmic zinc can describe export via ZnTs, but also the transport of zinc into one of
those organelles [44]. The significance of zinc transportation via nicotinic acetylcholine receptors,
voltage dependent calcium channels, transient receptor potential channels and glutamatergic receptors
as well as of facilitated diffusion of zinc bound to amino acids compared to specific zinc transport
through Zips and ZnTs remains to be defined in more detail [45]. Together, those zinc transporters
regulate zinc homeostasis on tissue but also single cell and even intracellular level.
Physiological changes in body zinc homeostasis during acute phase response include the temporal
transfer of serum zinc to the tissues, especially the liver, causing transient serum hypozincemia,
which is rebalanced during resolution of the inflammatory response. The transient change in
zinc homeostasis is proposed to act as a danger signal for immune cells [46]. In addition,
pro-inflammatory acute phase proteins including interleukin-6 (IL-6) upregulate expression of zinc
binding peptides such as metallothionein (MT) and A2M, augmenting zinc sequestration from
extracellular microorganisms [43]. Intracellularly increased zinc can intoxicate engulfed pathogens
and acts cytoprotective by promotion of neutralizing reactive oxygen and nitrogen species (ROS and
NOS) as will be discussed later. Undernourishment and severe inflammatory diseases are paralleled
with prolonged and severe forms of serum hypozincemia. An association of excessively elevated levels
of inflammatory markers, reactive oxygen species and antimicrobial peptides such as calprotectin or
matrix metalloproteases (MMP) that cause tissue injury especially in lung, liver and spleen with the
augmented serum hypozincemia was suggested [46–49].
Measuring free intracellular zinc levels results in extremely low numbers in the pico- to nanomolar
range, depending on the cell type. When zinc is transported into the cell, it is efficiently buffered
by high affinity proteins. As affinity of zinc to metal binding sites of proteins is rather high and
competitive towards other metal ions, free zinc concentrations fluctuate in a narrow range. Excess zinc
ions are transported into subcellular stores such as the including interleukin (ER) or Golgi or into
extracellular space [2]. Intracellular zinc-binding proteins include members of the MT family. If in
addition to their strong binding activity to extracellular zinc, members of the S100 family can also
chelate zinc intracellular is so contested [50]. As the decrease in intracellular zinc during monopoiesis
is paralleled by an increase in S100A8 and S100A9 expression but not changes were found for MT-1
levels, binding of intracellular zinc by calprotectin in myeloid cells is likely [38].
MTs are proteins of 6–7 kDA, which can bind and quickly release up to 7 zinc ions, thereby
sequestering up to 20% of intracellular zinc. Furthermore, they protect against various types of
environmental stress, as MTs can chelate other heavy metals, decreasing their cytotoxicity and they
can scavenge reactive oxygen species. Within the four MT classes, MT-1 and MT-2 are expressed
ubiquitous throughout the body, whereas MT-3 and MT-4 are expressed cell type specific [44].
Within innate immune cells, MT is an important molecule for zinc regulation. MT deficiency impairs
cytokine production and anti-microbial activities in macrophages after lipopolysaccharide (LPS)
stimulation [51]. The S100 protein family includes 24 members, all acting calcium dependent and
having calcium buffering capacities. Intracellular, they modulate apoptosis, transcription and enzyme
activities; extracellular S100 proteins regulate chemotaxis and wound healing, but also proliferation
and differentiation via surface receptors [52]. Zinc binding S100 proteins include S100B, S100A1,
S100A2, S100A3, S100A5, S100A7, S100A8/9, S100A12 and S100A16. Calprotectin, a heterodimer of
S100A8 and S100A9, is the most abundant protein of neutrophils. Increased plasma levels are found
during severe inflammatory diseases paralleling serum hypozincemia, suggesting a link that has
recently been explored [53,54]. Some low molecular binding partners of zinc have been found as well
including adenosine triphosphate (ATP), glutathione, citrate, nicotinamine or bacillithiol [2].
3. Classification of Zinc Signals
Signaling cascades are highly complex and very sensitive to altered intracellular second messenger
concentrations. Since zinc is established to act as second messenger comparable to calcium [55], it is
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free intracellular zinc level influence signaling pathways by binding reversibly to regulatory sites in
signaling proteins, altering protein activity and stability [56]. Moreover, alterations can result from
the transport of zinc through the plasma membrane, exchange with intracellular organelles or zinc
binding proteins as MT and calprotectin, or a combination of these mechanisms.
Intracellular zinc signals can be differently classified. One way is by the time scale they occur,
comprising: (1) a “zinc flux” occurring within seconds to minutes; (2) slightly slower zinc signals,
described as “zinc wave” occurring within several minutes; and (3) homeostatic zinc signals occurring
within several hours. Examples for each classification of zinc signals occurring in different cell types
and signaling pathways are summarized in Table 1.
A zinc flux can arise by triggering receptors such as Toll like receptor (TLR)4 in, e.g., monocytes.
In this connection, zinc acts as second messenger, comparable to calcium, by influencing signaling
cascades in a direct manner. This kind of zinc signal is independent of synthesis of the zinc transporter
proteins from the ZnT and Zip family responsible for zinc re-distribution and zinc uptake and is
therefore classified as zinc flux. Activation of a zinc transporter to enable a sharp rise in cytoplasmic
zinc is thus possible.
Second, zinc signals described as “zinc wave” were uncovered recently. Comparable to the zinc
flux, zinc waves act also as second messenger, but are induced indirectly depending on calcium influx.
This phenomenon was for instance observed in mast cells, when the Fc-epsilon receptor I (FcεRI) is
cross-linked [55,57].
Late zinc signals occur on a timescale significantly longer than the others, accompany cellular
differentiation, and last for several days. Those are usually involved in altered expression of proteins
participating in zinc homeostasis. In this regard, maturation of for instance monocytes and dendritic
cells (DC) as well as cytokine expression is highly dependent on zinc signals [38,58]. In general,
altered zinc homeostasis results in changes in signaling cascades without acting as second messenger.
Table 1. Effect of zinc signals on Immune function: Altered immunological functions can be induced
by different zinc signals, as zinc flux, zinc wave, and homeostatic zinc signal. Altered from [59].
Zinc Signal Duration Effect
Zinc Flux Seconds/minutes
• Inhibition of PDE in monocytes/macrophages [60]
• Inhibition of MKP in monocytes/macrophages [61,62]
• Induction of PMA-triggered NET-formation in PMN [40]
• Induction of Lck recruitment to TCR [63,64]
• Zinc release from lysosomes in T cells [65]
• Triggering T cell activation by APC [66]
• Induction of Lck homodimerization/activation in T cells [67]
• Redistribution of zinc from nucleus/mitochondria to
cytosol/microsomes [30]
Zinc wave Minutes • Zinc release from perinuclear area in mast cells [57]
homeostatic
Zinc Signal Hours
• Stabilization of MyD88 expression [5,68]
• Induction of A20 expression in T cells, monocytes [69]
• Negative regulation of IRAK signaling [70,71]
• MAPK activation in immune cells [72–74]
• Negative regulation of TRIF pathway in macrophages [5]
• Changed Zip and ZnT expression in DCs and T cells [58,72]
• Inhibition of AC transcription in T cells [75]
• Influence of cytokine production, e.g., IL-2 in T cells [72]
• Induction of Akt/ERK/p38 phosphorylation in T cells [73]
• Triggering of PTEN degradation in T cells [76]
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Table 1. Cont.
Zinc Signal Duration Effect
• Alteration of M1/M2 differentiation by inhibition of STAT6
phosphorylation [78]
• Induction/stabilization of regulatory T cells [79,80]
• Inhibition of Th17 and Th9 cell differentiation [81,82]
• Reduced cytokine production, e.g., IFN-γ in T cells [83]
• Induction of NK cell killing and granzyme expression [84,85]
• Inhibition of caspase activity
• Inhibition of cAMP/cGMP hydrolysis [86,87]
• Inhibition of DNA fragmentation [6]
• Epigenetic modifications due to inhibition of SIRT1 [79]
• Inhibition of IL-1/TNF CRP expression in myeloid cells [53,69,88]
AC: adenylate cyclase; cAMP: cyclic adenosine monophosphate; cGMP: cyclic guanine monophosphate;
CRP: c-reactive protein; DC: dendritic cell; IL: interleukin; IFN: interferon; IRAK: interleukin-1 receptor-associated
kinase; Lck: lymphocyte-specific protein tyrosine kinas; MAPK: mitogen-activated protein kinase; MKP: MAP-kinase
phosphatase; MyD88: myeloid differentiation primary response gene 88; NET: neutrophil extracellular traps;
NK: natural killer; PDE: phosphodiesterase; PMA: Phorbol-12-myristat-13-acetat; PTEN: phosphatase and tensin
homolog deleted on chromosome 10; STAT: signal transducers and activators of transcription; TCR: T cell receptor;
APC: Antigen presenting cell; Th: T helper; TNF: tumor necrosis factor; TRIF: Toll-interleukin-1 receptor (TIR)
domain-containing adaptor-inducing interferon.
4. Zinc, Signaling and Immunity
In addition to its function as second messenger, another suggested mechanism how zinc is
involved in signaling is that zinc alters ligand binding to receptors either by changing the ligand’s
or the receptor’s affinity. Here, LPS revealed altered fluidity depending on zinc’s availability and
thereby binding characteristics to receptors such as TLR4 and CD14 were affected as well as subsequent
signal transduction [89].
Another possible scenario is the alteration of cellular membrane composition and fluidity [90].
Here, zinc could influence the generation and stability of membrane complexes causing assembly or
disassembly of receptors and probably altering their endocytosis, as is well described for neuronal
cells, but has also been observed in immune cells [84,91]. Furthermore, alterations of extracellular zinc
conditions affect the concentration of free intracellular zinc so that persistent changes in extracellular
zinc modify cell metabolism on the long run. Recent data indicate, that there is a major difference in
the effects of zinc on signaling in innate compared to adaptive immune cells. Therefore, data will be
discussed separately.
4.1. Innate Immune Cell Functions
Cells of the innate immune system, including principally neutrophil granulocytes and
monocytes/macrophages, but also mast cells, DCs, and NK cells are the first to encounter invading
pathogens at the side of infection. Recognition of pathogens and initiation of their clearance needs to
be fast, which is only possible if specificity is compromised. Efficient immune response is completed
by adaptive immune cells, which need longer to be recruited and activated, but are highly specific.
Innate immune cells recognize pathogens via detection of general pathogen-associated molecular
patterns (PAMPs). Receptors are simply denoted pattern recognition receptors (PRRs) and
examples include TLR, retinoic acid-inducible gene-I-like receptors (RLR) and nucleotide-binding
oligomerization domain-like receptors (NLR). At least 10 different TLRs exist in humans, enabling
cells to distinguish groups of pathogens and their intracellular or extracellular location. Lipoprotein
(gram positive bacteria), zymosan (fungi) and LPS (gram negative bacteria) are for example detected
by TLR1, -2 and -4, respectively [92]. Binding of a PAMP activates signaling pathways leading to
antimicrobial processes including cytokine production, degranulation, phagocytosis of the pathogens
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Ligation of PRRs generally leads to activation of interleukin-1 receptor-associated kinase (IRAK)
family proteins through Myeloid differentiation primary response gene (MyD)88 signaling pathways
as depicted in Figure 1 and can either induce gene expression via nuclear factor kappa B (NFκB) or
mitogen activated protein kinases (MAPK). Binding to NLRs directly leads to activation of TAK1, NFκB
and MAP kinase pathways [93]. Of note, most cells are equipped with the identical sets of signaling
molecules, but choice of signaling pathway(s) activated depends on the type of pathogens, so that
appropriate reaction to attack the invader is induced. First data connecting zinc-induced changes in
immune cell function to regulation of intracellular signaling by zinc arose in the late 1970s [94,95].
Direct effects of zinc on signaling molecules or indirect effects via phosphatases, kinases and redox
metabolism have been described since then.
Figure 1. Zinc in TLR4 triggered signaling, illustrating explanations in the text. Black arrow:
activation, green arrow: activating function of zinc, red T bar: inhibiting function of zinc, black
dotted arrow, translocation of the molecule to nucleus, grey dotted arrow: secretion of the molecule.
Abbreviations: ERK: extracellular Signal-regulated Kinase; IFN: interferon; IRAK: Interleukin-1
receptor-associated kinase; IκB: Inhibitor of NFκB; IKK: IκB kinase; IRF: interferon related factor;
JAK: JNK janus kinase; JNK: c-Jun N-terminal Kinase; MAPK: mitogen activated protein kinases MEK:
MAPK/Erk kinase; MKK: MAPK kinase; MKP: MAPK phosphatase; MyD88: Myeloid differentiation
primary response gene 88; NFκB: nuclear factor (NF) κB. PI3K: phosphatidyl-inositol-3-phosphate;
STAT: signal transducers and activators of transcription; TBK: Tank-binding kinase 1; TIRAP:
toll-interleukin 1 receptor (TIR) domain containing adaptor protein; TLR: toll like receptor; TRAF: TNF
receptor-associated factor; TRAM: TRIF-related adaptor molecule; TRIF: Toll-interleukin-1 receptor
(TIR) domain-containing adaptor-inducing interferon.
4.2. Zinc and (De-)Phosphorylation
In the following, we will first discuss some general mechanisms of how zinc affects intracellular
signaling molecules and their activity in innate immune cells. Subsequently, we will use this
information to describe selected key receptor-induced signaling pathways for the different innate
immune cell types. This is far from being inclusive for all the pathways investigated so far, but should
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certain pathways from one cell type to another, over simplifying those mechanisms as other parameters
such as environmental circumstances, activation status, maturity grade and age of a cell have been
shown to matter as well.
In general, signal transduction is predominantly regulated by post-translational activation or
inactivation of existing signaling molecules via changes in their phosphorylation status. Each signaling
pathway involves phosphorylation of a whole cascade of molecules, where phosphorylation and
thereby the signal can be passed on from one molecule to the other within a short period of time.
Various residues within the molecules can be altered, but tyrosine and to a lesser extend serine
and threonine phosphorylation are most common in immune cells. In leukocytes, especially Src
family kinases are prevalent. As phosphorylation can be both at activating and inhibitory motifs,
there is not a general consequence of elevated kinase activity. Phosphorylation by kinases can be
removed by antagonizing phosphatases, balancing the extent of phosphorylation inside the cells.
CD45, a transmembrane protein tyrosine phosphatase (PTPs) found generally on all leukocytes, is for
example an important regulator of Src family kinase activity [65,73]. Zinc has a role in regulation of
PTP and PT kinase (PTK) activity. Of note, kinase and phosphatase activity is not only affected by
intracellular zinc homeostasis, but both are involved in changing expression of genes relevant for
regulation of zinc homeostasis, as well.
Over 107 PTPs have been identified in humans. They are primarily regulated via the redox state of
the cell, proteolysis, dimerization and phosphorylation. The IC50 for zinc of important PTPs involved in
immune cell signaling are summarized in Table 2. The table clearly shows that inhibition constants for
PTPs are very low (nanomolar), so that cellular zinc levels are sufficient to alter enzymatic activity [96].
PTP1B, for example, has a putative affinity for inhibitory zinc as low as 3–17 nM [10,97]. Zinc competes
with other co-factors of PTPs, which might explain their inhibition during high zinc conditions [98,99].
In addition, zinc directly acts on the highly conserved catalytic region of PTPs, suggesting that other
enzymes from this family might be inhibited by zinc in a similar way [98,100]. SHP-2, phosphatase
and tensin homolog deleted on chromosome 10 (PTEN) and PTP1B are discussed to be involved in
LPS-induced signaling pathways in macrophages via different pathways and molecules [5,101]. This is
in line with the observation that zinc prolonged the tyrosine phosphorylation of proteins in many
immune pathways [55,99,102], involving all kinds of signaling molecules, underlining the complexity
of zinc’s effects.
In addition to PTPs, zinc is able to inhibit the activities of other molecules involved in signaling.
However, most results were calculated from experiments using isolated enzymes or cell lysates.
The resulting IC50 concentrations for example for PDEs in the μM range will hardly be reached
within the cytosol of intact cells. However, a few studies indicate that high levels of zinc can be
enriched in cellular compartments such as vesicles and lysosomes. Hennigar et al. found 20×
higher zinc concentrations normalized to protein comparing cytosol and lysosomes [103]. Moreover,
in catalytically active lysosomes the non-bound Zn2+ concentration was measured to be close to the
permissive concentration of 0.1 μM. In inactive vesicles at neutral pH the Zn2+ concentration might
be much higher as the driving force of the proton gradient is missing [104]. In addition, Vinkenborg
et al. stated that free zinc(II) concentrations in vesicles are much higher than in the cytosol, due to
different buffering capacities. Estimates are 1–100 μmol/L in insulin-storing granules for example [105].
More investigations on intracellular effects of zinc on activity of those signaling molecules are necessary.
Close relatives to PTPs, the MAPK phosphatases (MKP), can dephosphorylate threonine residues
in addition to tyrosine in MAPK and might be zinc’s target as well. The zinc flux has indeed been
connected to inhibition of MKPs in neuronal cells, which should be tested for immune cells as well [61].
As zinc-induced secretion of cytokines by peripheral blood mononuclear cells (PBMCs) is
abolished if cells are pre-incubated with the kinase inhibitor Herbimycin A, zinc might not only
affect PTPs but also their antagonists, the tyrosine kinases (TK). Zinc-associated activation of tyrosine
kinases has been noted by Vener et al., in cells from Alzheimer patients [106]. Results from Bennasroune
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member of the receptor tyrosine kinase family [107]. Zinc was found within the molecular structure
of other TKs including Bruton’s (B)TK as well [108]. Here, zinc is probably involved in enzymatic
activity or substrate binding. BTK is an important regulator of for example TLR4 signaling via
Myeloid differentiation primary response gene (MyD)88 and also binds to TLR9, -8, and -6 [109].
Activation of mitochondrial Src tyrosine kinase by zinc indicates that effects of zinc are not limited to
the cytoplasm [110].
Well-known substrates for Tyrosine (de-)phosphorylation are the MAPKs, such as MAPK/Erk
kinase (MEK), Extracellular Signal-regulated Kinase (ERK), and p38, which are themselves involved in
phosphorylation of other signaling molecules. A role of zinc in alteration of signal transducers and
activators of transcription (STAT) phosphorylation has recently started to emerge [111,112]. Effects of
zinc on MAPK activity have been described for all kinds of cells, and seem to be a very general
molecular mechanism to translate the zinc signal into cellular function. PTP1 is known to alter
the phosphorylation of JAK2 and dephosphorylates MAPKs in immune cells [97,113]. High zinc
concentrations reduced phosphorylation of ERK in in rat glioma cells, while low zinc concentrations
activated this MAPK [98]. Along with this p38 was activated in myeloid cells during zinc deficiency [48].
In contrast, zinc activated ERK in fibroblasts. Similar effects of severe zinc deficiency and high levels of
zinc have been observed before, and might explain the variation of results. In addition, there might be
a certain threshold of intracellular zinc concentrations decisive for its influence on signaling pathways.
Table 2. IC50 values for signaling molecules in humans.
Signaling Molecule IC50 Reference
PTPRB 98 pM [114]
PTEN 0.6 nM [76]
PTP1B 3–17 nM [100]
SHP-1 92 nM [115]
SHP-2 1–2 μM [100]
TC PTP 200 mM [99]
Calcineurin 250 nM–7 μM [116]
Ca-dependent endonuclease 1 μM (in the presence of 10 μM Ca) [117]
LAR 20 μM [100]
PDE4A >5 μM [118]
PDE 5 >1 μM [119]
PDE 6 >1 μM [120]
IKK 8.7 μM [121]
Caspase 3 <10 nM, 100 nM [86,99]
PTPRB: Protein phosphotyrosylphosphatase receptor type B; PTEN: Phosphatase and tensin homologue deleted on
chromosome 10; PTP1B: Protein phosphotyrosylphosphatase 1B; SHP: SH2-containing phosphatase; TC PTP: T cell
PTP; LAR: Leukocyte common antigen-related protein; PDE: phosphodiesterase; IKK: IκB kinase.
4.3. Zinc and Redox Metabolism: Two Strongly Intertwined Second Messengers
Balancing the redox state of a cell is important for regulation of its metabolism. Amongst others,
ROS function as second messengers and interfere thereby with cellular signaling. Phorbol 12-myristate
13-acetate (PMA) activates the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase via
protein kinase C (PKC) resulting in ROS production. PMA is also a well-known inducer of a zinc
flux [122]. As NADPH oxidase inhibition blocked the PMA-induced zinc signal, the release of zinc
into the cytoplasm seems to be ROS-induced. H2O2 was shown to increase intracellular zinc in
granulocytic cells as well, underlining the association of zinc homeostasis with redox metabolism.
Both the zinc signal and the increased ROS levels are essential to subsequently activate key immune
functions [40]. ROS can induce release of zinc from proteins such as MTs or PKC itself, but the source
could also be a cellular compartment such as lysosomes as shown for T cells or the endoplasmatic
reticulum [65,102,123–125]. The source of zinc probably depends on cell type, magnitude of ROS
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Interestingly, not only does the redox metabolism influence intracellular zinc homeostasis,
but the zinc status of a cell also alters its redox state [126]. Pro-antioxidant functions have
long been attributed to zinc for decades, and underlying mechanisms for this phenotypic
observation are becoming increasingly clear. Although low concentrations of a zinc chelator TPEN
(N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine), 5 μM) were not able to affect PKC activity,
using 100 μM of TPEN inhibited PKC’s function and thereby ROS synthesis. The abrogation of PKC
activation when zinc is chelated is suggested to be due to the requirements of zinc finger structures
for PKC’s activity, but also because translocation of the enzyme between membrane and cytoskeleton
involves zinc [122,127,128]. MAPK phosphatase (MKP)-1 is possibly also involved in LPS-induced
cytokine induction via PKC. As MKP-1 is directly inhibited by zinc, the role of the trace metal in
regulating LPS-induced effects seems to be complex and involve several levels, PKC being rather
upstream of other effects. In contrast, long lasting zinc deficiency increased basal ROS levels and
augmented stimulation induced ROS synthesis in myeloid cells [48] underlining again the difference
between long- and short-term zinc alterations. Regarding signaling in innate cells, analyses of the
role of zinc in oxidative burst added nice data to the puzzle, but more data are still necessary as some
discrepancies exist [40,41]. An increase of ROS production by granulocytes during zinc deficiency
seems to be clearly documented, whereas the effect of high zinc conditions has not been clearly defined,
yet [40,41,48,129–131].
4.4. Zinc, Cyclic Nucleotides and Proteinases A and G
The intracellular second messengers cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP) are synthesized by adenylate cyclase (AC) and guanylate cyclase
(GC). Both are degraded by cyclic nucleotide phosphodiesterases (PDE). Their main targets are protein
kinase A (PKA) and PKG, respectively, mediating inflammatory gene expression. On the one hand,
PDEs need zinc for their activity, as zinc is tightly bound to the catalytic center [118,120]. This was
first observed in PDEs in Baker’s yeast, indicating that this is a conserved mechanism [132]. On the
other hand, PDEs have an inhibitory site, which binds zinc with lower affinity. If zinc is available in
high concentrations, hydrolysis of cAMP and cGMP is inhibited, causing their intracellular increase.
In human monocytes, PDE 1, 3 and 4 have been shown to be inhibited during high zinc conditions.
Furthermore, zinc seems to be involved in PDE expression as well, blocking LPS-induced increase in
PDE4B transcription in monocytes, adding one more way of how zinc regulates intracellular second
messenger levels and thereby signaling [60]. Finally, elevated cGMP does not only target PKG but also
cross activates PKA. Subsequently, PKA phosphorylates Raf-1 at serine 259, rendering it inactive and
preventing its activation by serine 338 phosphorylation. Thereby the whole cascade of LPS-induced
NFκB signaling pathway is suppressed [133]. Cyclic nucleotides are not only affected by zinc flux,
but the homeostatic zinc signal has been shown to inhibit AC, causing decreased cAMP levels, while GC
activity and cGMP levels are not affected [134,135]. Increased cAMP and cGMP levels have been
associated with monopoiesis, which will be discussed later.
4.5. Zinc-Mediated Regulation of NFκB Signaling and A20 Expression
In addition to MAPKs, signaling in innate immune cells centers on NFκB. This molecule is
involved in regulating a large set of genes, thereby affecting apoptosis, proliferation, cell adhesion,
pro-inflammatory responses, tissue remodeling and stress-responses [21]. Important molecules within
these signaling pathways include RelA (p65), RelB, c-Rel, p50/p105 (NFκB1) and p52/p100 (NFκB2),
which can form various homo- and heterodimers. Inhibitors of NFκB (IκBs) can bind to single
molecules and complexes, causing their sequestration in the cytoplasm, hindering the translocation
to the nucleus as well as subsequent DNA binding and gene activation. Inhibitors are IκBα, IκBβ,
IκBε, IκBγ, Bcl-3, p100 and p105 [36]. The complexity of this signaling process makes its investigation
regarding an association to zinc homeostasis a difficult task. Existing studies show conflicting results
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Diverse effects of zinc on NFκB signaling have been observed (see Figure 2) [136].
Chelating zinc using TPEN abrogated LPS-induced, NFκB-mediated signaling [102]. In contrast,
zinc has been found to be inhibitory for NFκB signal transduction as well by others [137].
Clear mechanistic insights are not available, but suggestions include the effect of zinc on A20,
a principally anti-inflammatory zinc-finger protein, important for tumor necrosis factor receptor (TNFR)-
and TLR-induced signaling. A20 can de-ubiquitinate receptor interacting protein (RIP)-1, preventing
its binding to I kappa B kinase (IKK)γ, which keeps sequestering NFκB in the cytoplasm. In addition,
A20 can remove polyubiquitin chains from TNFR-associated factor (TRAF)6, thereby inhibiting
TLR-mediated signaling.
Figure 2. Complex impact of zinc on NFκB-centered signaling as illustration of signaling pathways
described in the text. Red T bar: inhibitory function of zinc, green arrow: activating function of zinc,
black T bar: inhibition, black arrow activation. Abbreviations: cGMP: cyclic guanine monophosphate;
GC: guanine cyclase; GMP: guanine monophosphate; GTP: guanine triphosphate; ICAM: intercellular
adhesion molecule; iNOS: inducible nitric oxide synthase; IKK: IκB kinase; IL: interleukin;
MCP: monocyte chemoattractant protein; NIK: NFκB-inducing kinase; NFκB: nuclear factor (NF)κB;
PDE: phosphodiesterase; PKA: protein kinase A; PPAR: Peroxisome proliferator-activated receptor;
ROS: reactive oxygen species; STAT: Signal transducer and activator of transcription; TNF: tumor
necrosis factor; VCAM: vascular cell adhesion molecule.
In endothelial and pre-monocytic cells, zinc-dependent induction of A20 mRNA expression
and protein production was demonstrated, while information on the ubiquitination activity of the
enzyme regarding zinc availability is not clear yet. Zinc signals upregulated mRNA expression of
A20 in other immune cells as well [30,69,138]. Inhibition of gene expression by zinc via increased
A20 and decreased NFκB activity was found for various molecules, including decreased expression
of interleukin (IL)-1β and TNFα in myeloid cells and decreased C reactive protein (CRP) levels,
lipid peroxidation and inflammatory cytokines in elderly subjects [53,88,138–140]. In addition to A20,
peroxisome proliferator-activated receptor (PPAR) alpha is of interest as it alters the binding of NFκB
to the DNA. Its zinc-induced expression results in decreased NFκB binding and down regulation of
pro-inflammatory cytokine and adhesion molecule expression. [53]. NFκB is also inhibited by PKA
via zinc-induced alteration of cGMP levels, as described earlier adding one more explanation for the
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deficiency [133]. The complex postulated effects of zinc on NFκB centered signaling pathways are
summarized in Figure 2.
4.6. Zinc and Signaling Proteome
Most of the so far described effects of zinc in signaling depict consequences of immediate changes
in zinc homeostasis. Long-term alterations in intracellular zinc are often related to altered expression
of zinc transporters and zinc binding proteins. In a recent approach, Aude-Garcia et al. [68] cultured
macrophages with zinc oxide nanoparticles or an equivalent dose of zinc acetate for at least 24 h
and analyzed the proteome of the cells via 2D gel based analyses. In addition to changes regarding
energy, mitochondrial, cytoskeletal and DNA-control metabolism, authors found altered levels of
certain signaling molecules. Protein phosphatase 1a and 2a and S/T phosphatase were affected by zinc
acetate. Zinc oxide nanoparticles changed the levels of Prostaglandin reductase 2, Phosphatidylinositol
transfer protein (PITP)α, Acyl-protein thioesterase 2, Regulator of G-protein signaling 10, MOB kinase
activator 1B and Inositol-3-phosphate synthase 1. Protein levels of MyD88 were affected by both
the zinc ion and the nanoparticle in a similar manner [68]. If altered proteome is due to changes
in gene expression, posttranscriptional mechanisms or if protein stability is reduced remains open.
Furthermore, information on whether proteins are functional is missing. However, results suggest that
certain signaling pathways are prioritized during high zinc conditions and are important to the cell.
MyD88 might be stabilized to keep signaling pathways, important for the pro-inflammatory activity of
the cell active during high zinc conditions. The study provides molecules to the list of zinc-regulated
targets in signaling, but as protein species-based proteomics have some limitations, results have to be
verified carefully [68]. Effects of zinc deficiency should be investigated using a similar approach as well.
4.7. Zinc and Transcription Factors
As a note, many transcription factors governing innate immune cell functions are zinc finger
proteins, suggesting an additional direct or indirect role of zinc in intracellular signaling. Promyelocytic
leukemia zinc-finger (PLZF) is a critical transcription factor for induced natural killer T cell (iNKT
cell) development as is PU.1 for myelopoiesis [141,142]. GATA-4, -5, and -6 and krüppel like factor
(KLF)-4 and KLF-5 are additional examples of zinc finger transcriptionfactors important during
the development of innate immune cells [143,144]. The same is true for adaptive immune cells:
zinc finger transcription factors (ZEB1, ZNF292, and ZNF644) were confirmed to play a role in CD4+
T cells in Rheumatoid Arthritis. A lot of genes involved in regulating zinc homeostasis reveal metal
response elements in their promoters and can be induced by binding of metal-response element
binding transcription factor (MTF)-1, which acts as an intracellular zinc sensor, suggesting feedback
mechanisms [145]. After some initial analysis in this area of research, this topic has not been followed
much recently, but would be a great area for future experiments.
5. From Altered Zinc Homeostasis via Signaling to Innate Immune Cell Functions
As described above, the effects of zinc homeostasis on signaling are complex. Knowing the
effect of zinc on single signaling molecules does not enable prediction of the functional outcome of
zinc deficiency or supplementation. In the upcoming paragraphs, examples will be described for
some selected zinc-dependent key functions of innate immune cells. Predicted underlying molecular
mechanism for the particular setting will be mentioned as well.
5.1. TLR4 Signaling in Monocytes
One of the best-studied examples for the role of zinc in innate immune signaling is TLR4
triggering by LPS. Pathways involved are illustrated in Figure 1 and molecules where zinc is
potentially intervening in the signaling pathways are indicated. Long-term zinc deficiency augments
pro-inflammatory cytokine production, which is reversible if zinc is reconstituted [48]. In contrast,
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zinc can be detected, which is involved in activation of MAPK signaling pathways. Amongst others,
zinc inhibits dephosphorylation of MAPK and supports IKKα/β phosphorylation, NFκB translocation
to the nucleus and gene activation [102,146]. Wan et al. recently separated zinc-dependent and
-independent processes shortly after LPS triggering of TLR4 of murine macrophages. Depletion of zinc
inhibited the LPS-induced activation of several kinases including ERK1/2, IKKβ, MKK3/6 and IκB
in murine primary macrophages and cell lines. Interestingly, phosphorylation and ubiquitination of
IRAK1 was not affected by zinc deficiency, at least not early after stimulation, suggesting a selective
effect of zinc on certain signaling pathways, shortly after LPS-stimulation. However, degradation of
ubiquitinated IRAK1 required zinc but did not involve proteasome [70]. Zinc chelation caused the
accumulation of phosphorylated and ubiquitinated IRAK1. One can speculate, that inactivation
of zinc-containing metalloproteases during zinc deficiency, prevents the destruction of IRAK1,
which remains to be investigated. A membrane associated complex, which is phosphorylated after LPS
stimulation, contains IRAK1 in addition to IKKα and IKKβ [147]. Degradation of IRAK1 is essential to
release phosphorylated IKKs into the cytoplasm, which then degrade IκB and p105 activating NFκB
and ERK signaling. However, zinc deficiency might affect phosphorylation of ERK and IκB via its
effect on PTPs as well, which is not clear yet.
TLR4-induced pathways can be grouped into MyD88-dependent pathways, including MAPKs and
NFκB, which induce expression of inflammatory cytokines and MyD88-independent/Toll-interleukin-1
receptor (TIR) domain-containing adaptor-inducing interferon (TRIF)-dependent pathways involving
TRIF-related adaptor molecule (TRAM), TRIF and IRF-3 and triggering interferon (IFN)β expression
(see Figure 1). The latter has an autocrine function and can bind to surface interferon receptor (IFNR)
resulting in activation of the JAK-STAT pathway finally causing expression of CD40, CD80 and CD86,
necessary for interaction of myeloid cells with T cells [5,148]. Zinc has been suggested to be involved
in IFN signaling in hepatocytes recently, which should be tested for immune cells as well [149].
In addition, NFκB as well as the JAK-STAT pathway induce NO production via inducible nitric oxide
synthase (iNOS), which is a potent anti-microbial mediator. While our knowledge on the role of zinc in
MyD88-dependent pathways, especially early after receptor triggering, is broad and described in large
detail [102], an association of zinc to TRIF pathways and NO synthesis is less explicit. In addition,
most data originate from investigations of time points early after receptor triggering, representing
investigation of the zinc flux. Pre-existing zinc deficiency augmented LPS-induced NO synthesis in
murine macrophages and also increased LPS induced IFNβ expression as well as CD80 and CD86
(cell-line and bone marrow based). Effects were measured a few hours after the original stimulus and
where therefore assigned to be regulated by homeostatic zinc signals. Reconstitution of zinc abolished
the effect of the chelator. Interestingly, chelation of zinc caused decreased LPS-induced transcription of
IL-1β, IL-6, and IL-10 in macrophages compared to zinc adequate controls. This indicates zinc chelation
seems to inhibit the MyD88-depending pathways while triggering TRIF-dependent signaling. In line
with this, a time-course experiment revealed, that adding the chelator at the time of TRIF activation
caused the maximal increase in NO synthesis. This also indicates that TRIF-signaling is independent
from the initial zinc signal, induced quickly after LPS binding to TLR4. MyD88-dependent pathways
induce fast translocation of NFκB to the nucleus which was reduced, when cells were pre-incubated
with TPEN. However, TRIF-dependent delayed NFκB activation was not affected by TPEN, underlining
this hypothesis [5].
Regarding effects of persisting changes in intracellular zinc levels, the de-ubiquitination of
TRAF6 by A20 is probably involved in turning off TLR4-induced signaling and pro-inflammatory
activity of macrophages. Ubiquinated TRAF6 activates TAK1 a kinase phosphorylating IKKs and
MKKs, resulting in gene expression which is thereby blocked [138,150,151]. Thus, balanced zinc
homeostasis is important to prevent unwanted signaling disturbances. In macrophages, A20 is induced
by pro-inflammatory cytokines, possibly as a feedback mechanism to terminate their expression [152].
Increased cGMPs levels due to high intracellular zinc could explain elevated phosphorylation of Raf-1,
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TLR7 and TLR3-induced signaling showed dependents of TRIF/IRF/IFNβ signaling as well, while NO
production was not affected by zinc chelation after TLR3 activation.
Altogether, TLR4 signaling in macrophages is a great example of the combination of a short-lived
zinc peak and modulation of basal intracellular zinc levels for longer periods to balance MyD88-
and TRIF-dependent pathways, acting as a fine-tuning signal after TLR4 triggering. Using ligands
for other TLRs including Pam3CSK4 (TLR1/2), Listeria monocytogenes (TLR2), flagellin (TLR5),
FSL-1 (TLR6/2), ssRNA40 (TLR7) and ODN1826 (TLR9) all increased intracellular zinc in murine
macrophages and primary human monocytes [5,102]. If this has similar consequences on signaling
pathways remains to be investigated. Simplification of zinc’s effect such as stating that zinc generally
supports all TLR-induced signaling pathways, is difficult, as the whole environmental set up, including
the current zinc supply, activation and maturity state of the cell, chronic inflammation, time after
stimulation and more, can affect consequences of altered zinc levels.
5.2. Zinc Homeostasis, Hematopoiesis and STAT3
Long-term changes in zinc homeostasis usually involve changes in zinc transporter expression.
In dendritic cells, stimulation with LPS changes the expression of Zip6 and Zip10 as well as of ZnT-1,
-4 and -6 via pathways involving TRIF. An association of zinc with regulation of TRIF signaling has just
been described above, explaining this observation. This causes a long-term reduction in intracellular
zinc which is essential for cellular maturation [58]. This is just one of the examples explaining the
often-observed effect of zinc on hematopoiesis. Monopoiesis has been shown to be paralleled by a
decrease in intracellular zinc and similar data have just been generated for granulopoiesis [38,153].
IL-6 is one of the most potent inflammatory cytokines, activating immune cells via binding to
its gp130 receptor found within the plasma membrane. Amongst others, IL-6 induces the expression
of acute phase proteins (APP), which subsequently interact with TLRs and induce the NLRP3
inflammasome. Receptor ligation activates JAK-STAT3 and MAPK pathways. Recent years revealed
that especially the phosphorylation of STAT3 is broadly affected by zinc homeostasis. Zinc deficiency
increased IL-6-induced activation of JAK-STAT3 signaling pathways; reconstitution with zinc
normalized the effect while zinc supplementation was shown to inhibit STAT3 phosphorylation
induced by IL-6 and IL-1 [111]. Phosphorylation of STAT3 is known to be regulated by SHP1/2,
whose activity is increased by zinc [154]. If this is the only mechanism how zinc is involved in JAK-STAT
signal transduction remains to be further investigated. STAT3 seems to be an important player in
regular myelopoiesis as well as in demand adapted emergency myelopoiesis, during inflammatory
diseases such as sepsis [155]. The connection between disease-related serum hypozincemia,
STAT3 activity and grade of differentiation needs to be explored.
In murine hematopoietic stem cells, zinc chloride promotes transient STAT3 phosphorylation
(Tyr705), resulting in increased expression of pluripotency genes and inhibition of differentiation
genes [112]. Expression of STAT3 was not altered. Thus, zinc plays a critical role in maintaining
pluripotency and self-renewal of stem cells and can even replace leukemia inhibitory factor (LIF),
which is normally essential for this process. Zinc disrupted differentiation induced by retinoic
acid, at least for a certain period of time. Treatment of cells with zinc chloride and LIF did not
augment pluripotency, suggesting that both factors regulate the same pathway, which is centered
on STAT3. The observation that inhibition of STAT3 abrogates the effect of zinc chloride on the cells
underlines the importance of STAT3 as a central molecule in hematopoiesis. Along with this, B cell
proliferation, was increased during zinc deficiency [77]. Again, STAT3 phosphorylation was shown to
be responsible here.
Neuronal development is also strongly affected by zinc via STAT3-centered signaling. Results
from this very recent study add alteration in the redox-state as underlying mechanism for the effect
of zinc on STAT3 phosphorylation. In this study, moderate zinc deficiency (1.5 μM) caused oxidative
stress within 24 h, resulting in decreased tyrosine phosphorylation and retention of STAT3 in the
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tyrosine phosphorylation was decreased during zinc deficiency when whole cell lysates were tested,
in nuclear extracts phosphorylation of both residues was decreased [156]. If this is a cell-type specific
effect or if it can be extrapolated to innate immune cells remains to be tested, but as redox and zinc
metabolism are highly intertwined in innate immune cells, as described earlier, a similar mechanism is
highly likely.
Thus far, an association of zinc homeostasis with the activity of STAT molecules other than
STAT3 is barely investigated. The effect of zinc on phosphorylation of STAT1 and STAT6 was
suggested to be relevant for lineage determination of macrophages. Zinc supplementation decreased
STAT6 phosphorylation reducing the amount of M2 macrophages, while zinc deficiency increased
phosphorylation of STAT2, thereby supporting M1 development [78]. While studies in T cells did
not show an effect of zinc on STAT5 activity, recent results from myeloid cells suggest that zinc
supplementation inhibits STAT5 phosphorylation [157]. This indicates a general mechanism of zinc
affected STAT activity in cell differentiation, which should be investigates in more detail.
5.3. Zinc Alters Killing Activity of Natural Killer Cells
Although natural killer cells belong to the lymphoid lineage, they are counted as innate immune
cells and kill infected or transformed cells. Regular human cells carry major histocompatibility complex
(MHC)-I on their surface, which rescues them from being killed by binding to p58 killer cell inhibitory
receptor (KIR) on NK cells. KIR can bind zinc which alters recognition of MHC-I and thereby the
induction of subsequent signaling pathways. A zinc-dependent multimerization of KIR was suggested
to be essential for formation of the clusters of KIR and human leukocyte antigen (HLA) molecules,
also called “natural killer (NK) cell immune synapse” [84,158]. Effects of zinc deficiency on KIR
multimerization have not been investigated, yet, but might explain why the lytic activity of NK cells
is decreased when zinc supply is limited [159]. In general, existing studies for NK cells are limited
to experiments, where zinc has been extracellularly added, whereas effects of altered intracellular
zinc homeostasis can only be assumed, as measurements of intracellular zinc levels after stimulation
are not available. Only some very recent data are available that showed a zinc flux shortly after IL-1
stimulation [85]. However, NK cells carry a variety of cell surface receptors, essential for fine tuning of
their activities, which contain tyrosine phosphorylation sides such as immunoreceptor tyrosine-based
activation motif (ITAM) or immunoreceptor tyrosine-based inhibitory motif (ITIM). As described
earlier, the ability of zinc to inhibit PTPs is well accepted, so a role of intracellular zinc homeostasis in
regulation of signaling pathways in NK cells is highly likely, but remains to be analyzed.
5.4. Mast Cell Degranulation Depends on Zinc Levels
Knowledge of a role of zinc in signaling in mast cells (MCs) is scarce. Cytoplasm and granules
seem to represent two distinct zinc pools in this cell type. High amounts of zinc are stored in
the granules, lost during immunglobulin (Ig)E-induced degranulation, and are quickly replenished
thereafter. This zinc is probably not involved in signaling [160]. Zinc was however important
for the process of degranulation, mediating granule translocation to the plasma membrane Zinc
chelation inhibited degranulation. A transient increase in cytoplasmic zinc has been reported after cell
activation [161]. This zinc signal affected translocation of NFκB to the nucleus and phosphorylation of
ERK1/2, JNK1/2 and the translocation of PKC to the plasma membrane, as reported for other cells and
stimuli [55,161]. Abrogation of the zinc wave via incubation with the zinc chelator TPEN abrogated
activation of signaling pathways and blocked expression of IL-1β and TNFα. Zinc supplementation
was able to prolong activation of the signaling pathways. Different probes were used to measure zinc
here, enabling staining of the different zinc pools. It is well known, that low molecular weight probes
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6. The Adaptive Immunity
The adaptive immune system is built up of the humoral immune defense, represented by
B lymphocytes (B cells), and the cellular immune defense, represented by T lymphocytes (T cells).
Both cell types evolve off precursors and are educated to recognize their specific antigen in the thymus
(T cells) or bone marrow (B cells), respectively. According to antigen contact, naïve lymphocytes
differentiate into effector cells or memory cells, facilitating a stronger reaction to a known antigen
as a secondary response due to immunological memory. The immune system is a highly active
and proliferating organ influenced by a multitude of external factors such as nutrition. In this
regard, the immune response is highly dependent on zinc, since zinc deficiency is accompanied with
malfunctions and disorders, such as allergies, autoimmune diseases and cancer. In the past decade,
studies on animal models have provided considerable knowledge about the underlying molecular
mechanisms of the zinc-related modulation of the immune system, including new insights into how
nutritional deficiency can alter immune cell homeostasis and function of the adaptive immunity.
Zinc-related immunological changes in the adaptive immune response and altered signaling cascades
are discussed in the following sections.
6.1. Zinc Homeostasis in Development of T and B Cells
For a long time, zinc is known to be essential especially for proper T cell and B cell
development [163,164]. However, T cells are in particular much more sensitive to altered zinc
signals resulting in altered differentiation or function, since zinc directly influence the biological
activity of the thymic hormone thymulin by acting as essential co-factor. Thymulin, is produced
by the thymus and released by thymic epithelial cells [165]. By binding to high-affinity receptors
on T cells, it induces markers of differentiation in immature T cells, and promotes T cell function,
including allogenic cytotoxicity, suppressor functions, and IL-2 production [166]. It is therefore
not surprising that during zinc deficiency the recruitment of naïve Th cells and the percentage of
cytotoxic T lymphocytes (CTL) precursors is diminished respectively [167]. The loss of developing
T cells (pre-T cells) is ascribed to accelerated apoptosis consistent with the finding that pre-T cells
express the lowest amount of the anti-apoptotic proteins B cell lymphoma (Bcl)-2 and Bcl-xL thereby
increasing the vulnerability towards cell death. In general, zinc deficiency is described to affect for
instance the hypothalamus-adrenal-pituitary axis, resulting in increased circulating glucocorticoids,
being powerful apoptogens for immature lymphoid cells [168]. Additionally, caspase activity is known
to be regulated in a zinc-dependent manner and zinc deficiency directly induce caspase 3-dependent
cleavage of the cell cycle regulator p21 leading to an immediate induction of cyclin-dependent kinase
(CDK)2 activity which may result in premature entry of the cells into S-phase and apoptotic cell
death [169,170]. Since the thymus comprises of about 80% pre-T cells, its strong susceptibility towards
zinc deficiency account for a main cause of disturbed T cell-mediated immune responses. Interestingly,
in vitro and in vivo supplementation of serum zinc restored thymulin activity observed in moderately
zinc-deficient mice and men, emphasizing a direct effect of serum zinc on thymulin activity [165,171].
Besides intrathymic functions on thymocytes and immature T cells, mature T cells in the
periphery are also affected by thymulin. Herein, thymulin modulates cytokine release by PBMC,
and proliferation of cytotoxic CD8-expressing CTL in combination with IL-2 responsible for T cell
activation and proliferation [172]. Hence, it is obvious that zinc status has impact on immature as well
as mature T cells through the direct activation of thymulin. As a consequence of zinc deficiency, T cell
proliferation is decreased after mitogen stimulation, whereas zinc supplementation is able to reverse
zinc deficiency-induced changes in the thymus and on peripheral cells [173].
In general, both mature T cell types: CD4-expressing Th cells as well as CD8-expressing CTL,
are affected by zinc deficiency. On the one hand, the amount of CD8/CD73 co-expressing T cells is
decreased during zinc deficiency. Those are predominantly precursors of cytotoxic T cells, needing
CD73 expression for antigen recognition and proliferation as well as cytolytic process generation [167].
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and therefore changes in the Th1/Th2 ratio towards Th2 cells is observed leading to unbalanced
cell-mediated immune responses [174]. Herein, Th1 cell products as IFNγ and IL-2 are decreased,
whereas Th2 cell products like IL-4, IL-6, and IL-10 remain unaffected. Therefore, the incidence of
infections and Th2-driven allergies is increased by zinc deficiency [23,175]. Furthermore, the functional
impairment of T cell-mediated responses during zinc-deficiency is described to favor the development
of autoimmune diseases [20,176]. In this regard, patients suffering from multiple sclerosis (MS) show
lower plasma zinc level and lower zinc concentrations in chronic MS lesions [14,177,178]. Moreover,
adequate zinc status is essential for transplant rejections since zinc supplementation was shown to
beneficially influence allogeneic cardiac transplantation and intraportal islet transplantation [87,179].
Here, zinc as a pro-antioxidant is involved in the inhibition of apoptotic enzymes such as caspases and
acts tolerogenic [79,87,180]. Another mechanism to lower transplant rejections by zinc administration
in physiological doses is the capacity of zinc to induce and stabilize a specific subpopulation of
Th cells, namely regulatory T cells (Treg) in vitro and in vivo [79–81]. This is of great importance,
since the discovery of Treg offers a new paradigm for transplantation medicine since intra-graft
Treg frequency seems to correlate with clinical graft acceptance, survival, and function [181,182].
Moreover, pro-inflammatory graft-related immune reactions are tried to impede that might be
accomplished by Treg induction. To date, Treg gain more and more importance in combating
diseases in clinical approaches and a multitude of studies elicited transforming growth factor
(TGF)-β1 to be essential in conversion of Th cells into Treg in vitro [183–185]. In this connection,
TGF-β1 seem to be important in establishing immunological tolerance by induction of Treg cells
in mice [183,186,187] and humans [185,188] by triggering the TGF-β1-dependent Smad signaling
pathway. Herein, studies suggest an essential role for Smad 2/3 in Forkhead-Box-Protein (FoxP)3
induction and cytokine suppression [189,190]. Interestingly, TGF-β-induced Smad signaling was
shown to be intensified by zinc administration contributing to higher Treg cell induction (see Figure 3).
Because Smad-binding elements were found in the conserved non-coding DNA sequence (CNS) 1
region of the FoxP3 promoter [189], and zinc promoted FoxP3 stability by preventing proteasomal
degradation caused by the histone deacetylase Sirt1 [79], the synergistic effect of the combined
treatment could result from both triggered mechanism.
Another mechanism controlling Treg function probably is CK2-mediated activation of zinc
transporter Zip7 and thereby altering cellular zinc homeostasis. Zip7 is considered as gatekeeper
of cytosolic zinc release from the ER [191], highlighting the involvement of zinc in rapid signaling.
Protein kinase CK2 is a ubiquitously expressed tetrameric threonine/serine kinase composed of two
catalytic α-subunits and β-subunits respectively [192]. CK2 particularly is involved in regulation of
cell survival and proliferation, apoptosis and mitosis [193], by shuttling between the cytosol and nuclei
of cells in order to support apoptosis or mitosis, respectively. Zip7 phosphorylation by CK2 results
in Zip7-mediated zinc release from the ER and the subsequent activation of multiple downstream
pathways that enhance cell proliferation and migration. In the context of Treg function, genetic ablation
of the β-subunit of CK2 is addressed to insufficient potential to suppress allergic immune responses
in the lungs mediated by Th2 cells in vivo [194]. Therefore, inappropriate CK2 function impairs
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Figure 3. Influence of zinc signals on T cell signaling pathways. This figure presents an overview
of T cell receptor (TCR)-, Interleukin-1 receptor (IL-1R)-, IL-2R-, IL-4R-, Transforming growth factor
β1 receptor (TGF-β1R)-signaling in T cells, as well as zinc flux via zinc transporter ZIP6. Signaling
pathways are described in detail in the text. Black arrow: activation, green arrow: activating function
of zinc, red T bar: inhibiting function of zinc, black dotted arrow, translocation of the molecule to
nucleus. Abbreviations: CREB: cyclic adenosine monophosphate response element-binding protein;
Csk: c-src tyrosine kinase; Foxp3: forkhead-box-protein P3; IL: Interleukin; IRAK: interleukin-1
receptor-associated kinase; KLF-10: krüppel-like factor-10; Lck: lymphocyte-specific protein tyrosine
kinase; MAPK: mitogen-activated protein kinase; MKP: MAP-kinase phosphatase; NFAT: nuclear
factor of activated T cells; NFκB: nuclear factor kappa B; PKA: protein kinase A; PKC: protein
kinase C; SIRT1: Sirtuin1; STAT: signal transducer and activator of transcription; TCR: T cell receptor;
TGF-β1: transforming growth factor β1. ZAP: zeta-chain (TCR)-associated protein kinase.
In contrast to that, the ZIP8-zinc axis might have a negative impact on immune regulation.
ZIP8 is known to be highly expressed in human T cells on the lysosomal membrane and is even
more prominent when T cells are activated by TCR triggering [125]. Hence, after T cell activation free
intralysosomal zinc is released into the cytoplasm increasing the zinc available, which leads to altered T
cell function by modulation of distinct signaling pathways. In this connection, overexpression of ZIP8
was shown to trigger the pro-inflammatory immune responses by enhancing the IFN-γ production
due to zinc-mediated reduction of CN phosphatase activity and prolonged phosphorylation of the
transcription factor cyclic adenosine monophosphate response element-binding protein (CREB) [125].
Hence, the TCR-induced cytokine production is strengthened. In line with that, the NFκB activity is
triggered by downregulation of the IκB kinase activity in pro-inflammatory responses observed in
ZIP8 hypomorphic mice [137]. Hence, an overreacting immune system can lead to hyperinflammation,
autoimmune diseases or sepsis.
Nevertheless, one has to keep in mind that T cell function is sensitively regulated by zinc
concentration leading to cellular activation or deactivation respectively [31]. Additionally, results observed
in different species and different cellular models needs to be compared with wariness.
In general, Treg development and survival is dependent on a high number of key factors, such as
the transcription factor Foxp3 and additional signals, including IL-2, TGF-β, and co-stimulatory
molecules like CD28. Moreover, transcription factors as IRF-1 and KLF-10 are described to influence
Treg stability and function. One study elicited IRF-1 deficiency to result in a selective and marked
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a direct role in the generation and expansion of Treg cells by specifically repressing FoxP3 activity
that can be dampened by zinc supplementation supporting the pro-tolerogenic immune reaction [196].
In contrast to IRF-1, KLF-10 seem to be indispensable for appropriate Treg function, because animals
carrying a disruption in KLF-10 no longer show FoxP3 activation [197]. KLF-10-deficient Treg cells
display impaired cell differentiation, altered cytokine profiles with enhanced Th1, Th2, and Th17
cytokine expression. Furthermore, a reduced capacity for suppression by wild-type co-cultured
T effector cells, as well as accelerated atherosclerosis in immunodeficient atherosclerotic mice
was exhibited [197].
During the last decade, the pro-inflammatory Th9 cell subpopulation is reported to be involved
allergic asthma and autoimmune diseases like MS respectively [198,199]. Interestingly, comparable to
the zinc-mediated reduction of pro-inflammatory Th17 cells in allogeneic immunoreactions [81,200],
zinc supplementation in physiological doses facilitates a similar reduction of pro-inflammatory Th9
cells [82], subsequently leading to dampened allogeneic immunoreaction. Hence, an overreacting
immune response can be beneficially influenced by zinc administration seeming to be promising to
improve the life of patients suffering autoimmune or allergic diseases.
To date, zinc-related targets for the above-mentioned effects are still not fully known. However,
some zinc-related targets for the above mentioned effects were found, comprising receptor proteins,
kinases, phosphatases, caspases, and transcription factors. Those can be activated or inactivated by zinc
administration or zinc deficiency depending on type of zinc signal and zinc level [4,30]. The impact of
zinc signals on the adaptive immune system will be discussed in detail in the following paragraphs.
6.2. Zinc Signals in T Cell Receptor-Triggered Signaling Cascades
When T cell activation via T cell receptor (TCR) stimulation is examined into detail, already the
TCR activating complex is influenced by zinc signals (see Figure 3). One has to keep in mind that TCR
exhibit no intrinsic kinase activity and depend on Src-family tyrosine kinases for signal transduction,
like lymphocyte protein tyrosine kinase (Lck). Lck is one of the first kinases activated, essential for
T cell activation mediated either by proximal or distal Lck promoter activity, and is essential for
phosphorylation of the 10 ITAM motifs of the T cell antigen receptor-signaling complex augmenting
phosphorylation of the kinase ZAP70 [201,202]. Activation of ZAP70 phosphorylates downstream
targets eventually inducing MAPK signaling pathway contributing to T cell activation. Zinc-mediated
T cell activation is facilitated by either a zinc flux inducing direct or indirect Lck activation or SHP-1
deactivation, respectively, or homeostatic zinc signals altering gene expression, as for instance of
distinct zinc transporter.
Lck activation occurs by zinc flux-dependent Lck homodimerization by stabilization the dimer
interface of the SH3 domains [67]. Herein, the activation is highly complex by involving distinct
tyrosine residues either in the so-called activation loop or at the C-terminal negative regulatory
site [154,201]. On the other hand, Lck activation is facilitated by stabilization the interface site of
Lck and the membrane proteins CD4 and CD8 respectively [63,64]. By forming a so-called “zinc
clasp structure”, zinc bridges two cysteine residues of each protein facilitating a stable interaction
of Lck and CD4/CD8 [203]. Since the surface molecules CD8 and CD4 bind to MHC class I or II
respectively, all components are recruited in close proximity to the TCR signaling complex, leading to
T cell activation. On the other hand, Lck activity is influenced in an indirect manner due to reduced
recruitment of the enzyme SHP-1. Since Lck homodimerization and phosphorylation, as well as
TCR complex arrangement and signaling, is highly dependent on numerous PTP [204,205], all can
be considered as potential targets for zinc-mediated regulation. Consequently, it cannot be precisely
predicted whether a PTP regulation result in preferential dephosphorylation of an activating or
inactivating tyrosine by zinc in vivo eventually facilitation signaling activation or inactivation.
T cell activation can furthermore be influenced by altered intracellular zinc signals and zinc
concentrations mediated by specific zinc transporter, as for instance Zip6. Initiation of TCR signaling is
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antigen-presenting cell (APC) by formation of a functional immunologic synapse. This results in an
immediately influx of zinc from the extracellular environment through the transporter Zip6 after T cell
stimulation [66]. Hence, intracellular free zinc levels are altered influencing signaling pathways and
subsequently T cell activation, maturation and differentiation.
In response to TCR stimulation, specific transcription factors and signaling pathways are triggered
that are often zinc-regulated (see Figure 3). Nuclear factor of activated T cells (NFAT) mediates
the expression of plenty of genes, such as IL-2. In resting T cells, NFAT proteins are constitutively
phosphorylated remaining inactive and are located in the cytoplasm. In response to TCR/CD28-mediated
calcium signaling, NFAT is dephosphorylated by calcineurin (CN), a calcium/calmodulin-dependent
serine/threonine phosphatase, and eventually translocates into the nucleus [206]. Zinc and iron are
essential cofactors for the catalytic domain of CN, containing a Zn2+-Fe2+ binuclear center. However,
CN inhibition is only reported for zinc. Regarding this, physiologic zinc concentrations, ranging from 10
to 10 μM are described to exhibit a CN inhibition-capacity in vitro [116,207]. Zinc-dependent regulation
of T cell activation, proliferation and differentiation is much more complex than modifying transcription
factor activity as NFAT, since CN activity itself is regulated in a complex zinc-dependent manner. Herein,
CN remains in its inactive phosphorylated form, due to phosphatidyl-inositol-3-kinase (PI3K) [206].
PI3K is a lipid kinase and generates phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3).
PI(3,4,5)P3 acts as second messenger essential for the translocation of Akt to the plasma membrane
where it is phosphorylated and activated by phosphoinositide-dependent kinase (PDK)1 and PDK2.
Activation of Akt plays a pivotal role in fundamental cellular functions such as cell proliferation and
survival by phosphorylating a variety of substrates [208]. In PI3K pathway, zinc signals are well
reported to influence the signaling cascade in various cell types [209–212]. One possible explanation
for this mechanism is an increased enzyme degradation of phosphatase and tensin homolog deleted
on chromosome 10 (PTEN) [213,214]. PTEN in general functions as a dephosphorylase of PI(3,4,5)P3,
a product of PI3K mediating the activation of PDK-1/Akt. More recently, a study examining the
IL-2-induced PI3K/Akt signaling pathway uncovered an inhibition of PTEN. Here, homeostatic
zinc signals seem to be necessary for the regulation the PI3K/Akt pathway, since the IL-2-induced
Akt phosphorylation is diminished during zinc deficiency. Homeostatic zinc signals are known
to upregulate phosphorylation of Akt at Ser473 and inhibit PTEN at subnanomolar concentrations
(IC50~0.59 nM). This inhibition seems to be mediated by zinc binding to cysteine thiol at position
124 (Cys124) essential for the catalytic activity of PTEN [76]. Thus, a modulation of this pathway
occurs upstream of Akt, but down-stream of Jak1, because STAT-5 signaling is not influenced by zinc
signals [65]. These results suggest a comparable activation of PI3K via zinc in T cells. Zinc-mediated
inhibition of CN results in NFAT inactivation and reduction of TCR-mediated transcription, whereas
activation of PI3K signaling act agonistic.
Zinc signals as mediator of T cell signal transduction is known since the first reports of a potential
role of this ion in signaling were described. Its interaction with PKC is identified as biochemical
basis of these observations [215]. The PKC family members are serine/threonine kinases comprising
of several isoforms are known to play crucial roles in intracellular signal transduction elicited by
various extracellular stimuli, like growth factors, hormones, and neurotransmitters. PKC members
can be subdivided into: (1) classical PKCs, activated by cofactors like Ca2+ and diacylglycerol (DAC);
(2) novel PKC that bind DAC but no Ca2+; and (3) atypical PKCs that interact with neither Ca2+
nor DAC. Several isoforms are well described to be important in T cell function. Following T cell
activation via TCR/CD28 triggering, PKCθ is involved in the activation of several transcription factors.
Additionally, PKCα is involved in T cell proliferation and IL-2 production. Furthermore, several PKC
isoforms are involved in survival of B cells, pre-B cell development, and induction of tolerance toward
self-antigens [216]. PKC is described as a zinc metallo-enzyme. Atomic absorption measurements on
the intact enzyme indicated that four zinc atoms (4.2 ± 0.5) are bound per PKCα molecule. Similar
stoichiometric ratios were determined for PKCβII and PKCγ [217]. PKC comprise of four commonly
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of PKCα1, which contains two homologous regions containing six cysteine (Cys) and two histidine
(His) residues, forming a total of four Cys3His zinc binding motifs [218]. No information about a
differential effect of zinc on the different isoforms is available, and varying forms of C1 domains are
present in conventional, novel, and atypical PKCs, pointing to probable zinc binding to all known
PKC isoforms [216].
Late zinc signals are mentioned to affect multiple steps during PKC activation, as for instance
augmented PKC kinase activity, increased affinity to phorbol esters, and enhanced binding to the
cytoskeleton and plasma membrane [219]. Inhibition of the above mentioned events can be seen during
zinc deficiency in vitro, facilitated by membrane-permeable zinc chelators, as TPEN. Interestingly,
PKC itself can be a source for zinc release, thus interaction between PKC and zinc is not limited to
an effect of zinc on the PKC activation. PKC activation by lipid second messengers or thiol oxidation
lead to measurable zinc release from the regulatory domain [220,221]. In addition, PKC regulates
the intracellular free zinc concentration and distribution. In T cells, phorbol ester treatment lead to
a zinc flux resulting in redistribution of zinc from the nucleus and mitochondria to the cytosol and
microsomes [222].
Besides activating signaling cascades, also inhibition of TCR signaling and subsequent inhibition
of overall T cell activation is facilitated by phosphorylation status of different amino acids. One of those
is phosphorylation of the inactivating tyrosine 505 of Lck via c-src tyrosine kinase COOH-terminal Srk
kinase (Csk) [223]. The zinc flux interferes with this event in different ways: (1) zinc signals lead to
an inhibition of Csk [75]; and (2) activation of Csk in T cells can be observed via phosphorylation by
PKA [224]. Although zinc has no direct impact on PKA activity itself, it inhibit AC transcription by
a homeostatic zinc signal thereby inhibiting the formation of the PKA activator cAMP. Furthermore,
cAMP is influenced by zinc via inhibition of PDE that can block degradation of cyclic nucleotides,
leading to activation of PKA [60]. An inhibition of Csk and AC promote TCR signaling, while PDE
inhibition antagonizes it. However, the outcome on TCR signaling resulting from the modulation of
this pathway by zinc in vivo remains to be elucidated yet.
6.3. Zinc Signals in Interleukin Receptor Signaling Pathways in T Cells
Besides PI3K and PTEN modulation downstream of TCR activation, zinc signals also affects
signals originating from the IL-1 receptor (IL-1R). High zinc concentrations of about 100 μM inhibit
IL-1β-stimulated IFNγ production in primary human T cells and IL-1 dependent proliferation of
murine T cells. Zinc incubation leads to a reduced activity of IRAK that is a central kinase in
the signaling pathways downstream of the IL-1 receptor. IRAK comprise of four different genes
existing in the human genome (IRAK1, IRAK2, IRAK3, and IRAK4), and studies with transgenic
mice, have revealed distinct, non-redundant biological roles [225]. Interestingly, IRAK4 is reported
to be essential for the TLR signaling in innate immunity as well as for TCR-mediated signaling in
adaptive immunity leading to the activation of NFκB [226], however this is still matter of debate [227].
Since zinc signals show modulating capacity on TCR as well as on IL-1-dependent signaling via IRAK
inhibition, two central signaling pathways are uncovered in negative regulation of T cell activation.
Nevertheless, one has to keep in mind that IRAK function and zinc-mediated regulation is not limited
to T cells. High similarity between TLR4 and IL-1R signal transduction suggests IRAK inhibition
for another mechanism by which zinc negatively influences TLR4 signaling in innate immunity as
discussed before.
Moreover, triggering of interleukin receptor (IL-2R) also results in altered intracellular zinc signals.
Following IL-2R stimulation, zinc signal is releases of from lysosomal compartment called zincosomes
within several minutes after T cell stimulation [65]. Thus, an intracellular zinc flux is triggered
influencing PTP, as for instance dual-specificity phosphatases (DUSP) or Protein phosphatase (PP)2A
activity in a direct manner. Subsequently, ultimately signal transduction and protein expression,
such as diminished dephosphorylation of MAPK MEK and ERK, or elevated transcription of zinc








Int. J. Mol. Sci. 2017, 18, 2222
Not only is kinase activity regulated by zinc signals, but cytokine production is also influenced.
During zinc deficiency zinc administration leads to a fast rise in intracellular zinc levels, i.e., zinc flux,
due to an increased expression of cell membrane-located zinc transporters Zip10 and Zip12 because
of the former zinc deficiency. Due to altered intracellular zinc homeostasis, activity of signaling
molecules as MAPK p38, and NFκB p65 are affected consequently leading to highly increased IL-2
mRNA expression and IL-2 cytokine production [72].
In general, a forecast of zinc-related effects on T cell function is impossible due to the high number
of signaling pathways modulated by zinc signals. Several studies concerning zinc status and T cell
function in vivo, stated an increase of the delayed type hypersensitivity reaction upon correction of
zinc deficiency [228]. By contrast, zinc administration diminishes the allogeneic reaction in the mixed
lymphocyte culture (MLC) [229] and stabilizes regulatory T cell function in vitro and in vivo [79,230]
indicating that zinc may have multiple, opposing functions, depending on its concentration and
interaction with multiple other environmental factors.
6.4. Zinc Signals in B Cell Maturation, Survival and Function
B cells represent the specific humoral immunity and differentiate to antibody-producing plasma
cells after stimulation. Nearly all of the zinc regulated signaling pathways discussed above in T cells
are also important in B cells maturation and differentiation, such as tyrosine phosphorylation, PKC,
MAPK signaling, and activation of the transcription factors NFAT and NFκB. In contrast to other cell
types discussed before, mature B cell proliferation and function is not as dependent on the organisms’
zinc status. Hence, the impact of zinc deficiency on B cell maturation and function and its subsequent
impact on the immune system is not as profound as it is in the context of T cells [231]. Zinc signals
itself seem to have no impact on B cell activity in a direct manner. However, zinc deficiency affect B
cell lymphopoiesis in different ways. Following acute zinc deficiency, the B cell compartment is largely
reduced (about 50% to 70%) and the composition of surviving B cells within the B cell compartment
markedly changed [232]. In contrast, chronic zinc deficiency is reported to merely influence T cell
development and B cell development remains sustained [164].
During cellular development, lymphocytes are sensitive for apoptosis signals due to positive and
negative selection mechanisms in the primary lymphoid organs. Mature cells are apoptosis resistant
and getting inactivated in the case of autoreactivity known as anergy. A strict selection guarantees
adequate cellular function, thus avoiding cellular autoreactivity by eliminating the majority of newly
formed cells by apoptosis. Zinc deficiency increases apoptosis within the B cell population and leads
to cell depletion [11,233]. Thus, there are fewer naïve B cells during zinc deficiency that can react
to neoantigens. Contrarily to zinc deficiency, low zinc levels have no influence on the cell cycle
status of precursor B cells and only modest influence on cycling pro-B cells. Taking into account
that T cell numbers are reduced during zinc deficiency as well, and that recognition of most antigens
is T cell dependent, it is probable that the body is unable to respond with antibody production in
response to neoantigens. This assumption is consistent with findings showing a disturbed antibody
production by B cells during zinc depletion [234]. This disturbed feedback mechanism might also
be an explanation for zinc deficient patients, like elderly and hemodialysis patients, showing a
reduced response to vaccination [235–237]. Another possible mechanism impairing adequate immune
responses are epigenetic changes of DNA. The epigenome is highly influenced by environmental
changes, but also by nutrition [238]. Since histone modifying enzymes as histonedeacetylases are
known to be regulated in a zinc-dependent manner [79], the organism’s zinc status is important for
adequate epigenetic modification of DNA.
Studies uncovered B cell activity and antibody production to be impaired during zinc deficiency
respectively leading to higher risk of parasitic infection [239]. On a molecular mechanism this might be
due to diminished STAT6 phosphorylation during zinc deficiency. Hence, zinc signals are important
for proper IL-4 induced STAT6 phosphorylation [77]. Since IL-4 promotes activation of early B
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this mechanism explains the higher risk of parasitic infection during zinc deficiency. Furthermore,
zinc signals are important for IL-6 induced STAT3 phosphorylation shown to be increased due to zinc
deficiency. IL-6 mediates the activation and final differentiation of B cells into plasma cells and IL-6
overproduction is associated with autoantibody production. Diseases such as rheumatoid arthritis and
plasma cell neoplasia go along with reduced serum zinc levels, indicating potential co-effects of IL-6
overproduction and enhanced susceptibility of B cells due to zinc deficiency. Those observations
indicate that a strict regulation and proper zinc homeostasis is necessary to keep the immune
system balanced [77].
Studies reveal that antibody production as consequence to T cell-dependent antigen recognition
is more sensitive to zinc deficiency than antibody production in response to T cell-independent
antigens [240]. Zinc deficient mice show reduced antibody recall responses to antigens they have been
immunized with before. This effect was observed in T cell-independent as well as in T cell-dependent
systems. Thus, immunologic memory also seems to be influenced by zinc [241]. However, mature B
cells still are more resistant to zinc deficiency-induced apoptosis due to high Bcl2 level. Thus,
B cell memory is less affected than the primary response [233]. Homeostatic zinc signals influence
several regulatory proteins, such as those from the Bcl/Bax family [11] and furthermore several
aspects of apoptotic signal transduction. In this connection, the calcium-dependent endonuclease,
which mediates DNA fragmentation, is inhibited by zinc. However, this target is beyond the point
of no return for programmed cell death, and an inhibition could explain a suppression of DNA
fragmentation during apoptosis, but not the effect on cellular survival. Another important group of
enzymes in apoptosis is cysteine-aspartic acid proteases, also known as caspases. Inactive pro-caspases
first are activated by proteolytic cleavage and second form a signaling cascade to transduce initial
apoptotic signals to effector enzymes mediating the organized cellular destruction characteristic for
programmed cell death. Low micromolar zinc concentrations are reported to inhibit caspases-3, -6,
and -8 [242]. A half maximal inhibitory concentration for caspase-3 was found below 10 nM [99].
This value is within the physiological range of free intracellular zinc level, leading to the suggestion
that endogenous zinc can inhibit caspase-3 activity subsequently altering apoptosis signals and cellular
survival. More recently, similar results were observed in an in vivo rat heterotrophic heart transplant
model that might contribute to an increased allograft survival [87].
Even though both cell types of the adaptive immune system utilize the same signaling pathways,
B cell function seems to be affected by zinc to a lesser magnitude. Even the reduced antibody production
during zinc deficiency is based on reduced B cell numbers whereas it remains unaffected on a per-cell
basis [243]. This indicates an effect on cellular development rather than on function. One reason might
be a difference in zinc homeostasis, making mature B cells less susceptible to conditions of limited zinc
availability. Although B cells are highly susceptible to apoptosis during development, and zinc is one
factor that influences these signals, mature B cells can tolerate comparable conditions due to changes
in zinc-regulating proteins, but also by changing the expression patterns of several other factors that
regulate the cellular responsiveness to apoptotic signals. One highly important zinc-regulating protein
in B cells is the zinc importer Zip10.
Zip10 is essential for cell survival during early B-cell development as well as for adequate B-cell
receptor (BCR) signaling [244,245]. A loss of Zip10 during an early B cell stage was reported to
specifically abrogated cell survival. Eventually, this leads to an absence of mature B cells in vivo,
provoking spleno-atrophy and reduced Ig level. Moreover, the absence of Zip10 causes an impaired T
cell-dependent and -independent immune response respectively. Additionally, due to the dysregulated
BCR signaling, mature B cells proliferated poorly in response to BCR crosslinking. On the molecular
level, this is probable due to a disturbed JAK-STAT-Zip10 signaling axis, since the JAK-STAT pathway
is known to modulate expression of Zip10 [244]. Furthermore, a disturbed regulation of the BCR signal
strength is likely. This might be due to the positive regulator function of Zip10 regarding CD45R
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in hyperactivation of tyrosine-protein kinase Lyn that consequently provoke an altered threshold for
BCR signaling [245].
7. Conclusions
Summing up, all immune cells are directly affected by zinc signals. Most prominent pathologic
changes are found during zinc deficiency indicating that zinc is a main regulator of cellular function and
signal transduction. However, precise underlying molecular mechanisms still need to be investigated
in further detail, to guarantee beneficial effects of clinical zinc application to patients suffering of
distinct diseases.
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Abstract: Tuberculosis (TB) is a global epidemic caused by the infection of human macrophages with
the world’s most deadly single bacterial pathogen, Mycobacterium tuberculosis (M.tb). M.tb resides in
a phagosomal niche within macrophages, where trace element concentrations impact the immune
response, bacterial metal metabolism, and bacterial survival. The manipulation of micronutrients
is a critical mechanism of host defense against infection. In particular, the human zinc transporter
Zrt-/Irt-like protein 8 (ZIP8), one of 14 ZIP family members, is important in the flux of divalent
cations, including zinc, into the cytoplasm of macrophages. It also has been observed to exist on the
membrane of cellular organelles, where it can serve as an efflux pump that transports zinc into the
cytosol. ZIP8 is highly inducible in response to M.tb infection of macrophages, and we have observed
its localization to the M.tb phagosome. The expression, localization, and function of ZIP8 and other
divalent cation transporters within macrophages have important implications for TB prevention and
dissemination and warrant further study. In particular, given the importance of zinc as an essential
nutrient required for humans and M.tb, it is not yet clear whether ZIP-guided zinc transport serves as
a host protective factor or, rather, is targeted by M.tb to enable its phagosomal survival.
Keywords: zinc; zinc transporter; tuberculosis; lung; macrophage; innate immunity
1. Introduction
Tuberculosis (TB) is a major cause of global morbidity and mortality. One in three people are
infected with the pathogen responsible for TB, Mycobacterium tuberculosis (M.tb) [1]. Primary infection
is established in the lungs, following inhalation of aerosolized respiratory droplets expelled from
a contagious person [2]. Infection results in clinical latency in most healthy human hosts but may
reemerge as a potentially fatal pneumonia if immune competence is disrupted [3]. M.tb is a facultative
intracellular bacterium of macrophages that gains cellular entry through phagocytosis and resides
within distinctive phagosomes. The successful intraphagosomal survival of M.tb is predicated on its
circumvention of the mechanisms evolved to destroy phagocytosed pathogens [4]. Macrophage trace
element redistribution is a critical host defense strategy against M.tb [5].
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M.tb residence and growth in mononuclear phagocytes depends on its ability to acquire
host-derived nutrients within a suitable range. Macrophages and M.tb compete for control of elemental
cationic micronutrients, which are essential for mycobacterial growth but also toxic at elevated
concentrations [5–7]. The manipulation of trace element flux is the function of many microbial
virulence factors and host immune responses. Due to their charge, cationic micronutrients require
specialized transport mechanisms to penetrate the phospholipid bilayers of both the plasma membrane
and the phagosome. Infection by M.tb alters the battery of membrane spanning ion channels present
in macrophages [8–11]. Clearly a “tug of war” for the control of trace elements between host and
microbe exists, and transmembrane spanning metal ion transporters serve as the primary conduit of
micronutrient biodistribution during infection. Over the past decade, several examples have emerged
and will first be reviewed before a detailed discussion of zinc and zinc transporters.
2. Overview of Metal Metabolism at the Host-Pathogen Interface
The term nutritional immunity was coined to describe the anti-microbial benefits associated with
redistribution of iron from the vascular space to intracellular compartments [12]. However, it has come
to encompass both systemic and cellular nutrient deprivation of multiple trace elements, including
iron, manganese, and zinc, from extracellular or intracellular pathogens. A cadre of innate immune
effector cells mount that response with the production of trace element binding proteins, cellular
importers, and their associated regulatory factors, following pathogen recognition [13]. Macrophages
accumulate iron, copper, and zinc during mycobacterial infection [14].
TB is associated with anemia, which results from macrophage iron retention [15]. Although
protective against extracellular pathogen growth, iron loading of macrophages may be beneficial to M.tb
by providing access to essential nutrition. Impaired access to intracellular labile iron reduces the growth
of M.tb in macrophages from patients with hereditary hemochromatosis [16], a disease that disrupts
iron accumulation due to elevated ferroportin-1 (IREG1) export across the plasma membrane [17].
Macrophages have evolved a complex system of intracellular iron redistribution to counter microbial
exploitation of cellular iron internalization. The primary mechanism of that defense is the modulation
of intraphagosomal iron content. IREG1 is also localized to the mycobacterial phagosome and may
serve to sequester iron away from bacteria [9]. Iron is essential for M.tb growth [18] and enters the M.tb
phagosome from intracellular and extracellular stores [19,20]. It can be captured from transferrin or
lactoferrin by mycobacterial siderophores, including carboxymycobactins and exochelin, or by heme
import [21].
Previously described in detail, macrophage transporters hyper-concentrate trace elements within
the phagosome in order to limit mycobacterial growth [5]. Natural resistance-associated macrophage
protein 1 (NRAMP1) is a proton/divalent cation antiporter [22] with broad substrate specificity,
including iron, zinc, copper, and manganese [23]. Polymorphisms in NRAMP1 are associated with
increased susceptibility to pulmonary tuberculosis [24]. In murine models, NRAMP1 is rapidly
localized to the phagosome [25,26] and is associated with resistance to intracellular pathogens [27].
NRAMP1 actively acidifies the bacterial phagosome in mice [28]. It increases the translocation of
the proton ATPase to the phagosome, following interferon gamma (IFN-γ) activation, leading to
the generation of Fenton-mediated free radical production [29,30]. NRAMP1 is capable of shuttling
metals bi-directionally against a proton gradient, whereby the direction of transport is determined
by proton and divalent cation concentrations [22]. When phagosomal pH and iron levels are lower
than those of the cytoplasm, iron is imported into the phagosome through NRAMP1, resulting in
the generation of reactive oxygen species (ROS) through the Fenton and Haber-Weiss reactions [7,8].
Alternatively, in instances in which intraphagosomal concentrations are higher than those of the
cytosol, NRAMP1 can export iron and manganese and import protons into the phagosome, increasing
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Macrophages also use a strategy involving the phagosomal hyper-concentration of copper [14]
through a separate set of copper transporters [32]. IFN-γ activation of murine macrophages
induces the expression of the plasma membrane copper transporter CTR1, leading to copper uptake.
Subsequent translocation of the copper importer ATP7A to mycobacterial phagosomes leads to
increased intraphagosomal concentrations of copper and thereby generation of bactericidal Fenton free
radicals [10,33]. As a countermeasure, M.tb actively up-regulates the mycobacterial copper transport
protein B (MctB), which rescues it from copper toxicity [34].
3. Regulation of Zinc Balance between Host and Pathogen
The transient hyper-accumulation of zinc in the phagosomes of human macrophages reduces
the survival of phagocytosed extracellular pathogens. Zinc accumulation causes the up-regulation
of bacterial cation efflux pumps, which are critical for the adaptation of intracellular pathogens,
including Salmonella typhimurium and M.tb [35,36]. The mycobacterial manganese efflux pump Metal
cation-transporting p-type ATPase C (CtpC) is required for M.tb survival at high zinc conditions [37].
Although no definitive mechanism for zinc-associated toxicity has yet been identified in these
models, there are several potential avenues through which elevated zinc concentrations may be
toxic to M.tb. Those mechanisms include the displacement of iron from sulfhydryl moieties of
bacterial enzymes [38] or the disruption of manganese uptake, which reduces bacterial free radical
tolerance [39]. The mycobacterial transcriptional repressors Zur and IdeR sense elevations in zinc and
iron, respectively, leading to reduced expression of the gene cluster for the type VII secretion system 6
kDa early secretory antigenic target protein family secretion system-3 (ESX-3) [40,41]. Metal-dependent
suppression of the critical mycobacterial virulence factors EsxG and EsxH in the ESX3 locus thereby
reduces M.tb survival [42].
The mechanism through which zinc traverses macrophage membranes in response to M.tb
infection remains an area of active investigation. Twenty-four dedicated zinc transport proteins
are primarily responsible for zinc biodistribution. Each transporter has distinct induction patterns,
expression profiles, subcellular localization, and tissue distribution, providing each transporter with a
unique role in zinc metabolism. Ten solute carrier 30A (SLC30A) family members, the zinc transport
proteins (ZnTs), remove zinc from the cytoplasm across the plasma membrane or into cytosolic
organelles. Conversely, fourteen solute carrier 39A (SLC39A) family members, the Zrt-Irt-like-Proteins
(ZIPs) move zinc into the cytoplasm from the extracellular environment or out of intracellular
vesicles [43,44]. Individually, some ZIP and ZnT proteins have been shown to traffic other divalent
cations [45–47]. Further, other nondedicated divalent cation transporters have the capacity to transport
zinc, including NRAMP1, IREG1, and divalent metal transporter 1 (DMT1) [23,48,49].
There is constitutive mRNA expression above a threshold of one relative copy number (RCN),
for ZIPs 1, 6, 8, and 10, as well as ZnTs 1, 5, 6, 7, and 9, in resting human monocyte-derived macrophages
(MDMs). The infection of MDMs with virulent M.tb H37Rv for 8 h alters the expression pattern of
several ZIPs and ZnTs, indicating a global disruption of zinc homeostasis (Figure 1A). In RPMI media
supplemented with autologous human serum, infection does not significantly alter the expression of
ZIP1 or 6 but decreases ZnTs 5, 6, and 9 and slightly increases ZnT7. ZnT7 expression has previously
been shown to increase in response to infection by intracellular fungal pathogens [50]. The resting
expression of ZnT1, ZIP8, and ZIP10 is the highest among the 24 zinc transporters. M.tb infection
significantly increases ZnT1 and ZIP8 but decreases ZIP10. Although infection alters the expression
of multiple ZIPs and ZnTs, ZIP8 is unique as it is the sole ZIP zinc importer induced by M.tb in
MDMs. Human alveolar macrophages (hAMs) reside within a unique microenvironmental niche in
the alveolus (gas exchange apparatus) and are the phagocytic cells initially targeted by M.tb during
airborne infection [51]. As might be expected, the resting expression pattern of zinc transporters
in hAMs varies substantially from that of MDMs. There is constitutive mRNA expression above a
threshold of 10 reads per million (RPM), determined as described [52], for ZIPs 1, 4, 7, 8, and 9, as well
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expression. As compared to ZIP8 in MDMs, ZIP1 is the most highly expressed ZIP in resting hAMs,
and its expression is reduced following 72 h of M.tb infection. Additionally, infection results in the
reduced expression of ZIPs 4 and 9 within 24 h, as well as the reduced expression of ZIP7 and ZnT9
after 72 h. ZIP8, ZnT7, and ZnT1 are increased during infection. Although there is a comparative delay
in the induction of ZIP8 expression in hAMs, it again emerges as the most responsive zinc transporter
to M.tb infection. The alterations we observed in ZIP and ZnT expression in each of our in vitro
models likely impact zinc metabolism within particular macrophage subsets in distinct ways, with
each transporter contributing to specific aspects of cumulative cellular zinc flux. The expression profile
of ZIP8 is unique as it has high constitutive expression and is the most responsive zinc transporter to
M.tb infection in MDMs and hAMs. ZIP8 is the only zinc importer increased by M.tb in MDMs and
emerges as the dominant ZIP expressed in hAMs during infection, although ZIPs 12, 13, and 14 do
increase from low resting levels in that model. Overall, the stimulation of ZIP8 expression by M.tb is a
prominent feature of the macrophage response to infection, which should be viewed in the context of a
generalized shift in cellular zinc metabolism.
Figure 1. Macrophage zinc transporter mRNA expression during M.tb infection. Zrt-Irt-like-Protein
(ZIP) and zinc transport protein (ZnT) mRNA expression is altered by infection with
Mycobacterium tuberculosis (M.tb) H37Rv using a multiplicity of infection (MOI) of 5:1 for (A) 8 h
in monocyte-derived macrophages (MDMs) in the absence or presence of ZnSO4 18 μM, as determined
by qRT-PCR relative to GAPDH (n = 3) or (B) for 24 or 72 h in human alveolar macrophages (hAMs)
infected by M.tb H37Rv, as determined by AmpliSeq Transcriptome analysis (n = 6). (C) The mRNA
expression of ZIP8 is increased and ZnT1, ZIP1, and ZIP10 are decreased in M.marinum-infected
zebrafish granulomas compared to resting macrophages, as determined by RNA-Seq. (A and B
are unpublished data; C was generated using supplementary data published in Cronan et al. [53])
(mean ± SEM; *** p < 0.001; **** p < 0.0001; Prism-7: one-tailed Students t-test). MDM [54] and
hAM [55] isolation, culture, and infection with M.tb, as well as the assay of human zinc transporters
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In an important study, Botella et al. [36] revealed that M.tb infection of human macrophages
induces mRNA expression of metallothionein (MT) intracellular zinc binding proteins and ZnT1 by
activating the metal responsive transcription factor MTF-1. Based upon these observations, a model
of ZnT1 phagosomal localization as a mechanism for the hyper-accumulation of vesicular zinc was
proposed [36]. The contribution of phagosomal NRAMP1 relative to increases in zinc should also
be considered [23,25]. The activation of MTF-1 and subsequent MT transcription indicates that zinc
levels also increase within the cytosolic compartment during M.tb infection. In cell culture models
with limited extracellular zinc, MTF-1 transcriptional activation by zinc is likely exclusively due to
intracellular redistribution [36]. Knowing that cellular zinc trafficking within the human physiologic
range, both high and low, is an essential aspect of macrophage metal metabolism, future studies of
zinc flux across the plasma membrane during M.tb infection should include zinc levels that simulate
the human condition. Physiologically relevant zinc supplementation [56] of M.tb-infected MDMs
in vitro alters their mRNA expression profile. The addition of zinc during infection results in the
reduced expression of most zinc transporters (Figure 1A). It reduces the extent of ZIP8 induction
but increases ZnT1 expression and leads to further repression of ZIP1 and ZIP10 in response to
infection. Cumulatively these changes indicate a shift toward cytosolic zinc efflux. The increased
transcriptional activation of ZnT1 [57,58], coupled with the suppression of ZIP10 expression [59]
during supplementation, indicates that the extent of MTF-1 activation in infected macrophages is
dependent on extracellular zinc import.
In a recent study using the zebrafish model of TB pathogenesis, Cronan et al. evaluated the impact
of mycobacterial reprogramming of granuloma macrophages and provided a granuloma-specific
macrophage transcriptomic signature [53]. Parsing of that data revealed that ZIP8 is highly induced
and that ZIP1 and ZIP10 expression is reduced in mycobacterial granulomas (Figure 1C). Surprisingly,
ZnT1 expression is significantly reduced in granuloma macrophages, which may reflect altered zinc
metabolism during mesenchymal-epithelial transition or species-specific differences. However, ZIP8
induction during mycobacterial infection appears to be a critical, evolutionarily conserved response
that is maintained during granuloma formation and among the lineages of human macrophages that
are central to TB pathogenesis (Figure 1A,B).
4. ZIP8 in Macrophage Infection by M.tb
The manipulation of intracellular zinc through altered macrophage zinc transporter expression
impacts the growth of intracellular yeast [60,61], fungal [50,62], and bacterial [35] pathogens.
Zinc redistribution into the bacterial phagosome is Tol-like receptor (TLR)-dependent [35]. TLR4
activation of human macrophages induces the production of ZIP8 through Nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) [63], and M.tb infection transiently induces
NF-κB [55,64]. ZIP8 was discovered due to its production in human monocytes in response to
Mycobacterium bovis Bacillus Calmette Guérin (BCG) cell wall cytoskeletal extract and BCG infection [65].
It is expressed in human macrophages in response to infection with nonpathogenic and virulent
mycobacterial species, including M.tb, as well as to gram-negative and gram-positive bacteria [11].
In particular, MDM infection with virulent M.tb H37Rv results in the robust induction of ZIP8 mRNA
for at least 24 h post infection (Figure 2A). Consistent with our previously published results involving
other cell types [66], ZIP8 induction results in the production of a membrane bound, glycosylated
140 kDa protein. ZIP8 protein in MDMs is elevated within 24 h, following infection with M.tb H37Rv
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Figure 2. ZIP8 protein is induced and localizes with M.tb in human macrophages. MDM production
of ZIP8: (A) mRNA is significantly induced for 24 h, following infection with M.tb H37Rv (MOI 5:1),
as determined by qRT-PCR relative to GAPDH (n = 3) and (B) ZIP8 protein is robustly increased
by infection with M.tb H37Rv or M.bovis BCG (MOI 5:1) between 24 and 72 h, as determined by
Western blot relative to β-actin (n = 3). (C) The infection of MDMs with mCherry expressing M.tb
H37Rv (MOI 5:1) for 48 h leads to the extensive co-localization of ZIP8 with M.tb (yellow; indicated by
arrow heads) and TfR1 (abundant white; in merged upper panel) but very limited co-localization with
LAMP-1 (negligible white; in merged lower panel) (A, B, and C are unpublished data) (mean ± SEM;
* p < 0.05; Prism-7: one-tailed Students t-test). MDM isolation, culture, and infection [54]; qRT-PCR
and Western blot of ZIP8 in MDMs [56]; and confocal fluorescence microscopy using an Olympus
FV1000-Spectral System at 60× magnification in infected MDMs [67] were performed as previously
described. Rabbit polyclonal antiserum anti-peptide to amino acid residues 225 to 243 of human ZIP8
was purchased from Covance (Princeton, NJ, USA). Mouse anti-human monoclonal β-actin (#69101)
antibody was purchased from MP Biomedicals (Santa Ana, CA, USA). Mouse anti-human monoclonal
CD71 (#334102) antibody was purchased from Biolegend (San Diego, CA, USA). Mouse anti-human
monoclonal LAMP-1 (#ab25630) antibody was purchased from Abcam (Cambridge, UK).
Cytosolic zinc import in activated macrophages is ZIP8-dependent [56]. ZIP8 is present on
the plasma membrane and on intracellular vesicles in primary human macrophages, epithelial cells,
T-cells, and cell lines [63,65,66,68,69], indicating a role for ZIP8 in cytosolic cation increase through
cellular influx and vesicular efflux. Viral induced over-expression of ZIP8 in murine chondrocytes
increases MTF-1 nuclear localization and transcriptional activity [70]. Slc39a8 hypomorphic mouse
fetal fibroblasts have reduced MT expression in response to tumor necrosis factor alpha (TNFα) [63],
indicating that ZIP8-dependent zinc increases the transcription of MTF-1 target genes. Furthermore,
ZIP8 regulates ZnT1 expression in primary human macrophages [56]. Based upon these observations,
it is plausible that macrophage zinc loading during M.tb infection [14] is a function of zinc import
through ZIP8, which then leads to observed elevations in macrophage MT and ZnT1 mRNA expression
through the activation of MTF-1.
ZIP8 has multiple glycosylation sites and potential protein-binding partners that may influence
membrane orientation and localization [66,71,72]. Further, zinc deprivation of the bacterial phagosome
in macrophages and dendritic cells through the up-regulation and trafficking of ZIP8 to the
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localization of ZIP8 [63] in relation to early phagosome marker transferrin receptor-1 (TfR1), late
endosome/lysosome marker LAMP-1, and M.tb in macrophages by fluorescence confocal microscopy,
as previously described [67]. We observed that ZIP8 becomes abundant within the phagosome and
co-localizes with M.tb (Figure 2C). Further, the association of ZIP8 and the pathogen is durable
and persists within the phagosome over an extended time frame. Co-localization studies with TfR1
and LAMP-1 indicate that ZIP8 resides primarily within the phagosome, akin to TfR1, and not the
phagolysosome in macrophages (Figure 2C). In consideration of the zinc-poisoning paradigm that was
previously highlighted, this result indicates a potential role for ZIP8 in both macrophage zinc loading
and eventual phagosomal detoxification, following the initial super-concentration of vacuolar zinc that
has been observed within 24 h of infection [14,36]. The coordination of zinc efflux through the paired
induction of M.tb CtpC and macrophage ZIP8 expression may generate a complimentary safeguard
in favor of M.tb against zinc poisoning. In this context, the induction of ZIP8 expression during M.tb
infection may serve as a host susceptibility factor.
Alternatively, it is important to consider that all microbes require zinc for survival [74] and that
zinc at appropriate concentrations enhances mycobacterial growth [75]. Zinc has the capacity to
interact with many proteins in both eukaryotic and prokaryotic cells. The antioxidant properties of
zinc afford the protection of vulnerable sulfhydryl groups from damage by ROS [76], which are akin to
those generated by high phagosomal concentrations of iron [8] or copper [34]. Thus, high phagosomal
zinc concentrations may actually benefit M.tb in some regards by enhancing access and limiting the
damage incurred from free radical production by other trace elements. Therefore the ZIP8-dependent
sequestration of zinc away from M.tb, as with intracellular fungal pathogens [50,62], may actually have
some host protective effects.
Cation transport by ZIP8 is pH dependent and electroneutral, indicating that it facilitates the
co-transport of other ionic species as well [47,69,71]. ZIP8 participates in the cytosolic influx of
manganese, cadmium, iron, zinc, and selenite [71,77]. Iron and zinc inhibit the ZIP8-mediated uptake
of each other [69]. ZIP proteins contain binuclear metal centers, where metal binding at one site affects
the transporter metal selectivity at the second site [78]. Zinc uptake by ZIP8 is competitively inhibited
by both iron and cadmium and non-competitively by cobalt, nickel, and copper but is not inhibited by
magnesium or manganese [79]. Given that ZIP8 has a relatively high substrate promiscuity, along with
a directional transport and localization profile, it is reasonable to expect that, in combination with other
metal transporters, ZIP8 contributes to the flux of multiple divalent cations toward and or away from
M.tb across a number of macrophage membranes, including the mycobacterial phagosome (Figure 3).
ZIP8 and NRAMP1 share multiple substrates, raising the possibility that there may also exist
dynamic interplay between the two transporters on the M.tb phagosome for the regulation of iron and
zinc. Further, iron and zinc within the phagosome may antagonize the transport of one another in a
similar way to what occurs in the intestine [80]. ZIP8-dependent iron transport across the phagosomal
membrane has the potential to contribute to the previously proposed models of phagosomal iron
deprivation [15], involving other transporters such as NRAMP1 [30] or IREG1 [9]. That efflux
could counteract the host protective iron-dependent generation of intraphagosomal ROS [8]. ZIP8
activity is pH dependent and potentially drives bicarbonate flux [46]; therefore, it may also impact
intraphagosomal pH, which is critical to the maintenance of the intracellular mycobacterial niche [81].
Ultimately the impact of ZIP8 on mycobacterial growth and survival within the M.tb phagosome
depends on a complex array of variables, including but not limited to host nutritional status and
genetic variation [82–84], and the co-expression and localization of other trace element transporters,
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Figure 3. The hypothetical impact of ZIP8 on MTF-1 expression, as well as the localization and
direction of trace element transport in macrophages during early infection with M.tb. Arrows indicate
the direction of trace element transport.
5. Implications of ZIP8 Induction on TB
ZIP8 expression is highly induced in human and murine tissues and circulating cells during
systemic and local inflammation [70,85–87]. The increased intracellular sequestration of zinc, similar
to iron, is a mechanism of nutritional immunity in which vascular trace element deprivation limits the
extracellular growth of invading pathogens [12]. Zinc, as a vital commodity in times of need, is also
therefore redirected to biosynthetic processes that bolster host immune defense. Zinc mobilization
from the vasculature into the vital organs predominantly occurs due to ZIP14 induction in the liver [88].
Our group and others have shown that several ZIPs are involved in zinc redistribution into vital
organs other than the liver, which is in part due to sequestration of zinc folowing ZIP8 [63], as well as
ZIP14 [89] induction in tissue macrophages. ZIP8 is elevated in circulating peripheral blood monocytes
during the acute phase response, which is associated with reduced serum zinc concentrations [86].
Similarly, circulating levels of zinc in plasma or serum are reduced in patients with active TB [90–92].
In time, zinc levels recover with antibiotic therapy in the absence of zinc supplementation [90,93],
indicating that, similar to iron, the intracellular redistribution of vascular zinc occurs in TB. Based on
this and our findings, we propose that the ZIP8-dependent iron and zinc loading of macrophages is
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A balance between pro-inflammatory and immune suppressive cytokines is critical for the
control of M.tb [94,95]. ZIP8 activity modulates the inflammatory response as an intracellular second
messenger, thereby altering the production of pro-inflammatory cytokines and IL-10 [56,63,68,70].
IL-10 is an important immune modulator during M.tb infection. It is associated with TB progression [96]
and reactivation [97] in murine models and reduced macrophage host defense capabilities [98–100]
or, alternatively, may enhance the control of the infection [101]. ZIP8-dependent zinc import skews
cytokine signaling towards a pro-inflammatory profile in activated macrophages, particularly through
the inhibition of IL-10 production [56]. Conversely, in activated monocytes, ZIP8 induction leads
to negative feedback inhibition of NF-κB and the reduction of pro-inflammatory cytokines [63] that,
at balanced levels, are critical for the control of M.tb [4]. Further investigations are needed to clarify
the impact of ZIP8 on cytokine responses in TB.
Observations that M.tb infection increases macrophage intracellular zinc accumulation, leading
to MTF-1 nuclear localization and transcriptional activity 24 h after infection [36], are likely due,
in part, to ZIP8-dependent zinc influx. In a murine Slc39a8 floxed; Col2a1-Cre chondrocyte-specific
ZIP8 knockout model, ZIP8-dependent zinc increased intracellular zinc concentrations and the
MTF-1 dependent transcription of matrix metalloproteinases (MMPs) during inflammation [70].
Subsequent MMP activity resulted in the degradation of the surrounding tissue. M.tb infection
induces MMP production by macrophages and surrounding cells, which results in pulmonary tissue
destruction [102,103]. In animal models, during the early phase of mycobacterial granuloma formation,
MMP release enhances macrophage recruitment to the site of infection [104], which is associated
with increased macrophage infection and dissemination [105]. Furthermore MMP catalytic activity
and function requires zinc [106]. The antibiotic doxycycline is the only known Food and Drug
Administration-approved MMP inhibitor and has been suggested as an adjunct antibiotic therapy
because it reduces M.tb growth in vitro and in vivo [107]. In light of these findings, it is intriguing to
speculate that ZIP8 induction and subsequent zinc influx increases susceptibility to M.tb by driving
the MTF-1 transcription of MMPs, resulting in tissue destruction, increased macrophage recruitment,
and bacterial growth.
ZIP8 is an interesting target for host-directed pharmacotherapy for the treatment and prevention
of TB. To our knowledge, there are no specifically targeted pharmacological antagonists or agonists of
ZIP transporters currently available. If the induction of ZIP8 is confirmed to be a pathogenic process
during mycobacterial infection, the development of small molecule inhibitors or biopharmaceuticals
could prove valuable. However, within the framework of global zinc homeostasis, the selective
targeting of ZIP8 may have myriad effects. Alternatively, a strategy of zinc supplementation in an
effort to nullify the potential antagonism of zinc poisoning by phagosomal ZIP8 could have some
utility as a preventative therapy for high risk populations, although, to date, zinc supplementation has
not been shown to have clinical benefit during active TB [108].
6. Conclusions
Tuberculosis is the world’s most deadly infectious disease caused by a single pathogen. Globally
it is estimated that over 10 million people are infected with M.tb every year. Unfortunately, TB
treatment is limited by lack of universal availability of effective medications, drug toxicity, and
lack of compliance, the last resulting in the increasing incidence of multiple drug resistant strains.
This is further complicated because individuals with chronically depressed immunity have a much
higher risk of developing TB [1]. Zinc deficiency is a major cause of immune dysfunction and
infection [109]. M.tb infection influences human zinc metabolism. Understanding the complexities
of macrophage responses to M.tb is particularly important, given its substantial impact on global
human health. An alteration in the trafficking of divalent cations is an established host defense strategy
against extracellular and intracellular pathogens, including M.tb. Multiple metal binding proteins
and transporters contribute to those responses. ZIP8 is induced in response to M.tb infection and
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with other established cation transporters, ZIP8 may be positioned in the phagosome to render a
fundamentally important impact on macrophage host defense and TB pathogenesis. Further, ZIP8
has been shown to have potent immunomodulatory functions that are influenced by systemic and
cellular zinc status. The impact of zinc metabolism on macrophage host defense functions during M.tb
infection remains an underexplored area of research with promising potential for the generation of
translationally applicable future findings.
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NRAMP1 Natural resistance-associated macrophage protein 1
IFN-γ Interferon gamma
ROS Reactive oxygen species
CTR1 High affinity copper uptake protein-1
ATP7A ATPase copper transporting alpha
MctB Mycobacterial copper transport protein B
CtpC Metal cation-transporting p-type ATPase C
Zur Zinc uptake repressor
IdeR Iron-dependent repressor
ESX-3 6 kDa early secretory antigenic target protein family secretion system-3
EsxG ESAT-6-like protein G
EsxH ESAT-6-like protein H
ZnT Zinc transport protein
DMT1 Divalent metal transporter 1
MDM Monocyte-derived macrophage
hAM Human alveolar macrophage
MT Metallothionein
MTF-1 Metal responsive transcription factor-1
TLR Tol-like receptor
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
BCG Mycobacterium bovis Bacillus Calmette Guérin
kDa kiloDalton
qRT-PCR Quantitative Real-Time polymerase chain reaction
MOI Multiplicity of infection
TfR1 Transferrin receptor-1
LAMP-1 Lysosome-associated membrane protein-1
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Abstract: Zinc plays an important role in biological systems as bound and histochemically reactive
labile Zn2+. Although Zn2+ concentration is in the nM range in cardiomyocytes at rest and increases
dramatically under stimulation, very little is known about precise mechanisms controlling the
intracellular distribution of Zn2+ and its variations during cardiac function. Recent studies are
focused on molecular and cellular aspects of labile Zn2+ and its homeostasis in mammalian cells
and growing evidence clarified the molecular mechanisms underlying Zn2+-diverse functions in
the heart, leading to the discovery of novel physiological functions of labile Zn2+ in parallel to the
discovery of subcellular localization of Zn2+-transporters in cardiomyocytes. Additionally, important
experimental data suggest a central role of intracellular labile Zn2+ in excitation-contraction coupling
in cardiomyocytes by shaping Ca2+ dynamics. Cellular labile Zn2+ is tightly regulated against
its adverse effects through either Zn2+-transporters, Zn2+-binding molecules or Zn2+-sensors, and,
therefore plays a critical role in cellular signaling pathways. The present review summarizes the
current understanding of the physiological role of cellular labile Zn2+ distribution in cardiomyocytes
and how a remodeling of cellular Zn2+-homeostasis can be important in proper cell function
with Zn2+-transporters under hyperglycemia. We also emphasize the recent investigations on
Zn2+-transporter functions from the standpoint of human heart health to diseases together with their
clinical interest as target proteins in the heart under pathological condition, such as diabetes.
Keywords: zinc transporters; intracellular labile zinc; heart failure; endoplasmic reticulum stress;
left ventricle
1. Introduction
Zinc is a redox inactive element and presents in almost all biological tissues. Zinc is accepted
to be a component of antioxidant defense system and contributes to maintain the cell redox balance
through different mechanisms [1]. There is a close relation between cellular labile zinc (Zn2+),
endogenous processes, and biological macromolecules under physiological condition, mainly due
to its unique property being their structural component or major regulator of macromolecules [2].
Labile Zn2+ plays an important role as a signaling molecule in large number of cells and tissues
being a constituent of many proteins and enzymes in human body [3–5]. For this reason, even mild
zinc-deficiency may impact numerous aspects of human health, including heart function [6]. Although
Zn2+ has traditionally been regarded as relatively nontoxic, recent studies have shown how high
intracellular labile Zn2+ level ([Zn2+]i) can be a potent killer of numerous cell types [7] including
cardiomyocytes [8–10]. In cardiomyocytes, [Zn2+]i is measured to be less than one nanomolar under
physiological conditions being much less than the intracellular free Ca2+ ([Ca2+]i) [8,11]. Moreover,
oxidants caused about 30-fold increase in [Zn2+]i but only 2-fold in [Ca2+]i in cardiomyocytes [8].
Therefore, any increase in [Zn2+]i may be much more toxic biologically than is generally realized.
Furthermore, any evolution of biomolecules to scavenge [Zn2+]i is crucially important in ameliorating
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the cellular toxicity. Supporting these above statements, early studies showed that any disruption
in [Zn2+]i homeostasis could be associated with severe disorders, including injuries to cardiac
tissues [6,12]. Another interesting action of [Zn2+]i has been shown its insulino-mimetic activity
in diabetic patients [13].
It has been shown that [Zn2+]i in mammalian cardiomyocytes plays an important role in
excitation-contraction coupling [8,9] and in excitation-transcription coupling [14]. In mammalian
cells, [Zn2+]i homeostasis is regulated with different ways. Mainly, cellular [Zn2+]i is controlled
via its pools. It can be released from metalloproteins (a structural component) or metalloenzymes
(a cofactor) under pathological conditions. As up to 15% of the total cellular zinc can be bound to
metallothioneins (MT), they can represent a significant pool of Zn2+ [15,16]. Other type storage for
Zn2+ is intracellular compartments such as organelles and vesicles. Zn2+ transport is mediated by
Zn2+-dependent proteins, named Zn2+ transporters, which are localized to both sarcolemma and
intracellular membranes [17,18]. MTs and two Zn2+ transporter families, solute carrier 39A [SLC39A]
or Zrt-, Irt-like proteins 7ZIPs and solute carrier 30A (SLC30A) or ZnTs play crucial roles to maintain
the cellular Zn2+ homeostasis [19–23]. Although there are many recent very good review articles
focused on recent progress to describe the physiological and biological functions of ZIP and ZnT
transporters and provided a better understanding of Zn2+ biology, in here, we aimed to review the
recent data on Zn2+ signaling by Zn2+ transporters in the heart under physiological and pathological
conditions, and therefore, to update our current understanding on the role of cellular [Zn2+]i regulation
in heart function.
2. Role of Zinc in Human Health
Zinc, as one of important micronutrients in human nutrition, has very prominent role in
the maintenance of tissue functions. As mentioned in a number of studies and review articles,
its recognition for biological systems mostly depends on its being an essential component of many
enzymes and its role in many physiological or metabolic processes in the mammalian body due to
it being the most abundant intracellular metal ion found in cytosol, vesicles, organelles, and in the
nucleus [2–4,7,24–30]. Therefore, trace element zinc has greatly attracted the attention of biological
scientists for its importance in clinical medicine. Furthermore, its role in several nutritional disorders
has been clearly established [2,31–34]. Although the demonstration of zinc essentiality for the growth
of Aspergillus niger is very early in the literature [35], a recognition of its importance for the growth
of plants and animals was not appreciated until the 1950–60s, what was considered improbable until
1960. It was believed that this element could be toxic if it was over its physiological level with high
zinc intakes [36–38], although zinc was essential for human health and that its deficiency in humans
would never occur [39].
Although Zn2+ is the most abundant intracellular metal ion found in cytosol, vesicles, organelles,
and in the nucleus of mammalian cells including cardiomyocytes [11,40], even a small deficiency is a
disaster to human health due to the number of biological dysfunctions [39]. In the literature, there are
about 7000 articles searched using the key words “zinc deficiency and humans.” However, there is
an early study on this topic published in Nature related with role of zinc deficiency in fruit trees in
Britain by Bold C et al. [41]. Following this work, most studies were performed in animals, until
the first observation in humans by Prasad et al. [39]. Important roles of Zn2+ associated with health
implications and pharmacological targets have evoked further interest regarding its status in human
health and nutrition.
Several review articles besides original works emphasized the central role of zinc content in human
health starting from maternal period using documents from both underdeveloped and developing
countries [27]. Zinc deficiency in humans seems to be widespread throughout the world. Generally,
it is assumed that zinc deficiency in humans is due to inadequate dietary intake, gut malabsorption,
or defective metabolism whereas at the cellular level, decrease zinc level can be caused a large series of
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that there are conflicting results associated with zinc deficiency and related symptoms in different
populations [42–44]. Moreover, some studies showed a positive correlation between serum zinc and
type 2 diabetes risks in either middle-aged and older Finnish men or the Norwegian population as
well as in development of liver fibrosis in the Miami adults [45–48]. Additionally, Kunutsor and
Laukkanen [49] performed a population-based cohort study in the same country and, due to their
data, they suggested that a higher serum zinc concentration is positively and independently associated
with incident hypertension in men. However, clinical diagnosis of marginal zinc deficiency in humans
remains problematic [50].
It is now well accepted that a well-controlled Zn2+ homeostasis via Zn2+ regulatory mechanisms
can control influx/efflux of zinc to prevent toxic zinc accumulation into cells, particularly
endogenous labile Zn2+ plays a significant role in cytotoxic events at single cell level, including
cardiomyocytes [8–10,40,51]. As mentioned in many articles, Zn2+ is essential for growth and
development for both plants and mammalians. At the cellular level, it is critically involved in
proliferation, differentiation, and apoptosis [52–56]. Indeed, Zn2+ was known as relatively harmless
comparison to several other metal ions with similar chemical properties, while there is not much
interest to Zn2+ toxicity in biological systems although it has been known to be hazard in industrial
aspects [36,57,58]. It is believed that overt symptoms of zinc toxicity require its large amount ingestion
by the body. On the other hand, it has been known how zinc compounds as supplementary agents in
daily diets are important for humans, particularly under some special conditions.
However, there are still widespread controversies and ambiguities with respect to the toxic effects
and mechanisms of excess zinc in humans. Authors using different zinc-compounds, particularly
metallic nanoparticles including zinc, demonstrated that the solubility and the size of zinc compounds
have a major role in the induced toxic responses, whereas uptake of their large ones inside the cells was
likely to play a key role in the detected cell cycle arrest [59]. In a recent interesting study demonstrated
another important role of heavy metals including zinc in pathological biomineralization of cancer
tissue due to their important roles in morphogenesis of tumors considering their ability to enter into
covalent bonds with calcium salt molecules. Romanjuk et al. [60] examined the role of microelements
in breast cancer calcifications. Their data demonstrated how excess heavy metals (such as iron,
copper, chromium, and nickel) in the body could lead to pathologies in the tissues/organs, at most,
via progressively increasing rate of degenerative/necrotic alterations. However, Hoang et al. [61]
discussed in a widespread manner how zinc is an important metal as a possible preventive and
therapeutic agent in pancreatic, prostate, and breast cancer in humans.
As summary of this part, the body zinc level in humans as well as zinc intake with nutrition,
are receiving increasing attention, also due to its putative role in the development of different
pathological conditions, there are serious conflicts between publications.
3. Labile Zn2+ in Cardiac Physiology and Pathology
As discussed in many review articles, zinc is a vital nutrient for human health via its incredibly
important roles in physiology and pathology of many organ functions, at most, due to its important
roles in proteins and enzymes [62–64]. As a consequence, zinc is required for the function of organs,
including the heart. Furthermore, impairment of Zn2+ homeostasis is associated with a variety of health
problems such as cardiovascular disorders [65–68]. Previously, several authors have documented the
importance of zinc in cardiovascular function and diseases in many good review articles [1,66,69–73].
In these articles, it has been focused on the critical role of intracellular labile Zn2+ in the redox
signaling pathway, where certain triggers lead to release of Zn2+ from proteins/intracellular pools and
cause myocardial damage [8,14,40,51,74]. Thus, the area of Zn2+-homeostasis seems to be emerging
in cardiovascular disease. However, it has been demonstrated that labile Zn2+ outside a narrow
concentration range are toxic to a variety of cells [69], including cardiomyocytes [8–10,14,40,51,75].
It has been known, at cellular levels, that certain pathological conditions including hyperglycemia
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with the redox-state of the cells. Among these changes, the alterations in the voltage-dependent ionic
channels, ion transporters and some ion exchanges [76]. Similar to [Ca2+]i homeostasis, any alteration
in [Zn2+]i-homeostasis, including redox-status of the cells under hyperglycemia, can be involved in
development of cardiac dysfunction [8,9,77–81]. In that regard, it is clear that a well-controlled
redox-status in cardiomyocytes can be very beneficial, in part, via mediation of either [Ca2+]i
homeostasis, [Zn2+]i homeostasis or both for a cardioprotective approach in diabetic cardiomyopathy
as well as other pathologies in patients with heart disease [51,82]. Therefore, it can be suggested that
a well-controlled regulation of [Zn2+]i homeostasis at cellular level, similar to [Ca2+]i homeostasis,
can have important strategy to protect heart against redox-unbalanced pathologies [12]. In this
regard, in an early study by Kamalov et al. [83], it has been mentioned that [Zn2+]i/[Ca2+]i ratio
in cardiomyocytes and mitochondria have optimal ranges, having important roles to control the
redox-status as well as oxidative stress status of cells. As shown in many articles, any enhancement of
antioxidant defenses in cells are providing benefits against these pathological conditions, including
the control of [Zn2+]i associated control of [Ca2+]i homeostasis, particularly, via RyR2 [40,51,82,84,85].
As summary, ours and others’ studies have documented that, at tissue level, [Zn2+]i-homeostasis
in heart is impaired by different signaling mechanisms, including oxidative stress in the heart, and
thereby, plays important role in the pathogenesis of myocardial injury. Our current understanding of
the roles of [Zn2+]i homeostasis and [Zn2+]i signaling in human myocardial injury is yet limited under
any pathological stimulus.
The importance and complexity of Zn2+ action has been presumed to parallel the degree of Ca2+’s
participation in cellular processes [9,51,72,86]. At cellular level, Zn2+ homeostasis is regulated through
Zn2+ transporters, Zn2+-binding molecules, and Zn2+ sensors. Interestingly, most of studies related
with the role of intracellular labile Zn2+ in cell function are associated with its toxicity, most probably,
due to its service as an important secondary messenger in various intracellular signal transduction
pathways [79,87].
As mentioned, in previous paragraphs, the cellular toxicity of exogenous and a redox-inert
labile Zn2+ is characterized generally by cellular responses such as mitochondrial dysfunction,
elevated production of reactive oxygen species/reactive nitrogen species ROS/RNS, loss of signaling
quiescence leading to apoptosis in cells, cell death and increased expression of adaptive and
inflammatory genes [2,4–6,8,9,14,23,88]. Central to the molecular effects of Zn2+ are its interactions
with cysteinyl-thiols of proteins, which alter their functionality by modulating their reactivity and
participation in redox reactions, as well as its a cis-acting element that is the binding site for
metal-responsive transcription factor-1 (MTF-1). When cytosolic labile Zn2+ is increased, it can lead
to an increase in MTF-1 activity, which in turn leads to an increase in activation of MTF-1 target
genes [8,9,51,78,89].
Ongoing studies together with early studies demonstrated that both Zn2+ deficiency and excess
are detrimental to cells, causing growth retardation, important metabolic disorders and, particularly,
inducing an impaired excitation-contraction cycling in cardiomyocytes [8,9,14,90]. Although total
cellular Zn2+ is about 200 μM, the cytosolic labile [Zn2+]i in cardiomyocytes is less than 1 nM under
physiological conditions [8,11], whereas it can increase either ~30-fold with acute oxidant exposure or
~2-fold under chronic hyperglycemia [8,9,51]. Therefore, in general, not only can Zn2+ deficiency be
detrimental, causing depressed growth and serious metabolic disorders, but excess Zn2+ can also be
toxic to many cells [8,70,91,92].
4. Role of Cellular Labile Zn2+ in Electrical Properties of Cardiomyocytes
It is well accepted that a controlled Ca2+ signaling is key essential mechanism for regular function
of cardiomyocytes. As mentioned in Section 3, the intracellular Ca2+ accumulation induced by
increased production of ROS can cause injury and dysfunction of cardiomyocytes [93–95].
The sarcoplasmic reticulum (SR) is a main intracellular Ca2+ store in cardiomyocytes and
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signaling. These SR Ca2+ release channels contain many cysteine residues in their regulatory domain
and putative Ca2+ pore region. These residues are susceptible to modification by oxidants [94,96,97].
Supporting the previous data, Woodier and co-workers [98] demonstrated nicely how cytosolic
Zn2+ can act as a high affinity activator of RyR2 while their experimental approach enabled the
study of RyR2 function under tight control of the chemical environment. Importantly, it has been
widely discussed later how Zn2+ at 1 nM concentration has an ability to directly activate RyR2,
which have a much higher affinity for Zn2+ than Ca2+ (about three-fold) [99]. Moreover, their
data provided important information on the role of Zn2+ on RyR2 modulatory function in the
absence of Ca2+ and presented a paradigm shift in our general understanding RyR2 activation during
excitation-contraction coupling. Therefore, the already known data together with these new data
provided an important mechanistic explanation associated with [Zn2+]i dishomeostasis and certain
cardiomyopathies, including diabetic cardiomyopathy [51,82,98,99].
In our early study, we, for the time, have shown that the intracellular labile Zn2+ level, [Zn2+]i in
rabbit cardiomyocytes, is less than 1 nM in physiological conditions [8], about 100-fold less than
[Ca2+]i. At various concentrations, labile Zn2+ leads to the release of toxic ROS [79]. More importantly,
our data demonstrated that [Zn2+]i was increased markedly (about 30-fold but only doubled [Ca2+]i)
with thiol-reactive oxidants and contributed to oxidant-induced alterations of excitation-contraction
coupling ECC under in vitro conditions. Therefore, that information emphasized the importance
of [Zn2+]i measurement such as, how it could lead to significant overestimation of [Ca2+]i, if it
was overlooked [8]. In later studies, under in vivo conditions, [Zn2+]i was increased by 70% in
diabetes [51,78] and over 200% in aldosteronism [100]. Interestingly, Xie and Zhu [101] aimed to
understand better the modulation of RyR2s during oxidative stress and showed how RyR2 in rat
ventricular myocytes was modulated biphasically by sulfhydryl oxidation, contribution of increased
[Zn2+]i besides increased [Ca2+]i.
Although it has been shown the resting level of [Zn2+]i in cardiomyocytes, there was very
little information about precise mechanisms controlling intracellular distribution of Zn2+ and its
variations during cardiac function. Therefore, we aimed to investigate the rapid changes in Zn2+
homeostasis in detailed and using the Zn2+-specific fluorescent dye, FluoZin-3, in comparison to
Ca2+-dependent Fluo-3 fluorescence, we, for the first time, vizualised the existence of Zn2+ sparks and
Zn2+ transients, in quiescent and electrically-stimulated cardiomyocytes, similarly to known rapid Ca2+
changes, while both Zn2+ sparks and Zn2+ transients required Ca2+ entry [9]. Inhibiting the SR-Ca2+
release, or increasing the Ca2+ load in a low-Na+ solution, suppressed or increased Zn2+ movements,
respectively. Moreover, oxidation by H2O2 facilitated, and acidic pH inhibited the Ca2+-dependent
Zn2+ release in freshy isolated rat ventricular cardiomyocytes.
In historical background, studies show that most experimental studies on the role of [Zn2+]i were
performed in nervous system, at most, due to the localization of Zn2+ in nerve terminals and synaptic
vesicles of excitatory neurons in the central nervous system [102,103]. The [Zn2+]i homeostasis in
mammalian cells results from a coordinated regulation by different proteins involved in the uptake,
excretion, and intracellular storage/trafficking of Zn2+ [104]. It has been shown the Zn2+ influx via
the L-type Ca2+ channels in heart cells [8,14,75] while it was via L-type and N-type Ca2+ channels
in neurons [105]. As can be seen in Figure 1, here, we reinvestigated the effects of extracellular and
intracellular Zn2+ on the L-type Ca2+ current. In the presence of external Ca2+, the L-type Ca2+ current
is inhibited by external Zn2+ (ZnCl2) and intracellular Zn2+ loading (with Zn2+-pyrithione, ZnPT) also
reduces the L-type Ca2+ current as a concentration- and time-dependent manner (Figure 1A). Although
both effects are washable, the intracellular Zn2+ loading induced a marked leftward shift in inactivation
of the channels (Figure 1C) without any effect under external Zn2+ exposure (Figure 1B). Similar to
ours, Alvarez-Collazo et al. [106] demonstrated the modulation of transmembrane Ca2+ movements
and their regulation by β-adrenergic stimulation with both basal intracellular and extracellular Zn2+,
emphasizing the importance of well-controlled cellular [Zn2+]i-homeostasis for prevention/treatment
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L-type Ca2+ current are inhibited by excess external Zn2+ via inhibition of N-methyl-D-aspartate
(NMDA) receptors. Although the exact underlying mechanisms of Zn2+ effects are not clear yet,
surface charge effects could be invoked to explain some of the Zn2+ actions. However, as for other
divalent metal cations, most of the effects of Zn2+ could be well explained by changes in the gating of
ion channels [108–110] that we have shown in Figure 1 similar to our previous data [75]. Furthermore,
squid K+ channels are far more sensitive to Zn2+ than Na+ channels but the interactions of Zn2+
with gating charges appear similar in both cases [109]. In that regard, Aras [111] reported that,
during sublethal ischemia, the early rise in neuronal Zn2+, preceding the rise in intracellular Ca2+,
was responsible for the hyperpolarizing shift in the voltage dependency of the delayed rectifier
Kv2.1 channels.
Figure 1. A patch-clamp study on the time course of L-type Ca2+-current (ICa), depressed by Zn2+
exposed either extracellulary (ZnCl2) or intracellularly (i.e., loaded with Zn2+-ionophore pyrithione,
ZnPT). (A) The ICa was evoked at 0 mV from a holding potential −80 mV and ICa was recorded in
the presence of either ZnCl2 (10 and 100 μM) or ZnPT (1 and 10 μM) in whole-cell patch-clamped
ventricular cardiomyocytes in the presence of 1.8 mM external Ca2+. WO represents the washout of
applications. Corresponding availability curves of the ICa by either ZnCl2 (B) or ZnPT (C). Note about
10 mV left-shift by ZnPT application in availability curve of ICa.
Labile Zn2+, with even picomolar concentrations, modulates many cellular processes via either
inhibiting or activating many proteins, enzymes, kinases and phosphatases, particularly, at Ser/Thr
or Tyr sites [2,29,112–114]. Therefore, these findings indicate clearly that cellular labile Zn2+ level has
critical importance for cellular physiological function besides its physiopathological or toxicological
role, and strongly suggest its modulatory activity of signal transduction processes [106,115].
Furthermore, it is known that fluctuations of [Zn2+]i participate in important cellular functions of
not only breast cancer cells [116] but also mammalian cardiomyocyte [51,82,89]. In diabetic rat heart,
an important actor in contractile machinery family, RyR2 and its accessory kinases protein kinase
A (PKA) and calmodulin-dependent protein kinase II (CaMKII) are phosphorylated, significantly,
at most, due to increased oxidative stress via increased [Zn2+]i. Interestingly, these changes could
be prevented with antioxidant treatment under either in vivo or in vitro conditions. Indeed, either
excess Zn2+ exposure to cardiomyocytes or labile Zn2+ loading of cardiomyocytes with zinc-ionophore
could induce marked phoshorylation in RyR2, PKA and CaMKII as well as transcription factors such
as nuclear factor κB (NFκB) and glycogen synthase kinase-3 (GSK) and other endogenous actors
such as protein kinase B also known as Akt [89]. Parallel to our data, it has been shown that labile
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of cAMP synthesis in N18TG2 cells [117], and, by preventing guanosine-5'-triphosphate (GTP)
binding to the GTPase [118]. Also, in the presence of Ca2+ and calmodulin, increasing concentrations
(in micromolars) of Zn2+ caused a progressive inhibition of substrate phosphorylation by CaMKII
such as to produce a concentration-dependent inhibition of phospholamban phosphorylation [119].
However, Yi and coworkers [120] examined the role of extracellular Zn2+ exposure on cardiomyocyte
contraction-relaxation function by using molecular and cellular techniques and showed that RyR2
and phospholamban were markedly dephosphorylated after permeating the hearts with 50 μM Zn2+.
The different results associated with RyR2 phosphorylation level with Zn2+-exposures, most probably
depending on the differences between Zn2+-exposure periods. One group experiments were performed
in hours, while others in minutes.
Recently, since M-type (Kv7, KCNQ) potassium channels are important for the control of the
excitability of neurons and muscle cells, Gao et al. [121] studied the effect of intracellular labile Zn2+ on
M-type (Kv7, KCNQ) K+-channels. Their results reported that [Zn2+]i directly and reversibly augments
the activity of recombinant and native M channels, being mechanistically distinct from the known
redox-dependent KCNQ channel potentiation.
Taken into consideration the facts of [Zn2+]i in many cell types such as operation of many
physiological and pathological mechanisms of cell excitation via the suppression of activity or
expression of ion-channels, transporters, pumps, and receptors or pharmacological augmentation
of their activities as a recognized strategy for the treatment of hyper-excitability disorders, it would
be very helpful to understand well the action of [Zn2+]i in cardiomyocytes. However, physiological
mechanisms resulting in ionic channel potentiation are rare. As short due to already known data,
a large amount of Zn2+-proteins that are modulated by or contain Zn2+ can directly or indirectly
affect the many cellular processes, at most, due to labile Zn2+ action on cell redox-balance [9,76].
At the cellular level, the effects of labile Zn2+ in cardiomyocytes via its action in membrane receptors,
transporters and ionic channels as well as endogenous accessory proteins of contractile machinery and
some transcription factors are summarized in Tables 1 and 2, respectively.
Table 1. Effect of excess Zn2+ on cardiomyocyte electrical and mechanical activity.
Parameters Excess Zn2+ Parameters Excess Zn2+
Electrical activity Mechanical activity
Resting membrane potential ↔ Muscle Contraction ↓
Action potential duration (APD)







Ca2+ transients ↓ Time to peak contraction ↔
L-type Ca2+ currents ↓ Time at 50% of relaxation ↔
Mitochondrial membrane potential ↑
Arrows represent the increased (↑) decreased (↓) or unchanged (↔) electrical and mechanical activity as time or
amplitude of the parameters.
Table 2. Effects of excess Zn2+ on biochemical and ultrastructural parameters in cardiomycoytes.
Parameters Excess Zn2+ Parameters Excess Zn2+
Biochemical parameters
pRyR2/RyR2 ↑ Promyelocytic leukemia(PML) ↑
pPKA/PKA ↑ Bcl-2/BAX ↓
FK506-binding protein(FKBP12.6) ↔ pAkt/Akt ↑
pCaMKII/CaMKII ↑ pNFκB/NFκB ↑
Calregulin ↑ pGSK/GSK ↑
Glucose regulated protein (GRP78) ↑
Ultrastructure parameters
Morphological changes in mitochondria ↑ Electron density of Z-lines ↓
Number of lysosomes ↑
Arrows represent the increased (↑), decreased (↓), or unchanged (↔) protein expression levels in biochemical
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5. Labile Zn2+ Pools in Cardiomyocytes
As described in previous sections, labile Zn2+ regulates the expression and activation of biological
molecules such as ion channels, transcription factors, enzymes, adapters, and growth factors, along
with their receptors in many cell types, including cardiomyocytes. Excess Zn2+ can be detrimental
to cells, particularly that of cardiomyocytes [8–10,14]. As an intracellular signal transducer in
multiple cellular functions, it has been shown that intracellular labile Zn2+ has an important role
in ECC in cardiomyocytes by shaping Ca2+ dynamics [9,51,98], while it acts as a neuromodulator in
synaptic transmissions [122,123]. In the regulation of cellular labile Zn2+, subcellular pools as well as
metalloproteins are important actors, which also include manyZn2+-transporters [29,87,124].
In our previous study performed with freshly isolated ventricular cardiomyocytes, we
demonstrated that rapid changes in labile Zn2+ mostly resulted from Zn2+ displacement by Ca2+ ions
from intracellular binding sites that were highly sensitive to the redox status of the cardiomyocytes
by using Zn2+-specific fluorescence dye, FluoZin-3 [9]. In order to examine the physiological
importance of the protein-bound Zn2+ pools, similar to other studies [125] by applying acidic pH to
the cardiomyocytes or by causing an oxidative stress with H2O2, we induced chemical modifications
of the thiol groups in the proteins and demonstrated that Zn2+ binding to metallothioneins decreased
at acid pH and significantly reduced contraction without altering [Ca2+]i.
Our testing S(E)R as an possible intracellular Zn2+ pool by using ryanodine application,
we observed significantly and simultaneously decreases in the intensities of both Zn2+ transients and
Ca2+ transients in field-stimulated cardiomyocytes without affecting their basal levels [9]. Furthermore,
we performed additional experiments with caffeine. As can be seen in Figure 2, we observed two
different responses in Fluo-3 or FluoZin-3 loaded cells. In Fluo-3 loaded cells, there was fast transitory
and short-lived large increase as response to caffeine application, whereas there was a slow initial large
increase followed with a stable long-lived plateau in FluoZin-3 loaded cells. These data support
the hypothesis of sarco(endo)plasmic reticulum, S(E)R could be a Zn2+ pool similar to Ca2+ in
cardiomyocytes. Furthermore, recently by using Förster resonance energy transfer (FRET)-based
recombinant-targeted Zn2+-probes [11], we have shown that [Zn2+]i in cardiomyocytes is calculated
less than 1 nM, while ~5-fold higher in S(E)R, and less than cytosolic-level in mitochondria. Elevated
cytosolic Zn2+ appears to contribute to deleterious changes in many cellular signaling-pathways
including hyperglycemia-challenged cardiomyocytes [8–10,19,51]. Moreover, we also demonstrated
that elevated cytosolic Zn2+ appears to be associated with loss of S(E)R Zn2+ via hyperphosphorylation
of Zn2+-transporter ZIP7, which further induces endoplasmic reticulum (ER) stress in cardiomyocytes
in the diabetic rat heart [40]. Of note, in eukaryotes, Ellis et al. [126] demonstrated the Zn2+-deficiency
associated disruption in ER such as alteration in its function and induction of ER stress.
Additional studies also pointed out mitochondria to be another intracellular Zn2+-pool
in cardiomyocytes [9]. Expose of FluoZin-3 loaded cardiomyocytes either to a mitochondrial
complex I inhibitor or to carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) a
mitochondrial protonophore induced rapid and significant inhibitory effects on the Zn2+-changes
with only mild initial effects on the Fluo-3 loaded cells. In this regard, in cortical neurons,
it was proposed that the source of Ca2+-dependent Zn2+ release appears largely to be
mitochondria [127]. In cardiomyocytes, since mitochondria constitute the major source of intracellular
ROS production [128], mitochondria-related excessive ROS production has been implicated in the
pathogenesis of many cardiovascular diseases. Indeed, the Ca2+-dependency of the glutamate
mobilization of intracellular Zn2+ in neurons is attributed to the generation of ROS arising from
both cytosolic and mitochondrial sources [129]. In cardiomyocytes, Ca2+ influx might trigger transitory
change in ROS production leading to Zn2+ transients even on this time scale. Such a hypothesis could
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Figure 2. FluoZin-3 and Fluo-3 responses to caffeine application demonstrate sarco(endo)plasmic
reticulum as an intracellular labile Zn2+ pool in cardiomyocytes performed with confocal imaging.
We used either a Zn2+-specific fluorescence dye, FluoZin-3 (A) or a Ca2+-specific fluorescence dye,
Fluo-3 (B) loaded ventricular cardiomyocytes isolated from rat heart and stimulated them with 10 mM
caffeine (Caff) in the either absence (A and B, respectively) or presence of a membrane-permeant
Zn2+ chelator TPEN (N,N,N′,N′-tetrakis(2-pyridylmethyl) ethylenediamine, 30-μM) (C), respectively.
Normalized caffeine responses are given as F/F0, where F is the fluorescence signal and F0 is the
diastolic fluorescence. The mean (± standard error of mean (SEM)) values are given for the protocols
in (D), n = 5–6 for hearts/protocol. * p < 0.05 vs. before application.
Besides voltage-dependent ionic channels, transient receptor potential (TRP) channels are a
large family associated with multi-signal transducers and play important roles in different organ
function, including heart function. The functional and structural control of TRP channels by trace
metal ions, including Zn2+, has been demonstrated in different cell types [130]. For example, the high
expression levels of both transient receptor potential cation channel3(TRPC3) and TRPC6 have been
shown in the heart and could participate in the pathogenesis of cardiac hypertrophy and heart
failure as a pathological response to chronic mechanical stress [131]. Additionally, the activation
of transient receptor potential cation channel subfamily M member 4 (TRPM4), a Ca2+-activated,
but Ca2+-impermeable non-selective cation channel, has been also demonstrated to have role
in conduction block and other arrhythmic propensities associated with cardiac remodeling and
injury [132]. Furthermore, Uchida and coworkers [133] have documented that extracellular Zn2+
regulates TRPM5 channel activation [133]. On the other hand, Lambert and coworkers demonstrated
that extracellular Zn2+ exposure to HEK293 cells did inhibit TRPM5 and TRPM1 activity [134].
Moreover, Abiria and coworkers [135] recently showed that the majority of TRPM7 is localized
in abundant intracellular vesicles in HEK293 cells and ROS-mediated TRPM7 activation releases Zn2+
from these vesicles following Zn2+ overload. They emphasized the important role of TRPM7-mediated
Zn2+ release and the regulation of ROS signaling processes during postnatal stress/injury. Therefore,
one can emphasized how will be very important to understand the roles of TRP channels as detailed in
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Furthermore, it seems that they may provide basic scientific knowledge for the development of new
preventive and therapeutic approaches to manage patients with cardiovascular diseases [136].
On this basis, the effects of increased intracellular labile Zn2+ on the structure of cardiomyocytes
particularly focused on ultrastructure of mitochondria were examined by electron microscopy by
using short-term ZnPT incubation (0.1 or 1 μM for 15–20 min) in freshly isolated ventricular cells.
As can be seen in Figure 3A–C, marked irregular mitochondrial cristae and significantly clustered and
degenerated mitochondria between the myofibrils together with electron-dense matrix were observed
in labile Zn2+ loaded cells. Additionally, there were an important amount of fragmented mitochondria
and rounding and swelling in mitochondrion. Although the sarcomere showed normal structural
appearance with regular myofibrils and mitochondrial structure in the control group cells (Figure 3A),
there were dramatic signs of injury in the form of condensation, increased matrix density, and deposits
of electron-dense material in the loaded cardiomyocytes. These Zn2+ loading effects in mitochondria
can support its Zn2+ sensing pool in cardiomyocytes. However, the early data by Jang et al. [137]
showed that NO mobilizes intracellular Zn2+ via Cyclic guanosine monophosphate/Protein Kinase G
(cGMP/PKG) signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes.
Figure 3. An electron microscopy examination of the effect of increased intracellular labile Zn2+ on
ultrastructure of cardiomyocytes. The microscopic examination of freshly isolated cardiomyocytes
under physiological condition (A) showing regular myofibrils and mitochondrial (m) structure and
under 0.1 μM ZnPT incubation for 15–20 min (B) showing irregular mitochondrial cristae (white arrows).
Magnification is ×21, 560 and bars represent 500 nm. On the right, cardiomyocytes showing clustered
and degenerated mitochondria (m) under 1 μM ZnPT incubation for 15–20 min(C). Black arrows are
showing irregular Z-lines. Magnification is ×12,930 and bar represents 1000 nm.
6. Zn2+ Transporters in Cardiomyocytes
Recent review articles well summarized the already published data, performed in different
mammalian cells except cardiomyocytes, which showed the regulation of Zn2+ homeostasis via a
number of Zn2+-transporters and how they are crucial for proper cellular functions [22,23,29,138–142].
In the review by Kambe [143], it has been pointed out how the impaired Zn2+ transporter functions
into and out of cells strongly linked to clinical human diseases [144]. Since the membrane transporters
having the great potential for drug targets [145,146], hence, cytosolic labile Zn2+ and Zn2+ transporters
should be considered as novel therapeutic targets for diseases, including heart diseases. In this
section, we aimed to describe the physiological and molecular functions of Zn2+-transporters, which
regulate [Zn2+]i homeostasis and are involved in signal transduction and heart diseases, particularly
such as diabetes.
Even in early reviews, tightly control of [Zn2+]i homeostasis is defined due to existence of specific
Zn2+-transporters, including the coordinated regulation of [Zn2+]i homeostasis in terms of its uptake,
efflux, distribution, and storage, which are documented in several review articles, nicely [20,147].
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across cellular membranes into cytosol (ZIPs) and out of cytosol (ZnTs) in many types of cells, therefore,
contribute to the distribution, storage, and compartmentalization of Zn2+. Additionally, these all
predict proteins with multiple membrane spanning regions, and most have a histidine-rich intracellular
loop. The first described Zn2+ transporter in mammalian cells is ZnT-1 in kidney cells [148] while the
second one is ZnT3 in regions of the brain [149]. The ZnT proteins (solute-linked carrier 30, SLC30)
and the ZIP (zinc-regulated trans- porte /iron-regulated transporter Zrt/Irt)-like, solute-linked carrier,
39, SLC39) have been identified in mammalian tissues [22,23,150]. In mammals, there are 10 members
of the Zn2+ efflux transporters (ZnT1–10) and 14 members of the zinc influx transporters (ZIP1–14).
ZIP proteins are thought to form homodimers to transport Zn2+ across the cellular membrane [151],
while the conserved hydrophilic residue seems to sense metal specificity [152]. Supporting this
statement, it has been demonstrated that ZIP8 and ZIP14, possessing glutamic acid instead of the
conserved histidine, can efficiently transport Fe2+, Mn2+, and Cd2+ in addition to Zn2+. Human genetic
disorders caused by mutations and single-nucleotide polymorphisms in Zn2+ transporter genes
were summarized by Kambe et al. [144,153]. They documented that a number of genetic disorders
are caused by mutations in the genes encoding ZIPs and ZnTs, such as ZIP4 in acrodermatitis
enteropathica, ZIP13 in the spondylocheiro dysplastic form of Ehlers-Danlos syndrome, ZnT2 in
transient neonatal zinc-deficiency, ZnT8 in type 1 and 2 diabetes mellitus, and ZnT10 in Parkinsonism
and dystonia [22,23,141,142].
Furthermore, in the recent review article by Hara et al. [29], mechanisms of Zn2+-transporter
expression and modification have been documented, very widely in different mammalian cells/tissues,
focusing on their physiological roles from their molecular basis to genetic importance. In that review,
they presented the role of ZnTs such as ZnT2, ZnT3, ZnT4, and ZnT8, which localize to acidic
compartments and to vesicles such as endosomes/lysosomes, synaptic vesicles, and insulin granules
as well as the ZIPs such as ZIP4, ZIP5, ZIP6, ZIP7, ZIP8, ZIP10, ZIP12, ZIP13, and ZIP14 in different
cells. A number of cellular proteins, enzymes, kinases and phosphatases interact with Zn2+ for their
biological functions. Studies have revealed that Zn2+ acts not only as an accessory molecule for proteins
but also as a signaling molecule, much like Ca2+ [15,29].
Among others, ZnT7 has been demonstrated to play an important role in both growth and the
accumulation of body fat in mice [154] as well as the association between its deficiency and metabolic
disorders such as insulin and glucose intolerance and hyperglycemia [155]. Furthermore, studies on
ZnT8 showed that the ZnT8 is strongly related to type 1 and 2 diabetes [156,157]. In this regard,
later studies emphasized that ZnT8 expressed in pancreatic β-cells is involved in secreting insulin,
forming crystals [158–160], and eliminating insulin by the liver [161]. In this field, the recent review
articles by Chabosseau and Rutter [162] and by Rutter et al. [163] reviewed the regulation and roles of
Zn2+ in islet cells and the mechanisms by which ZnT8 variants might affect glucose homeostasis and
diabetes risk. Correspondingly, they presented that genetic variants in the ZnT8 gene, which encodes
the diabetes-associated granule-resident ZnT8, are associated with an altered risk of type 2 diabetes.
Additionally, they discussed the effects on insulin secretion and action of deleting or over-expressing
ZnT8 highly selectively in the pancreatic β-cell, and the role of Zn2+ in insulin signaling. Due to
their own data together with the others’ data, it has been concluded that maintenance of glucose
homeostasis, and therefore lower diabetes risk, due to a proper intake level of dietary zinc at systemic
level and a well-controlled [Zn2+]i homeostasis at cellular level is provided with both insulin release
and insulin action at physiological levels.
In the content of ZIPs’ roles, there are a limited number of studies in mammalian cells in
the literature without any in cardiomyocytes except our study [40]. However, Ellis et al. [126]
demonstrated that the zinc deficiency in ER leads to an unfolded protein response (UPR) in human
cells. In a later study, Huang et al. [155] proposed that ZIP7 is localized to Golgi apparatus in
Chinese-Hamster Ovary-cells, allowing Zn2+-release from Golgi lumen into cytosol. It has been also
suggested that ZIP7 facilitates release of Zn2+ from ER [164] and behaves as a critical component in
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that protein kinase-2 (CK2) triggers cytosolic Zn2+-signaling-pathways by phosphorylating ZIP7 [116],
while some studies have also highlighted its important contribution to Zn2+-homeostasis under
pathological conditions [166–168]. In addition, in a recent study, it was demonstrated that ZIP7,
which predominantly localizes to the ER membrane, promotes rapid cell proliferation in intestinal
crypts by maintaining ER function. They also found that mice with an intestinalepithelium-specific
ZIP7 deletion exhibited extensive apoptosis in the stem-cell-derived transit-amplifying cells due to
increased ER stress. They further showed that UPR signaling upregulates ZIP7, which maintains [Zn2+]i
homeostasis under ER stress and facilitates epithelial proliferation. Therefore, ZIP7 is considered as a
novel regulator of [Zn2+]i homeostasis of the intestinal epithelium [169].
Although studies have shown the presence of weakly expressed ZIP7 and ZnT7 in mammalian
heart [170,171], their subcellular localizations and functional roles in cardiomyocytes were not yet
known well. In that regard, we hypothesized that disruption of Zn2+-transporters and Zn2+-axis such
as ZIP7 and ZnT7 might contribute to deleterious changes in diabetic cardiomyocytes. Therefore,
we first clarified their subcellular localizations into S(E)R and then explored their functional roles in
Zn2+ homeostasis, particularly under hyperglycemia. Additionally, we tested their roles in cytosolic
Zn2+ re-distribution and development of ER-stress in hyperglycemic conditions, at most due to
activation of casein kinase 2 alpha (CK2α) [40]. We observed markedly increased mRNA and protein
levels of ZIP7 in ventricular cardiomyocytes from diabetic rats or high glucose-treated H9c2 cells
whilst ZnT7 expression was low comparison to those of controls. Additionally, we observed increased
ZIP7 phosphorylation in response to high glucose in vivo and in vitro in ventricular cardiomyocytes.
Using recombinant targeted FRET-based sensors, we showed that hyperglycemia induced a marked
redistribution of cellular labile Zn2+, increasing cytosolic labile Zn2+ and lowering labile Zn2+ in
the S(E)R. These changes involve alterations in ZIP7-phosphorylation and were suppressed by
siRNA-mediated silencing of CK2α. Due to our whole data, we, for the first time, demonstrated that
opposing changes in the expression of ZIP7 and ZnT7 observed in hyperglycemia is very important for
development of ER stress in the heart. In addition, we also pointed out an importance of sub-cellular
labile Zn2+ re-distribution in the hyperglycemic heart, which is resulting from altered ZIP7 and ZnT7
activity and contributing to cardiac dysfunction in diabetes [40]. Furthermore, Myers [140] previously
discussed very widely the roles of Zn2+ transporters and Zn2+ signaling by using recent new roles
of Zn2+ and its transporters in the synthesis, secretion, and action of insulin are dependent on zinc
and the transporters in type 2 diabetes. Author, particularly, emphasized the role of cellular Zn2+’s
dynamic as a “intracellular second messenger” to control insulin signaling and glucose homeostasis.
Therefore, it was raised extensively a new research field into the pathophysiology of insulin resistance
and possibility of new this-field related drug targets in diabetes [13,172–175].
In conclusion, the already known data associated with the role of ZIPs and ZnTs provide novel
insights into regulation of cellular-Zn2+ and its role in the heart under pathological conditions,
including hyperglycemia/diabetes-associated cardiac dysfunction. Additionally, all findings can
provide new targets such as cellular [Zn2+]i-regulation via mediation of Zn2+-transporters and suggest
that modulation of some endogenous kinases such as CK2α may provide a novel means to correct
cardiac dysfunction under any pathological condition.
7. Concluding Remarks
Both early and recent studies strongly emphasized how [Zn2+]i homeostasis is tightly controlled
by the coordinated regulation of its uptake, efflux, distribution, and storage in mammalian cells.
A number of proteins involved in different signaling pathways, mitochondrial metabolism, and ion
channels, which are also common targets of labile Zn2+, play pivotal roles in controlling cardiac
contractility. The already known documents associated with the role of zinc in cardiac function are
summarized in Figure 4. However, these regulatory actions of Zn2+ are not limited to the function of the
heart, but also extend to numerous other organ systems in mammalians. In this review, the regulation
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S(E)R, and finally, the roles of Zn2+ transporters in healthy and diseased heart, including diabetic heart,
were outlined to help widen the current understanding of the versatile and complex roles of Zn2+.
Although much has been learned from recent studies, revealed important relationships between Zn2+
transporters and heart diseases and indicating the potential of Zn2+ transporters as therapeutic targets,
their precise physiological functions are not clear. Given the multiple roles of Zn2+ in various cell types
and the detailed research development of Zn2+-containing new markers/sensors will improve the
ways to handle heart failure in humans.
Figure 4. A summary of zinc and its role in cardiac function. Basic mechanisms affected with
either zinc-deficiency or zinc-excess and, the, in turn, underline the heart dysfunction, mainly as
a zinc-concentration dependent manner in the heart.
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Abstract: While zinc is known to be important for many biological processes in animals at a molecular
and physiological level, new evidence indicates that it may also be involved in the regulation of sleep.
Recent research has concluded that zinc serum concentration varies with the amount of sleep, while
orally administered zinc increases the amount and the quality of sleep in mice and humans. In this
review, we provide an exhaustive study of the literature connecting zinc and sleep, and try to evaluate
which molecular mechanism is likely to be involved in this phenomenon. A better understanding
should provide critical information not only about the way zinc is related to sleep but also about how
sleep itself works and what its real function is.
Keywords: sleep; zinc; nutrition; brain; randomized controlled trial
1. Introduction
Zinc is the second most abundant trace metal in the human body, and is essential for many
biological processes. Nevertheless, many new functions remain to be discovered for this unique
divalent cation. A very recent body of evidence suggests that zinc is involved in the regulation of sleep,
one of the most essential physiological functions in the entire animal kingdom. The aim of this review
is to provide an overview of the current data suggesting that zinc influences sleep in mice and humans.
We first provide a brief background on what sleep is, and what we know of its regulation. We then
explore the identified roles of zinc in the brain, as well as how food regulates sleep. Furthermore,
we perform a comprehensive review of the literature connecting zinc and sleep. Finally, we discuss
possible molecular mechanisms by which zinc can act in the brain and regulate sleep.
2. Sleep
Sleep is defined as a natural periodic state of rest, in which the eyes remain closed and
consciousness is completely or partially abolished, so that there is a decrease in bodily movement and
responsiveness to external stimuli. However, an important aspect of sleep, unlike coma or anesthesia,
is that it must be easily and immediately reversible. While everybody experiences sleep, 2500 years of
research since Alcmaeon, Hippocrates and Aristotle (450–350 B.C.) could not yet clearly elucidate the
most simplest question as “why do we need to sleep?”. To finally answer this question, today’s sleep
research efforts are mostly focused on understanding how sleep is regulated.
Sleep is a process common to the whole animal kingdom, from Caenorhabditis elegans to Drosophila
melanogaster, zebrafish and of course mammals [1]. Sleeplessness has a huge impact on the human
physiology and is commonly associated with metabolic disorders (obesity and diabetes), cardiovascular
diseases (hypertension) and mental disorders (anxiety and depression). Furthermore, insomnia has
also recently been associated with neurodegenerative diseases such as Alzheimer’s disease [2], while
large cohort studies demonstrated that short (5 h or less) and long sleepers (more than 9 h) live shorter
than people with an appropriate amount of sleep (6 to 8 h per night) [3–5]. In electroencephalogram
(EEG) recordings, there are two distinct stages characterizing sleep: non-rapid eye movement (NREM)
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sleep, sometimes also called slow wave sleep, and rapid eye movement (REM) sleep or paradoxical
sleep. NREM sleep is characterized by slow but relatively high-amplitude oscillations, while REM
sleep exhibits an EEG with higher frequency but lower amplitude, similar to (but distinct from) that
of wakefulness. Sleep has an essential function to allow the human body to physically restore and
heal itself. It is especially important to maintain an efficient immune system and avoid metabolic and
cardiovascular disorders associated with insomnia. In the brain, sleep is also essential in some memory
consolidation processes [6] and possibly for brain detoxification [7,8].
The regulation of sleep and wakefulness involves many regions and cellular subtypes in the brain.
Indeed, the ascending arousal system promotes wakefulness through a network composed of the
monaminergic neurons in the locus coeruleus (LC), histaminergic neurons in the tuberomammilary
nucleus (TMN), glutamatergic neurons in the parabrachial nucleus (PB) and orexinergic neurons
in the lateral hypothalamus, among others. On the other hand, only a handful of regions able to
promote sleep have been identified so far. The ventrolateral pre-optic area (VLPO) was the first
“sleep center” to be identified by Saper’s team [9], and is considered as the master regulator for the
so-called “wake/sleep flip-flop switch” [10]. More recently, Fuller’s laboratory also discovered that
sleep can be promoted by the activation of a gamma-aminobutyric acid-ergic (GABAergic) population
of neurons located in the parafacial zone [11,12], while the role of the GABAergic A2AR-expressing
neurons of the nucleus accumbens [13] and the striatum has just been revealed [14,15]. In total, more
than 50 neurotransmitters and their respective receptors are involved in the process of controlling the
vigilance state of the brain.
3. Zinc and the Central Nervous System
The trace metal zinc is an essential cofactor for more than 300 enzymes and 1000 transcription
factors [16]. A moderate deficiency of zinc is sometimes observed in humans, and is responsible for
growth retardation, male hypogonadism, taste alteration, inefficient wound healing and immune
system, as well as mental retardation. In the central nervous system, zinc is the second most abundant
trace metal and is involved in many processes. In addition to its role in enzymatic activity, it also plays
a major role in cell signaling and modulation of neuronal activity. Zinc finger proteins, a huge family
of zinc-containing proteins, play key roles in the mechanisms of DNA replication and transcription
regulation [17–20]. Zinc has also been implicated in neurodegenerative diseases. Some Alzheimer’s
disease patients exhibit a systemic deficiency in zinc [21], however, it has also been proven that amyloid
plaques are highly enriched in zinc. It is possible that the amyloid plaques immobilize the pool of zinc
in the brain and therefore reduce the bioavailability into the neurons.
Zinc is utilized by tissue as a function of zinc transporters. Zinc transporters are playing an
important role in the homeostasis of zinc and are tightly controlling concentration of this ion in
the different organs in order to allow proper biological functions, while impaired zinc transporter
function correlates with clinical human diseases [22]. Interestingly, a research in Drosophila studied
the molecular polymorphisms of the gene Catecholamines up, strongly associated with day sleep [23],
and characterized it as the Drosophila ortholog of the mammalian ZIP7 zinc transporter [24].
In addition to its role as a cofactor, zinc is also a modulator of neuronal activity in the
brain. While the majority of zinc is protein-bound, some specific subpopulations of neurons
contain vesicles filled with weakly bound or free zinc ions (Zn2+). These zinc-containing neurons
were first identified in the mossy fibers of the hippocampus [25]. The first reported and most
abundant population of zinc-containing neurons is glutamatergic (sometimes called “gluzinergic”
neurons), and zinc released from the vesicles of these neurons into the synaptic cleft could
modulate N-methyl-D-aspartate receptor (NMDAR) activity in a dose-dependent and reversible
manner [26–28]. However, zinc can also modulate the activity of other glutamate receptors, such
as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) [29], metabotropic receptors [30]
as well as the receptors for other neurotransmitters [31] such as adenosine [32], dopamine [33] and
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transporters, and it exhibits various effects on calcium [37], potassium [38], sodium [39] and
chloride [40] channels, while recent evidence demonstrates that zinc can also be released into
glycinergic synapses [41].
One of the best-characterized physiological functions of zinc after its release into the synaptic cleft
involves the modification of hippocampus-dependent memory by the amygdala. The lateral nucleus
of the amygdala, a component of the limbic system that is essential for emotion, receives massive
projections from the entorhinal cortex. Kodirov et al. suggested that synaptically released Zn2+ in that
location was responsible for long-term potentiation (LTP) by depressing feed-forward GABAergic
inhibition of the post-synaptic neurons and thus serves as an essential mechanism for the acquisition
and storage of spatial memory in a learning task [42].
For a long time, measuring zinc concentration in the synaptic cleft remained approximate at best,
and reported results could vary by several orders of magnitude [43]. Finally, a recent in vivo study
determined that the resting concentration of synaptic zinc is extremely low (<10 nM), but after being
released from pre-synaptic vesicles after ischemic stroke zinc concentration rises quickly (within a
few milliseconds) and remains in the nanomolar range, which is sufficient to activate high-affinity
receptors (such as NMDA Receptor 2A “GluN2A”) but not low-affinity receptors [44].
After zinc has been released from gluzinergic neurons into the synaptic cleft, its concentration
is rapidly decreased through several mechanisms. First, a very efficient mechanism of zinc reuptake
is in charge to remove available zinc and reconstitute zinc vesicles [44]. Second, unlike conventional
neurotransmitters, zinc can be translocated from the synaptic cleft (or even the pre-synaptic vesicle)
into post-synaptic neurons through zinc-permeable gated channels such as NMDAR [45]. Furthermore,
an unknown amount of zinc is expected to diffuse away from the synaptic cleft due to the concentration
difference between the cleft and the cerebrospinal fluid (CSF). It is also hypothesized that glial cells
play a critical role not only in the removal of released zinc but also in the integration of synaptic
transmission modulated by zinc [46]; however, the precise mechanisms remain elusive.
4. “Sleep as You Eat” or How Food Can Regulate Sleep
Eating and sleeping are two intrinsic essential activities in animals. Numerous studies have
reported how our sleep status can modulate the way we eat. For example, total sleep deprivation for
one night in healthy adults resulted in an increase of desire for highly palatable food compared to
control non-sleep deprived subjects [47]. Even partial but chronic sleep deprivation was sufficient to
increase food consumption beyond the physiological balance and induce weight gain [48]. Interestingly,
recent experiments on mice demonstrated that a partial inhibition of REM sleep increased the
absorption of high-calorie food; however, blocking neuronal activity in the medial prefontal cortex
could reverse the effect on sucrose but not fat consumption [49]. On the other hand, a growing
number of studies has reported the opposite effect, where diet regulates sleep [50–52]. In a pioneering
clinical study, Phillips et al. provided an isocaloric high carbohydrate/low fat (HC/LF) or low
carbohydrate/high fat (LC/HF) diet to eight healthy young men. They observed a significant decrease
of NREM sleep after consumption of the HC/LF diet, and an increase of REM sleep for both diets
compared to a balanced control diet [53].
Not only the quantity of sleep, but also its quality can be modulated by our eating behavior.
A recent study demonstrated the surprising beneficial effects of kiwifruit consumption on sleep quality
in a four-week trial on 24 subjects. The score of the Chinese version of the Pittsburgh Sleep Quality
Index (CPSQI) auto-evaluation test, the waking time after sleep onset, as well as the sleep onset latency
were significantly decreased, while the total sleep time and the sleep efficiency were significantly
increased [54]. While the mechanisms involved in such effects remain elusive, recent efforts permit the
identification of active compounds and their molecular mechanisms in sleep-promoting foods and
natural compounds including saffron [55,56], honokiol [57], magnolol [58], phlorotannin [59], sake
yeast [60,61] or ashwagandha leaf extracts [62]. Finally, Grandner et al. analyzed data from the National








Int. J. Mol. Sci. 2017, 18, 2334
associated with short and long sleep duration [63]. They identified several vitamins and minerals
whose dietary intake correlated with a modification of sleep amount, and notably characterized zinc as
one of them. According to their results, very short sleepers (<5 h) ingested significantly less zinc than
did normal or long sleepers. These results are in accordance with the very limited number of studies
that have compared zinc amount in humans and sleep patterns. The difference of zinc consumption
observed in this study might be the result of the consumption of food more or less rich in zinc between
subjects such as oyster, other seafood and meat. It would also be interesting to measure to which extent
blood-zinc concentration correlates with zinc consumption and to determine if this parameter also
varies with the amount of sleep.
5. Sleep Regulation, an Unexpected Function of Zinc
5.1. Clinical Studies
In 2009, a population study on 890 healthy Jinan residents in China evaluated the relationship
between zinc/copper serum concentrations and several physiological factors such as sex, age, drinking
and smoking behavior, and sleep [64]. Regarding sleep, the mean concentration of serum copper
remained constant regardless of the amount of sleep; however, the highest concentration of serum zinc
was found in subjects sleeping a “normal” amount of 7 to 9 h per night (1.337–1.442 mg/L), compared
to short (<7 h) and long (>9 h) sleepers (0.789–0.934 mg/L). A later cross-sectional study measured
zinc and copper content in the serum and hair of 126 adult Korean women [65]. This time, the group
of women with the highest serum and hair zinc/copper ratio had the highest percentage of optimal
amount of sleep (7–7.9 h). Recently, another Chinese cohort study compared blood zinc concentration
and sleep quality in 1295 children from the Jintan Child Cohort [66]. Blood sampling was performed
on the same children twice: at preschool (3–5 years old) and several years later during their 6th grade
(11–15 years old). No significant association between zinc status and sleep could be found in these
children in their younger age; however, blood zinc concentration correlated with sleep duration and
sleep quality (CPSQI test) in their pre-adolescent age. Furthermore, a longitudinal association between
the first and second sampling periods demonstrated that zinc blood concentration at preschool age
predicted the development of poor sleep quality and efficiency several years later.
As well as these reports, to the best of our knowledge only three studies have more or less directly
evaluated the effect of zinc supplementation on sleep in humans. In the first study, the authors focused
on the effect of a 12-month iron and zinc supplementation on sleep in 877 infants from Zanzibar
and 567 infants from Nepal, both groups being vastly subjected to malnutrition [67]. Infants from
Zanzibar not suffering from iron deficiency anemia (IDA) and who received supplemental zinc slept
an extra 1.3 h at night and a total of 1.7 h extra per day (night sleep + naps) compared to infants
receiving a placebo. Zinc supplementation also resulted in sleep time increase in Nepalese infants with
IDA, albeit to a smaller extent. In another double-blind placebo-controlled clinical trial, the authors
evaluated the effect of a triple supplementation of melatonin, magnesium and zinc on 43 residents
of a long-term care facility in Italy who exhibited primary insomnia [68]. Patients ingested daily a
combination of melatonin (5 mg), magnesium (225 mg) and zinc (11.25 mg) mixed in 100 g of pear
pulp for 60 days, one hour before bedtime. Patients that received this mineral supplement exhibited
a remarkable improvement of sleep quality with a Pittsburgh Sleep Quality Index reduced from
12.7 ± 2.6 to 5.5 ± 1.9. On the other hand, placebo-treated patients did not show any sleep quality
improvement (12.3 ± 3.6 and 12.0 ± 4.4, respectively, before and after placebo treatment). Finally,
the most recent study determined the effect of zinc supplementation from natural sources (zinc-rich
oysters and zinc-containing yeast extracts) on 120 healthy subjects in a randomized controlled trial in
Japan [69]. Compared with the placebo group, individuals treated for three months with daily zinc












































Figure 1. Dietary zinc improves sleep quality in humans and increases NREM sleep in mice. (A) Two
groups of 30 volunteers absorbed daily 15 mg of zinc (in 40 g of Pacific oysters) or placebo (40 g of
scallops). After 12 weeks of supplementation, sleep efficiency and sleep onset latency improved in the
group treated with zinc compared to the control group. (B) Oral administration of zinc-containing
yeast extract (80 mg/kg) in mice at the onset of dark time increased the amount of NREM sleep for 6 h
compared to mice receiving vehicle. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with vehicle treatment.
5.2. Experimental Evidence
All these human studies measure the amount or the quality of sleep in correlation with zinc
supplementation, and conclude with an improvement of the sleep pattern of the tested subjects.
However, because zinc is not provided alone, the effects might arguably arise from different compounds
administered at the same time as zinc. For instance, zinc supplementation was complemented with
iron in the Zanzibar and Nepal study, while clinical examination demonstrated iron deficiency in a
substantial amount of the children before the beginning of the study. Providing iron to IDA infants
might account for the improvement of sleep observed by the authors. In the Italian study, zinc was
complemented with melatonin and magnesium; however, melatonin’s effect on sleep patterns has
been extensively studied and demonstrated [70] and it is unfortunate that the authors did not decipher
how important each component was on sleep. Similarly, oysters contain a large amount of taurine,
a γ-aminobutyric acid (GABA) receptor agonist known to promote sleep-like resting behavior in
D. melanogaster [71]. Furthermore, environmental factors as well as emotional condition also have a
major impact on how well and how long humans sleep, and can interfere with zinc’s effects on sleep.
The most convincing study to date about the effect of zinc on sleep was obtained in our study
published in 2015 [72]. In these experiments, we used a mouse model, which eliminates all the
environmental and psychological factors that might have negatively influenced the previous human
studies. Feeding the mice with zinc-containing yeast extract (equivalent to a dose of 10 to 160 mg/kg
of elemental zinc) at the onset of the dark phase resulted in a drastic reduction of locomotor activity
for a period of up to 6 h. Such an effect could not be observed if the mice were fed with a similar
amount of yeast extract rich in the other divalent cations manganese, iron or copper, proving a specific
effect for zinc. We could also precisely measure and characterize the zinc-induced sleep by recording
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40 or 80 mg/kg, dose-dependently and specifically increased the total amount of NREM sleep when
administered at the onset of the dark phase, when the animal is most active (Figure 1B). Furthermore,
the power spectrum of NREM sleep remained indistinguishable from that of physiological NREM
sleep, demonstrating a good sleep quality.
However, the same doses of zinc-containing yeast extract had no significant effect on the amount
of sleep when administered during daytime, when the animal is already mostly sleeping. Under basal
conditions, a mouse sleeps an average of 20 min/h during nighttime and 40 min/h during daytime.
When mice were fed with zinc at the onset of the dark phase, the total amount of sleep increased by up
to 20–30 min/h, but, when they were fed during daytime, it remained at around the usual 40 min/h.
In other words, zinc never induced sleep beyond the physiological level, contrary to more classical
sleep-inducing molecules such as benzodiazepine, which also reduce the power density of NREM
sleep and result in poor sleep quality. It is possible that zinc acts on circadian regulators and induces
sleep when the animal is usually sleeping.
6. Solving the Mystery of Zinc-Induced Sleep
One may wonder how dietary zinc might act so quickly on the central nervous system (CNS)
and regulate a function as essential as sleep. It is well accepted that the blood–brain barrier (BBB)
has a very low permeability for zinc and the concentration of this ion remains extremely stable in the
CSF regardless of serum zinc concentration [73]. However, a higher time-resolution measurement
in rats revealed a rapid exchange of zinc between blood and brain during the first 30 min following
intravenous administration, and zinc was not stored in the CSF but in an undetermined compartment
of the brain [74,75]. A later study demonstrated the variable permeability of the BBB for zinc using an
in vitro experimental model [76]. In this experiment, the BBB exhibited a constant zinc permeability
when the plasma compartment concentration remained between 10 and 25 μM; however if this
concentration increased further, BBB permeability for zinc increases suddenly and markedly. In our
experiments, we found that zinc concentration increased in the serum up to 10-fold after the oral
administration as compared to baseline. We therefore hypothesize that orally administered zinc
reaches some specific compartment of the CNS after rapidly increasing in the blood, thus activating
a signaling pathway that is responsible for the promotion of sleep. It would be unrealistic to think
that, in physiological conditions, dietary zinc could be responsible for regulating sleep in animals and
humans, especially since it seems unlikely that it would affect the concentration of zinc in the CNS.
However, local zinc concentration may be less stable in the CNS than one would expect. Indeed, it was
also reported that plasma zinc concentration, while being tightly controlled by diverse mechanisms,
exhibits a circadian variation, with a minimum concentration measured in the evening while it reaches
its peak in the morning [77]. Similarly, we hypothesize that the zinc concentration also varies in some
specific regions of the CNS during the course of a day.
The idea that ions can regulate wake and sleep is actually not new. In 1927, Demole discovered
that the injection of CaCl2 into the pituitary of cats increased sleep for several hours. More
recently, Nedergaard’s lab thoroughly studied the interaction between sleep/wake status and the
CSF concentration of three ions: K+, Ca2+ and Mg2+ [78]. They reported that the concentration of
extracellular K+ increases in the CSF of mice during wakefulness, while those of Ca2+ as well as
Mg2+ decreases. Moreover, the authors assessed whether the sleep/wake status was responsible
for the change in ion concentrations or if the change in ion concentrations was physiologically
responsible for the promotion of sleep and wakefulness. They demonstrated that infusion of artificial
CSF mimicking the concentration of ions in wake or sleep reversed the neuronal activity and the
behavioral state. Involvement of Ca2+ in the control of sleep was also recently demonstrated in
mammals [79]. These results shed new light on the importance of the non-neurotransmitter type of
communication within the brain, involving ions such as Ca2+, Mg2+ and also Zn2+, to control even the
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The specific mechanism of action of zinc in the CNS to promote sleep remains elusive. Most studies
looking at the activity of Zn2+ in the brain have focused on its interaction with the glutamatergic
receptors, because Zn2+ exists predominantly in the presynaptic vesicles of glutamatergic neurons to
be co-released with glutamate. Some other receptors also interact with zinc. Zn2+ is also found not only
in glutamatergic axon terminals but also in some inhibitory axon terminals, potentially glycinergic, of
the cerebellum and in the spinal cord [80]. Glycinergic neurons project to orexin neurons in the lateral
hypothalamus (well characterized neurons that are involved in the maintenance of wakefulness),
and can inhibit their activity [81]. The glycinergic receptor (GlyR) exhibits an atypical reaction in
the presence of zinc. First, the synaptic activity of the α1β GlyR isoform is increased in vitro even in
the presence of a very low concentration of zinc (10 nM–1 μM). However, at a higher concentration
(3–300 μM), zinc exhibits a dose-dependent inhibition of GlyR excitability. A recent in vivo study
revealed that the free Zn2+ concentration in the glycinergic synaptic cleft could rises to at least 1 μM
following a single presynaptic stimulation, which is higher than the concentration in glutamatergic
synapses [41]. Furthermore, selective mutation in the α1 subunit of the glycine receptor identified
Zn2+ as an essential endogenous modulator of glycinergic transmission, leading to the development of
a hyperekplexia phenotype in mice, and demonstrated that zinc is essential for the proper functioning
of the glycinergic system [82]. However, it remains unclear whether zinc is released directly from
presynaptic glycinergic neurons or from neighboring zinc-containing glutamatergic neurons.
As well as acting as a cofactor for various receptors, zinc has its own receptor called G
protein-coupled receptor 39 (GPR39) [83], which is a Gαs protein-coupled receptor to activate
adenylate cyclase and cAMP-dependent signaling. In the brain, it is mainly expressed in the
amygdala, the hippocampus and the auditory cortex, as well as in many other regions to a lesser
extent [84]. The administration of zinc to hippocampal slices activated GPR39 in the CA3 region and
regulated neuronal activity by inducing intracellular release of calcium, as well as phosphorylation
of extracellular-regulated kinase and Ca2+/calmodulin kinase II [85]. Deletion of GPR39 in mice led
to the development of a depression-like behavior [86,87] as well as an increased risk of Alzheimer’s
disease [88], two well-characterized pathologies related to sleep disturbance [89]. To the best of our
knowledge, nobody has yet checked the potential involvement of GPR39 in the regulation of sleep and
wakefulness, let alone the potential role of zinc in this physiological process.
7. Conclusions
The role of zinc in the CNS has become increasingly important, since we first recognized its
central role in the regulation of essential functions such as memory and, now, sleep. However, much
work remains to comprehend properly the key functions of zinc in glutamatergic transmission and
other types of neurotransmission. Although zinc ion was of little interest to the scientific community
for a long time, accumulating evidence proves that endogenous zinc as well as available dietary zinc
is of high importance, not only as an enzyme cofactor but also as a signaling molecule. One of the
most unexpected functions of zinc to date may be in the regulation of sleep, an essential physiological
function shared by the entire animal kingdom. While the mechanisms by which zinc regulates sleep
remain unclear, rapid progress towards their elucidation is to be anticipated.
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Abstract: Our previous study demonstrated that colchicine-induced dentate granule cell death is
caused by blocking axonal flow and the accumulation of intracellular zinc. Zinc is concentrated
in the synaptic vesicles via zinc transporter 3 (ZnT3), which facilitates zinc transport from the
cytosol into the synaptic vesicles. The aim of the present study was to identify the role of ZnT3
gene deletion on colchicine-induced dentate granule cell death. The present study used young
(3–5 months) mice of the wild-type (WT) or the ZnT3−/− genotype. Colchicine (10 μg/kg) was
injected into the hippocampus, and then brain sections were evaluated 12 or 24 h later. Cell death was
evaluated by Fluoro-Jade B; oxidative stress was analyzed by 4-hydroxy-2-nonenal; and dendritic
damage was detected by microtubule-associated protein 2. Zinc accumulation was detected by
N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ) staining. Here, we found that ZnT3−/−
reduced the number of degenerating cells after colchicine injection. The ZnT3−/−-mediated inhibition
of cell death was accompanied by suppression of oxidative injury, dendritic damage and zinc
accumulation. In addition, ZnT3−/− mice showed more glutathione content than WT mice and
inhibited neuronal glutathione depletion by colchicine. These findings suggest that increased
neuronal glutathione by ZnT3 gene deletion prevents colchicine-induced dentate granule cell death.
Keywords: ZnT3; colchicine; axonal transport; zinc; neuron death; oxidative stress; glutathione
1. Introduction
Colchicine, a potent neurotoxin derived from plants of the genus Colchicum autumnale, is well
known to cause selective loss of dentate granule cells in the hippocampus [1,2], and to cause cognitive
dysfunction [3] resulting from cytoskeletal alterations and impaired axonal transport, followed by
progressive neuronal loss. The neuronal cytoskeleton is a system of highly complex structures that
consist of microtubules, neurofilaments and microfilaments. These components are responsible for
the supportive shape of neurons, as well as for crucial processes such as transport of materials in
the axon [4]. It has been found that colchicine injection decreases the soluble tubulin pool and
inhibits microtubule polymerization by binding tightly to tubulin, the major structural protein of
microtubules [5]. Kumar et al. demonstrated that intracerebral administration of colchicine induces
excessive free radical generation and consequently oxidative damage [6,7]. The central nervous system
(CNS) is highly vulnerable to oxidative stress because of its increased oxygen consumption for lipid
peroxidation and is relatively deficient in antioxidant systems [8,9]. Therefore, generation of free
radicals and oxidative stress can cause neuronal death.
Glutathione (GSH) is an intracellular non-protein thiol that plays a central role in antioxidant
defense against free radical production, especially reactive oxygen species (ROS) production. Excess of
ROS may result in GSH depletion [10–12]. The onset of cell death is associated with a reduction of
intracellular GSH levels in various cellular systems [13,14]. Therefore, attenuation of oxidative stress
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by increasing antioxidant defense through modulation of GSH can be a useful tool in the management
of neurodegeneration processes [15–17].
The zinc (Zn2+) ion, one of the most abundant trace metals in the CNS, is enriched in the human
body and has been known to be important in the control of physiological and pathological functions
in the brain [18–21]. Anterograde and retrograde zinc transporters between the cell body and the
axon terminal are important for maintaining neuronal function [22,23]. Previously, our laboratory
demonstrated that blocking of axonal flow by colchicine administration and then accumulation
of intracellular free zinc caused dentate granule cell death [24]. Recently, an interesting study
demonstrated that genetic deletion of zinc transporter 3 (ZnT3), a putative transporter of zinc into
synaptic vesicles, increases free zinc levels in the cytosol of neurons [25]. In addition, numerous studies
have argued that Zn2+ has antioxidant properties in most systems, indicating a positive correlation
between Zn2+ and GSH content [26–29]. Parat et al. reported that these antioxidant properties can be
related to various actions, the most commonly described being Zn2+ interference with the absorption
of other metals, such as Cu or Fe, and metal-catalyzed oxidation reactions, Zn2+ involvement in
cooper/zinc superoxide dismutase (CuZnSOD) stability and the protection of thiol groups by Zn2+ [28].
In concert with the above findings, we propose the hypothesis that increased intracellular free zinc
levels by ZnT3 gene deletion may increase neuronal GSH levels, thereby preventing colchicine-induced
oxidative injury in the dentate granule cell.
2. Results
2.1. Colchicine-Induced Dentate Granule Cell Degeneration Is Reduced in ZnT3−/− Mice
It has previously been shown that the dentate granule cell is particularly vulnerable to colchicine
and that this may contribute to subsequent cognitive impairment [30,31]. We first investigated whether
genetic deletion of ZnT3 influenced dentate granule cell death at 24 h after colchicine injection.
Colchicine-induced dentate granule cell degeneration was analyzed by Fluoro-Jade B (FJB) staining to
detect dying cells. Sham-operated groups didn’t show any FJB (+) cells. Intrahippocampal colchicine
injection induced several FJB (+) cells in the dentate gyrus (DG). However, we found that ZnT3−/−
(KO) mice had a significantly reduced number of FJB (+) cells in the DG after colchicine injection,
compared to the colchicine-injected WT mice (WT, 428.3 ± 84.06; KO, 55.5 ± 19.93; an 87% reduction).
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Figure 1. ZnT3−/− mice exhibit reduced dentate granule cell death after colchicine injection.
Brain sections obtained from WT and ZnT3−/− (KO) mice at 24 h after colchicine injection
(WT-colchicine, n = 4; KO-colchicine, n = 5) were analyzed by Fluoro-Jade B (FJB) staining to measure
the degree of neurodegeneration. Representative images (A) and quantification (B) for the degree of
neurodegeneration are shown as the number of degenerating cells of dentate gyrus (DG). Scale bar
= 50 μm. Data are the mean ± SEM, * p < 0.05 versus WT mice; (C) Fluorescence photomicrographs
show zinc-specific TSQ staining in the hippocampal DG and cornus ammonis 3 (CA3) at 24 h after
colchicine injection. The dark holes represent the normal appearance of cell bodies, and the bright
white fluorescence in the cell bodies (marked by a white arrow) indicates abnormal zinc accumulation.
Scale bar = 100 μm. MF: mossy fiber. GCL: granular cell layer. PL: pyramidal cell layer.
2.2. ZnT3 Gene Deletion Prevents Intracellular Zinc Accumulation in the Dentate Granule Cells after
Colchicine Injection
Next, we assessed if the ZnT3 gene deletion can prevent intracellular zinc accumulation in the
granule cells of DG after colchicine injection. Colchicine-induced intracellular zinc accumulation was
detected by the zinc-specific stain TSQ. Hippocampal sections harvested 24 h after colchicine injection
showed an intense fluorescence signal in the cell bodies of dentate granule cells, indicative of labile
zinc accumulation in these cells. However, the number of TSQ (+) neurons in the DG and cornus
ammonis 3 (CA3) was significantly reduced in ZnT3−/− mice, compared to the colchicine-injected
WT mice, indicating that deletion of the ZnT3 gene prevented colchicine-induced intracellular zinc
accumulation (Figure 1C).
2.3. ZnT3 Gene Deletion Showed Less Oxidative Injury after Colchicine Injection
We next examined whether reduced neuronal death after colchicine injection in mice lacking
the ZnT3 was related to less oxidative injury in the DG. To assess oxidative injury, brain sections
were immunohistochemically stained with 4HNE at 12 h after colchicine injection. One of the
major generators of oxidative stress, 4-hydroxynonenal (4HNE), has been widely considered as
a bioactive marker of lipid peroxidation [32,33]. There were almost no 4HNE-stained granule cells in
sham-operated mice of either WT or ZnT3−/− (WT, 32.5 ± 2.77; KO, 33.6 ± 1.99; average gray scale
intensities). The intensity of 4HNE-immunoreactivity (IR) was remarkably increased in DG of WT mice
after colchicine injection. However, colchicine-injected ZnT3−/− mice showed markedly less intensity
of 4HNE-IR in the granule cell of DG, compared to the colchicine-injected WT mice (WT, 147.1 ± 7.49;
KO, 91.4 ± 4.75; average gray scale intensities, a 38% reduction). These results suggested that the
resistance of ZnT3−/− mice to colchicine-induced dentate granule cell degeneration might be related
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Figure 2. Colchicine-induced oxidative injury is reduced in ZnT3−/− mice. WT and ZnT3−/−
mice were either sham-operated (WT-sham, n = 3; KO-sham, n = 3) or colchicine-injected
(WT-colchicine, n = 4; KO-colchicine, n = 5). Brain sections were immunohistochemically stained
with anti-4-hydroxynonenal (4HNE) to detect oxidative injury. (A) Representative images reveal
4HNE-labeled cells in the hippocampal DG from either WT or ZnT3−/− mice at 12 h after sham
surgery or colchicine injection. Scale bar = 10 μm; (B) The bar graph shows the intensity of
4HNE-immunoreactivity (IR) in the granule cell of DG from sham-operated and colchicine-injected
mice of either WT or ZnT3−/−. Data are the mean ± SEM, * p < 0.05 versus WT mice, # p < 0.05 versus
sham-operated mice.
2.4. ZnT3 Gene Deletion Reduced Dendritic Damage after Colchicine Injection
We also determined whether deletion of ZnT3 reversed colchicine-induced dendritic damage in
the hippocampus. MAP2 is exclusively expressed by dendrites of neurons where it binds to tubulin [34]
and is thought to be involved in microtubule assembly, acting to stabilize microtubules [35]. It is
considered that the loss of MAP2 protein is a characteristic of dendritic damage [36]. There were no
significant differences in the distribution of MAP2-IR between the sham-operated WT and ZnT3−/−
mice (cornus ammonis 1 (CA1): WT, 106.5 ± 5.10; KO, 108.9 ± 3.99; cornus ammonis 3 (CA3):
WT, 137.3 ± 2.22; KO, 140.3 ± 5.07; DG: WT, 65.2 ± 4.54; KO, 68.7 ± 5.11; average gray scale intensities).
In both cases, MAP2-IR was observed in the apical dendrites of the CA1 and CA3, as well as the
dendrites of granule cells within the DG. Compared with the sham-operated group, expression
levels of MAP2 in the hippocampal CA1, CA3 and DG were significantly reduced in WT mice 24 h
after colchicine injection. In contrast, colchicine-injected ZnT3−/− mice revealed highly increased IR
to MAP2, compared to the colchicine-injected WT mice (CA1: WT, 30.6 ± 4.03; KO, 58.6 ± 4.53,
a 91% increase; CA3: WT, 35.2 ± 6.42; KO, 74.3 ± 6.25, a 111% increase; DG: WT, 35.9 ± 3.70;
KO, 48.0 ± 4.02, a 34% increase; average gray scale intensities). These results suggested that the
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Figure 3. Genetic deletion of ZnT3 reduces colchicine-induced dendritic damage. WT and ZnT3−/−
mice were either sham-operated (WT-sham, n = 3; KO-sham, n = 3) or colchicine-injected (WT-colchicine,
n = 4; KO-colchicine, n = 5). Brain sections were immunohistochemically stained with 4HNE to detect
oxidative injury. (A) Representative images reveal MAP2-IR in the hippocampal CA1, CA3 and DG
from either WT or ZnT3−/− mice at 24 h after sham surgery or colchicine injection. Scale bar = 100 μm;
(B) The graph represents the intensity of MAP2-IR in the CA1, CA3 and DG from sham-operated and
colchicine-injected mice of either WT or ZnT3−/−. Data are the mean ± SEM, * p < 0.05 versus WT
mice, # p < 0.05 versus sham-operated mice.
2.5. Colchicine-Induced Neuronal GSH Depletion Is Prevented in ZnT3−/− Mice
To evaluate whether ZnT3 gene deletion affected neuronal GSH, sections were histologically
analyzed by probing for GSH-N-NEM adducts at 24 h after colchicine injection. Neurons in the
hippocampal regions including subiculum, CA1, CA2, CA3 and DG were immunoreactive to the
GS-NEM antibody, as can be seen in Figure 4A. GS-NEM IR in the subiculum, CA1 and CA2 of
ZnT3−/− mice was similar to that in the WT mice, but was higher in CA3 and DG (subiculum:
WT, 44.0 ± 3.17; KO, 46.0 ± 4.00; CA1: WT, 44.5 ± 3.43; KO, 48.8 ± 5.39; CA2: WT, 49.4 ± 3.57;
KO, 52.6 ± 4.17; CA3: WT, 36.9 ± 9.02; KO, 58.9 ± 1.83, a 60% increase; DG: WT, 27.6 ± 1.89;
KO, 49.8 ± 3.73, a 81% increase). Colchicine injection caused a decrease in the level of GS-NEM IR in
all hippocampal regions. In addition to that, ZnT3−/− mice subjected to colchicine injection showed a
significant increase of GS-NEM IR in all hippocampal regions, compared to colchicine-injected WT mice
(subiculum: WT, 6.2 ± 0.35; KO, 17.9 ± 4.98, a 189% increase; CA1: WT, 7.5 ± 2.14; KO, 20.0 ± 5.66,
a 167% increase; CA2: WT, 5.5 ± 1.81; KO, 20.4 ± 3.12, a 274% increase; CA3: WT, 6.3 ± 0.74;
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indicate that ZnT3−/− mice have increased neuronal glutathione and decreased vulnerability to
oxidants induced by colchicine injection (Figure 4).
Figure 4. ZnT3−/− mice have increased neuronal glutathione and reversed a reduction of neuronal
glutathione (GSH) content after colchicine injection. Brain sections obtained from WT and ZnT3−/−
mice at 24 h after sham surgery or colchicine injection (WT-sham, n = 3; KO-sham, n = 3; WT-colchicine,
n = 4; KO-colchicine, n = 5) were stained by GSH-N-ethylmaleimide (NEM) adduct (GS-NEM)
antibody to detect the reduced form of GSH in the neurons. Representative immunofluorescence
images (A) and quantification (B) for the degree of neuronal GSH levels are shown as the intensity of
GS-NEM in the individual neurons of hippocampal regions including subiculum, CA1, CA2, CA3 and
DG. Scale bar = 20 μm. Data are the mean ± SEM, * p < 0.05 versus WT mice, # p < 0.05 versus
sham-operated mice.
3. Discussion
In the present study, we found that ZnT3−/− mice exhibited reduced dentate granule cell death in
the hippocampus after colchicine injection compared to WT mice. The reduction of colchicine-induced
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dendritic damage and zinc accumulation in the hippocampus. In addition, ZnT3−/− mice showed a
higher GSH level than WT mice in the hippocampus and showed reduced neuronal GSH depletion
after colchicine injection. These findings suggest that the increased intracellular free zinc level by ZnT3
gene deletion increased the neuronal GSH levels, thereby preventing the colchicine-induced dentate
granule cell death.
Microtubules are one of the crucial cytoskeletal components in neurons, having an important
role in stabilizing neuronal morphology because they provide platforms for intracellular transport
that are involved in a variety of cellular cascades, including the movement of organelles, secretory
vesicles and intracellular macromolecular assemblies, as well as controlling local signaling events [37].
Colchicine inhibits polymerization of microtubules by binding to β-tubulin [5], which is essential for
cellular mitosis. It is also well-known to effectively act as a mitotic inhibitor used for cancer treatment.
Since one of the characteristics of cancer cells is an increased rate of mitosis, cancer cells are more
vulnerable to colchicine toxicity than normal cells. However, the therapeutic value of colchicine against
cancer is limited by its toxicity against normal cells. Numerous studies indicated that colchicine causes
the selective destruction of granule cells in the DG of the hippocampus [1,2]. In addition, our previous
study has shown that cytoskeleton-disrupting agents such as colchicine or vincristine induce dentate
granule cell death by blocking axonal zinc flow and intracellular zinc accumulation [24]. Therefore,
these results suggest a new mechanism of neuronal death that arises by the blockade of the axonal zinc
transport and subsequent intracellular zinc accumulation as intermediary steps in colchicine-induced
dentate granule cell death.
It has been well established that the generation of free radicals and subsequent oxidative stress
occur prior to neuronal death and play important roles in the pathogenesis of neurodegenerative
diseases [15–17]. A previous study reported that central administration of colchicine is associated with
an increase in free radical generation, and subsequent oxidative stress leads to cognitive dysfunction [3].
It has been reported that colchicine induces oxidative damage, possibly by the following mechanisms:
(i) it causes an increase of the glutamate/γ-aminobutyric acid (GABA) ratio in the cortex of mice [38],
and this relative increase in glutamate activity exhibits neurotoxic effects by generating hydroxyl free
radicals [39]; (ii) colchicine also leads to increased production of nitric oxide (NO) and inducible nitric
oxide synthase (iNOS) in the brain [40]; the generated NO can induce the peroxynitrite-mediated
formation of free radicals by interacting with the superoxide anion; (iii) the generated NO also causes
nitrosylation of diverse enzymes, thereby inhibiting glycolysis and inducing brain damage [41]. Our lab
also demonstrated that NO increased vesicular zinc release and subsequent intracellular free zinc
accumulation [42].
In the present study, intrahippocampal injection of colchicine caused significant injury of dentate
granule cells as evidenced by increased oxidative stress, dendritic damage, zinc accumulation and
neuronal death. Furthermore, the colchicine-induced dentate granule cell death was significantly
reduced in ZnT3−/− mice. ZnT3 is mainly localized at Zn2+-containing synaptic glutamatergic vesicles
in the hippocampus, cortex and olfactory bulb. Yoo et al. have demonstrated that the free Zn2+ level
is higher in neuronal somata of ZnT3−/− mice than those of wild-type mice, and metallothioneins
1 and 2 (Mt1/2), which are known to be induced by increases in cytosolic free Zn2+ levels, were also
substantially increased in ZnT3−/− mice [25]. Glutathione is a tripeptide composed of glutamate,
glycine and cysteine. It plays a major role as an endogenous antioxidant present in the reduced
form within cells [12]. It has been shown to react with free radicals and prevents the generation of
hydroxyl free radicals [14]. The decreased GSH level and glutathione S-transferase (GST) activity after
colchicine injection suggest that there was an increase in free radical generation and a depletion of
the GSH-dependent antioxidant system during oxidative stress. Several studies have argued that
Zn2+ status affects glutathione concentrations in tissues [26,27,29,43]. Parat et al. demonstrated a
positive correlation between intracellular zinc deprivation and GSH depletion in cells treated with the
zinc chelator NNN′N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) [28]. In the present study,
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hippocampal CA3 and DG. Furthermore, ZnT3−/− mice showed prevention of colchicine-induced
neuronal GSH depletion in the hippocampal subiculum, CA1, CA2, CA3 and DG. Although the present
study suggests that ZnT3 gene deletion causes an increased intracellular free zinc level and increased
neuronal GSH levels, the exact mechanism of how ZnT3 gene deletion provides neuroprotective effects
is not clear. The present study is seemingly paradoxical insofar that ZnT3−/− mice showed increased
intracellular levels of zinc as presented in the previous study [25], but the proposed diagram in Figure 5
suggests that there is less accumulation of zinc. Thus, we hypothesize that this is in relation to the
effect that the accumulation of zinc in response to colchicine is due to impaired axonal transport
specifically at 24 h, whereas ZnT3−/− mice might have alternative mechanisms for dealing with a
normally elevated level of zinc.
Figure 5. Proposed mechanism by which ZnT3 knockout reduces colchicine-induced dentate granule
cell degeneration. This schematic drawing indicates several chain reactions that are thought to occur
after colchicine injection in ZnT3−/− mice. (A) Cytoplasmic and vesicular zinc are normally moved
by the axonal flow in WT mice. Zinc transport is essential for axonal flow in neurons. In addition,
the concentration of GSH is much greater in the neuronal cytoplasm; (B) Blocked axonal flow by
colchicine induces depletion of GSH content and an increase of intracellular zinc accumulation,
thereby causing neuronal death; (C) ZnT3 gene deletion causes an increased intracellular free zinc level
and increased neuronal GSH levels; (D) Genetic deletion of ZnT3 attenuates colchicine-induced zinc
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Taken together, we suggest that the increased intracellular free zinc level by ZnT3 gene deletion is
correlated with increased neuronal GSH levels, which in part provide neuroprotective effects in the
colchicine-induced oxidative injury in dentate granule cell.
4. Materials and Methods
4.1. Mouse Colonies
The animal care protocol and experimental procedures were approved by the committee on
animal use for research and education at Hallym University (Protocol # Hallym 2014-28), in accordance
with NIH guidelines. This manuscript was written in compliance with the guidelines of ARRIVE
(animal research: reporting in vivo experiments) [44]. Wild-type (WT) and ZnT3 KO male mice
(background strains, C57BL/6 and Sv129 hybrid), aged 8 weeks, were propagated and maintained in
the facility of Hallym University, College of Medicine. Mice were housed in a regulated environment
(22 ± 2 ◦C, 55 ± 5% humidity, 12:12 h light:dark cycle with lights on at 8:00 a.m.) and received a
standard diet by Purina (Purina, Gyeonggi, Korea). Food and water were accessed ad libitum. As
described previously [45], PCR genotyping was performed with a primer set to amplify WT (5′-GGT
ATC CAT GCC CTT CCT CTA GAG-3′), or common (5′-ATA GTC ACT GGC ATC CTC CTG TAC
C-3′), or the KO allele (5′-CCT GTG CTC TAG TAG CTT TAC GG-3′) prior to all experiments. The WT
band is 650 bp in size, and the KO band is 400 bp in size.
4.2. Colchicine Intrahippocampal Injection and Experimental Design
To assess the role of ZnT3 on colchicine-induced dentate granule cell degeneration, colchicine
(10 μg/kg; Sigma, St. Louis, MO, USA) was intrahippocampally injected as previously described [24].
Briefly, mice were deeply anesthetized with isoflurane (1–2% for maintenance; 3% for induction) in a
70:30 mixture of nitrous oxide and oxygen using an isoflurane vaporizer (VetEquip Inc., Livermore,
CA, USA) and positioned in a stereotaxic apparatus (David-Kopf Instruments, Tujunga, CA, USA).
A burr hole was made in the skull, and a 29-gauge needle was inserted through the burr hole into
the hippocampus (coordinates: 1.4 mm lateral from the midline, 1.5 mm posterior to the bregma and
1.8 mm below the cortical surface). We then slowly injected colchicine and removed it after placement
for another 5 min. The burr hole was sealed with bone wax. Following the suture of the skin incision,
anesthetics were discontinued. When mice showed spontaneous respiration, they were returned to a
recovery room maintained at 37 ◦C. Core temperature was kept at 36.5–37.5 ◦C with a homoeothermic
blanket control unit (Harvard apparatus, Holliston, MA, USA). Sham-operated mice received the same
skin incision under isoflurane anesthesia, but they were administered with 1 μL sterile saline into the
hippocampus. Mice were divided into four groups for histological evaluation: (1) sham-operated WT
mice (WT-sham, n = 6), (2) sham-operated ZnT3−/− mice (KO-sham, n = 6), (3) colchicine-induced WT
mice (WT-colchicine, n = 8) and (4) colchicine-induced ZnT3−/− mice (KO-colchicine, n = 10).
4.3. Tissue Preparation
Mice were perfused with 0.9% saline followed by 4% paraformaldehyde (PFA) under urethane
(1.5 g/kg, i.p.) anesthesia. The brains were post-fixed with 4% PFA in phosphate-buffered saline
(PBS) for 1 h and then immersed in 30% sucrose until subsided for cryo-protection. Thereafter,
the entire brain was frozen and coronally sectioned at a 30 μm thickness using a cryostat
(CM1850, Leica, Wetzlar, Germany).
4.4. Detection of Cell Death
Cell death after colchicine injection was evaluated after a 24 h survival period. To identify
degenerating cells, Fluoro-Jade B (FJB, Histo-Chem, Jefferson, AR, USA) staining was used [46].
Five coronal sections (180 μm intervals, collected from 1.2–2.1 mm caudal to bregma) were analyzed
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hippocampal dentate gyrus (DG) from the ipsilateral hemisphere. Data were represented as the
average number of degenerating cells per each region.
4.5. Detection of Neuronal Glutathione (GSH)
To detect the reduced form of GSH in the brain sections, we probed for GSH-N-ethylmaleimide
(NEM) adducts on the free-floating coronal sections [47–49]. Brain sections were incubated with
10 mM NEM for 4 h at 4 ◦C, washed and incubated with mouse anti-GS-NEM (diluted 1:100, Millipore,
Billerica, MA, USA). After washing, the sections were incubated with Alexa Fluor 488-conjugated goat
anti-mouse IgG (diluted 1:250, Invitrogen, Carlsbad, CA, USA) for 2 h. The sections were mounted
on gelatin-coated slides, and fluorescence signals were detected using a Zeiss LSM 710 confocal
imaging system (Carl Zeiss, Oberkochen, Germany). Stacks of images (1024 × 1024 pixels) from
consecutive slices of 0.9–1.2 μm in thickness were obtained by averaging eight scans per slice and were
processed with ZEN 2010 (Carl Zeiss, Oberkochen, Germany). To quantify GSH intensity, individual
neurons from the brain section images were selected as regions of interest (ROIs) and measured using
ImageJ (NIH, Bethesda, MA, USA). Briefly, to quantify the GSH intensity, the image was loaded into
ImageJ v. 1.50f and converted into an 8-bit image through the menu option Image → Type → 8-bit.
Then, regions comprising individual neurons in the subiculum, CA1, CA2, CA3 and DG images were
selected as ROIs. The resulting image was then binarized and restricted to the region of measurement
for individual neurons. To measure this area, the menu option Analyze → Measure was selected,
and then the signal from individual neurons was expressed as the mean gray value [49–51].
4.6. Immunofluorescence Staining
The immunolabeling procedures were performed as per routine immunostaining protocols.
To block endogenous peroxidase activity, sections were immersed in 3% hydrogen peroxide for 15 min
at room temperature. After washing in PBS, the sections were incubated with the following antibodies
as primary antibodies: a rabbit polyclonal anti-4-hydroxynonenal (4HNE, recognizing oxidative
stress, diluted 1:500, Alpha Diagnostic International, San Antonio, TX, USA) or a mouse monoclonal
anti-microtubule-associated protein 2 (MAP2, recognizing a neuron-specific cytoskeletal protein,
diluted 1:200, Millipore, Billerica, MA, USA). For visualization of antibody binding, Alexa Fluor
488- and 594-conjugated antibodies were applied at a dilution of 1:250 as secondary antibodies.
Between incubations, the sections were washed with PBS 3 times for 10 min each and then
mounted on gelatin-coated slides. According to the method modified from the above-described
method, 4HNE or MAP2 intensity was quantified using ImageJ. The image was converted to
8 bit through the menu options (Image/Type/8-bit). Next, the image was thresholded as follows
(Image/Adjust/Threshold): the type was set to black and white and the bottom slider moved to a
value sufficient to show only the 4HNE or MAP2 immunoreactive area. The thresholded image was
binary and only represented 4HNE or MAP2 immunoreactivity. The selected part in the whole image
was sorted, and then the intensity of 4HNE or MAP2 was expressed as the mean gray value.
4.7. Free Zinc Staining
For analyzing the vesicular and intraneuronal free zinc, the fresh frozen brain sections were stained
with N-(6-methoxy-8-quinolyl)-para-toluenesulfonamide (TSQ, Molecular Probes, Eugene, OR, USA)
fluorescent probes as previously described [52]. TSQ is a membrane-permeant Zn2+ indicator.
Mice were anesthetized with 3–5% isoflurane in oxygen. Brain tissue was harvested without perfusion,
quickly frozen on powdered dry ice and then stored at −80 ◦C. Unfixed fresh frozen brains were
coronally sectioned with a 25 μm thickness. Sections were immersed for 1 min in a solution of
4.5 μM TSQ, 140 mM sodium barbital and 140 mM sodium acetate (pH 10.5–11), then rinsed for 1 min
in 0.9% normal saline. TSQ–zinc binding was evaluated using an Olympus upright fluorescence
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charge-coupled device (CCD) cooled digital color camera (Hamamatsu Co., Bridgewater, NJ, USA)
with Infinity 3 (Lumenera Co., Ottawa, ON, Canada).
4.8. Statistical Analysis
Comparisons between experimental groups were conducted using repeated measures analysis of
variance (ANOVA) followed by the Student–Newman–Keuls post hoc test. Data were presented as the
mean ± SEM, and differences were considered significant at p < 0.05.
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Abstract: Zinc transporter 3 (ZnT3) is a member of the solute-linked carrier 30 (SLC 30) zinc
transporter family. It is closely linked to the nervous system, where it takes part in the transport of zinc
ions from the cytoplasm to the synaptic vesicles. ZnT3 has also been observed in the enteric nervous
system (ENS), but its reactions in response to pathological factors remain unknown. This study,
based on the triple immunofluorescence technique, describes changes in ZnT3-like immunoreactive
(ZnT3-LI) enteric neurons in the porcine ileum, caused by chemically-induced inflammation.
The inflammatory process led to a clear increase in the percentage of neurons immunoreactive
to ZnT3 in all “kinds” of intramural enteric plexuses, i.e., myenteric (MP), outer submucous (OSP)
and inner submucous (ISP) plexuses. Moreover, a wide range of other active substances was noted in
ZnT3-LI neurons under physiological and pathological conditions, and changes in neurochemical
characterisation of ZnT3+ cells in response to inflammation depended on the “kind” of enteric plexus.
The obtained results show that ZnT3 is present in the ENS in a relatively numerous and diversified
neuronal population, not only in physiological conditions, but also during inflammation. The reasons
for the observed changes are not clear; they may be connected with the functions of zinc ions and
their homeostasis disturbances in pathological processes. On the other hand, they may be due to
adaptive and/or neuroprotective processes within the pathologically altered gastrointestinal tract.
Keywords: zinc transporter 3 (ZnT3); enteric nervous system (ENS); inflammation; pigs
1. Introduction
The enteric nervous system (ENS) is localised in the wall of the gastrointestinal (GI) tract and
takes part in all regulatory processes connected with digestive actions, such as intestinal motility and
excretion [1]. It is characterised by significant independence from the central nervous system, as well as
complex conformation. The ENS is made up of millions of neurons grouped in intramural ganglionated
plexuses interconnected with a very dense network of nerves. The number and form of these plexuses
clearly depend both on the animal species and the fragment of the GI tract [1–3]. In the porcine
intestine, the ENS is built of three intramural plexuses: the myenteric plexus (MP)—located between
the longitudinal and circular muscle layers, the outer submucous plexus (OSP)—in the inner side of
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the circular muscle layer, and the inner submucous plexus (ISP)—between the muscularis mucosa and
lamina propria [4]. Enteric neurons vary in terms of their conformation, functions, electrophysiological
properties and neurochemical coding [2]. Besides acetylcholine, which is the main transmitter in
enteric neurons [5,6], several dozen other neuronal active substances have been described within
the ENS [2,3]. The most important of these include, among others, vasoactive intestinal peptide (VIP),
galanin (GAL), neuronal isoform of nitric oxide synthase (nNOS) and substance P (SP) [7–9]. Most of
the abovementioned factors act as neuromediators and/or neuromodulators, but the functions of
some neuronal substances described in the ENS remain unknown. One of these is zinc transporter 3
(ZnT3) [10].
ZnT3 is one of the solute-linked carrier 30 (SLC 30) protein family of zinc transporters, which in
mammals consists of 10 members (ZnT1 to ZnT10) [11]. These molecules allow zinc ions to permeate
from the cytoplasm to the intercellular space, as well as intracellular organelles [12]. From among
the ZnT family of zinc transporters, only ZnT3 is closely linked to neuronal cells, where it is responsible
for transport of zinc ions from the cytoplasm to synaptic vesicles, and thereby may influence neuronal
conduction [12]. ZnT3 has been described in the brain, spinal cord and autonomic peripheral nervous
system [13–15]. Within the central nervous system, this protein may be responsible for both sensory
conduction and secretory activity and is also considered to be a marker of zinc-enriched nerves (ZEN),
which have an inhibitory function [16]. Furthermore, it is known that ZnT3 can take part in some
pathological processes within the central nervous system, such as epilepsy, mechanical damage or
ischemia [15,17,18].
In contrast to the brain and spinal cord, knowledge about the distribution and functions of ZnT3 in
the peripheral autonomic nervous system is very sparse [14]. This is particularly visible with reference
to the ENS. Admittedly, ZnT3 has been described in the human descending colon [10], as well as in
the porcine duodenum and jejunum [19,20], but some aspects of the functions of this peptide within
the GI tract, especially during pathological states, remain within the realm of conjecture.
The roles of ZnT3 are probably closely linked to the functions of zinc in a living organism. This metal
is known to be a very important factor, as it is a component of various enzymatic systems and takes
part in the stabilisation of cellular membranes, DNA synthesis, cell division and the correct functioning
of the immune system [21]. Relatively high levels of zinc have been described in the central nervous
system, where this metal is indispensable to normal brain development and neuronal functioning [22].
Moreover, “free pool” reactive zinc ions can act as neurotransmitters and/or neuromodulators [23].
Zinc also plays an important role within the GI tract, where first of all it stimulates the absorption of
ions in enterocytes by modulating intracellular cAMP concentration, and therefore it is used as a drug
to decrease the severity and duration of diarrhoea [24]. Moreover, zinc as a component of zinc finger
E-box-binding homeobox (Zeb) 2 protein takes part in the formation, migration and specification of
cells in the neural crest, from which the ENS arises, and is also necessary for the correct functioning of
enteric neurons [25].
On the other hand, it is relatively well known that the ENS regulates the functions of the intestinal
mucosa, which is the first barrier against various pathological factors [1]. Therefore, enteric neurons
may undergo changes caused by adaptive and/or neuroprotective processes during many intestinal
and extra-intestinal diseases, and these changes mainly manifest themselves in modifications of
neuronal chemical coding [25–29].
The aim of the present study was to investigate the changes in ZnT3-like immunoreactive
(ZnT3-LI) enteric neurons in the porcine ileum during experimental chemically induced inflammation.
The choice of the pig as the experimental animal during the present study was determined by the fact
that this species more and more often appears to be an optimal animal model for pathological processes
in the human organism, due to similarities in anatomical, histological and physiological properties








Int. J. Mol. Sci. 2017, 18, 338
2. Results
In the present study, neurons immunoreactive to ZnT3 were observed within the porcine ileal
enteric nervous system, both under physiological conditions and during inflammation (Table 1).
All ZnT3-positive cells noted in the ganglionated plexuses of the ENS were also immunoreactive to
protein gene product 9.5 (PGP 9.5—used as a panneronal marker). Moreover, during the present
investigation, ZnT3-LI cells were noted outside of the enteric plexuses. These cells were scattered in
various parts of the intestinal wall and were not PGP 9.5-positive.
2.1. ZnT3 in the ENS under Physiological Conditions
Under physiological conditions, the percentage of these neurons was relatively high, levelised in
all “kinds” of plexuses, and amounted to 42.3% ± 4.7% in the MP (Figure 1), 43.5% ± 6.8% in the OSP
(Figure 2) and 48.6% in the ISP (Figure 3). In individual enteric ganglion, most often three or more
ZnT3-LI cells were noted (Figure 2c), but ganglia with one or two such perikarya were also observed
(Figure 1a). There are no differences between particular “kinds” of plexuses in the distribution of
ZnT3+ cells in individual enteric ganglia.
2.1.1. Neurochemical Characterisation of ZnT3+ Cholinergic Enteric Neurons
A wide range of neuronal active substances was investigated in ZnT3-positive enteric neurons
under physiological conditions (Table 1). A significant percentage of cells were immunoreactive
to ZnT3, regardless of whether the “kind” of enteric plexus was cholinergic (positive to vesicular
acetylcholine transporter—VAChT) (Figure 1a,c,d, Figures 2a–c and 3b–d). These neurons accounted
for 85.0% ± 5.8%, 82.0% ± 5.9% and 90.0% ± 7.2% of all ZnT3+ perikarya in the MP, OSP and ISP,
respectively. Neurochemical coding of cholinergic neurons immunoreactive to ZnT3 was variable in
different “kinds” of enteric plexuses. Some ZnT3+/VAChT+ neuronal cells in the MP and OSP were
also immunoreactive to somatostatin (SOM), VIP and SP, but the degree of co-localisation of ZnT3 with
the abovementioned particular substances was slight and did not exceed 7.5% (Table 1).
A completely different situation was observed in the ISP. In this plexus, a much higher percentage
of cholinergic ZnT3-LI neurons were immunoreactive to SOM, VIP and/or SP. These values amounted
to 24.1% ± 1.2%, 33.0% ± 3.6% and 55.1% ± 1.3%, respectively (Table 1). Moreover, 65.2% ± 1.2%
of cholinergic ZnT3+ cells in the ISP were also immunoreactive to GAL, contrary to MP and
OSP, where ZnT3+/VAChT+/GAL+ neurons were not observed at all. During the present study,
immunoreactivity to nNOS, leu-enkephalin (LENK), neuropeptide Y (NPY) and calcitonin gene-related
peptide (CGRP) was not observed in cholinergic ZnT3+ neurons in any enteric plexus.
2.1.2. Neurochemical Characterisation of ZnT3+ Non-Cholinergic Enteric Neurons
Non-cholinergic neurons in the MP amounted to 15.0% ± 5.6% of all ZnT3+ cells (Figure 1a,c,d).
In the OSP and ISP, these values stood at 18.0% ± 5.9% and 10.0% ± 7.2%, respectively (Figures 2c and 3b).
The degree of co-localisation of ZnT3 with other substances studied in non-cholinergic cells clearly
depended on the “kind” of plexus (Table 1). The most visible differences were observed in the event of
nNOS and GAL. In the MP, 17.1% ± 1.1% of non-cholinergic ZnT3+ cells were also nNOS-positive,
whereas in the OSP, this value amounted to only 7.4% ± 1.3%, and in the ISP, such cells were not
observed at all. Cells simultaneously immunoreactive to ZnT3 and GAL comprised 11.9% ± 1.5% of
all ZnT3-LI non-cholinergic neurons in the MP, but such perikarya were not noted in the OSP, and in
the ISP, they amounted to only 2.8% ± 0.3%. The degree of co-localisations of ZnT3 with VIP, SOM and
SP was levelised in all “kinds” of plexuses and was rather slight, because they did not exceed
5% of all non-cholinergic ZnT3-LI cells regardless of the “kind” of plexus. An especially low level of
co-localisation of ZnT3 with LENK was observed. Cells simultaneously immunopositive to ZnT3 and
LENK were observed only in the MP, and the percentage of these amounted to barely 0.5% ± 0.2% of
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as well as ZnT3 and CGRP, were not observed in non-cholinergic ZnT3-LI cells in any plexus of the ileal
enteric nervous system under physiological conditions.
Table 1. Zinc transporter 3-like immunoreactive (ZnT3-LI) neurons in the enteric nervous system




C Group I Group C Group I Group C Group I Group
PGP+/ZnT3+ 1 42.3 ± 4.7 84 ± 3.9 43.5 ± 6.8 85.6 ± 2.0 48.6 ± 4.8 79.0 ± 3.2
ZnT3+/VAChT+ 2 85.0 ± 5.8 41.0 ± 2.7 82.0 ± 5.9 31.3 ± 2.8 90.0 ± 7.2 34.0 ± 3.0
ZnT3+/VAChT+/CGRP+ 3 0 0 0 0 0 0
ZnT3+/VAChT+/GAL+ 3 0 5.4 ± 1.5 0 4.7 ± 0.9 65.2 ± 1.2 4.7 ± 1.3
ZnT3+/VAChT+/LENK+ 3 0 0 0 0 0 0
ZnT3+/VAChT+/NOS+ 3 0 0 0 0 0 0
ZnT3+/VAChT+/NPY+ 3 0 0 0 0 0 0
ZnT3+/VAChT+/SOM+ 3 2.9 ± 1.4 0 7.4 ± 1.4 1.1 ± 0.8 24.1 ± 1.2 4.1 ± 0.8
ZnT3+/VAChT+/SP+ 3 1.2 ± 0.5 4.2 ± 1.2 4.6 ± 1.6 2.8 ± 1.4 55.1 ± 1.3 6.8 ± 1.5
ZnT3+/VAChT+/VIP+ 3 2.9 ± 1.4 11.2 ± 1.9 1.4 ± 0.8 3.8 ± 1.4 33.0 ± 3.6 7.3 ± 1.6
ZnT3+/VAChT− 2 15.0 ± 5.6 59.0 ± 2.7 18.0 ± 5.9 68.7 ± 2.8 10.0 ± 7.2 66.0 ± 3.0
ZnT3+/VAChT−/CGRP+ 3 0 0 0 0 0 0
ZnT3+/VAChT−/GAL+ 3 11.9 ± 1.5 30.2 ± 3.4 0 36.3 ± 7.5 2.8 ± 0.1 54.7 ± 7.4
ZnT3+/VAChT−/LENK+ 3 0.5 ± 0.2 41.2 ± 2.7 0 0 0 0
ZnT3+/VAChT−/NOS+ 3 17.1 ± 1.1 57.0 ± 4.0 7.4 ± 1.3 10.3 ± 2.4 0 0
ZnT3+/VAChT−/NPY+ 3 0 0 0 0 0 0
ZnT3+/VAChT−/SOM+ 3 3.4 ± 1.3 0 1.4 ± 0.6 43.0 ± 3.6 3.7 ± 1.0 38.6 ± 1.5
ZnT3+/VAChT−/SP+ 3 1.1 ± 0.6 32.2 ± 0.4 4.7 ± 1.8 9.5 ± 2.4 4.1 ± 1.2 36.9 ± 1.5
ZnT3+/VAChT−/VIP+ 3 3.9 ± 0.3 52.1 ± 2.8 4.6 ± 1.6 20.7 ± 9.7 2.9 ± 1.3 51.4 ± 3.5
MP: myenteric plexus; OSP: outer submucous plexus; ISP: inner submucous plexus; 1 The relative frequency of
ZnT3-LI neuronal cells is presented as % (mean ± SEM) in relation to all neurons counted within the enteric
ganglionated plexuses stained for PGP 9.5 (PGP 9.5-LI cells were treated as 100%); 2 The percentage of VAChT+
or VAChT− neurons is presented as % (mean ± SEM) of all neurons counted within the ganglionated plexuses
stained for ZnT3; 3 The relative frequency of neurons immunoreactive to particular substances is presented as
% (mean ± SEM) of all ZnT3+/VAChT+ or ZnT3+/VAChT− neurons counted within the ganglionated plexuses.
Statistically significant data (p ≤ 0.05) are marked by a different colour (red—increase, green—decrease of
the percentage of a particular neuronal population in I group compared to C group).The main groups of cells
(general percentage of ZnT3+, cholinergic ZnT3+ and non-cholinergic ZnT3+ neurons) are indicated with bold font.
A completely different situation was observed in the ISP. In this plexus, a much higher percentage
of cholinergic ZnT3-LI neurons were immunoreactive to SOM, VIP and/or SP. These values amounted
to 24.1% ± 1.2%, 33.0% ± 3.6% and 55.1% ± 1.3%, respectively (Table 1). Moreover, 65.2% ± 1.2% of
cholinergic ZnT3+ cells in the ISP were also immunoreactive to GAL, contrary to MP and
OSP, where ZnT3+/VAChT+/GAL+ neurons were not observed at all. During the present study,
immunoreactivity to nNOS, leu-enkephalin (LENK), neuropeptide Y (NPY) and calcitonin gene-related
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Figure 1. Representative images of ZnT3+ neurons located in the myenteric plexus (MP) of the porcine
ileum: myenteric ganglia. All images are composites of merged images taken separately from blue,
red and green fluorescent channels. Control (C) group: (a) ZnT3+/VAChT+/PGP9.5+ neurons are
indicated with double-headed arrows, ZnT3−/VAChT−/PGP9.5+ neurons are indicated with small
arrows; (b) ZnT3+/VAChT+/VIP+ neurons are indicated with an arrow, ZnT3+/VAChT+/VIP− neurons
are indicated with small arrows; (c) ZnT3+/VAChT+/SP− neurons are indicated with small arrows;
ZnT3+/VAChT−/SP− neurons are is indicated with arrows; (d) ZnT3+/VAChT+/SOM− neuron is
indicated with a small arrow; ZnT3+/VAChT−/SOM− neurons are indicated with arrows. Inflammatory
(I) group (a’) ZnT3+/VAChT+/PGP9.5+ neurons are indicated with arrows, ZnT3+/VAChT−/PGP9.5+
neurons are indicated with double-headed arrows; (b’) ZnT3+/VAChT−/VIP+ neurons are indicated
with arrows; ZnT3+/VAChT−/VIP− neurons are indicated with a small arrow; (c’) ZnT3+/VAChT+/SP−
neuron is indicated with a small arrow; ZnT3+/VAChT−/SP+ neurons are indicated with
double-headed arrows; ZnT3+/VAChT−/SP− neurons are indicated with arrows; Control group (d’)
ZnT3+/VAChT+/SOM− neuron is indicated with a small arrow; ZnT3+/VAChT−/SOM− neurons are
indicated with arrows. Scale bar 25 μm.
2.2. ZnT3 in the ENS during the Inflammatory Process
Experimentally induced colitis changed both the percentage of ZnT3-positive cells and the degree
of co-localisation of ZnT3 with the other active factors studied (Table 1). The observed modifications
clearly depended on the “kind” of enteric plexus, as well as the type of neurochemical substance.
During the inflammatory process, an evident increase in the percentage of ZnT3+ neurons (in
relation to all protein gene product (PGP 9.5)-positive cells) was observed within all enteric plexuses.
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to 84.1% ± 3.9% and 85.6% ± 2.0%, respectively. Changes in the ISP were less pronounced, but also
clearly visible (an increase from 48.6% ± 4.8% to 79.0% ± 3.2%).
Changes in Neurochemical Characterisation of ZnT3+ Enteric Neurons during Inflammation
Myenteric Plexus
Inflammation influenced the neurochemical characterisation of both cholinergic and non-cholinergic
enteric neurons immunoreactive to ZnT3. In the MP (Figure 1, Table 1), an increase of immunoreactivity
in the majority of substances studied was observed in both classes of neurons, and the magnitude
of these changes was most visible in non-cholinergic (VAChT−) cells. The highest percentage
of ZnT3+/VAChT− neuronal cells during inflammation was also immunopositive to nNOS
(57.0% ± 4.0%), VIP (52.1% ± 2.8%) and/or LENK (41.2% ± 2.7%). ZnT3-LI cholinergic cells (VAChT+)
contained only VIP (11.2% ± 1.9%), GAL (5.4% ± 1.5%) and SP (4.2% ± 1.1%). Contrary to the majority
of substances studied, the number of ZnT3-positive cells (both cholinergic and non-cholinergic)
immunoreactive to SOM within MP dropped to zero.
Outer Submucous Plexus
In the OSP (Figure 2), an increase in the percentage of cholinergic ZnT3-positive cells simultaneously
immunoreactive to VIP (from 1.4% ± 0.8% to 3.8% ± 1.4%) and/or GAL (from 0% to 4.7% ± 0.9%) was
noted, contrary to neurons ZnT3+/VAChT+/SOM+ and ZnT3+/VAChT+/SP+, where inflammation
caused a decrease from 7.4% ± 1.4% to 1.1% ± 0.8% and 4.6% ± 1.6% to 2.8% ± 1.4%, respectively.
Moreover, in the population of OSP non-cholinergic neurons (just as in the MP), the observed changes
were most visible. The percentage of ZnT3+/VaChT− neurons immunoreactive to the majority of
substances studied was higher during inflammation. The highest number of ZnT3+ non-cholinergic cells
was also immunopositive to SOM (43.0% ± 3.6%) and/or GAL (36.3% ± 7.5%) (Table 1).
Figure 2. Representative images of ZnT3+ neurons located in the outer submucous plexus (OSP) of
the porcine ileum. All images are composites of merged images taken separately from blue, red and
green fluorescent channels. Control (C) group: (a) ZnT3+/VAChT+/VIP− neurons are indicated with
arrows; (b) ZnT3+/VAChT+/SOM− neurons are indicated with arrows; (c) ZnT3+/VAChT+/GAL−
neurons are indicated with arrows; ZnT3+/VAChT−/GAL− neuron is indicated with a double-headed
arrow. Inflammatory (I) group: (a’) ZnT3+/VAChT+/VIP− neuron is indicated with an arrow;
ZnT3+/VAChT−/VIP+ neuron is indicated with a small arrow; (b’) ZnT3+/VAChT−/SOM+ neuron
is indicated with a small arrow; ZnT3+/VAChT+/VIP− neurons are indicated with arrows;
(c’) ZnT3+/VAChT−/GAL+ neuron is indicated with a small arrow; ZnT3+/VAChT+/GAL− neuron is
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Inner Submucous Plexus
During inflammation, the degree of co-localisation of ZnT3 with the majority of substances
studied in cholinergic neurons within the ISP (Figure 3) was several times lower than in control
animals. The inflammatory process caused a decrease in the percentage of neurons immunoreactive to
ZnT3/VAChT/SOM (from 24.1% ± 1.2% to 4.1% ± 08%), ZnT3/VAChT/VIP (from 33.0% ± 3.6% to
7.3% ± 1.6%), ZnT3/VAChT/SP (from 55.1% ± 1.3% to 6.8% ± 1.5%) and ZnT3/VAChT/GAL (from
65.2% ± 1.2% to 4.7% ± 1.3%) (Table 1). Contrary to cholinergic neurons, an increase of the percentage
of cells immunoreactive to the majority of all substances studied was observed in non-cholinergic
ZnT3-positive perikarya. During inflammation, most of the ZnT3+/VAChT− neurons were also
immunopositive to GAL (54.7% ± 7.4%) and/or nNOS (51.4% ± 3.5%) (Table 1).
Figure 3. Representative images of ZnT3+ neurons located in the inner submucous plexus (ISP) of
porcine ileum. All images are composites of merged images taken separately from blue, red and green
fluorescent channels. Control (C) group: (a) ZnT3+/VAChT−/VIP− neurons are indicated with arrows;
I group (b) ZnT3+/VAChT+/SOM− neurons are indicated with small arrows; ZnT3+/VAChT−/SOM−
neuron is indicated with an arrow; (c) ZnT3+/VAChT−/SP− neurons are indicated with small
arrows; ZnT3+/VAChT+/SP+ neuron is indicated with an arrow; (d) ZnT3+/VAChT−/GAL−
neurons are indicated with small arrows; ZnT3+/VAChT+/GAL− neuron is indicated with an
arrow; ZnT3−/VAChT+/GAL− neuron is indicated with a double-headed arrow; Inflammatory (I)
group: (a’) ZnT3+/VAChT+/VIP− neurons are indicated with small arrows; ZnT3+/VAChT−/VIP+
neurons are indicated with double-headed arrows; ZnT3+/VAChT−/VIP− neuron is indicated with
an arrow; (b’) ZnT3+/VAChT−/SOM+ neurons are indicated with arrows; ZnT3+/VAChT+/SOM−
neurons are indicated with small arrows; (c’) ZnT3+/VAChT−/SP+ neurons are indicated with arrows;
ZnT3+/VAChT+/SP− neurons are indicated with small arrows; (d’) ZnT3+/VAChT+/GAL− neuron
is indicated with a double-headed arrow; ZnT3+/VAChT−/GAL− neuron is indicated with a small
arrow; ZnT3+/VAChT−/GAL+ neurons are indicated with arrows. Scale bar 25 μm.
3. Discussion
The results obtained during the present study show that ZnT3-positive neurons are relatively
numerous in the ENS of the porcine ileum, which is in accordance with previous studies on humans [10]
and other parts of the porcine digestive tract [19,20]. In terms of the numerical account of ZnT3-positive
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nervous system, where such perikarya were rather sparse [14]. These observations strongly suggest
the important role of ZnT3 within enteric neurons, but the factors that affect the expression of this
peptide in enteric neurons under physiological conditions, as well as the exact functions of ZnT3
in the GI tract, are unknown. During the present study, all ZnT3-LI cells observed in the enteric
plexuses were also immunoreactive to PGP 9.5. This fact shows that ZnT3 in the ENS is present
solely in neuronal cells, which is in agreement with previous studies [10,19,20]. On the other hand,
ZnT3-positive cells scattered in the intestinal wall outside of the enteric plexuses were not neurons
(PGP 9.5-negative). This observation confirms previous studies describing the presence of ZnT3 in
pancreatic β cells [33]. Presently, ZnT3-LI non-neuronal cells have not been observed in the intestine,
and the character and functions of such cells are completely unknown.
One of the more interesting aspects of the occurrence of ZnT3 in the GI tract is the dependence of its
level on the amount of zinc in food. Previous studies showed that a diet deficient in zinc caused changes
in mRNA levels for various ZnT family peptides in the pancreas, digestive tract and central nervous
system of rodents [34–36], but at present, the influence of food on ZnT3 in the ENS has not been studied.
The role of this zinc transporter in the GI tract also remains unknown, and all assumptions concerning
this problem are based on an analogy with the central nervous system, where the functions of ZnT3
are better known. Namely, this zinc transporter could take part in the conduction of sensory stimuli
and regulate neuronal secretion [37,38]. Moreover, ZnT3 is regarded as a marker of zinc-enriched
terminals, which are associated with inhibitory processes [16]. The present study, in which many
other neuroactive substances were observed in ZnT3+ neurons, suggests that this zinc transporter
is present in varied classes of enteric neurons and, consequently, could play various roles not only
in the central nervous system, but also in the ENS. Proof of this seems to be the presence of ZnT3
in both cholinergic and non-cholinergic nNOS+ enteric neurons, observed during the present study.
Acetylcholine, the main neuromediator of the ENS, present in different functional classes of enteric
neurons [2], is responsible for the activation of intestinal motility [5,6] and the secretory functions
of the GI tract [39]. In contrast, nitric oxide (NO), which is characteristic mainly for non-cholinergic
neuronal cells, may act as an inhibitory factor. It is known that NO has a relaxatory effect on intestinal
muscles, suppressing the exudation of electrolytes and hormones by the GI tract and also regulating
blood flow in the gut by blood vessel relaxation [40–42]. Moreover, differences in neurochemical
characterisation between ZnT3-positive enteric neurons in the ileum (this study) and the jejunum [19]
or duodenum [20] may suggest that the exact functions of ZnT3 in the ENS depend on the fragment of
the digestive tract.
The influence of experimental colitis on ZnT3-positive enteric neurons has been observed during
the present study. These observations confirm the relatively well-known capabilities of the ENS
to changes under various pathological factors [26] and strongly suggest that ZnT3 can take part in
adaptive, neuroprotective and/or regenerative reactions within the GI tract. Previous studies on
the central nervous system described the increase in mRNA levels for various ZnT family peptides
under cerebral ischemia [43], which is probably connected with the augmentation of the amount of
zinc in neuronal tissue during this type of pathological process [44,45]. It should be pointed out that
zinc in non-physiological conditions can act on neurons in two ways. On the one hand, zinc exhibits
neuroprotective activity and reduces neuronal damage [46], but on the other hand, it is known that this
metal can be deposited in the cytoplasm and present neurotoxic effects [44]. In this case, the increase
in the expression of ZnT transporters is intended to protect neuronal cells. Similar mechanisms
probably occur in the GI tract and are the basis of the changes observed during the present study.
This is all the more likely as the neuroprotective role of ZnT3 has been described in the central
nervous system during Alzheimer’s disease [47], and interactions between ZnT transporters and NO
in neuroprotective activity have also been observed. The high degree of co-localisation of ZnT3 with
nNOS, noted in the present study especially during inflammation, seems to confirm these interactions.
Moreover, other substances (VIP, GAL) that co-localised with ZnT3+ enteric neurons observed during
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Another argument for the neuroprotective role of ZnT3 in the ENS is the fact that pathological
processes cause an increase in the expression of active factors that exhibit neuroprotective effects with
a simultaneous decline in the amount of other substances [49]. This situation has been observed in
the present study. Namely, a decrease in the percentage of ZnT3-positive cholinergic neurons has been
noted, and acetylcholine is the main neuromediator in the ENS under physiological conditions [5,6].
At the same time, an increase in the degree of co-localisation of ZnT3 with other substances, such as
nNOS, VIP, SP, SOM, LENK and/or GAL, has generally been observed.
The co-localisation of ZnT3 with the abovementioned neurochemical factors suggests that this
zinc transporter can play similar roles (besides neuroprotective) for these neurochemical factors.
ZnT3 are possibly inhibitory factors in the ENS, like VIP or nNOS [40,41,51], and can also take part in
the conduction of sensitive stimuli, like SP or LENK [9,52,53]. These functions of ZnT3 have also been
described in the central nervous system [16].
On the other hand, it should be pointed out that the functions of ZnT3 in the central nervous
system, although important (by analogy) to explain its role in the ENS, do not clarify all doubts.
For example, ZnT3-positive nerve fibres, known as zinc-enriched nerves, which can play an inhibitory
role, have been studied in the central nervous system [16], where both the present experiment and
previous studies [10,19,20] did not reveal nerve fibres to be immunoreactive to this zinc transporter in
the intestinal wall. Moreover, the exact reasons for changes in immunoreactivity to ZnT3 observed
during the present study are difficult to explain, as they may arise from modifications in various
stages of peptide synthesis, such as transcription or translation, as well as during post-translational
modifications and even shifts in the transport of ZnT3 within neuronal cells.
The changes observed during the present investigations are most likely related to disturbances
in zinc homeostasis. It is relatively well established that zinc, as one of the essential micronutrients,
plays important roles during diseases localised in various organs and systems. Previous studies
showed that the deregulation of zinc homeostasis can be involved in processes connected with
Alzheimer’s disease, asthma and diabetes [47,54,55], as well as pathological processes within the GI
tract, including inflammatory bowel disease, ulcerative colitis and Crohn’s disease [56,57].
On the other hand, zinc transporters are key factors implicated in the regulation of zinc
distribution in a living organism. There are two main families of zinc transporters: the ZnT proteins
(SLC30) and the Zip (Zrt- and Irt-like proteins) family (solute-linked carrier 39—SLC39) [58]. The first
of these transport zinc ions from the cytoplasm outside of cells or into the intracellular vesicle,
thereby reducing intracellular zinc concentration. The second group has the opposite action, as they
promote zinc transport from extracellular space into the cytoplasm.
ZnT3, which is mainly localised in neuronal cells, transports zinc ions from the cytoplasm into
synaptic vesicles [12], and the correlation between the expression of this zinc transporter and synaptic
Zn2+ levels has been described [12,59].
The exact roles in the maintenance of synaptic zinc ions homeostasis in the ENS remain unknown,
but they are probably similar to those observed within the CNS. It is known that synaptic Zn2+
in the brain and spinal cord plays a modulatory role in synaptic transmission, and its homeostasis
determines the correct functioning of the nervous system [59]. Both synaptic Zn2+ deficiency and excess
causes disturbances in postsynaptic neurons. In the first case, dysfunctions of postsynaptic neurons
have been observed, and in the second neurodegeneration has been observed [59,60]. Given this
context, Zn2+ is regarded as a potentially neurotoxic factor that is involved in neuronal loss and plays
some role in neurodegenerative diseases, including Huntington’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis [60]. On the other hand, it is known that both ZnT3 and synaptic Zn2+
are inherent to correct brain development [61,62].
The increase of ZnT3-like immunoreactivity observed in the present study was probably
connected with synaptic zinc ions excess. This effect could be due to the direct neurodegenerative
influence of the inflammatory process. On the other hand, it has been connected with neuroprotective
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for the dysfunction of postsynaptic neurons, which is often connected with a deficiency of synaptic
Zn2+ [59]. For this reason, presynaptic neurons enhanced the expression of ZnT3 in order to maintain
zinc homeostasis. The increase in ZnT3-like immunoreactivity could also be the result of an excessive
concentration of intracellular cytoplasmic zinc. This is more likely as previous studies described
the activation of ZIP transporters (responsible for the transport of zinc ions from extracellular fluid
into the cytoplasm) during inflammatory processes [63].
The observed changes could also be connected with other functions of zinc in the intestine,
including participation in the maintenance of intestinal mucosal layer integrity, controlling leukocyte
infiltration, as well as excretion of pro-inflammatory factors [64–66]. Moreover, it is known that ZnT3
probably takes part in sensory stimuli conduction [67], and fluctuations in this transporter’s levels
observed during the present study were caused by pain processes during inflammation.
4. Materials and Methods
The present study was performed on 10 immature female pigs of the Large White Polish breed at
the age of approximately eight weeks. The animals were kept under standard laboratory conditions.
All actions connected with the experiment were carried out in compliance with the regulations of
the Local Ethical Committee in Olsztyn (Poland)—(decision numbers: 90/2007 from 20 November
2007—submission 90/2007/N and 27/2009 from 18 March 2009—submission 26/2009/DTN).
Sows were randomly divided into two experimental groups: control (C group; n = 5) without
any surgical operations, and animals in which experimental acute colitis and visceral pain were
induced according to the method described previously by Miampamba et al. [68] and modified by
Gonkowski et al. [69] (Inflammatory—I group; n = 5).
The pigs of I group were subjected to the following experimental procedures: (a) premedication
with Stressnil (Janssen, Beerse, Belgium, 75 μL/kg of body weight given intravenously) 15 min
before the application of the main anaesthetic; (b) general anaesthesia using sodium thiopental
(Thiopental, Sandoz, Kundl-Rakúsko, Austria; 20 mg/kg of body weight given intravenously);
and (c) median laparotomy. During laparotomy, the sows were injected with 80 μL of 10% formalin
solution (microinjections of 5–8 μL) into the wall of the ileum five centimetres before the ileocecal
valve. The group of “sham” operated animals (injections of saline solution instead of formalin) was
deliberately abandoned during the experiment due to the fact that previous studies clearly showed
that this type of manipulation of the intestine does not influence the neurochemical coding of enteric
neurons [9,27,70]. Reducing the number of animals was in accordance with the regulations of the Local
Ethical Committee.
After five days, all animals (C and I groups) were euthanized by an overdose of sodium thiopental
and then perfused transcardially with 4% buffered paraformaldehyde (pH 7.4) prepared ex tempore.
The same parts (about 2 cm long) of the ileum (from the area where injections of the formalin
solution were made and inflammatory changes were observed in animals of I group) were collected
and post-fixed by immersion in the same solution used during transcardial perfusion for 20 min.
Then tissues were rinsed in a phosphate buffer (0.1 M; pH 7.4; 4 ◦C) for three days with the buffer
changing every day and, finally, stored in 18% sucrose (at least 10 days). After this period, the fragments
of ileum were frozen at −25 ◦C and cut into 10 μm-thick cryostat sections, which were subjected
to standard triple-labelling immunofluorescence according to the method described previously by
Wojtkiewicz et al. [19]. In short, the immunofluorescence technique was performed as follows:
slices with tissue sections were air-dried at room temperature (rt) for 45 min and incubated with
a blocking solution (10% normal goat serum, 0.1% bovine serum albumin, 0.01% NaN3, Triton x-100 and
thimerozal in PBS) for 1 h (rt). After this period, tissues were incubated overnight in a humid chamber
(rt) with a mixture of three primary antibodies: (1) anti-protein gene product 9.5 (PGP 9.5—used here as
a pan-neuronal marker); (2) anti-vesicular acetylcholine transporter (VAChT—used here as a marker of
cholinergic neurons); and (3) directed against one of the following substances: calcitonin gene-related
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(Nnos—used here as a marker of nitrergic neurons), neuropeptide Y (NPY), somatostatin (SOM),
substance P (SP) and vasoactive intestinal polypeptide (VIP). The following day, slices were incubated
(1 h, rt) with species-specific secondary antisera conjugated to 7-amino-4-methylcoumarin-3-acetic acid
(AMCA), fluorescein isothiocyanate (FITC) or biotin, which was then visualised by a streptavidin-CY3
complex (1 h; rt). The specification of primary and secondary antibodies used in the present
study is shown in Table 2. Each stage of immunofluorescence labelling was followed by rinsing
the slices with PBS (3 × 10 min, pH 7.4). The specificity of antisera was tested by standard controls,
including pre-absorption of antibodies with the appropriate antigen, omission test and replacement
of antisera by non-immune sera. The abovementioned controls completely eliminated labelling in
the tissue.
The overall percentage of ZnT3-LI neurons was defined by the examination of at least
700 PGP-9.5-labelled cell bodies for ZnT3-like immunoreactivity in each “kind” of enteric plexus
(i.e., muscular, outer submucous and inner submucous plexuses), and the number of neurons
immunoreactive to PGP 9.5 was treated as 100%. In the case of the study on the co-localisation
of ZnT3 with acetylcholine, at least 300 ZnT3-positive cell bodies in particular types of enteric
ganglia were examined for immunoreactivity to VAChT. In these studies, ZnT3-positive neurons were
considered as representing 100%. To determine the chemical coding of cholinergic and non-cholinergic
neurons immunoreactive to ZnT3, at least 300 ZnT3+/VAChT+ and ZnT3+/VAChT− were studied for
immunoreactivity against particular substances. Evaluation of immunopositive cells and the counting
of neurons were performed by two independent investigators. During the present study, only double-
or triple-labelled neuronal cell bodies with a clearly visible nucleus were determined under an Olympus
BX51 microscope equipped with epi-fluorescence and appropriate filter sets, pooled and presented as
mean ± SEM. The section of ileum that was the subject of the study was located at least 100 μm apart
to prevent double counting of neurons. All pictures were captured with a digital camera connected to
a PC. Statistical analysis was performed with the Anova test using Statistica 10 software (StatSoft Inc.,
Tulsa, OK, USA). The differences were considered statistically significant at p ≤ 0.05.
Table 2. Specification of immune reagents used in the study: PGP9.5—protein gene
product 9.5, ZnT3—zinc transporter 3, NOS—nitric oxide synthase, VIP—vasoactive intestinal
peptide, SOM—somatostatin, VAChT—Vesicular acetylcholine transporter, NPY—neuropeptide
Y, GAL—galanin, CGRP—calcitonin-gene related peptide, FITC—fluorescein isothiocyanate,
AMCA—7-amino-4-methylcoumarin-3-acetic acid, H heavy chain, L light chain.
Primary Antibody
Antisera Code Host Species Dilution Supplier
PGP9.5 7863-2004 Mouse 1:2000 Biogenesis Inc., Poole, UK;www.biogenesis.co.uk
ZnT3 - Rabbit 1:600 Gift from prof. Palmiter, University ofWashington Seattle, WA, USA
NOS N2280 Mouse 1: 2000 Sigma-Aldrich, Saint Louis, MS, USA;www.sigma-aldrich.com
VIP 9535-0504 Mouse 1: 2000 Biogenesis Inc.
SP 8450-0505 Rat 1:300 Biogenesis Inc.
SOM 8330-0009 Rat 1: 100 Biogenesis Inc.
LENK 4140-0355 Mouse 1: 1000 Biogenesis Inc.
VAChT H-V007 Goat 1: 2000 Phoenix, Pharmaceuticals, INC., Belmont,CA, USA; www.phoenixpeptide.com
NPY NZ1115 Rat 1:300 Biomol Research Laboratories Inc.,Plymouth, PA, USA
GAL T-5036 Guinea pig 1:1000 Peninsula Labs., San Carlos, CA, USA;see Bachem AG; www.bachem.com












FITC-conjugated donkey-anti-mouse IgG (H+L) 1:800 Jackson, 715-095-151, West Grove, PA, USA
FITC-conjugated donkey-anti-rat IgG (H+L) 1:800 Jackson, 712-095-153
FITC-conjugated donkey-anti-guinea pig IgG (H+L) 1:1000 Jackson, 706-095-148
FITC-conjugated donkey-anti-goat IgG (H+L) 1:1000 Jackson, 705-096-147
Biotinylated goat anti-rabbit immunoglobulins 1:1000 DAKO, E 0432, Carpinteria, CA, USA
Biotin conjugated F(ab)’ fragment of affinity
Purified anti-rabbit IgG (H+L) 1:1000 BioTrend, 711-1622, Cologne, Germany
AMCA-conjugated donkey-anti-mouse IgG (H+L) 1:50 Jackson, 715-155-151
AMCA-conjugated donkey-anti-rat IgG (H+L) 1:50 Jackson, 715-155-153
AMCA-conjugated donkey-anti-goat IgG (H+L) 1:50 Jackson, 705-156-147
CY3-conjugated Streptavidin 1:9000 Jackson, 016-160-084
5. Conclusions
In summary, the present investigation shows that ZnT3 is present in relatively numerous
populations of enteric neurons in the porcine ileum, both under physiological conditions and during
experimental inflammation in cholinergic and non-cholinergic cells. The wide range of active
substances (including SP, VIP, SOM, nNOS and GAL) that co-localise with ZnT3 suggests that this
zinc transporter occurs in various classes of enteric neurons and may take part in different regulatory
processes within the intestinal wall. Meanwhile, changes in ZnT3-like immunoreactivity during
experimental inflammation could denote the functions of ZnT3 in adaptive and/or regenerative
reactions in the ENS. ZnT3 is probably present in enteric neurons, which use zinc ions as
a neuromodulator, and fluctuations in ZnT3 expression are connected with disturbances in zinc
ions homeostasis. Moreover, it is known that, on the one hand, zinc is essential for correct
development and functioning of the ENS [25], and during inflammation or nerve damage, ZnT3 can
play a neuroprotective role. On the other hand, zinc ions can exhibit neurodegenerative activity [59].
Therefore, a lot of aspects connected with the role of ZnT3 within the ENS remain unknown and
require further investigations.
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Abstract: The common carp can tolerate extremely low oxygen levels. These fish store zinc in a specific
zinc-binding protein presented in digestive tract tissues, and under low oxygen, the stored zinc is
released and used as a signal to stimulate erythropoiesis (red blood cell formation). To determine
whether the environmental supply of zinc to other fish species can serve as a signal to induce
erythropoiesis as in the common carp, head kidney cells of four different fish species were cultured
with supplemental ZnCl2. Zinc stimulated approximately a three-fold increase in immature red
blood cells (RBCs) in one day. The stimulation of erythropoiesis by zinc was dose-dependent.
ZnSO4 solution was injected into an experimental blood loss tilapia model. Blood analysis and
microscopic observation of the blood cells indicated that, in vivo, the presence of additional zinc
induced erythropoiesis in the bled tilapia. In the fish species studied, zinc could be used as a signal to
stimulate erythropoiesis both in vitro and in vivo. The present report suggests a possible approach
for the induction of red blood cell formation in animals through the supply of a certain level of zinc
through either diet or injection.
Keywords: zinc; erythropoiesis; red blood cells; fish; erythropoietin
1. Introduction
In humans and other mammals, erythropoiesis, the process of red blood cell production, occurs in
the bone marrow; in fish, the head kidney is the main erythropoietic organ [1]. The cellular composition
of the teleost head kidney resembles that of mammalian bone marrow [2]. Erythropoiesis in fish is
similar to that in other vertebrates [3,4]. Erythropoiesis in mammals is regulated by the hormone
erythropoietin (EPO) [5,6]. Fish and mammalian erythropoietic systems have similar responses to
hypoxia because erythropoiesis is influenced by EPO in fish [7]. The human hepatoma cell lines
HepG2 and Hep3B have been utilized to study the regulation of EPO. Studies of Hep3B cells revealed
that Co2+, Ni2+, and Mn2+ can stimulate EPO synthesis, whereas Zn2+ is ineffective [8]. However,
Chen et al. [1] observed zinc stimulation of erythropoiesis in vitro when common carp head kidney
cells were cultured with ZnCl2 supplementation. In vivo, an increase in the rate of erythropoiesis in
the common carp was triggered and facilitated by zinc in the head kidney when the common carp
were exposed to air [9]. In nature, stimulation of erythropoiesis in common carp by zinc occurs via
the high concentration of zinc stored in a specific 43 kDa zinc-binding protein present in the digestive
tract tissue of the common carp [10]. When needed, such as under conditions of anoxia, the zinc in the
43-kDa zinc-binding protein is released [11] and used as a signal to stimulate the formation of new
red blood cells (RBCs) in the head kidney of the common carp [1,9]. It is of great interest to determine
whether the supply of additional zinc to other fish species from the environment can serve as a signal
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to induce erythropoiesis as in the common carp. In this report, the effects of supplementation of ZnCl2
to cultures of the head kidney cells of four fish species were determined: (1) crucian carp, Carassius
carassius; (2) grass carp, Ctenopharyngodon idella; (3) silver carp, Aristichthys nobilis; and (4) tilapia,
Oreochromis aureus. In addition to this in vitro study, ZnSO4 solution was injected into an experimental
blood loss tilapia model to determine whether zinc serves as a signal to stimulate erythropoiesis in fish
in vivo. Our results indicated that zinc could be used as a signal to induce RBC formation in fish both
in vitro and in vivo.
2. Results
2.1. Suspension Culture of the Head Kidney Cells from Four Fish Species with or without ZnCl2
In teleost fish, the maturation of erythrocytes involves a progressive increase in cell size [12].
For common carp, immature RBCs can be separated from mature RBCs through two-fraction separation
with discontinuous Percoll density centrifugation. The immature RBCs are separated into fraction l
(p = 1.020 g/mL) due to their smaller cell size, whereas the mature RBCs and other larger cells are
separated into fraction 2 (p = 1.070 g/mL) [1]. The morphology of the head kidney cells of crucian carp,
grass carp, silver carp and tilapia were found to be similar as in other species of fish, the major cells were
lymphocytes, granulocytes, and erythrocytes [1–4]. After Percoll density centrifugation, it was found
that the immature RBCs were separated into fraction 1 the same as that reported before [1]. As shown
in Figure 1, after suspension culture of head kidney cells with or without ZnCl2, the total cell density
changed only slightly during the four-day period for all four fish species (Figure 1A-a,B-a,C-a,D-a).
However, an increase in the number of cells in fraction 1 and a decrease in the number of cells in fraction
2 were observed for all four fish species (Figure 1A-b,B-b,C-b,D-b). In fraction 1, for all four fish species,
the increased cell density was significantly higher in the ZnCl2 groups than in the groups without ZnCl2
after day one and entered the plateau phase from day two to four (Figure 1A-b-1,B-b-1,C-b-1,D-b-1).
At day one, the ratio of cell numbers in fraction l were approximately three-fold higher in the ZnCl2
groups than in groups without ZnCl2 for all four fish species. These results demonstrate that zinc
stimulated the growth of the fraction 1 cells in all four fish species in one day, with an approximately
three-fold increase in the proliferation of new immature RBCs.
2.2. Effects of ZnCl2 Levels on the Growth of Fraction 1 Cells
For crucian carp, grass carp, silver carp, and tilapia, significant activation of fraction 1 cell growth
was observed at 0.6, 0.2, 0.3, and 1.2 mM ZnCl2, and maximal cell growth was approximately 500%,
520%, 660%, and 290%, respectively (Figure 2).
2.3. Characteristics of the Cultured Head Kidney Cells of the Crucian Carp
As shown in Figure 3A-b, when crucian carp head kidney cells were cultured with supplemental
ZnCl2 for one day, many new cells proliferated that were identified as erythrocytes at different stages
of development. Immunofluorescence staining of the transferrin receptor was only observed in RBCs
at stages 1, 2, and 3, and not in RBCs at stages 4 and 5 (Figure 3B-b). This result indicates that
immunofluorescence staining of the transferrin receptor can be used to identify immature RBCs
(RBC stages 1, 2, and 3).
2.4. Characteristics of the Cultured Head Kidney Cells of Grass Carp, Silver Carp and Tilapia
Immunofluorescent staining of the transferrin receptor revealed the proliferation of new immature
RBCs when the three fish species (grass carp, silver carp, and tilapia) were supplemented in culture








Int. J. Mol. Sci. 2017, 18, 138
Figure 1. Suspension cultures of head kidney cells from the four fish species with or without ZnCl2
supplementation. (A) Crucian carp; (B) grass carp; (C) silver carp; and (D) tilapia. All cells remained in
suspension for four days. The growth curve of the total cells is shown in (a). The total cells were further
separated by Percoll density centrifugation into fractions 1 and 2 (p = 1.020 and 1.070 g/mL), and the
growth curves are shown in b(1) and b(2), respectively. Filled symbols and continuous lines represent
cultures supplemented with ZnCl2; open symbols and broken lines represent cultures without ZnCl2.
The data are expressed as the means ± SDs of four independent experiments. * Statistically significant
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Figure 2. Effects of ZnCl2 concentrations on erythropoiesis in fish head kidney cells: (A) crucian carp,
(B) grass carp, (C) silver carp, and (D) tilapia. The fish head kidney cells were suspension cultured
with 0.01 (control), 1.0, or 1.8 mM ZnCl2 in the presence of 10% fish serum. Measurement of the cell
growth is described in Materials and Methods. The results are the means ± SDs of six independent
experiments. Values with different letter superscripts are significantly different at p < 0.05.
Figure 3. Cells collected from the suspension cultures of crucian carp head kidney cells grown in
medium supplemented with ZnCl2. (A-a) Giemsa-stained cells collected at day zero. The major
cells were lymphocytes (a) (approximately 70%); other cells, including neutrophilic progranulocytes
(b) and basophilic granulocytes (c) were also observed; (A-b) Giemsa-stained cells collected at
day one. Various newly proliferated cells (approximately 42%) were identified as erythrocytes of
different development stages: 1. lymphoid hemoblasts, 2. early erythroblasts, 3. polychromatophilic
erythroblasts, 4. orthochromatic erythroblasts, and 5. erythrocytes; (B-a) Immunofluorescent staining
of the transferrin receptor of the cells at day zero; no cells were stained; and (B-b) Immunofluorescent
staining of the transferrin receptor of the cells at day one. Comparing the cell size and cell morphology
in (A-b) and (B-b), the transferrin receptor immunofluorescent-stained cells were RBC stages 1, 2, and
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Figure 4. Immunofluorescent staining of the transferrin receptor of cells collected from suspension
cultures of head kidney cells from (A) grass carp, (B) silver carp, and (C) tilapia at day zero and day
one. At day 0, virtually no cells were immunofluorescently stained in the three fish species, as shown
in (A-a), (B-a), and (C-a). At day one, various cells were immunofluorescently stained, representing
newly proliferated RBC cells in stages 1, 2, and 3, as shown in (A-b), (B-b), and (C-b).
2.5. Isolation of the Active Substance in Fish Serum That Stimulates the Proliferation of Fraction 1 Cells in the
Head Kidney Cells of the Four Fish Species
When common carp head kidney cells were cultured with supplemental ZnCl2 in the presence
of carp serum, transferrin was identified as the active substance in fish serum that stimulates the
proliferation of immature RBCs [1]. As shown in Figure 5, transferrin was confirmed as the active
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Figure 5. Isolation of the fish serum component stimulating the proliferation of new RBCs in head
kidney cells of (A) crucian carp, (B) grass carp, (C) silver carp, and (D) tilapia. The head kidney cell
suspension was supplemented with 10% serum from each fish species and ZnCl2 and then cultured for
three days before being harvested. The harvested cells were separated into fractions 1 and 2 using a
Percoll density gradient. The cells collected from fraction 1 were extracted using a detergent buffer, and
the detergent extract was purified by Zn2+-IMAC. The acetate buffer eluates were pooled and analyzed
by SDS-PAGE under reducing conditions, followed by staining with Coomassie blue to visualize the
protein bands. The arrowhead denotes the position of the protein identified by nano-LC-MS/MS
analysis as transferrin in crucian carp, grass carp, silver carp, and tilapia, respectively.
2.6. Effects of the Injection of ZnSO4 on Erythropoiesis in a Blood Loss Tilapia Model
Two hours after the loss of approximately 20% of the blood in the tilapia, the RBC counts,
hematocrit, and hemoglobin levels of the fish decreased to approximately 55%–65% of the baseline
values (Figure 6). However, the group of tilapia injected with ZnSO4 exhibited significantly higher
RBC counts, hematocrit values, and hemoglobin levels than the control group (injection of saline)
after three days and until 12 days. Microscopic observation of the blood cells revealed few immature
RBCs in the group injected with saline throughout the experimental period (Figure 7A-a,A-b,A-c).
In contrast, immature RBCs of different stages were observed three and six days after injection of
ZnSO4 (Figure 7B-b,B-c). These results indicate that excess in vivo zinc induced erythropoiesis in fish
in three days. At day six, the blood cells from the fish injected with ZnSO4 included more stage 4 RBCs
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Figure 6. Effects of the injection of ZnSO4 on erythropoiesis in the blood loss tilapia model. At day
zero, blood was withdrawn from the fish, and saline or ZnSO4 was injected. At day three, day six, and
day 12, blood was sampled from the treated fish and analyzed. The data are expressed as the ratios of
the RBC count (A), hematocrit (B) and hemoglobin (C) level at different days to the values at baseline.
The results are the means ± SDs of three independent experiments. * Significant difference (p < 0.05)
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Figure 7. Giemsa staining of the blood cells sampled from tilapia subjected to blood loss and injected
with saline (A) or ZnSO4 (B). At day zero, approximately 95% of the blood cells were stage 5 RBCs,
erythrocytes (A-a,B-a). At day three and day six, the blood cell composition of the fish injected with
saline (A-b,A-c) was similar to that on day zero; that is, approximately 95% stage 5 RBCs and 3% stage
4 RBCs (orthochromatic erythroblasts). However, for fish injected with ZnSO4, newly proliferated cells
were observed on day three (B-b), such as stage 1 RBCs (lymphoid hemoblasts), stage 2 RBCs (early
erythroblasts), and stage 3 RBCs (polychromatophilic erythroblasts). At day six, the blood cells from
the fish injected with ZnSO4 included more stage 4 RBCs (orthochromatic erythroblasts) (B-c).
3. Discussion
The common carp has extraordinarily high zinc levels in digestive tract tissues (~300 μg/g
tissue) compared to other fish (~20 μg/g tissue), as first reported more than 40 years ago [13].
The physiological relevance of this high level of zinc was not clear until recently [1,9,11,14]. At low
oxygen concentrations, zinc is released from the digestive tract tissue of the common carp and used
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a signal to induce erythropoiesis was unique to this fish species was unclear, but the present report
indicates that this type of “zinc signaling” pathway also exists in other fish if a sufficient amount of
zinc is sent to the head kidney cells.
Despite the variety of the four fish studied (crucian carp, grass carp, and silver carp belong to
the Cyprinidae family, but the tilapia are in a completely different family, Cichlidae) and the different
zinc levels (crucian carp have zinc levels as high as ~500 μg/g fresh tissue, but grass carp, silver carp,
and tilapia all have zinc levels of ~20 μg/g fresh tissue), the stimulation of erythropoiesis by zinc was
dose-dependent, with a significant activation concentration of 0.2–1.2 mM and maximum cell growth
of 300%–600% (Figure 2). In vitro, zinc could be used as a signal to induce blood cell formation in fish.
In the blood, the zinc is carried by transferrin (Figure 5).
An experimental blood loss model has been established in several fish species [15–17].
The response to blood loss appears to depend on the fish species: some species recovered in several
days [15], whereas others require weeks [16,17]. In the present study, the bled tilapia exhibited no
significant stimulation of erythropoiesis in 12 days (Figure 6, control group). However, the ZnSO4
injection group exhibited increased RBC, hematocrit and hemoglobin levels. These values decreased
to 55%–65% of baseline in the control group but only 70%–80% of baseline in the ZnSO4 group
at three days post-bleeding (Figure 6, ZnSO4 group). Microscopic observation of the blood of
the ZnSO4-injected fish confirmed that many new immature RBCs proliferated (Figure 7). In vivo,
the presence of additional zinc induced erythropoiesis in the bled tilapia.
In recent years, “zinc signaling” was reported to play a role in brain function, immunology,
inflammation, growth control and bone diseases, and cancer [18]. To date, the use of zinc as a signal to
stimulate erythropoiesis appears to only have been observed in the common carp [1,9,11]. Although it
is not clear whether this mechanism also exists in other animals, the present report suggests a possible
approach for the induction of erythropoiesis in animals through the supply of a certain additional
level of zinc through either diet or injection. If zinc can act as a signal to trigger erythropoiesis in many
fish species, this mechanism might also exist in a broader range of species. Mammalian red cells lack a
nucleus and differ fundamentally from the red blood cells of fish, birds, and reptiles. Erythropoiesis
occurs in the head kidney in teleost fish but in the bone marrow in mammals. We recently studied
whether zinc could be used as a signal to induce red blood formation in rat bone marrow cells, and our
results suggest that at certain levels, zinc could trigger erythropoiesis in mammals (unpublished paper).
Anemia is a global human health concern, and the use of zinc as a signal to induce red blood cell
formation in patients through zinc supplementation might be a possible treatment. Thus, the special
feature of using zinc as a signal to stimulate red blood formation in the common carp might have
implications for human health.
4. Materials and Methods
4.1. Fish
Cultured live fish (crucian carp, grass carp. silver carp, and tilapia) were obtained from a local
fish farm and housed in a polyethylene tank in the laboratory for 2 months before the experiment [11].
The total length and total mass of the fish were: crucian carp, 22 ± 3 cm, 207 ± 69 g, (n = 44); grass
carp, 41 ± 2 cm, 680 ± 101 g, (n = 6); silver carp, 39 ± 3 cm, 556 ± 73 g, (n = 6); and tilapia, 27 ± 1 cm,
362 ± 43 g, (n = 15). Animal use was reviewed and approved by the institutional animal care and use
committee at National Taiwan Ocean University (105-J29803; License No. 102072).
4.2. Preparation of Head Kidney Cell Suspensions and Fish Serum
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4.3. Suspension Culture of Head Kidney Cells with or without ZnCl2 Supplementation
The head kidney cell suspension (approximately 60 × 106 cells/mL) from each different fish
species was cultured with or without ZnCl2 as described previously [1]. The cultures were incubated
at 27 ◦C in an atmosphere of 5% CO2. After 0, 1, 2, 3, and 4 days, cells were harvested to measure
the total cell number and subjected to separation by Percoll density centrifugation. Four independent
experiments were performed.
4.4. Separation of Harvested Head Kidney Cells into Two Fractions by Discontinuous Percoll
Density Centrifugation
The harvested head kidney suspension was separated by discontinuous Percoll centrifugation
(2.0 mL of 1.020 g/mL Percoll and 6.0 mL of 1.070 g/mL Percoll, both in 0.15 M NaCl solution) into
2 fractions as reported previously [9]. The cell numbers of fractions 1 and 2 were measured with an
electronic cell counter.
4.5. Effects of ZnCl2 on the Growth of Fraction 1 Cells from the Head Kidneys of Different Fish Species
Aliquots of 0.1 mL of head kidney cell suspension (60 × 106 cells/mL) from different fish species
were added to equal volumes of DMEM/F12 medium supplemented with 20% fish serum from the
respective fish species and different concentrations of ZnCl2. Zinc concentrations in the control groups
were determined, and found to be about 0.01 mM. The cells were cultured as described above. At day
0 and 1, the cells were harvested and separated by Percoll density centrifugation. The cell numbers in
fraction 1 were counted. Cell growth was expressed as the ratio of the fraction 1 cell number to that at
the start of culture relative to the control. Six independent experiments were performed.
4.6. Microscopic Observation of Head Kidney Cells or Tilapia Blood by Giemsa Staining
The harvested head kidney cells or tilapia blood were directly fixed on slides, stained with the
Giemsa method [19], and subjected to microscopic observation. RBCs were identified according to
previous reports [3,12,20].
4.7. Immunofluorescence Staining of the Transferrin Receptor in Fish Head Kidney Cells
The fish head kidney cells were subjected to immunofluorescence staining of the transferrin
receptor as previously reported [1] and were observed through fluorescence microscopy.
4.8. Isolation of the Active Substance in Fish Serum That Stimulates the Proliferation of Fraction 1 Cells in Fish
Head Kidneys
Preparation of proliferated cells, detergent extraction of zinc-binding proteins from fraction
1 cells, immobilized metal affinity chromatography (IMAC) purification of zinc-binding proteins,
electrophoresis, and nano-LC-MS/MS were performed as reported previously [1].
4.9. Experimental Blood Loss in Tilapia and Injection of ZnSO4 Solution
In each experiment, 54 acclimated tilapias were used. Before the experiment, 6 fish were removed,
and 0.2 mL of blood was sampled from resting fish as the baseline. The remaining 48 fish were
subjected to experimental blood loss by withdrawal (caudal venipuncture) of 3.0 mL blood from each
fish, which represented approximately 20% blood loss because preliminary experiments indicated that
the extractable blood of the tilapia was approximately 15 mL. After bleeding, the fish were allocated
to two groups of 24 fish. Group A (control group) was injected with saline solution (0.25 mL), and
Group B (experimental group) was injected with (1.47 mg/mL, or 5.1 mM) ZnSO4 solution (0.25 mL).
The fish were returned to the culture tank, and no feed was given during the experimental period.
Two hours after the injection of saline or ZnSO4 solution, 0.2 mL of blood was sampled from each fish
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6 fish in each group. The collected blood was used for blood analysis and microscopic observation.
Three different experiments were performed.
4.10. Blood Analysis
At each sampling time, the hematocrit, hemoglobin, and total RBC counts were determined
using an auto hematology analyzer (Excell 500; Danam Electronics, Dallas, TX, USA) as reported
previously [9]. Blood smears were microscopically observed.
4.11. Data Analysis
The data are expressed as the means ± standard deviations (SDs). The statistical significance of
experimental results was calculated by one-way analysis of variance, followed by the least significant
difference post hoc test, using SPSS 10.0 (SPSS Inc., Chicago, IL, USA).
5. Conclusions
Zinc is an essential element in organism, it has many function in life. In nature, the common
carp has a unique way to use it as a signal to stimulate red blood cell formation by having a specific
zinc-binding protein. Many fish do have no this specific zinc-binding protein, but the present report
indicated that supplying a specific additional level of zinc exogenously could also induce erythropoiesis.
It is very possible that this mechanism also exist in other animals including human beings. The potential
of using this mechanism to treat anemia in human beings is high. However, how zinc stimulates
erythropoiesis in fish (and may be in other animals) must be further investigated.
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Abstract: Stem cells from human exfoliated deciduous tooth (SHED) offer several advantages over
other stem cell sources. Using SHED, we examined the roles of zinc and the zinc uptake transporter
ZIP8 (Zrt- and irt-like protein 8) while inducing SHED into insulin secreting β cell-like stem cells
(i.e., SHED-β cells). We observed that ZIP8 expression increased as SHED differentiated into
SHED-β cells, and that zinc supplementation at day 10 increased the levels of most pancreatic
β cell markers—particularly Insulin and glucose transporter 2 (GLUT2). We confirmed that
SHED-β cells produce insulin successfully. In addition, we note that zinc supplementation
significantly increases insulin secretion with a significant elevation of ZIP8 transporters in
SHED-β cells. We conclude that SHED can be converted into insulin-secreting β cell-like cells
as zinc concentration in the cytosol is elevated. Insulin production by SHED-β cells can be regulated
via modulation of zinc concentration in the media as ZIP8 expression in the SHED-β cells increases.
Keywords: dental pulp; insulin; stem cells; zinc; Zrt- and irt-like protein (ZIP)
1. Introduction
Type-1 diabetes (T1D), a major and difficult-to-manage health problem [1], results from
dysfunctional and/or insufficient pancreatic β cells, leading to a loss of insulin as well as glucose
homeostasis as the disease advances [2]. Interventions include insulin injection, which isoften
accompanied by significant side-effects (e.g.,hypoglycemia), particularly in children. A more
amenable approach provides an alternative, supplemental source for the generation of functional
insulin-producing β cells using mesenchymal stem cells which can overcome the shortage of donated
islets and limitations in the ability to expand β cells in vitro. Stem cells from human exfoliated
deciduous tooth (SHED) offer advantages over other stem cell sources for conversion into insulin
secreting cells [3,4], including circumvention of ethical issues, noninvasiveness, long-term banking,
abundance of tissue source, availability for autologous cells to avoid immunosuppressive regimen for
graft rejection responses, and no chance of potential transfection from donors.
Several studies were performed to evaluate “multipotency” and “stemness” of SHED-derived
insulin-secreting cell aggregates [5–7]; however, few studies focused on what factors control insulin
secretion. We previously reported that β cells start losing the capability to secrete insulin before signs
of inflammatory cell infiltration or conspicuous cytokine expression emerged in [8], and this notion
was supported by such observations in a recent clinical report [9]. We also observed that a lack of
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zinc results in a significant decline of insulin secretion in conjunction with decreased ZIP8 (Zrt- and
irt-like protein 8, a zinc uptake transporter) expression in Sprague-Dawley rats [10]. In accordance
with these previous results and other studies [8,10], we presumed that zinc supplementation would
up-regulate insulin secretion from insulin-secreting β cell-like cells (or SHED-β cells) via up-regulation
of ZIP8. Based on our previous observation and published data, we hypothesized that without zinc
accumulation in the cytosol, SHED cannot fully differentiate into insulin-producing SHED-β cells,
and therefore, the existance of zinc uptake transporters and maintaining an optimum level of
intracellular zinc are critical for maximizing insulin production.
For this preliminary study, we successfully generated SHED-β cells from SHED, based on
a published protocol [5]. Using these SHED-β cells, we tested a set of hypotheses: first, if zinc is an
essential factor in the regulationprocess of insulin production and secretion. Second, if SHED-β cells
contain ZIP8, a zinc uptake transporter. Third, if ZIP8 is involved in the insulin secretion mechanism in
SHED-β cells. The purposes of this study were: (1) to demonstrate β cell markers which show SHED
differentiating to β cell lineage to become SHED-β cells; (2) to show that ZIP8 expression increasesas
SHED-β cell differentiates; (3) to demonstrate the effect of zinc supplementation on insulin secretion.
2. Results
2.1. SHED Express a Strong “Stemness” Compared to Dental Pulp and Periodontal Ligament Originated Stem
Cells (DPSC and PDLSC)
Results of real-time quantitative PCR (qPCR) assays showed significantly strong expressions of
pluripotent stem cell markers in SHED compared to dental pulp stem cells (DPSC) and periodontal
ligament originated stem cells (PDLSC) (see Figure 1). This result prompted us to focus on SHED
rather than using other stem cell origins. Error bars and P values were calculated from triplicates of
each measurements.
Figure 1. Expression of pluripotent transcription factors determined by quantitative PCR (qPCR)
normalized with the level of GAPDH. DPSC: dental pulp stem cells; PDLSC: periodontal
ligament stem cells; SHED: stem cells from human exfoliated deciduous tooth. SHED show
a significantly stronger expression than other (asterisk * p < 0.05) markers, except KLF4. Gene
Descriptions: NANOG, Nanog homeobox; OCT4, Octamer-binding protein 4; KLF4, Kruppel
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2.2. Genetic Markers in Pancreatic β Cell Lineage Expressed in SHED Indicate a Successful Conversion of
SHED to SHED-β Cells
SHED-β cells differentiated through the three-step media treatment as previously offered by
Govindasamy et al. [5] expressed biomarkers in the pancreatic lineage, such as pancreatic and duodenal
homeobox 1 (PDX1), neurogenin 3 (NEUROG3), NK6 homeobox 1 (NKX6.1), paired box 4 (Pax4), and
aristaless related homeobox (ARX), which were markedly increased between d5 and d10 (see Figure 2).
Figure 2. Differentiation of biomarkers in pancreatic lineage shown in the levels of (A) mRNA;
and (B) protein. Every day 5 (or d5) and day 10 (d10) marker expression differed from one another and
from d0 in mRNA. n = 3. Gene Descriptions: PDX1, pancreatic and duodenal homeobox 1; NEUROG3,
neurogenin 3; NKX6.1, NK6 homeobox 1; PAX4, paired box 4; ARX, aristaless related homeobox; INS,
insulin; GLUT2, glucose transporter 2.
Particularly, mRNA expressions for insulin (INS) and glucose transporter2 (GLUT2, a main
transporter importing glucose molecules into the β-cell cytosol) increased significantly at both mRNA
and protein levels. Compared to Day-5 (d5), d10 cells show significantly stronger expression of every
gene (see Figure 2A).
2.3. ZIP8 Expression and Zinc Supplementation Effects on the Markers in β Cell Lineage
To examine the hypothesized one-to-one relationship between zinc and the markers expressed in
β cell lineage, we measured ZIP8 expression changes because we assumed that the ZIP8 transporter
mediates the insulin production and secretion in SHED-β cells (Figure 3). The transcriptional activity
of the ZIP8 gene increased significantly as differentiation proceeded (See Figure 3A).
Zinc (50 μM) was added to the media on day 10. This supplementation of zinc increased not only
the genes in the β cell lineage, but also INS and GLUT2. This may indicate that zinc supplementation
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Figure 3. mRNA level changes in Zrt- and irt-like protein 8 (ZIP8) expression and β cell differentiation
markers. (A) ZIP8 expression increased between d0 and d10; (B) Zinc supplementation at d10 increased
the levels of most markers, particularly Insulin and GLUT2. n = 3.
2.4. Levels of Zinc in Conjunction with ZIP8 in the Cytosol of SHED-β Cells Modulate Insulin Secretion
To investigate the roles of zinc in the cytosol of SHED-β cells in association with ZIP8 expression,
we augmented the zinc concentration of the media by 50 μM, and then we compared before and
after supplementation. Figure 4 contrasts the changes in SHED-β cells in the images obtained
by immunofluorescence staining. Figure 4A demonstrates a marked increase in the number of
insulin-containing β cell-like stem cells after zinc supplementation. Insulin molecules in the cytosolare
shown in brighter red color after the augmentation (Figure 4A). Figure 4B demonstrates a significant
increase of ZIP8 protein after zinc supplementation. Lastly, supplementation of 50 μM of zinc
significantly increased insulin secretion by approximately 25% (9.8 ± 0.025 vs. 12.39 ± 0.035 ng/mL)
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Figure 4. Zn supplementation affects the production and secretion of insulin and the expression of ZIP8
in SHED-β cells. (A) Immunofluorescence staining of insulin (indicated by red color and white arrow
heads) in SHED-β cells with or without zinc supplementation. Note the more prominent expression of
insulin after zinc supplementation in the merged panel; (B) Western blot analysis of ZIP8 expression in
different time points with or without zinc supplementation; (C) Constitutive secretion of insulin from
SHED-β cells evaluated by ELISA on n = 3. In these assays, 50 μM of zinc was supplemented.
3. Discussion
Several previous studies thoroughly demonstrated the process by which mesenchymal stem cells
from various sources could convert to insulin-secreting cells [3,4,6]. However, most studies focused
on proving the pluripotency of their cells or showing β-cell-like phenotypes of their cells. A scarce
number of studies have reported what factors play a key role in influencing quantity and quality
of insulin secretion. Based on previous experience and understanding, our study focused on what
factors play a key role in the augmentation of insulin secretion. The results of this study support
a new concept that zinc and zinc uptake transporters (particularly ZIP8) may affect the proliferation of
SHED-β cells. Zinc is an essential element involved in many basic cellular biochemical processes for
human physiology. Zinc plays its roles as a part of protein structure, signaling process, and enzymatic
regulation [11,12]. For instance, when zinc and osteocalcin are lacking during perinatal growth, brittle
bones in rats [13] and a short height [14] may result. Conversely, Zinc supplementation dampens
osteoclastic activity [15] and upregulates osteoprotegerin [16] in diabetic rodents and cell lines. Zinc
in calcium phosphate is known to modulate bone induction [17] and mineralization [18]; therefore,
zinc plays a significant role in bone formation. Bones in patients with type 1 diabetes often suffer from
a lack of bone (i.e., osteopenia and osteoporosis) [19–21]. Indeed, a lack of bone in diabetes is associated
with zinc deficiency [22,23].
Zinc homeostasis in the cytosol is tightly regulated via ubiquitous zinc-bound intracellular
proteins such as metallothionein as well as zinc pool in intracellular organelles such as Golgi apparatus.
Due to these reservoirs inside the cells, pathologic symptoms of zinc depletion cannot be easily
recognized [24]. Particularly, insulin-producing pancreatic β cells are specified to contain a high level
of zinc because insulin hexamer molecules are structured around zinc ions [25]. In addition, β cells are
exposed to oxidative stress due to reactive oxygen species (ROS) produced during the cleaving process
from proinsulin to insulin and during glucose metabolism, which consume anti-oxidants such as zinc
containing metallothionein [26,27]. Thus, zinc is an essential metal for synthesizing insulin.
Previous studies have shown that lack of zinc in pancreatic islets is associated with reduced
insulin secretion [8,10]. Our current results indicate that zinc supplementation assists the process
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the increased expressions of ZIP8 in SHED-β cells. A recent publication revealed that their culture
media contained 10 μM Zn2+ [4]. Then, since we used 50 μM, a question would merge if 10 μM of zinc
is optimal.
Zinc transporters are cell structures involved in regulating zinc homeostasis. Therefore, questions
must start from which zinc transporter(s) play a role in zinc homeostasis. We reported that one
of the zinc uptake transporters—Zip8—plays a major role in insulin secretion [10] using primary
β cells harvested from rats. More recently, a research group investigated a role of Zip4 in insulin
secretion; however, Zip4 zinc uptake transporters were not directly associated with insulin secretion in
mice [28]. Another independent study concluded that ZIP6 and ZIP7 are functionally important [29]
for maintaining zinc homeostasis in human islets and β cell lines; however, they did not measure
changes in insulin secretion in pancreatic cells in response to ZIP expression changes. Therefore,
ZIP8 may be an unknown zinc uptake transporter involved in the regulation of insulin production
and secretion. We confirmed that ZIP8 may be an important functional transporter in SHED-β cells
essential for optimal production of insulin via the regulation of intracellular zinc levels. We found
that ZIP8 up-regulation for increased accumulation of zinc is an important factor in the differentiation
process of SHED into SHED-β cells.
Finally, our findings could develop an ex vivo study model determining what important factors
play a major role as zinc and ZIP8 augmented SHED-β cells are transplanted to human β cells
aggregates. Glucose-stimulated insulin secretion studies on SHED-β cells with and without zinc
supplementation would confirm our conclusion. Future experiments to determine the optimized
conditions for the mechanism involved in zinc regulation for the optimal insulin production in




Three types of human dental mesenchymal stem cells were cultured and used for the study.
Primary SHED cells were isolated from normal exfoliated deciduous incisors. Dental pulp stem
cells (DPSCs) were isolated from extracted teeth. Periodontal ligament stem cells (PDLSCs) were
scraped from harvested third molars. All three cell types were cultured in α-minimum essential
media (or α-MEM)medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Invitrogen), 5 μg/mL gentamicin sulfate (Gemini Bio-Products, West Sacramento, CA, USA),
and 20 mmol/L L-glutamine (Invitrogen).
4.2. In Vitro SHED-β Cell Differentiation
Collected SHED cells were amplified to passage 5 in the media, as described above. SHED-β cells
were differentiated using the previously established protocol with slight modifications [5]. After
trypsin-treated and centrifuged, the cells were resuspended in Medium-A (containing Dulbecco’s
modified Eagle’s medium/F-12 Knock-out (DMEM-KO), 17.5 mM Glucose, 1% bovine serum albumin
Cohn Fraction V (BSA-CF; fatty acid free), 1× insulin-transferrin selenium (ITS), 4 nM Activin A,
1 mM Sodium Butyrate, 50 μM 2-Mercaptoethanol, and 5 μg/mL gentamicin sulfate) and plated
in sterilized borosilicate glass plates (60 mm, Corning, Keene, NH, USA) without serum. After the
cultures were incubated for 48 h, the medium was changed to Medium-B (containing DMEM-KO,
17.5 mM Glucose, 1% BSA-CF, 1× ITS, 0.3 mM taurine, and 5 μg/mL gentamicin sulfate), and was
substituted with Medium-C (DMEM-KO, 17.5 mM Glucose, 1.5% BSA-CF, 1× ITS, 3 mM Taurine,
100 nM glucagon-like peptide-1, 1× non-essential amino acids, and 5 μg/mL gentamicin sulfate) on
the fifth day. Gravity-downed aggregated cell pellets were gently aspirated, and the medium was
replaced with fresh Medium-C every 2 days for the next 5 days. To make the zinc-rich environment








Int. J. Mol. Sci. 2016, 17, 2092
reagents were purchased from Sigma-Aldrich, St. Louis, MO, USA; Invitrogen, Carlsbad, CA, USA;
R&D Systems, Minneapolis, MN, USA.
4.3. Real-Time qPCR
Stem cells and differentiated SHED-β cells were harvested, and total RNAs were purified using
RNeasy Mini Kit (QIAGEN Sciences, Germantown, MD, USA) in accordance with the manufacturer’s
protocol. First-strand cDNA was synthesized from 1 μg of RNAs using the High Capacity cDNA
Reverse Transcription Kits (Applied Biosystems, Foster City, CA, USA) primed with a mixture of
random primers. A 2 μL volume of cDNA template was used on the mixture of 25 μL volume of SYBR
Green master mix (Applied Biosystems, Carlsbad, CA, USA) with 5 pmol of primers. The primer
sequences (5 to 3 primes) for each gene are the following:
NANOG, F: AGATGCCTCACACGGAGACT; R: TCTCTGCAGAAGTGGGTTGTT.
OCT4, F: GAAAACCCACACTGCAGATCA; R: CGGTTACAGAACCACACTCG.
KLF4, F: GGGAGAAGACACTGCGTCA; R: GGAAGCACTGGGGGAAGT.
SOX2, F: TCTCATGATGTTCAACCATTCAC; R: CACATTTACATTCAAAGCACCAG.
LIN28A, F: GAAGCGCAGATCAAAAGGAG; R: GCTGATGCTCTGGCAGAAGT.
GAPDH, F: GGTGTGAACCATGAGAAGTATGA; R: GAGTCCTTCCACGATACCAAAG.
PDX1, F: GGGTGACCACTAAACCAAAGA; R: GGTCATACTGGCTCGTGAATAG.
NEUROG3, F: GCTGCTCATCGCTCTCTATTC; R: GGCAGGTCACTTCGTCTTC.
NKX6.1, F: GAAGAGGACGACGACTACAATAAG; R: CTGCTGGACTTGTGCTTCT.
PAX4, F: TGGGAAGGAGATGGCATAGA; R: ATCACAGGAAGGAGGAAGGA.
ARX, F: GGCAAGGAGGTGTGCTAAA; R: GCTGGTCCTCTGTTTCCATT.
INS, F: CTGGAGAACTACTGCAACTAGAC; R: TGCTGGTTCAAGGGCTTTAT.
GLUT2, F: CCGCTGAGAAGATTAGACTTGG; R: GACTAGCTCCTGCCTGTTTATT.
SLC39A8, F: GCTGGCTATTGGGACTCTTT; R: GCAACTGCCTTCTCAACATAAC.
ACTB, F: GGATCAGCAAGCAGGAGTATG; R: AGAAAGGGTGTAACGCAACTAA.
Quantitative PCR reactions were triplicated for each sample with the Eppendorf Realplex System
(Eppendorf, Hamburg, Germany), and the threshold cycle (Ct) for each reaction was normalized (ΔCt)
by the value of the β-ACTIN (ACTB) housekeeping gene. The value of ΔCT was further normalized to
exhibit the comparative expression levels with respect to the mean value.
4.4. Western-Blots
Collected SHED and SHED-β cells were lysed in ice-cold RIPA buffer containing protease inhibitor
cocktails (Roche Applied Science, Indianapolis, IN, USA). The same amount of proteins was resolved on
the SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane using an electroblot.
After blocking with 5% milk TBS-T, the membrane was incubated with anti-PDX1, anti-β-actin
(Cell Signaling Technology Inc., Beverly, MA, USA), anti-NEUROG3, anti-ARX, anti-GLUT2
(Sigma-Aldrich, St. Louis, MO, USA), anti-NKX6.1 (R&D Systems, Minneapolis, MN, USA), anti-PAX4
(GeneTex Inc., Irvine, CA, USA), and anti-ZIP8 (Thermo Scientific Inc., Rockford, IL, USA) antibodies.
A horseradish peroxidase-conjugated secondary antibody was added, and chemiluminescent reagents
were used to detect immunoreactive proteins on X-ray films. A density measurement was performed
on Multi Gauge V3.0 (Fujifilm, Tokyo, Japan), and the quantities were calculated by subtraction
between ZIP8 and β-actin bands.
4.5. Immunofluorescence Assay
On the ninth day of differentiation, aggregated SHED-β cells were transferred on the Lab-Tek
II CC2 Chamber Slide (Thermo Scientific Inc., New York, NY, USA) and incubated for 24 h to
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(Biocare Medical, Concord, CA, USA) for 20 min, and incubated in blocking solution (CAS-BLOCK;
Invitrogen, Halethorpe, MD, USA) for 15 minutes at room temperature. SHED-β cells were stained
with anti-Insulin (GenScript, Piscataway, NJ, USA) antibody at room temperature for 2 hours, washed
three times with PBS, and then incubated with Alexa Fluor 594-conjugated secondary antibody
(Invitrogen, Eugene, OR, USA) for 1 h. After being washed with PBS, the slide was mounted in
Vectashield mounting medium containing DAPI (4′,6-diamidino-2-phenylindole) (Vector Laboratories,
Burlingame, CA, USA). Fluorescent images of the samples were obtained using a Zeiss LSM530 META
Confocal Microscope (Carl Zeiss, Thornwood, NY, USA).
4.6. ELISA Assay for Insulin
On day 10 of the differentiation of SHED-β cells, incubation medium was refreshed and
maintained for 2 h to allow insulin secretion. The media were collected to quantify insulin levels
using Insulin ELISA Kit (EMD Millipore Corp., Billerica, MA, USA). An equal amount of sample was
incubated on the anti-insulin antibody-coated plate with biotinylated capture antibody for 90 min.
After the plate was washed, a horseradish peroxidase-conjugated streptavidin was added, and TMB
(3,3′,5,5′-tetramethylbenzidine) substrate and stop solution were mixed for color developing reaction.
Absorbance was measured at 450 nm using a spectrophotometer (BioTek Instrument Inc., Winooski,
VT, USA).
4.7. Statistical Analysis
For group comparison, Student’s t-tests were performed with SPSS v. 21 (IBM Co., Armonk,
NY, USA). Significance level of p < 0.05 was adopted for inference tests on mRNA and protein
measurements. Samples collected from multiple teeth were used for triplicated measurements.
5. Conclusions
(1) β cell-differentiation markers emerge when SHED convert into SHED-β cells; (2) ZIP8
expression increases as SHED differentiate into SHED-β cells; (3) zinc supplementation enhances
insulin secretion by SHED-β cells; (4) insulin secretion is augmented by ZIP8 elevation.
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Abstract: The ZIP (Zrt/Irt-like protein) family of zinc transporters is found in all three domains
of life. However, little is known about the phylogenetic relationship amongst ZIP transporters,
their distribution, or their origin. Here we employed phylogenetic analysis to explore the evolution
of ZIP transporters, with a focus on the major human fungal pathogen, Candida albicans. Pan-domain
analysis of bacterial, archaeal, fungal, and human proteins revealed a complex relationship amongst
the ZIP family members. Here we report (i) a eukaryote-wide group of cellular zinc importers,
(ii) a fungal-specific group of zinc importers having genetic association with the fungal zincophore,
and, (iii) a pan-kingdom supercluster made up of two distinct subgroups with orthologues in bacterial,
archaeal, and eukaryotic phyla.
Keywords: ZIP; zinc; transport; transporter; evolution; pathogenic fungi; Candida albicans
1. Introduction
Zinc is an essential micronutrient for all living organisms. This is because many proteins
(particularly enzymes and transcription factors) require zinc to function. In fact, 9% of eukaryotic
proteins are predicted to interact with this metal. As well as acting as an essential cofactor for proteins
involved in a large number of cellular processes, zinc can also be toxic if present in excess. Therefore,
zinc acquisition, homeostasis, and detoxification is crucial for cell survival and proliferation. However,
pathogenic microbes have to deal with extremes in zinc bioavailability due to the action of nutritional
immunity. This term describes a variety of host processes which manipulate microbial exposure to
trace metals, particularly zinc, iron, manganese, and copper. For example, following phagocytosis by
macrophages, bacterial cells can face potential zinc and copper toxicity [1]. However, most examples
of nutritional immunity involve host-driven metal sequestration together with microbial starvation [2].
Many bacterial pathogens utilise an ABC (ATP-binding cassette) transporter (ZnuABC) for
high-affinity zinc uptake during infection. These systems consist of a substrate-binding protein
ZnuA, permease ZnuB, and ATPase (ZnuC). An increasing body of literature is demonstrating an
important role for ZnuABC-mediated zinc assimilation in bacterial pathogenicity. For a recent review
on bacterial zinc assimilation, readers are directed to Capdevila et al. [3].
In contrast, with the exception of some recent studies in fungi, far less is known about how zinc
homeostasis in eukaryotic pathogens influences their virulence. Zinc import via a ZnuABC-like
system has not been reported in eukaryotes. Rather, they appear to predominantly employ
ZIP-type transporters for cellular zinc import [4]. The name derives from fungal Zrt (zinc regulated
transporter) [5] and plant Irt (iron-regulated transporter) [6] proteins.
However, the understanding of this ZIP-mediated zinc transport is complicated by the architecture
of the eukaryotic cell. Unlike most bacteria and archaea, where cellular import only occurs at the
plasma membrane, eukaryotic ZIPs can also deliver zinc from various intracellular organelles into
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the cytoplasm. Metal promiscuity may also confound phylogenetic interpretation: certain bacterial
ZIPs have been shown to transport multiple metals. For example, Salmonella enterica ZupT transports
both zinc and manganese [7]. In eukaryotes, different ZIP transporters can transport different metals.
For example, Saccharomyces cerevisiae Atx2 is implicated in Golgi manganese homeostasis [8]. However,
most eukaryotic ZIPs are implicated in zinc transport [4].
S. cerevisiae is one of the best understood models of eukaryotic ZIP-mediated zinc transport.
This yeast encodes five ZIP transporters: two plasma membrane importers and three intracellular
organellar transporters. There is an emerging and important role for ZIP transporters in the
pathogenicity of human fungal pathogens [9–12], but little is known about the phylogeny, distribution,
or origin of these transporters either within fungal pathogens or throughout different domains of
life. Here we take advantage of OrthoMCL, to investigate the evolution of ZIP-type zinc transporters,
with a focus on the medically important fungus Candida albicans.
2. Phylogenetic Analysis of ZIP Transporter
In order to investigate their phylogenetic relationships, ZIP orthologue groups were constructed
using OrthoMCL (Available online: http://orthomcl.org/orthomcl/) [13]. OrthoMCL generates
orthologue superclusters from 36 Bacteria (including six Firmicutes and 19 Proteobacteria), 16 Archaea,
9 Euglenozoa (Trypanosomes, Leishmania), 4 Amoebae, 11 Viridiplantae (plants, algae), 15 Alveolates
(e.g., Apicomplexa such as Plasmodium), 24 Fungi (including 4 Basidiomycetes, 3 Microsporidia,
and 17 Ascomycetes), 29 Metazoa, and 6 miscellaneous Eukaryotes (Oomycete, Giardia) genomes.
This approach resulted in 38 orthologue groups with ZIP zinc transporter Pfam annotations.
The majority of these contained only few poorly connected ZIP proteins, and several represented
likely expansions in metazoans or Viridiplantae; that is, likely associated with the development of
multicellularity. However, several superclusters of interest were identified, which we discuss below.
3. Conserved Plasma Membrane Importer Cluster (OG5_126707)
OG5_126707 member ZIP transporters were exclusively eukaryotic and contained transporters
from all studied eukaryotic groups. Figure 1 shows the cluster graph of OG5_126707. With the
exception of the three Microsporidian species, fungal orthologues clustered together, as did
Viridiplantae, Euglenozoa parasites (e.g., Trypanosomes), and to a lesser extent, Alveolates. Amoebic
orthologues (blue circles) distributed between parasite clusters. The large cluster to the central right of
Figure 1 includes Metazoan ZIP transporters. Not only were all eukaryotic groups represented in this
supercluster, but most analysed species were also present. For example, 23 of the 24 analysed fungal
species were represented.
 
Figure 1. Conserved plasma membrane importer Cluster (OG5_126707). Clustering performed using
OrthoMCL. Orthologues of C. albicans Zrt2 are conserved within eukaryotes. All characterised members
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Several members of the OG5_126707 supercluster have already been characterised. These include
human ZIP1 and ZIP3, S. cerevisiae Zrt1 and Zrt2, S. pombe Zrt1, A. fumigatus ZrfA and ZrfB,
C. neoformans Zip1 and Zip2, C. albicans Zrt2, and Leishmania infantum. Notably, all 11 of these
transporters are implicated in cellular zinc import at the plasma membrane [5,11,14–19].
4. The Fungal Zincophore Locus Cluster (OG5_141027)
This cluster was unique to fungi (with the exception of two very loosely connected Trypanosomal
sequences). However, unlike OG5_126707 which included 23 of the 24 fungal species, this cluster only
contained 10 species. These included C. albicans (Zrt1) and A. fumigatus (ZrfC). Interestingly, both of
these transporters have been reported to be up-regulated specifically at neutral/alkaline pH, and in the
case of C. albicans Zrt1, to act as a cell surface docking protein for the secreted zincophore, Pra1 [20,21].
We have previously reported that the Zrt1 and Pra1 encoding genes are syntenic, not only in C. albicans,
but in multiple fungal species [21,22]. Moreover, for C. albicans and A. fumigatus, the gene pairs are
known to be co-expressed in response to zinc limitation [20,21]. Based on these observations, we have
proposed that the ZRT1/PRA1 locus may function as a conserved zincophore/receptor in multiple
fungal species [22]. We therefore interrogated the genetic loci of those species identified in cluster
OG5_141027. Gene order analysis revealed that seven of the 10 species here have maintained a syntenic
relationship between orthologues of C. albicans PRA1 and ZRT1. Two species—Yarrowia lipolytica
and Neurospora crassa—have lost PRA1, and in one (Gibberella zeae, also called Fusarium graminearum),
PRA1-ZRT1 synteny has broken. One of the PRA1-negative species, Yarrowia lipolytica, has undergone
duplication and divergence of the Zrt1 orthologue (Figure 2).
 
Figure 2. The fungal zincophore locus cluster (OG5_141027). Clustering performed using OrthoMCL.
Orthologues of the zincophore-associated ZIP, Zrt1 (zinc regulated transporter 1) in C. albicans are
specific to the fungal kingdom.
These observations are similar to our previous study—of 16 selected species analysed in Citiulo
et al., 10 encoded PRA1 orthologues and, of these 10 species, six maintained synteny with a ZRT1
orthologue. To examine how widespread the syntenic relationship is, we interrogated the NCBI
database. Of 102 species analysed, we identified Pra1 orthologues in 87 (85.3%) species and, of the
Pra1+ species, 61 (70.1%) have maintained a syntenic relationship between PRA1 and ZRT1 (Table S1).
The fact that only ascomycete ZIPs were identified within this OrthoMCL cluster is probably
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C. albicans Zrt1 against non-ascomycetes identified numerous ZIPs which reciprocally hit C. albicans
Zrt1. Moreover, both ascomycete and basidiomycete species exhibit synteny of zincophore and ZIP
orthologues (see [21] and Table S1).
While it should be pointed out that both PRA1 [21] and ZRT1 [22] orthologues have been
lost multiple times throughout the fungal kingdom, this indicates that, when present, the genes
tend to share a syntenic relationship. This most likely serves to simplify modular co-expression.
The observations reported here support our earlier conclusion that PRA1-ZRT1 synteny represents an
ancient and highly successful adaption within the fungal kingdom [21].
5. The ZupT/ZIP11/Zrt3 Pan-Domain Supercluster (OG5_127397)
The OG5_127397 supercluster (Figure 3) was the only cluster to contain ZIP proteins from all
three domains of life. In fact, all phyla, with the exception of Alveolate and Euglenozoa parasites
were represented.
Figure 3. Fungal Zrt3, Prokaryote ZupT, Metazoan Zip11 pan-domain supercluster (OG5_127397).
Clustering performed using OrthoMCL. Note the separation of eukaryotic (Fungi and Metazoan)
subclusters by prokaryotic proteins.
A number of bacterial (16) and archaeal (5 or 6) members were present in the OG5_127397
supercluster. No archaeal ZIP transporters have been studied to-date. In bacteria, the Zip transporter,
ZupT, has been characterised in Escherichia coli, Cupriavidus metallidurans, and Salmonella enterica. In all
three species, a role in zinc import has been described [7,23,24]. E. coli ZupT appears to transport
several other cations in addition to zinc [25], and S. enterica ZupT imports both zinc and manganese [7].
Orthologues were present throughout the fungal kingdom, but are absent from the Microsporidia
and Basidiomycota. The S. cerevisiae member, Zrt3, has been shown to transport zinc out of the fungal
vacuole [26], and our own work indicates that the C. albicans orthologue plays a similar role [27].
The human member, ZIP11, has been implicated in Golgi zinc transport [28].
Based on similarity between human ZIP11 and bacterial ZIP (ZupT) proteins, Yu et al. [27]
have proposed that this family represents the most ancient ZIP [27], present in the last universal
common ancestor.
Similarly, the identification of S. cerevisiae Zrt3 led to the recognition of prokaryotic ZIP-type
transporters in the first place, as Zrt3 (but not the previously characterised yeast Zrt1 and Zrt2) shared
sequence similarity with bacterial and archaeal proteins [26].
In this context, the position of metazoan ZIP11, fungal Zrt3, and prokaryotic ZupT within the
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Surprisingly, however, Fungal (Zrt3) and Metazoan (ZIP11) clusters were very distinct, and both
had higher similarity to prokaryotic ZIPs than to each other (Figure 3). Furthermore, direct alignments
showed that fungal Zrt3 and human ZIP11 shared only 28% sequence identity (e-value 3.1 × 10−2).
This was unexpected, as within the Eukarya, fungi and metazoans are very closely related [30].
This suggests that fungal Zrt3 and metazoan ZIP11 may not be closely related.
We therefore compared fungal (Zrt3-type) and metazoan (ZIP11-type) with more bacterial and
archaeal sequences.
In order to capture bacterial and archaeal diversity as broadly as possible, fungal (C. albicans Zrt3)
and metazoan (human ZIP11) sequences were subjected to individual BLASTp searches against
Firmicutes, Proteobacteria, Actinobacteria, Spirochetes, Euryarchaeota, and Crenarchaeota species
available at NCBI. These analyses identified predicted ZIP transporters in all six prokaryotic phyla.
Sequence similarities between fungal Zrt3 and prokaryotic best hits were 30–40% (e-value
1016–1015) for bacteria, and even lower, ≤30% identity (e-value ~10−12), for archaea. Sequence similarity
between fungal Zrt3 and bacterial proteins was limited to the C-terminal 200 amino acids. Indeed,
when we repeated BLASTp analysis with the C-terminal 200 amino acids alone, we identified greater
similarity (e-value 6 × 10−19). No sequence identity was observed for the N-terminal 391 amino acids
out with the fungal kingdom.
We observed a higher degree of sequence similarity between Hs ZIP11 and bacterial and archaeal
species (~45% identity, e-value 10−81–10−60).
Next, we aligned fungal, mammalian, bacterial, and archaeal species’ ZIP sequences using
Phylo.fr [31,32]. The resulting tree formed two distinct branches: one containing the fungal Zrt3 and
the other, metazoan ZIP11 (Figure 4). Remarkably, both branches contained ZIP transporters from
Firmicutes, Proteobacteria, Actinobacteria, Spirochete, and Euryarchaeota species, whilst the Human
Zip11 branch rooted against the two identified Crenarchaeota. This suggests that prokaryotes have
two different ZIP transporters: one related to fungal Zrt3 and the other to metazoan ZIP11.
Figure 4. Pan-domain supercluster phylogeny. Phylogenetic tree generated using Phylogeny.fr
(Available online: http://www.phylogeny.fr/). Note the presence of two branches with prokaryotic
ZIPs related to both Fungal Zrt3 and Metazoan Zip11.
If this is the case, we may anticipate the existence of extant prokaryotic species with both types.
Indeed, the respective best hits of fungal Zrt3 and metazoan ZIP11 against Spirochetes were two
independent ZIP transporters in the same species: Marispirochaeta aestuarii (Figure 4).
We therefore subjected human ZIP11 to BLASTp analysis against prokaryotic species which
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same ZIP as in the previous search round, or the sequence similarity was too low to return a
subject. However, when we queried fungal Zrt3 against the Firmicute Planomicrobium flavidum and
the Euryarchaeota Methanofollis ethanolicus (two species which had metazoan ZIP11 orthologues),
we identified independent ZIP transporters. The ZIP pairs from these three species clustered on the
two distinct branches of the tree (Figure 4). Therefore, it would appear that these three prokaryotic
species encode two independent ZIP transporters.
This is interesting because it demonstrates the existence of two distinct classes of ZIP transporter
in multiple prokaryotic phyla.
Although fungal Zrt3 and metazoan ZIP11 were identified as belonging to the same
orthologue supercluster, their similarity was very low (identity 28%, e-value 3.1 × 10−2). Moreover,
their relationship to distinct prokaryotic proteins (Figures 3 and 4) is not suggestive of a close
phylogenetic relationship.
We therefore performed BLASTp analysis of fungal Zrt3 excluding the fungal kingdom (NCBI).
Intriguingly, outside of the fungal kingdom, Zrt3 shares highest similarity with bacterial sequences
and not with other Eukaryotes, as would be expected.
We therefore systematically analysed ZupT from Desulfovermiculus halophilus (which was one of
the bacterial ZIPs with highest similarity to fungal Zrt3) against the major eukaryotic phyla.
D. halophilus ZupT did not share sequence identity with any proteins within the Parabasalia,
Diplomonadida, Ciliophora, or Euglenozoa. Only one species within the Heterolobosea
(the Apicomplexa), and a handful of Dictyostelium and Acytostelium species within the Mycetozoa had
proteins with similarity to D. halophilus ZupT (not shown).
We retrieved a large number of hits from within the Heterokonta (e-value 7 × 10−60 [47% identity]
to e-value 4 × 10−26 [28% identity]) and Viridiplantae (10−50, 43% identity) and, of those top hits
analysed, they aligned to the fungal Zrt3 branch of Figure 4. Within the Metazoa, we did identify ZIP
transporters with sequence similarity to D. halophilus ZupT, but (with the exception of Oikopleura dioica)
these aligned to the human ZIP11 branch of the tree (not shown).
Therefore, it appears that the origin of fungal Zrt3 is complex. It is possible that the gene was
inherited vertically into the fungi, and that it has been lost multiple times within extant eukaryotic
lineages. However, given the absence of Zrt3 orthologues from basal eukaryotes, its acquisition via
horizontal gene transfer may represent an alternative explanation.
We note that the observed similarities of ZIP11 and Zrt3 with prokaryotic proteins are in agreement
with the conclusions of both MacDiarmid (2000) and Yu (2013) [26,29], that these proteins may represent
ancient ZIP transporters in metazoans and in fungi, respectively. However, the diversity of bacterial
and archaeal protein sequences within this orthologue supercluster (Figure 4) suggests that they arose
from distinct genes.
In summary, our analysis of fungal ZIP transporters indicates that there are three major orthologue
groups with different degrees of conservation within and outside of the eukaryotes.
(i) A conserved group of eukaryotic proteins (OG5_126707) encompassing fungal, metazoan, and
parasite plasma membrane importers; (ii) A fungal-specific group of zinc importers (OG5_141027),
genetically associated with the fungal zincophore; (iii) A pan-domain supercluster (OG5_127397),
formed of two distinct groups with orthologues in all three domains of life.
At this stage, it is unclear whether eukaryotic members of this supercluster were inherited
vertically or horizontally. However, our analyses indicate the presence of two relatively distinct groups
of ZIP transporters in extant bacterial and archaeal species. Interestingly, the fungal members of this
group appear to be involved in organellar (vacuolar) zinc export, rather than plasma membrane import.
Since the emergence of the Eukarya, ZIP transporter genes have clearly undergone multiple
rounds of expansion. This is presumably to meet the requirements of an organellar lifestyle and, in the
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Because zinc can be highly limited during infection due to the action of nutritional immunity,
understanding the nature of pathogen (and host) zinc transporters may help inform future therapeutic
or diagnostic strategies.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2631/s1.
Table S1. ZIP and zincophore gene synteny. Table lists the presence (denoted by respective accession numbers) or
absence (N) of PRA1 and ZRT1 orthologues in 102 fungal species (NCBI). In species where both genes are present,
column 4 indicates syntenic (Y), or non-syntenic (N) relationship.
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